Method of treatment

ABSTRACT

The present invention relates to a method of treating T cell mediated inflammatory immune diseases or T cell mediated hypersensitivity diseases, which comprises administering to a human in need thereof an effective amount of a compound which inhibits EZH2 and/or EZH1, or a pharmaceutically acceptable salt thereof.

FIELD OF THE INVENTION

This invention relates to compounds which inhibit EZH2/EZH1 and theiruses for treating T cell mediated inflammatory immune diseases.

BACKGROUND OF THE INVENTION

Posttranslational modifications of proteins play a critical role in theregulation of signal transduction from receptors, chromatin remodellingand gene transcription. These modifications include acetylation,methylation, phosphorylation, ubiquitinylation, SUMOylation. EZH(enhancer of zeste homolog) 1 and 2 are the catalytic subunits of thePolycomb Repressor Complex 2 (PRC2) and exhibit methyltransferaseactivity that can catalyse the methylation of lysine amino acids(Margueron R, Reinberg D: The Polycomb complex PRC2 and its mark inlife. Nature. 2011 Jan. 20; 469 (7330):343-9)

EZH1 and EZH2 play a critical role in the epigenetic long term silencingof gene expression by di- or tri-methylating lysine 27 of histone H3(H3K27me2/3). Histone H3 is one of the five main histone proteinsinvolved in the structure of chromatin in eukaryotic cells. Chromatin isthe complex combination of DNA and protein that makes up chromosomes. Itis found inside the nuclei of eukaryotic cells and is divided betweenheterochromatin (condensed) and euchromatin (extended). The basicbuilding blocks of chromatin are nucleosomes, each of which is composedof 146 base pairs of DNA wrapped around a histone octamer that consistsof 2 copies of each H2A, H2B, H3 and H4. The functions of chromatin areto package DNA into a smaller volume to fit in the cell, to strengthenthe DNA to allow mitosis and meiosis, and to serve as a mechanism tocontrol gene expression and DNA replication. The chromatin structure iscontrolled by a series of post translational modifications to histoneproteins, notably histones H3 and H4, and most commonly within the“histone tails” which extend beyond the core nucleosome structure.Binding of enzymes and adaptor proteins to posttranslationalmodification in histone tails regulates chromatin dynamics and geneexpression. H3K27me3 is thought to silence gene expression by recruitinghistone deacetylases to the modified nucleosomes and stalltranscriptional elongation by polymerase II. Thus, inhibition of theenzymatic activity of EZH1 and EZH2 may result in a loss of H3K27me3 andup-regulation of target genes.

In addition to its nuclear function in histone H3 modification EZH2 hasbeen implicated in the regulation of signal transduction that leads toactin polymerization in the cytoplasm of cells (Su I H, Dobenecker M W,Dickinson E, Oser M, Basavaraj A, Marqueron R, Viale A, Reinberg D,Wülfing C, Tarakhovsky A: Polycomb group protein ezh2 controls actinpolymerization and cell signaling. Cell. 2005 May 6; 121(3):425-36). Thereorganization of the actin cytoskeleton critically contributes to Tcell responses by facilitating the interaction of T cells with antigenpresenting cells or target cells. In addition, actin remodelling playsan important role in T cell migration and motility during theirrecruitment to the sites of inflammation. A fraction of EZH2 protein wasfound to localize to the cytoplasm of T cells and to interact with thesmall GTPase VAV1, which is involved in actin remodelling. Geneticelimination of EZH2 resulted in impaired polymerization of actin in TCRstimulated T cells or at the T cell-antigen presenting cell interphase.Furthermore, actin polymerization induced by EZH2 over-expression wasdependent on the methyltransferase activity of EZH2. Proliferation of Tcells in response to TCR was also impaired in the absence of EZH2. Thus,inhibition of EZH1 and/or EZH2 may suppress the activation of T cells.

Mature T cell respond to foreign peptide antigens in the presence ofappropriate co-stimulation by antigen presenting cells. They have thecapability to discriminate between self and non self as a consequence ofthe selection of a TCR repertoire specific for foreign antigens in thethymus, tolerance induction of self reactive T cell clones in theperiphery, and control of T cell activation by self antigen byregulatory T cells. T cells provide protection against different classesof pathogens by mediating distinct types of adaptive immune responses asa consequence of the expression of distinct sets of cytokines and othersoluble and cell-bound products. In addition, they act as principleamplifiers and inducers of the appropriate inflammatory and effectorresponses in cells of the innate immune system and nonimmune cells.While such concerted immune responses can provide powerful protectionagainst pathogens it can also result in inflammation associated withunwanted immune responses against self and environmental antigens andcommensal microorganisms as well as collateral damage to the host as aside effect of immune responses against pathogens. CD8 T cells can lysecells bearing intracellular pathogens but may also contribute to tissuedamage and secrete pro-inflammatory cytokines, e.g. TNF and IFNg. CD4 Tcells can have diverse functions in inflammation depending on theirspecific cytokine expression profiles. CD4⁺ Th1 cells are important forthe clearance of intracellular pathogens but also play a critical rolein inflammation through the expression of TNF and IFNg. IL-17 expressingCD4⁺ Th17 cells, which mediate neutrophilia and tissue remodelling andrepair, have also been shown to be involved in many inflammatoryconditions. CD4⁺ Th2 cells are involved in allergic responses byexpressing IL-13, IL-5 and IL-4 which mediate airway hyper reactivity,eosinophil recruitment and IgE production. Thus, T cell activation isconsidered central to many inflammatory immune diseases. Accordingly,compounds that inhibit EZH1 and/or EZH2 activity and suppress T cellactivation would be useful for the treatment of T cell mediatedinflammatory immune diseases.

Inhibitors of EZH1/EZH2 that are useful in treating cancer have beenreported in PCT applications PCT/US2011/035336, PCT/US2011/035340, andPCT/US2011/035344.

SUMMARY OF THE INVENTION

The present invention relates to a method of treating T cell mediatedinflammatory immune diseases or T cell mediated hypersensitivitydiseases, which comprises administering to a human in need thereof aneffective amount of a compound which inhibits EZH2 and/or EZH1, or apharmaceutically acceptable salt thereof.

In a further aspect the invention relates to a compound or apharmaceutically acceptable salt thereof which inhibits EZH2 and/or EZH1for use in treating T cell mediated inflammatory immune diseases or Tcell mediated hypersensitivity diseases.

In a further aspect the invention relates to the use of a compound or apharmaceutically acceptable salt thereof which inhibits EZH2 and/or EZH1in the manufacture of a medicament for treating T cell mediatedinflammatory immune diseases or T cell mediated hypersensitivitydiseases.

BRIEF DESCRIPTION OF DRAWINGS

FIG. 1: EZH₁/EZH₂ inhibitors impair T cell receptor-induced CD4+ T cellproliferation. Division index was calculated by CFSE fluorescence 6 dayspost stimulation with 10 μg/mL αCD3+2 μg/mL αCD28. Data are presented asmean±standard error of the mean, n=4.

FIG. 2: EZH₁/EZH₂ inhibitors impair T cell receptor-induced effectorcytokine production in CD4+ T cells. Cytokine production was measured 72h post stimulation with 10 μg/mL αCD3+2 μg/mL αCD28. Data are presentedas means±standard error of the mean, n=4.

FIG. 3: EZH₁/EZH₂ inhibitors impair T cell receptor-induced IL-2production in CD4+ T cells. IL-2 production was measured 18 h poststimulation with 10 μg/mL αCD3+2 μg/mL αCD28. Data are presented asmeans 1 standard error of the mean, n=4.

FIG. 4: EZH₁/EZH₂ inhibitors impair T cell receptor-induced effectorcytokine production in CD4+ T cells. Cytokine production was measured 72h post stimulation with 10 μg/mL αCD3+2 μg/mL αCD28. Data are presentedas pIC₅₀±sem; n=4

DETAILED DESCRIPTION OF THE INVENTION

The present invention relates to a method of treating T cell mediatedinflammatory immune diseases as described above.

The present invention relates to a method of treating T cell mediatedhypersensitivity diseases as described above.

The present invention relates to a method of treating T cell mediatedinflammatory immune disease or T cell mediated hypersensitivitydiseases, which comprises administering to a human in need thereof aneffective amount of a compound of Formula (I)

wherein

X and Z are selected independently from the group consisting ofhydrogen, (C₁-C₈)alkyl, (C₂-C₈)alkenyl, (C₂-C₈)alkynyl, unsubstituted orsubstituted (C₃-C₈)cycloalkyl, unsubstituted or substituted(C₃-C₈)cycloalkyl-(C₁-C₈)alkyl or —(C₂-C₈)alkenyl, unsubstituted orsubstituted (C₅-C₈)cycloalkenyl, unsubstituted or substituted(C₅-C₈)cycloalkenyl-(C₁-C₈)alkyl or —(C₂-C₈)alkenyl,(C₆-C₁₀)bicycloalkyl, unsubstituted or substituted heterocycloalkyl,unsubstituted or substituted heterocycloalkyl-(C₁-C₈)alkyl or—(C₂-C₈)alkenyl, unsubstituted or substituted aryl, unsubstituted orsubstituted aryl-(C₁-C₈)alkyl or —(C₂-C₈)alkenyl, unsubstituted orsubstituted heteroaryl, unsubstituted or substitutedheteroaryl-(C₁-C₈)alkyl or —(C₂-C₈)alkenyl, halo, cyano, —COR^(a),—CO₂R^(a), —CONR^(a)R^(b), —CONR^(a)NR^(a)R^(b), —SR^(a), —SOR^(a),—SO₂R^(a), —SO₂NR^(a)R^(b), nitro, —NR^(a)R^(b), NR^(a)C(O)R^(b),—NR^(a)C(O)NR^(a)R^(b), —NR^(a)C(O)OR^(a), —NR^(a)SO₂R^(b),—NR^(a)SO₂NR^(a)R^(b), —NR^(a)NR^(a)R^(b), —NR^(a)NR^(a)C(O)R^(b),—NR^(a)NR^(a)C(O)NR^(a)R^(b), —NR^(a)NR^(a)C(O)OR^(a), —OR^(a),—OC(O)R^(a), and —OC(O)NR^(a)R^(b);

Y is H or halo;

R¹ is (C₁-C₈)alkyl, (C₂-C₈)alkenyl, (C₂-C₈)alkynyl, unsubstituted orsubstituted (C₃-C₈)cycloalkyl, unsubstituted or substituted(C₃-C₈)cycloalkyl-(C₁-C₈)alkyl or —(C₂-C₈)alkenyl, unsubstituted orsubstituted (C₅-C₈)cycloalkenyl, unsubstituted or substituted(C₅-C₈)cycloalkenyl-(C₁-C₈)alkyl or —(C₂-C₈)alkenyl, unsubstituted orsubstituted (C₆-C₁₀)bicycloalkyl, unsubstituted or substitutedheterocycloalkyl or —(C₂-C₈)alkenyl, unsubstituted or substitutedheterocycloalkyl-(C₁-C₈)alkyl, unsubstituted or substituted aryl,unsubstituted or substituted aryl-(C₁-C₈)alkyl or —(C₂-C₈)alkenyl,unsubstituted or substituted heteroaryl, unsubstituted or substitutedheteroaryl-(C₁-C₈)alkyl or —(C₂-C₈)alkenyl, —COR^(a), —CO₂R^(a),—CONR^(a)R^(b), —CONR^(a)NR^(a)R^(b);

R² is hydrogen, (C₁-C₈)alkyl, trifluoromethyl, alkoxy, or halo, in whichsaid (C₁-C₈)alkyl may be substituted with one to two groups selectedfrom: amino, and (C₁-C₃)alkylamino;

R⁷ is hydrogen, (C₁-C₃)alkyl, or alkoxy;

R³ is hydrogen, (C₁-C₈)alkyl, cyano, trifluoromethyl, —NR^(a)R^(b), orhalo;

R⁶ is selected from the group consisting of hydrogen, halo,(C₁-C₈)alkyl, (C₂-C₈)alkenyl, —B(OH)₂, substituted or unsubstituted(C₂-C₈)alkynyl, unsubstituted or substituted (C₃-C₈)cycloalkyl,unsubstituted or substituted (C₃-C₈)cycloalkyl-(C₁-C₈)alkyl,unsubstituted or substituted (C₅-C₈)cycloalkenyl, unsubstituted orsubstituted (C₅-C₈)cycloalkenyl-(C₁-C₈)alkyl, (C₆-C₁₀)bicycloalkyl,unsubstituted or substituted heterocycloalkyl, unsubstituted orsubstituted heterocycloalkyl-(C₁-C₈)alkyl, unsubstituted or substitutedaryl, unsubstituted or substituted aryl-(C₁-C₈)alkyl, unsubstituted orsubstituted heteroaryl, unsubstituted or substitutedheteroaryl-(C₁-C₈)alkyl, cyano, —COR^(a), —CO₂R^(a), —CONR^(a)R^(b),—CONR^(a)NR^(a)R^(b), —SR^(a), —SOR^(a), —SO₂R^(a), —SO₂NR^(a)R^(b),nitro, —NR^(a)R^(b), —NR^(a)C(O)R^(b), —NR^(a)C(O)NR^(a)R^(b),—NR^(a)C(O)OR^(a), —NR^(a)SO₂R^(b), —NR^(a)SO₂NR^(a)R^(b),—NR^(a)NR^(a)R^(b), —NR^(a)NR^(a)C(O)R^(b),—NR^(a)NR^(a)C(O)NR^(a)R^(b), —NR^(a)NR^(a)C(O)OR^(a), —OR^(a),—OC(O)R^(a), —OC(O)NR^(a)R^(b);

-   -   wherein any (C₁-C₈)alkyl, (C₂-C₈)alkenyl, (C₂-C₈)alkynyl,        cycloalkyl, cycloalkenyl, bicycloalkyl, heterocycloalkyl, aryl,        or heteroaryl group is optionally substituted by 1, 2 or 3        groups independently selected from the group consisting of        —O(C₁-C₆)alkyl(R^(c))₁₋₂, —S(C₁-C₆)alkyl(R^(c))₁₋₂,        —(C₁-C₆)alkyl(R^(c))₁₋₂, (C₁-C₈)alkyl-heterocycloalkyl,        (C₃-C₈)cycloalkyl-heterocycloalkyl, halo, (C₁-C₆)alkyl,        (C₃-C₈)cycloalkyl, (C₅-C₈)cycloalkenyl, (C₁-C₆)haloalkyl, cyano,        —COR^(a), —CO₂R^(a), —CONR^(a)R^(b), —SR^(a), —SOR^(a),        —SO₂R^(a), —SO₂NR^(a)R^(b), nitro, —NR^(a)R^(b),        —NR^(a)C(O)R^(b), —NR^(a)C(O)NR^(a)R^(b), —NR^(a)C(O)OR^(a),        —NR^(a)SO₂R^(b), —NR^(a)SO₂NR^(a)R^(b), —OR^(a), —OC(O)R^(a),        —OC(O)NR^(a)R^(b), heterocycloalkyl, aryl, heteroaryl,        aryl(C₁-C₄)alkyl, and heteroaryl(C₁-C₄)alkyl;        -   wherein any aryl or heteroaryl moiety of said aryl,            heteroaryl, aryl(C₁-C₄)alkyl, or heteroaryl(C₁-C₄)alkyl is            optionally substituted by 1, 2 or 3 groups independently            selected from the group consisting of halo, (C₁-C₆)alkyl,            (C₃-C₈)cycloalkyl, (C₅-C₈)cycloalkenyl, (C₁-C₆)haloalkyl,            cyano, —COR^(a), —CO₂R^(a), —CONR^(a)R^(b),        -   —SR^(a), —SOR^(a), —SO₂R^(a), —SO₂NR^(a)R^(b), nitro,            —NR^(a)R^(b), —NR^(a)C(O)R^(b), —NR^(a)C(O)NR^(a)R^(b),            —NR^(a)C(O)OR^(a), —NR^(a)SO₂R^(b), —NR^(a)SO₂NR^(a)R^(b),            —OR^(a), —OC(O)R^(a), and —OC(O)NR^(a)R^(b);

R^(a) and R^(b) are each independently hydrogen, (C₁-C₈)alkyl,(C₂-C₈)alkenyl, (C₂-C₈)alkynyl, (C₃-C₈)cycloalkyl, (C₅-C₈)cycloalkenyl,(C₆-C₁₀)bicycloalkyl, heterocycloalkyl, aryl, heteroaryl, wherein said(C₁-C₈)alkyl, (C₂-C₈)alkenyl, (C₂-C₈)alkynyl, cycloalkyl, cycloalkenyl,bicycloalkyl, heterocycloalkyl, aryl or heteroaryl group is optionallysubstituted by 1, 2 or 3 groups independently selected from halo,hydroxyl, (C₁-C₄)alkoxy, amino, (C₁-C₄)alkylamino,((C₁-C₄)alkyl)((C₁-C₄)alkyl)amino, —CO₂H, —CO₂(C₁-C₄)alkyl, —CONH₂,—CONH(C₁-C₄)alkyl, —CON((C₁-C₄)alkyl)((C₁-C₄)alkyl), —SO₂(C₁-C₄)alkyl,—SO₂NH₂, —SO₂NH(C₁-C₄)alkyl, or —SO₂N((C₁-C₄)alkyl)((C₁-C₄)alkyl);

each R^(c) is independently (C₁-C₄)alkylamino, —NR^(a)SO₂R^(b),—SOR^(a), —SO₂R^(a), —NR^(a)C(O)OR^(a), —NR^(a)R^(b), or —CO₂R^(a);

or R^(a) and R^(b) taken together with the nitrogen to which they areattached represent a 5-8 membered saturated or unsaturated ring,optionally containing an additional heteroatom selected from oxygen,nitrogen, and sulfur, wherein said ring is optionally substituted by 1,2 or 3 groups independently selected from (C₁-C₄)alkyl,(C₁-C₄)haloalkyl, amino, (C₁-C₄)alkylamino,((C₁-C₄)alkyl)((C₁-C₄)alkyl)amino, hydroxyl, oxo, (C₁-C₄)alkoxy, and(C₁-C₄)alkoxy(C₁-C₄)alkyl, wherein said ring is optionally fused to a(C₃-C₈)cycloalkyl, heterocycloalkyl, aryl, or heteroaryl ring;

or R^(a) and R^(b) taken together with the nitrogen to which they areattached represent a 6- to 10-membered bridged bicyclic ring systemoptionally fused to a (C₃-C₈)cycloalkyl, heterocycloalkyl, aryl, orheteroaryl ring;

or a salt thereof.

The present invention also relates to the above method, wherein thecompound of Formula (I) is further defined in one of the subgroupsbelow:

Subgroup (I)(A)

X and Z are selected from the group consisting of (C₁-C₈)alkyl,(C₃-C₈)cycloalkyl, heterocycloalkyl, aryl, heteroaryl, —NR^(a)R^(b), and—OR^(a);

Y is H or F;

R¹ is selected from the group consisting of (C₁-C₈)alkyl,(C₃-C₈)cycloalkyl, heterocycloalkyl, aryl, and heteroaryl;

R² is hydrogen, (C₁-C₈)alkyl, trifluoromethyl, alkoxy, or halo, in whichsaid (C₁-C₈)alkyl maybe substituted with one to two groups selectedfrom: amino, and (C₁-C₃)alkylamino;

R⁷ is hydrogen, (C₁-C₃)alkyl, or alkoxy;

R³ is selected from the group consisting of hydrogen, (C₁-C₈)alkyl,cyano, trifluoromethyl, —NR^(a)R^(b), and halo;

R⁶ is selected from the group consisting of hydrogen, halo, cyano,trifluoromethyl, amino, (C₁-C₈)alkyl, (C₃-C₈)cycloalkyl, aryl,heteroaryl, acylamino, (C₂-C₈)alkynyl, arylalkynyl, heteroarylalkynyl,—SO₂R^(a), —SO₂NR^(a)R^(b), and —NR^(a)SO₂R^(b); wherein any(C₁-C₈)alkyl, (C₃-C₈)cycloalkyl, (C₂-C₈)alkynyl, arylalkynyl,heteroarylalkynyl group is optionally substituted by 1, 2 or 3 groupsindependently selected from —O(C₁-C₆)alkyl(R^(c))₁₋₂,—S(C₁-C₆)alkyl(R^(c))₁₋₂, —(C₁-C₆)alkyl(R^(c))₁₋₂,(C₁-C₈)alkyl-heterocycloalkyl, (C₃-C₈)cycloalkyl-heterocycloalkyl, halo,(C₁-C₆)alkyl, (C₃-C₈)cycloalkyl, (C₅-C₈)cycloalkenyl, (C₁-C₆)haloalkyl,cyano, —COR^(a), —CO₂R^(a), —CONR^(a)R^(b), —SR^(a), —SOR^(a),—SO₂R^(a), —SO₂NR^(a)R^(b), nitro, —NR^(a)R^(b), —NR^(a)C(O)R^(b),—NR^(a)C(O)NR^(a)R^(b), —NR^(a)C(O)OR^(a), —NR^(a)SO₂R^(b),—NR^(a)SO₂NR^(a)R^(b), —OR^(a), —OC(O)R^(a), —OC(O)NR^(a)R^(b),heterocycloalkyl, aryl, heteroaryl, aryl(C₁-C₄)alkyl, andheteroaryl(C₁-C₄)alkyl;

each R^(c) is independently (C₁-C₄)alkylamino, —NR^(a)SO₂R^(b),—SOR^(a), —SO₂R^(a), —NR^(a)C(O)OR^(a), —NR^(a)R^(b), or —CO₂R^(a);

R^(a) and R^(b) are each independently hydrogen, (C₁-C₈)alkyl,(C₂-C₈)alkenyl, (C₂-C₈)alkynyl, (C₃-C₈)cycloalkyl, (C₅-C₈)cycloalkenyl,(C₆-C₁₀)bicycloalkyl, heterocycloalkyl, aryl, heteroaryl, wherein said(C₁-C₈)alkyl, (C₂-C₈)alkenyl, (C₂-C₈)alkynyl, cycloalkyl, cycloalkenyl,bicycloalkyl, heterocycloalkyl, aryl or heteroaryl group is optionallysubstituted by 1, 2 or 3 groups independently selected from halo,hydroxyl, (C₁-C₄)alkoxy, amino, (C₁-C₄)alkylamino,((C₁-C₄)alkyl)((C₁-C₄)alkyl)amino, —CO₂H, —CO₂(C₁-C₄)alkyl, —CONH₂,—CONH(C₁-C₄)alkyl, —CON((C₁-C₄)alkyl)((C₁-C₄)alkyl), —SO₂(C₁-C₄)alkyl,—SO₂NH₂, —SO₂NH(C₁-C₄)alkyl, and —SO₂N((C₁-C₄)alkyl)((C₁-C₄)alkyl);

or R^(a) and R^(b) taken together with the nitrogen to which they areattached represent a 5-8 membered saturated or unsaturated ring,optionally containing an additional heteroatom selected from oxygen,nitrogen, and sulfur, wherein said ring is optionally substituted by 1,2 or 3 groups independently selected from (C₁-C₄)alkyl,(C₁-C₄)haloalkyl, amino, (C₁-C₄)alkylamino,((C₁-C₄)alkyl)((C₁-C₄)alkyl)amino, hydroxyl, oxo, (C₁-C₄)alkoxy, and(C₁-C₄)alkoxy(C₁-C₄)alkyl, wherein said ring is optionally fused to a(C₃-C₈)cycloalkyl, heterocycloalkyl, aryl, or heteroaryl ring;

or R^(a) and R^(b) taken together with the nitrogen to which they areattached represent a 6- to 10-membered bridged bicyclic ring systemoptionally fused to a (C₃-C₈)cycloalkyl, heterocycloalkyl, aryl, orheteroaryl ring. An aryl or heteroaryl group in this particular subgroupA is selected independently from the group consisting of furan,thiophene, pyrrole, oxazole, thiazole, imidazole, pyrazole, oxadiazole,thiadiazole, triazole, tetrazole, benzofuran, benzothiophene,benzoxazole, benzothiazole, phenyl, pyridine, pyridazine, pyrimidine,pyrazine, triazine, tetrazine, quinoline, cinnoline, quinazoline,quinoxaline, and naphthyridine or another aryl or heteroaryl group asfollows:

wherein in (1),

A is O, NH, or S; B is CH or N, and C is hydrogen or C₁-C₈ alkyl; or

wherein in (2),

D is N or C optionally substituted by hydrogen or C₁-C₈ alkyl; or

wherein in (3),

E is NH or CH₂; F is O or CO; and G is NH or CH₂; or

wherein in (4),

J is O, S or CO; or

wherein in (5),

Q is CH or N;

M is CH or N; and

L/(5) is hydrogen, halo, amino, cyano, (C₁-C₈)alkyl, (C₃-C₈)cycloalkyl,—COR^(a), —CO₂R^(a), —CONR^(a)R^(b), —CONR^(a)NR^(a)R^(b), —SO₂R^(a),—SO₂NR^(a)R^(b), —NR^(a)R^(b), —NR^(a)C(O)R^(b), —NR^(a)SO₂R^(b),—NR^(a)SO₂NR^(a)R^(b), —NR^(a)NR^(a)R^(b), —NR^(a)NR^(a)C(O)R^(b),—NR^(a)NR^(a)C(O)NR^(a)R^(b), —OR^(a),

-   -   wherein any (C₁-C₈)alkyl, (C₃-C₈)cycloalkyl, group is optionally        substituted by 1, 2 or 3 groups independently selected from        (C₁-C₆)alkyl, (C₃-C₈)cycloalkyl, (C₅-C₈)cycloalkenyl,        (C₁-C₆)haloalkyl, cyano, —COR^(a), —CO₂R^(a), —CONR^(a)R^(b),        —SR^(a), —SOR^(a), —SO₂R^(a), —SO₂NR^(a)R^(b), nitro,        —NR^(a)R^(b), —NR^(a)C(O)R^(b), —NR^(a)C(O)NR^(a)R^(b),        —NR^(a)C(O)OR^(a), —NR^(a)SO₂R^(b), —NR^(a)SO₂NR^(a)R^(b),        —OR^(a), —OC(O)R^(a), —OC(O)NR^(a)R^(b); wherein R^(a) and R^(b)        are defined as above; or

wherein in 6,

L/(6) is NH or CH₂; or

wherein in 7,

-   -   M/(7) is hydrogen, halo, amino, cyano, (C₁-C₈)alkyl,        (C₃-C₈)cycloalkyl, heterocycloalkyl, —COR^(a), —CO₂R^(a),        —CONR^(a)R^(b), —CONR^(a)NR^(a)R^(b), —SO₂R^(a),        —SO₂NR^(a)R^(b), —NR^(a)R^(b), —NR^(a)C(O)R^(b),        —NR^(a)SO₂R^(b), —NR^(a)SO₂NR^(a)R^(b), —NR^(a)NR^(a)R^(b),        —NR^(a)NR^(a)C(O)R^(b), —NR^(a)NR^(a)C(O)NR^(a)R^(b), —OR^(a),    -   wherein any (C₁-C₈)alkyl, (C₃-C₈)cycloalkyl, heterocycloalkyl        group is optionally substituted by 1, 2 or 3 groups        independently selected from (C₁-C₆)alkyl, (C₃-C₈)cycloalkyl,        (C₅-C₈)cycloalkenyl, (C₁-C₆)haloalkyl, cyano, —COR^(a),        —CO₂R^(a), —CONR^(a)R^(b), —SR^(a), —SOR^(a), —SO₂R^(a),        —SO₂NR^(a)R^(b), nitro, —NR^(a)R^(b), —NR^(a)C(O)R^(b),        —NR^(a)C(O)NR^(a)R^(b), —NR^(a)C(O)OR^(a), —NR^(a)SO₂R^(b),        —NR^(a)SO₂NR^(a)R^(b), —OR^(a), —OC(O)R^(a), —OC(O)NR^(a)R^(b);        wherein R^(a) and R^(b) are defined as above; or

wherein in (8),

P is CH₂, NH, O, or S; Q/(8) is CH or N; and n is 0-2; or

wherein in (9),

S/(9) and T(9) is C, or S/(9) is C and T(9) is N, or S/(9) is N andT/(9) is C;

R is hydrogen, amino, methyl, trifluoromethyl, halo;

U is hydrogen, halo, amino, cyano, nitro, trifluoromethyl, (C₁-C₈)alkyl,(C₃-C₈)cycloalkyl, —COR^(a), —CO₂R^(a), —CONR^(a)R^(b), —SO₂R^(a),—SO₂NR^(a)R^(b), —NR^(a)R^(b), —NR^(a)C(O)R^(b), —NR^(a)SO₂R^(b),—NR^(a)SO₂NR^(a)R^(b), —NR^(a)NR^(a)R^(b), —NR^(a)NR^(a)C(O)R^(b),—OR^(a), 4-(1H-pyrazol-4-yl),

-   -   wherein any (C₁-C₈)alkyl, (C₃-C₈)cycloalkyl, group is optionally        substituted by 1, 2 or 3 groups independently selected from        (C₁-C₆)alkyl, (C₃-C₈)cycloalkyl, (C₅-C₈)cycloalkenyl,        (C₁-C₆)haloalkyl, cyano, —COR^(a), —CO₂R^(a), —CONR^(a)R^(b),        —SR^(a), —SOR^(a), —SO₂R^(a), —SO₂NR^(a)R^(b), nitro,        —NR^(a)R^(b), —NR^(a)C(O)R^(b), —NR^(a)C(O)NR^(a)R^(b),        —NR^(a)C(O)OR^(a), —NR^(a)SO₂R^(b), —NR^(a)SO₂NR^(a)R^(b),        —OR^(a), —OC(O)R^(a), —OC(O)NR^(a)R^(b);

wherein R^(a) and R^(b) are defined as above.

Subgroup (I)(B)

X and Z are selected independently from the group consisting of(C₁-C₈)alkyl, (C₃-C₈)cycloalkyl, heterocycloalkyl, aryl, heteroaryl,—NR^(a)R^(b), and —OR^(a);

Y is H;

R¹ is (C₁-C₈)alkyl, (C₃-C₈)cycloalkyl, or heterocycloalkyl;

R₂ is hydrogen, (C₁-C₃)alkyl, or halo, in which said (C₁-C₃)alkyl maybesubstituted with one to two groups selected from: amino, and(C₁-C₃)alkylamino;

R⁷ is hydrogen, (C₁-C₃)alkyl, or alkoxy;

R³ is hydrogen, (C₁-C₈)alkyl or halo;

R⁶ is hydrogen, halo, cyano, trifluoromethyl, amino, (C₁-C₈)alkyl,(C₃-C₈)cycloalkyl, aryl, heteroaryl, acylamino, (C₂-C₈)alkynyl,arylalkynyl, heteroarylalkynyl, —SO₂R^(a), —SO₂NR^(a)R^(b), or—NR^(a)SO₂R^(b);

-   -   wherein any (C₁-C₈)alkyl, (C₃-C₈)cycloalkyl, (C₂-C₈)alkynyl,        arylalkynyl, heteroarylalkynyl group is optionally substituted        by 1, 2 or 3 groups independently selected from halo,        (C₁-C₆)alkyl, (C₃-C₈)cycloalkyl, (C₅-C₈)cycloalkenyl,        (C₁-C₆)haloalkyl, cyano, —COR^(a), —CO₂R^(a), —CONR^(a)R^(b),        —SR^(a), —SOR^(a), —SO₂R^(a), —SO₂NR^(a)R^(b), nitro,        —NR^(a)R^(b), —NR^(a)C(O)R^(b), —NR^(a)C(O)NR^(a)R^(b),        —NR^(a)C(O)OR^(a), —NR^(a)SO₂R^(b), —NR^(a)SO₂NR^(a)R^(b),        —OR^(a), —OC(O)R^(a), —OC(O)NR^(a)R^(b), heterocycloalkyl, aryl,        heteroaryl, aryl(C₁-C₄)alkyl, and heteroaryl(C₁-C₄)alkyl;

R^(a) and R^(b) are each independently hydrogen, (C₁-C₈)alkyl,(C₂-C₈)alkenyl, (C₂-C₈)alkynyl, (C₃-C₈)cycloalkyl, (C₅-C₈)cycloalkenyl,(C₆-C₁₀)bicycloalkyl, heterocycloalkyl, aryl, heteroaryl, wherein said(C₁-C₈)alkyl, (C₂-C₈)alkenyl, (C₂-C₈)alkynyl, cycloalkyl, cycloalkenyl,bicycloalkyl, heterocycloalkyl, aryl or heteroaryl group is optionallysubstituted by 1, 2 or 3 groups independently selected from halo,hydroxyl, (C₁-C₄)alkoxy, amino, (C₁-C₄)alkylamino,((C₁-C₄)alkyl)((C₁-C₄)alkyl)amino, —CO₂H, —CO₂(C₁-C₄)alkyl, —CONH₂,—CONH(C₁-C₄)alkyl, —CON((C₁-C₄)alkyl)((C₁-C₄)alkyl), —SO₂(C₁-C₄)alkyl,—SO₂NH₂, —SO₂NH(C₁-C₄)alkyl, and —SO₂N((C₁-C₄)alkyl)((C₁-C₄)alkyl);

or R^(a) and R^(b) taken together with the nitrogen to which they areattached represent a 5-8 membered saturated or unsaturated ring,optionally containing an additional heteroatom selected from oxygen,nitrogen, and sulfur, wherein said ring is optionally substituted by 1,2 or 3 groups independently selected from (C₁-C₄)alkyl,(C₁-C₄)haloalkyl, amino, (C₁-C₄)alkylamino,((C₁-C₄)alkyl)((C₁-C₄)alkyl)amino, hydroxyl, oxo, (C₁-C₄)alkoxy, and(C₁-C₄)alkoxy(C₁-C₄)alkyl, wherein said ring is optionally fused to a(C₃-C₈)cycloalkyl, heterocycloalkyl, aryl, or heteroaryl ring;

or R^(a) and R^(b) taken together with the nitrogen to which they areattached represent a 6- to 10-membered bridged bicyclic ring systemoptionally fused to a (C₃-C₈)cycloalkyl, heterocycloalkyl, aryl, orheteroaryl ring. Aryl and heteroaryl in this definition are selectedfrom the group consisting of furan, thiophene, pyrrole, oxazole,thiazole, imidazole, pyrazole, oxadiazole, thiadiazole, triazole,tetrazole, benzofuran, benzothiophene, benzoxazole, benzothiazole,phenyl, pyridine, pyridazine, pyrimidine, pyrazine, triazine, tetrazine,quinoline, cinnoline, quinazoline, quinoxaline, and naphthyridine as ora compound of or another aryl or heteroaryl group as follows:

wherein in (1),

A is O, NH, or S; B is CH or N, and C is hydrogen or C₁-C₈ alkyl; or

wherein in (2),

D is N or C optionally substituted by hydrogen or C₁-C₈ alkyl; or

wherein in (3),

E is NH or CH₂; F is O or CO; and G is NH or CH₂; or

wherein in (4),

J is O, S or CO; or

wherein in (5),

Q is CH or N;

M is CH or N; and

L/(5) is hydrogen, halo, amino, cyano, (C₁-C₈)alkyl, (C₃-C₈)cycloalkyl,—COR^(a), —CO₂R^(a), —CONR^(a)R^(b), —CONR^(a)NR^(a)R^(b), —SO₂R^(a),—SO₂NR^(a)R^(b), —NR^(a)R^(b), —NR^(a)C(O)R^(b), NR^(a)SO₂R^(b),—NR^(a)SO₂NR^(a)R^(b), —NR^(a)NR^(a)R^(b), —NR^(a)NR^(a)C(O)R^(b),—NR^(a)NR^(a)C(O)NR^(a)R^(b), —OR^(a),

-   -   wherein any (C₁-C₈)alkyl, (C₃-C₈)cycloalkyl, group is optionally        substituted by 1, 2 or 3 groups independently selected from        (C₁-C₆)alkyl, (C₃-C₈)cycloalkyl, (C₅-C₈)cycloalkenyl,        (C₁-C₆)haloalkyl, cyano, —COR^(a), —CO₂R^(a), —CONR^(a)R^(b),        —SR^(a), —SOR^(a), —SO₂R^(a), —SO₂NR^(a)R^(b), nitro,        —NR^(a)R^(b), —NR^(a)C(O)R^(b), —NR^(a)C(O)NR^(a)R^(b),        —NR^(a)C(O)OR^(a), —NR^(a)SO₂R^(b), —NR^(a)SO₂NR^(a)R^(b),        —OR^(a), —OC(O)R^(a), —OC(O)NR^(a)R^(b),        wherein R^(a) and R^(b) are defined as above; or

wherein in 6,

L/(6) is NH or CH₂; or

wherein in 7,

-   -   M/(7) is hydrogen, halo, amino, cyano, (C₁-C₈)alkyl,        (C₃-C₈)cycloalkyl, heterocycloalkyl, —COR^(a), —CO₂R^(a),        —CONR^(a)R^(b), —CONR^(a)NR^(a)R^(b), —SO₂R^(a),        —SO₂NR^(a)R^(b), —NR^(a)R^(b), —NR^(a)C(O)R^(b),        —NR^(a)SO₂R^(b), —NR^(a)SO₂NR^(a)R^(b), —NR^(a)NR^(a)R^(b),        —NR^(a)NR^(a)C(O)R^(b), —NR^(a)NR^(a)C(O)NR^(a)R^(b), —OR^(a),    -   wherein any (C₁-C₈)alkyl, (C₃-C₈)cycloalkyl, heterocycloalkyl        group is optionally substituted by 1, 2 or 3 groups        independently selected from (C₁-C₆)alkyl, (C₃-C₈)cycloalkyl,        (C₅-C₈)cycloalkenyl, (C₁-C₆)haloalkyl, cyano, —COR^(a),        —CO₂R^(a), —CONR^(a)R^(b), —SR^(a), —SOR^(a), —SO₂R^(a),        —SO₂NR^(a)R^(b), nitro, —NR^(a)R^(b), —NR^(a)C(O)R^(b),        —NR^(a)C(O)NR^(a)R^(b), —NR^(a)C(O)OR^(a), —NR^(a)SO₂R^(b),        —NR^(a)SO₂NR^(a)R^(b), —OR^(a), —OC(O)R^(a), —OC(O)NR^(a)R^(b);        wherein R^(a) and R^(b) are defined as above; or

wherein in (8),

P is CH₂, NH, O, or S; Q/(8) is CH or N; and n is 0-2; or

wherein in (9),

S/(9) and T(9) is C, or S/(9) is C and T(9) is N, or S/(9) is N andT/(9) is C;

R is hydrogen, amino, methyl, trifluoromethyl, halo;

U is hydrogen, halo, amino, cyano, nitro, trifluoromethyl, (C₁-C₈)alkyl,(C₃-C₈)cycloalkyl, —COR^(a), —CO₂R^(a), —CONR^(a)R^(b), —SO₂R^(a),—SO₂NR^(a)R^(b), —NR^(a)R^(b), —NR^(a)C(O)R^(b), —NR^(a)SO₂R^(b),—NR^(a)SO₂NR^(a)R^(b), —NR^(a)NR^(a)R^(b), —NR^(a)NR^(a)C(O)R^(b),—OR^(a), 4-(1H-pyrazol-4-yl),

-   -   wherein any (C₁-C₈)alkyl, (C₃-C₈)cycloalkyl, group is optionally        substituted by 1, 2 or 3 groups independently selected from        (C₁-C₆)alkyl, (C₃-C₈)cycloalkyl, (C₅-C₈)cycloalkenyl,        (C₁-C₆)haloalkyl, cyano, —COR^(a), —CO₂R^(a), —CONR^(a)R^(b),        —SR^(a), —SOR^(a), —SO₂R^(a), —SO₂NR^(a)R^(b), nitro,        —NR^(a)R^(b), —NR^(a)C(O)R^(b), —NR^(a)C(O)NR^(a)R^(b),        NR^(a)C(O)OR^(a), —NR^(a)SO₂R^(b), —NR^(a)SO₂NR^(a)R^(b),        —OR^(a), —OC(O)R^(a), —OC(O)NR^(a)R^(b),

wherein R^(a) and R^(b) are defined as above.

Subgroup (I)(C)

X is methyl, ethyl, n-propyl, isopropyl, cyclopropyl, cyclobutyl,cyclopentyl, cyclohexyl, phenyl, trifluoromethyl, tetrahydropyran,hydroxymethyl, methoxymethyl, or benzyl;

Y is H;

Z is methyl, ethyl, n-propyl, isopropyl, trifluoromethyl, or benzyl;

R¹ is isopropyl, tert-butyl, cyclobutyl, cyclopentyl, cyclohexyl,(1-methylethyl)cyclopropyl, 1,1-dioxo-tetrahydrothiophene-3-yl,1-Me-piperidin-4-yl, tetrahydrofuran-3-yl, tetrahydropyran-4-yl,N,N-dimethyl-1-propanaminyl, benzyl, or 4-pyridyl;

R₂ is hydrogen, (C₁-C₃)alkyl, or halo, in which said (C₁-C₃)alkyl may besubstituted with one to two groups selected from: amino, and(C₁-C₃)alkylamino;

R⁷ is hydrogen, (C₁-C₃)alkyl, or alkoxy;

R³ is H, methyl, or Br; and

R⁶ is methyl, bis(1,1-dimethylethyl), bis(1-methylethyl), cyclopropyl,propyl, dimethylamino, ethylamino, (2-hydroxyethyl)amino,2-propen-1-ylamino, 1-piperazinyl, 1-piperidinyl, 4-morpholinyl,4-piperidinylamino, tetrahydro-2H-pyran-4-ylamino, phenylamino,(phenylmethyl)amino, (4-pyridinylmethyl)amino,[2-(2-pyridinylamino)ethyl]amino, 2-(dimethylamino)ethyl]amino,4-pyridinylamino, 4-(aminocarbonyl)phenyl]amino,3-hydroxy-3-methyl-1-butyn-1-yl, 4-pyridinylethynyl, phenylethynyl,2-furanyl, 3-thienyl; 1H-pyrazol-4-yl, 1H-indazol-5-yl, 1H-indazol-6-yl,3-methyl-1H-indazol-5-yl, 1H-1,2,3-benzotriazol-5-yl,2-oxo-2,3-dihydro-1H-benzimidazol-5-yl, 2-oxo-2,3-dihydro-1H-indol-5-yl,2-oxo-2,3-dihydro-1H-indol-6-yl, 2,1,3-benzoxadiazol-5-yl,2-amino-6-quinazolinyl, 2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl,2-amino-5-pyrimidinyl, 7-oxo-1,5,6,7-tetrahydro-1,8-naphthyridin-3-yl,phenyl, 2-methylphenyl, 2-nitrophenyl, 2-phenylethyl, 3-aminophenyl,4-aminophenyl, 4-chlorophenyl, 4-fluorophenyl, 4-(methyloxy)phenyl,3-(acetylamino)phenyl, 4-(acetylamino)phenyl, 4-(aminocarbonyl)phenyl,4-(1H-pyrazol-4-yl)phenyl, 4-(aminosulfonyl)phenyl,4-(methylsulfonyl)phenyl, 4-[(dimethylamino)sulfonyl]phenyl,4-[(methylamino)carbonyl]phenyl, 4-[(methylamino)sulfonyl]phenyl,4-[(methylsulfonyl)amino]phenyl, 3-pyridinyl, 4-pyridinyl,2-(4-morpholinyl)-4-pyridinyl, 2-amino-4-pyridinyl,5-(methyloxy)-3-pyridinyl, 5-(methylsulfonyl)-3-pyridinyl,5-[(cyclopropylsulfonyl)amino]-6-(methyloxy)-3-pyridinyl,5-[(phenylsulfonyl)amino]-3-pyridinyl,6-(4-methyl-1-piperazinyl)-3-pyridinyl, 6-(4-morpholinyl)-3-pyridinyl,6-(acetylamino)-3-pyridinyl, 6-(dimethylamino)-3-pyridinyl,6-(methyloxy)-3-pyridinyl, 6-[(methylamino)carbonyl]-3-pyridinyl,6-[(methylamino)sulfonyl]-3-pyridinyl, 6-methyl-3-pyridinyl,4-pyridinyloxy.

The present invention also relates to a method of treating T cellmediated inflammatory immune diseases or a T cell mediatedhypersensitivity diseases, which comprises administering to a human inneed thereof an effective amount of a compound, which is selected fromthe group comprising:

-   6-Bromo-N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-1-(1-methylethyl)-1H-indole-4-carboxamide;-   N-[(4,6-Dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-1-(1-methylethyl)-6-[6-(4-methyl-1-piperazinyl)-3-pyridinyl]-1H-indole-4-carboxamide;-   N-[(4,6-Dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-1-(1-methylethyl)-6-phenyl-1H-indole-4-carboxamide;-   N-[(4,6-Dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-1-(1-methylethyl)-6-(2-oxo-2,3-dihydro-1H-benzimidazol-5-yl)-1H-indole-4-carboxamide;-   1-(1-methylethyl)-N-[(6-methyl-2-oxo-4-propyl-1,2-dihydro-3-pyridinyl)methyl]-6-[2-(4-methyl-1-piperazinyl)-4-pyridinyl]-1H-indole-4-carboxamide;-   1-(1-Methylethyl)-N-[(6-methyl-2-oxo-4-propyl-1,2-dihydro-3-pyridinyl)methyl]-6-(2-oxo-2,3-dihydro-1H-benzimidazol-5-yl)-1H-indole-4-carboxamide;-   6-Bromo-1-cyclopentyl-N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-1H-indole-4-carboxamide;-   1-(1-Methylethyl)-N-[(6-methyl-2-oxo-4-propyl-1,2-dihydro-3-pyridinyl)methyl]-6-(3-pyridinyl)-1H-indole-4-carboxamide;-   6-Bromo-1-(1-methylethyl)-N-[(6-methyl-2-oxo-4-propyl-1,2-dihydro-3-pyridinyl)methyl]-1H-indole-4-carboxamide;-   1-(1-Methylethyl)-N-[(6-methyl-2-oxo-4-propyl-1,2-dihydro-3-pyridinyl)methyl]-6-phenyl-1H-indole-4-carboxamide;-   6-Bromo-N-[(4-cyclopropyl-6-methyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-1-(1-methylethyl)-1H-indole-4-carboxamide;-   6-Bromo-1-(1-methylethyl)-N-{[6-methyl-4-(1-methylethyl)-2-oxo-1,2-dihydro-3-pyridinyl]methyl}-1H-indole-4-carboxamide;-   6-Bromo-N-[(4-cyclobutyl-6-methyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-1-(1-methylethyl)-1H-indole-4-carboxamide;-   6-Bromo-1-(1-methylethyl)-N-[(4-methyl-2-oxo-6-propyl-1,2-dihydro-3-pyridinyl)methyl]-1H-indole-4-carboxamide;-   6-Bromo-1-(1-methylethyl)-N-[(6-methyl-2-oxo-4-phenyl-1,2-dihydro-3-pyridinyl)methyl]-1H-indole-4-carboxamide;-   N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-6-(6-(2-oxopyrrolidin-1-yl)pyridin-3-yl)-1H-indole-4-carboxamide;-   1-isopropyl-N-((6-methyl-2-oxo-4-propyl-1,2-dihydropyridin-3-yl)methyl)-6-(2-methylpyridin-3-yl)-1H-indole-4-carboxamide;-   1-isopropyl-N-((6-methyl-2-oxo-4-propyl-1,2-dihydropyridin-3-yl)methyl)-6-(2-methylpyrimidin-5-yl)-1H-indole-4-carboxamide;-   1-isopropyl-N-((6-methyl-2-oxo-4-propyl-1,2-dihydropyridin-3-yl)methyl)-6-(6-methylpyridin-3-yl)-1H-indole-4-carboxamide;-   N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-6-(4-((dimethylamino)methyl)phenyl)-1-isopropyl-3-methyl-1H-indole-4-carboxamide;-   N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-6-(6-methoxypyridin-3-yl)-3-methyl-1H-indole-4-carboxamide;-   N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-3-methyl-6-(6-morpholinopyridin-3-yl)-1H-indole-4-carboxamide;-   N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-3-methyl-6-(4-(4-methylpiperazin-1-yl)phenyl)-1H-indole-4-carboxamide;-   N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-3-methyl-6-(3-((methylsulfonyl)methyl)phenyl)-1H-indole-4-carboxamide;-   N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-3-methyl-6-(2-methylpyrimidin-5-yl)-1H-indole-4-carboxamide;-   6-(2-aminopyrimidin-5-yl)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-3-methyl-1H-indole-4-carboxamide;-   6-(6-aminopyridin-3-yl)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-3-methyl-1H-indole-4-carboxamide;-   N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-6-(6-(dimethylamino)pyridin-3-yl)-1-isopropyl-3-methyl-1H-indole-4-carboxamide;-   N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-3-methyl-6-(6-(pyrrolidin-1-yl)pyridin-3-yl)-1H-indole-4-carboxamide;-   N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-6-(4-fluorophenyl)-1-isopropyl-3-methyl-1H-indole-4-carboxamide;-   N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-6-(4-(4-isopropylpiperazin-1-yl)phenyl)-3-methyl-1H-indole-4-carboxamide;-   N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-6-(1H-indazol-6-yl)-1-isopropyl-3-methyl-1H-indole-4-carboxamide;-   6-bromo-N-[(4-ethyl-6-methyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-3-methyl-1-(1-methylethyl)-1H-indole-4-carboxamide;-   N-[(4-ethyl-6-methyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-3-methyl-1-(1-methylethyl)-6-[6-(4-methyl-1-piperazinyl)-3-pyridinyl]-1H-indole-4-carboxamide;-   6-{3-[(dimethylamino)methyl]phenyl}-N-[(4-ethyl-6-methyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-3-methyl-1-(1-methylethyl)-1H-indole-4-carboxamide;-   6-{4-[(dimethylamino)methyl]phenyl}-N-[(4-ethyl-6-methyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-3-methyl-1-(1-methylethyl)-1H-indole-4-carboxamide;-   N-[(4-ethyl-6-methyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-3-methyl-1-(1-methylethyl)-6-[6-(methyloxy)-3-pyridinyl]-1H-indole-4-carboxamide;-   N-[(4-ethyl-6-methyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-3-methyl-1-(1-methylethyl)-6-(2-methyl-5-pyrimidinyl)-1H-indole-4-carboxamide;-   6-(6-amino-3-pyridinyl)-N-[(4-ethyl-6-methyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-3-methyl-1-(1-methylethyl)-1H-indole-4-carboxamide;-   6-[6-(dimethylamino)-3-pyridinyl]-N-[(4-ethyl-6-methyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-3-methyl-1-(1-methylethyl)-1H-indole-4-carboxamide;-   N-[(4-ethyl-6-methyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-3-methyl-1-(1-methylethyl)-6-(6-methyl-3-pyridinyl)-1H-indole-4-carboxamide;-   N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-3-methyl-1-(1-methylethyl)-6-(1H-pyrazol-3-yl)-1H-indole-4-carboxamide;-   N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-3-methyl-1-(1-methylethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-indole-4-carboxamide;-   N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-3-methyl-1-(1-methylethyl)-6-(1H-pyrazol-4-yl)-1H-indole-4-carboxamide;-   N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-3-methyl-1-(1-methylethyl)-6-[1-(2-pyridinylmethyl)-1H-pyrazol-4-yl]-1H-indole-4-carboxamide;-   N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-3-methyl-1-(1-methylethyl)-6-(1H-pyrrolo[2,3-b]pyridin-5-yl)-1H-indole-4-carboxamide;-   N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-3-methyl-1-(1-methylethyl)-6-[1-(2-thienylmethyl)-1H-pyrazol-4-yl]-1H-indole-4-carboxamide;-   N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-3-methyl-6-(3-(methylsulfonamidomethyl)phenyl)-1H-indole-4-carboxamide;-   N-((4-benzyl-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-6-bromo-1-isopropyl-3-methyl-1H-indole-4-carboxamide;-   6-(6-acetamidopyridin-3-yl)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-3-methyl-1H-indole-4-carboxamide;-   6-(6-acetamidopyridin-3-yl)-1-isopropyl-3-methyl-N-((6-methyl-2-oxo-4-propyl-1,2-dihydropyridin-3-yl)methyl)-1H-indole-4-carboxamide;-   1-isopropyl-3-methyl-N-((6-methyl-2-oxo-4-propyl-1,2-dihydropyridin-3-yl)methyl)-6-(1-(2-morpholinoethyl)-1H-pyrazol-4-yl)-1H-indole-4-carboxamide;-   N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-3-methyl-1-(1-methylethyl)-6-(3-pyridinyl)-1H-indole-4-carboxamide;-   6-bromo-3-methyl-1-(1-methylethyl)-N-[(6-methyl-2-oxo-4-propyl-1,2-dihydro-3-pyridinyl)methyl]-1H-indole-4-carboxamide;-   N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-3-methyl-1-(1-methylethyl)-6-[6-(4-methyl-1-piperazinyl)-3-pyridinyl]-1H-indole-4-carboxamide;-   3-methyl-1-(1-methylethyl)-N-[(6-methyl-2-oxo-4-propyl-1,2-dihydro-3-pyridinyl)methyl]-6-(2-methyl-3-pyridinyl)-1H-indole-4-carboxamide;-   3-methyl-1-(1-methylethyl)-N-[(6-methyl-2-oxo-4-propyl-1,2-dihydro-3-pyridinyl)methyl]-6-[6-(4-methyl-1-piperazinyl)-3-pyridinyl]-1H-indole-4-carboxamide;-   3-methyl-1-(1-methylethyl)-N-[(6-methyl-2-oxo-4-propyl-1,2-dihydro-3-pyridinyl)methyl]-6-[5-(4-methyl-1-piperazinyl)-3-pyridinyl]-1H-indole-4-carboxamide;-   3-methyl-1-(1-methylethyl)-N-[(6-methyl-2-oxo-4-propyl-1,2-dihydro-3-pyridinyl)methyl]-6-(6-methyl-3-pyridinyl)-1H-indole-4-carboxamide;-   6-{4-[(dimethylamino)methyl]phenyl}-3-methyl-1-(1-methylethyl)-N-[(6-methyl-2-oxo-4-propyl-1,2-dihydro-3-pyridinyl)methyl]-1H-indole-4-carboxamide;-   N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-3-methyl-1-(1-methylethyl)-6-[6-(4-methyl-1-piperazinyl)-3-pyridinyl]-1H-indole-4-carboxamide;-   N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-1-(1-methylethyl)-6-(3-pyridinyl)-1H-indole-4-carboxamide;-   6-bromo-1-cyclopentyl-N-[(6-methyl-2-oxo-4-propyl-1,2-dihydro-3-pyridinyl)methyl]-1H-indole-4-carboxamide;-   1-(1-methylethyl)-N-[(6-methyl-2-oxo-4-propyl-1,2-dihydro-3-pyridinyl)methyl]-6-[6-(4-methyl-1-piperazinyl)-3-pyridinyl]-1H-indole-4-carboxamide;-   6-bromo-1-cyclobutyl-N-[(6-methyl-2-oxo-4-propyl-1,2-dihydro-3-pyridinyl)methyl]-1H-indole-4-carboxamide;-   1-cyclobutyl-6-{4-[(dimethylamino)methyl]phenyl}-N-[(6-methyl-2-oxo-4-propyl-1,2-dihydro-3-pyridinyl)methyl]-1H-indole-4-carboxamide;-   1-cyclopropyl-6-{4-[(dimethylamino)methyl]phenyl}-N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-3-methyl-1H-indole-4-carboxamide;-   1-cyclopropyl-N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-3-methyl-6-[6-(methyloxy)-3-pyridinyl]-1H-indole-4-carboxamide;-   N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-3-methyl-1-(1-methylethyl)-6-[3-(methylsulfonyl)phenyl]-1H-indole-4-carboxamide;-   6-bromo-1-cyclopentyl-N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-3-methyl-1H-indole-4-carboxamide;-   1-cyclopentyl-6-{4-[(dimethylamino)methyl]phenyl}-N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-3-methyl-1H-indole-4-carboxamide;-   3-methyl-1-(1-methylethyl)-N-[(6-methyl-2-oxo-4-propyl-1,2-dihydro-3-pyridinyl)methyl]-6-(1-methyl-1H-pyrazol-4-yl)-1H-indole-4-carboxamide;-   N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-3-methyl-6-(2-(4-methylpiperazin-1-yl)pyrimidin-5-yl)-1H-indole-4-carboxamide;-   6-bromo-1-(1-methylethyl)-N-[(6-methyl-2-oxo-1,2-dihydro-4,4′-bipyridin-3-yl)methyl]-1H-indole-4-carboxamide;-   6-bromo-N-{[4-(ethylamino)-6-methyl-2-oxo-1,2-dihydro-3-pyridinyl]methyl}-1-(1-methylethyl)-1H-indole-4-carboxamide;-   N-{[4-(ethylamino)-6-methyl-2-oxo-1,2-dihydro-3-pyridinyl]methyl}-1-(1-methylethyl)-6-[6-(4-methyl-1-piperazinyl)-3-pyridinyl]-1H-indole-4-carboxamide;-   6-bromo-1-(1-methylethyl)-N-{[6-methyl-2-oxo-4-(1-pyrrolidinyl)-1,2-dihydro-3-pyridinyl]methyl}-1H-indole-4-carboxamide;-   1-(1-methylethyl)-N-{[6-methyl-2-oxo-4-(phenylamino)-1,2-dihydro-3-pyridinyl]methyl}-6-[6-(4-methyl-1-piperazinyl)-3-pyridinyl]-1H-indole-4-carboxamide;-   6-bromo-N-[(4-ethyl-6-methyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-1-(1-methylethyl)-1H-indole-4-carboxamide;-   6-{4-[(dimethylamino)methyl]phenyl}-N-[(4-ethyl-6-methyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-1-(1-methylethyl)-1H-indole-4-carboxamide;-   N-[(4-ethyl-6-methyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-1-(1-methylethyl)-6-[6-(4-methyl-1-piperazinyl)-3-pyridinyl]-1H-indole-4-carboxamide;-   N-[(4-ethyl-6-methyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-1-(1-methylethyl)-6-[6-(methyloxy)-3-pyridinyl]-1H-indole-4-carboxamide;-   6-[6-(acetylamino)-3-pyridinyl]-1-(1-methylethyl)-N-[(6-methyl-2-oxo-4-propyl-1,2-dihydro-3-pyridinyl)methyl]-1H-indole-4-carboxamide;-   6-(4-fluorophenyl)-1-(1-methylethyl)-N-[(6-methyl-2-oxo-4-propyl-1,2-dihydro-3-pyridinyl)methyl]-1H-indole-4-carboxamide;-   6-[4-(acetylamino)phenyl]-1-(1-methylethyl)-N-[(6-methyl-2-oxo-4-propyl-1,2-dihydro-3-pyridinyl)methyl]-1H-indole-4-carboxamide;-   methyl    4-[4-({[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]amino}carbonyl)-3-methyl-1-(1-methylethyl)-1H-indol-6-yl]benzoate;-   methyl    5-[3-methyl-1-(1-methylethyl)-4-({[(6-methyl-2-oxo-4-propyl-1,2-dihydro-3-pyridinyl)methyl]amino}carbonyl)-1H-indol-6-yl]-2-pyridinecarboxylate;-   methyl    3-[3-methyl-1-(1-methylethyl)-4-({[(6-methyl-2-oxo-4-propyl-1,2-dihydro-3-pyridinyl)methyl]amino}carbonyl)-1H-indol-6-yl]benzoate;-   6-bromo-N-((6-ethyl-4-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-1H-indole-4-carboxamide;-   N-((6-benzyl-4-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-6-bromo-1-isopropyl-1H-indole-4-carboxamide;-   6-bromo-N-((6-cyclobutyl-4-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-1H-indole-4-carboxamide;-   6-bromo-1-(1-methylethyl)-N-({6-methyl-4-[(methyloxy)methyl]-2-oxo-1,2-dihydro-3-pyridinyl}methyl)-1H-indole-4-carboxamide;-   1-(1-methylethyl)-N-({6-methyl-4-[(methyloxy)methyl]-2-oxo-1,2-dihydro-3-pyridinyl}methyl)-6-[6-(4-methyl-1-piperazinyl)-3-pyridinyl]-1H-indole-4-carboxamide;-   1-(1-methylethyl)-N-({6-methyl-4-[(methyloxy)methyl]-2-oxo-1,2-dihydro-3-pyridinyl}methyl)-6-[2-(4-methyl-1-piperazinyl)-4-pyridinyl]-1H-indole-4-carboxamide;-   1-(1-methylethyl)-N-({6-methyl-4-[(methyloxy)methyl]-2-oxo-1,2-dihydro-3-pyridinyl}methyl)-6-(3-pyridinyl)-1H-indole-4-carboxamide;-   1-(1-methylethyl)-N-({6-methyl-4-[(methyloxy)methyl]-2-oxo-1,2-dihydro-3-pyridinyl}methyl)-6-[6-(4-morpholinyl)-3-pyridinyl]-1H-indole-4-carboxamide;-   6-bromo-1-cyclopropyl-N-[(6-methyl-2-oxo-4-propyl-1,2-dihydro-3-pyridinyl)methyl]-1H-indole-4-carboxamide;-   1-cyclopropyl-N-[(6-methyl-2-oxo-4-propyl-1,2-dihydro-3-pyridinyl)methyl]-6-[6-(4-methyl-1-piperazinyl)-3-pyridinyl]-1H-indole-4-carboxamide;-   1-cyclopropyl-N-[(6-methyl-2-oxo-4-propyl-1,2-dihydro-3-pyridinyl)methyl]-6-(3-pyridinyl)-1H-indole-4-carboxamide;-   N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-3-methyl-6-(4-(piperazin-1-yl)phenyl)-1H-indole-4-carboxamide;-   N-[(4-ethyl-6-methyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-3-methyl-1-(1-methylethyl)-6-[6-(1-piperazinyl)-3-pyridinyl]-1H-indole-4-carboxamide;-   1-isopropyl-3-methyl-N-((6-methyl-2-oxo-4-propyl-1,2-dihydropyridin-3-yl)methyl)-6-(2-(piperazin-1-yl)pyridin-4-yl)-1H-indole-4-carboxamide;-   N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-3-methyl-6-(2-(piperazin-1-yl)pyridin-4-yl)-1H-indole-4-carboxamide;-   1-cyclopropyl-N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-3-methyl-6-[6-(1-piperazinyl)-3-pyridinyl]-1H-indole-4-carboxamide;-   methyl    4-[4-({[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]amino}carbonyl)-3-methyl-1-(1-methylethyl)-1H-indol-6-yl]benzoate;-   methyl    3-[3-methyl-1-(1-methylethyl)-4-({[(6-methyl-2-oxo-4-propyl-1,2-dihydro-3-pyridinyl)methyl]amino}carbonyl)-1H-indol-6-yl]benzoate;-   methyl    5-[3-methyl-1-(1-methylethyl)-4-({[(6-methyl-2-oxo-4-propyl-1,2-dihydro-3-pyridinyl)methyl]amino}carbonyl)-1H-indol-6-yl]-2-pyridinecarboxylate;-   1-isopropyl-N-((6-methyl-2-oxo-4-propyl-1,2-dihydropyridin-3-yl)methyl)-6-(methylsulfonyl)-1H-indole-4-carboxamide;-   N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-3-methyl-6-(methylsulfonyl)-1H-indole-4-carboxamide;-   N-((4-ethyl-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-3-methyl-6-(methylsulfonyl)-1H-indole-4-carboxamide;-   N-((4-benzyl-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-3-methyl-6-(methylsulfonyl)-1H-indole-4-carboxamide;-   1-isopropyl-3-methyl-N-((6-methyl-2-oxo-4-propyl-1,2-dihydropyridin-3-yl)methyl)-6-(methylsulfonyl)-1H-indole-4-carboxamide;-   3-({2-[6-(cyclopropylsulfonyl)-3-methyl-1-(1-methylethyl)-1H-indol-4-yl]-2-oxoethyl}amino)-4,6-dimethyl-2(1H)-pyridinone;-   3-({2-[6-(cyclopropylsulfonyl)-3-methyl-1-(1-methylethyl)-1H-indol-4-yl]-2-oxoethyl}amino)-4,6-dimethyl-2(1H)-pyridinone;-   3-methyl-1-(1-methylethyl)-N-{[6-methyl-2-oxo-4-(phenylmethyl)-1,2-dihydro-3-pyridinyl]methyl}-6-(methyloxy)-1H-indole-4-carboxamide;-   N-[(4-ethyl-6-methyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-3-methyl-1-(1-methylethyl)-6-(methyloxy)-1H-indole-4-carboxamide;-   3-methyl-1-(1-methylethyl)-N-[(6-methyl-2-oxo-4-propyl-1,2-dihydro-3-pyridinyl)methyl]-6-(methyloxy)-1H-indole-4-carboxamide;-   6-bromo-N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-3-methyl-1-(1-methylethyl)-1H-indole-4-carboxamide;-   N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-1-(1-methylethyl)-6-(methyloxy)-1H-indole-4-carboxamide;-   N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-3-methyl-1-(1-methylethyl)-6-(methyloxy)-1H-indole-4-carboxamide;-   6-chloro-N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-3-methyl-1-(1-methylethyl)-1H-indole-4-carboxamide;-   6-{3-[(dimethylamino)methyl]phenyl}-N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-3-methyl-1-(1-methylethyl)-1H-indole-4-carboxamide;-   6-bromo-3-methyl-1-(1-methylethyl)-N-{[6-methyl-4-(4-morpholinylmethyl)-2-oxo-1,2-dihydro-3-pyridinyl]methyl}-1H-indole-4-carboxamide;-   N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-6-iodo-1-(1-methylethyl)-1H-indole-4-carboxamide;-   6-iodo-1-(1-methylethyl)-N-[(6-methyl-2-oxo-4-propyl-1,2-dihydro-3-pyridinyl)methyl]-1H-indole-4-carboxamide;-   6-bromo-1-ethyl-N-[(6-methyl-2-oxo-4-propyl-1,2-dihydro-3-pyridinyl)methyl]-1H-indole-4-carboxamide;-   6-bromo-N-[(6-methyl-2-oxo-4-propyl-1,2-dihydro-3-pyridinyl)methyl]-1-propyl-1H-indole-4-carboxamide;-   3-({2-[6-chloro-1-(1-methylethyl)-1H-indol-4-yl]-2-oxoethyl}amino)-4,6-dimethyl-2(1H)-pyridinone;-   3-({2-[6-chloro-1-(1-methylethyl)-1H-indol-4-yl]-2-oxoethyl}amino)-6-methyl-4-propyl-2(1H)-pyridinone;-   3-({2-[6-chloro-3-methyl-1-(1-methylethyl)-1H-indol-4-yl]-2-oxoethyl}amino)-6-methyl-4-propyl-2(1H)-pyridinone;-   N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-6-fluoro-1-(1-methylethyl)-1H-indole-4-carboxamide;-   3-({2-[6-fluoro-1-(1-methylethyl)-1H-indol-4-yl]-2-oxoethyl}amino)-6-methyl-4-propyl-2(1H)-pyridinone;-   N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-3-methyl-6-(1H-tetrazol-5-yl)-1H-indole-4-carboxamide;-   1-isopropyl-3-methyl-N-((6-methyl-2-oxo-4-propyl-1,2-dihydropyridin-3-yl)methyl)-6-(2H-tetrazol-5-yl)-1H-indole-4-carboxamide;-   6-cyano-3-methyl-1-(1-methylethyl)-N-[(6-methyl-2-oxo-4-propyl-1,2-dihydro-3-pyridinyl)methyl]-1H-indole-4-carboxamide;-   6-bromo-3-chloro-1-isopropyl-N-((6-methyl-2-oxo-4-propyl-1,2-dihydropyridin-3-yl)methyl)-1H-indole-4-carboxamide;-   6-bromo-3-chloro-1-(1-methylethyl)-N-({6-methyl-4-[(methyloxy)methyl]-2-oxo-1,2-dihydro-3-pyridinyl}methyl)-1H-indole-4-carboxamide;-   6-bromo-3-chloro-N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-1-(1-methylethyl)-1H-indole-4-carboxamide;-   3-chloro-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-6-(4-(morpholinomethyl)phenyl)-1H-indole-4-carboxamide;-   3-chloro-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-6-(3-fluoro-4-(morpholinomethyl)phenyl)-1-isopropyl-1H-indole-4-carboxamide;-   6-(4-((1H-pyrazol-1-yl)methyl)phenyl)-3-chloro-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-1H-indole-4-carboxamide;-   3-chloro-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-6-(2-fluorophenyl)-1-isopropyl-1H-indole-4-carboxamide;-   3-chloro-6-{4-[(dimethylamino)methyl]phenyl}-N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-1-(1-methylethyl)-1H-indole-4-carboxamide;-   3-chloro-N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-1-(1-methylethyl)-6-[6-(methyloxy)-3-pyridinyl]-1H-indole-4-carboxamide;-   3-chloro-N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-1-(1-methylethyl)-6-(3-pyridinyl)-1H-indole-4-carboxamide;-   3-chloro-6-{4-[(dimethylamino)methyl]phenyl}-1-(1-methylethyl)-N-[(6-methyl-2-oxo-4-propyl-1,2-dihydro-3-pyridinyl)methyl]-1H-indole-4-carboxamide;-   3-chloro-1-(1-methylethyl)-N-[(6-methyl-2-oxo-4-propyl-1,2-dihydro-3-pyridinyl)methyl]-6-[6-(methyloxy)-3-pyridinyl]-1H-indole-4-carboxamide;-   3-chloro-6-{4-[(dimethylamino)methyl]phenyl}-1-(1-methylethyl)-N-({6-methyl-4-[(methyloxy)methyl]-2-oxo-1,2-dihydro-3-pyridinyl}methyl)-1H-indole-4-carboxamide;-   3-chloro-1-(1-methylethyl)-N-({6-methyl-4-[(methyloxy)methyl]-2-oxo-1,2-dihydro-3-pyridinyl}methyl)-6-[6-(methyloxy)-3-pyridinyl]-1H-indole-4-carboxamide;-   3-chloro-1-isopropyl-N-((4-(methoxymethyl)-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-6-(pyridin-3-yl)-1H-indole-4-carboxamide;-   3-chloro-1-isopropyl-N-((6-methyl-2-oxo-4-propyl-1,2-dihydropyridin-3-yl)methyl)-6-(6-(4-methylpiperazin-1-yl)pyridin-3-yl)-1H-indole-4-carboxamide;-   3-chloro-N-((4-ethyl-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-6-(6-(4-methylpiperazin-1-yl)pyridin-3-yl)-1H-indole-4-carboxamide;-   3-chloro-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-6-(6-(4-methylpiperazin-1-yl)pyridin-3-yl)-1H-indole-4-carboxamide;-   3-chloro-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-6-(4-(trifluoromethyl)phenyl)-1H-indole-4-carboxamide;-   3-chloro-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-6-(6-(trifluoromethyl)pyridin-3-yl)-1H-indole-4-carboxamide;-   3-chloro-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-6-(3-fluorophenyl)-1-isopropyl-1H-indole-4-carboxamide;-   3-chloro-6-(3,5-difluorophenyl)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-1H-indole-4-carboxamide;-   3-chloro-6-(3,4-difluorophenyl)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-1H-indole-4-carboxamide;-   3-chloro-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-6-(4-fluoro-3-hydroxyphenyl)-1-isopropyl-1H-indole-4-carboxamide;-   3-chloro-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-6-(4-fluoro-3-methoxyphenyl)-1-isopropyl-1H-indole-4-carboxamide;-   3-chloro-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-6-(4-methoxyphenyl)-1H-indole-4-carboxamide;-   3-chloro-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-6-(3-methoxyphenyl)-1H-indole-4-carboxamide;-   3-chloro-6-(3-cyano-4-fluorophenyl)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-1H-indole-4-carboxamide;-   3-chloro-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-6-phenyl-1H-indole-4-carboxamide;-   3-chloro-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-6-(4-fluorophenyl)-1-isopropyl-1H-indole-4-carboxamide;-   3-chloro-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-6-(3-fluoro-4-morpholinophenyl)-1-isopropyl-1H-indole-4-carboxamide;-   3-chloro-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-6-(6-fluoropyridin-3-yl)-1-isopropyl-1H-indole-4-carboxamide;-   3-chloro-N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-1-(1-methylethyl)-6-(1H-pyrrolo[2,3-b]pyridin-5-yl)-1H-indole-4-carboxamide;-   3-chloro-1-(1-methylethyl)-N-[(6-methyl-2-oxo-4-propyl-1,2-dihydro-3-pyridinyl)methyl]-6-(1-methyl-1H-pyrazol-4-yl)-1H-indole-4-carboxamide;-   6-bromo-1-cyclopropyl-N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-3-methyl-1H-indole-4-carboxamide;-   6-bromo-3-chloro-1-cyclopentyl-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1H-indole-4-carboxamide;-   6-cyano-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-3-methyl-1H-indole-4-carboxamide;-   3-methyl-1-(1-methylethyl)-N-{[6-methyl-4-(1-methylethyl)-2-oxo-1,2-dihydro-3-pyridinyl]methyl}-6-[6-(4-methyl-1-piperazinyl)-3-pyridinyl]-1H-indole-4-carboxamide;-   6-(4-{[2-(dimethylamino)ethyl]oxy}phenyl)-N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-3-methyl-1-(1-methylethyl)-1H-indole-4-carboxamide;-   6-bromo-N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-3-fluoro-1-(1-methylethyl)-1H-indole-4-carboxamide;-   6-bromo-3-fluoro-1-(1-methylethyl)-N-[(6-methyl-2-oxo-4-propyl-1,2-dihydro-3-pyridinyl)methyl]-1H-indole-4-carboxamide;-   N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-3-fluoro-1-(1-methylethyl)-6-[6-(4-methyl-1-piperazinyl)-3-pyridinyl]-1H-indole-4-carboxamide;-   3-bromo-N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-1-(1-methylethyl)-6-[6-(4-methyl-1-piperazinyl)-3-pyridinyl]-1H-indole-4-carboxamide;-   3-fluoro-1-(1-methylethyl)-N-[(6-methyl-2-oxo-4-propyl-1,2-dihydro-3-pyridinyl)methyl]-6-[6-(4-methyl-1-piperazinyl)-3-pyridinyl]-1H-indole-4-carboxamide;-   3-methyl-1-(1-methylethyl)-N-[(6-methyl-2-oxo-4-propyl-1,2-dihydro-3-pyridinyl)methyl]-6-(4-pyridazinyl)-1H-indole-4-carboxamide;-   N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-3-methyl-1-(1-methylethyl)-6-(6-phenyl-3-pyridinyl)-1H-indole-4-carboxamide;-   6-[3-(aminomethyl)phenyl]-N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-3-methyl-1-(1-methylethyl)-1H-indole-4-carboxamide;-   N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-3-methyl-1-(1-methylethyl)-6-[5-(4-morpholinylcarbonyl)-3-pyridinyl]-1H-indole-4-carboxamide;-   3-methyl-1-(1-methylethyl)-N-{[6-methyl-4-(1-methylethyl)-2-oxo-1,2-dihydro-3-pyridinyl]methyl}-6-[6-(1-piperazinyl)-3-pyridinyl]-1H-indole-4-carboxamide;-   N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-6-(6-formyl-3-pyridinyl)-3-methyl-1-(1-methylethyl)-1H-indole-4-carboxamide;-   N-[(4-cyclopropyl-6-methyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-3-methyl-1-(1-methylethyl)-6-[6-(1-piperazinyl)-3-pyridinyl]-1H-indole-4-carboxamide;-   N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-3-methyl-6-[6-(4-methyl-1-piperazinyl)-3-pyridinyl]-1-(1-methylpropyl)-1H-indole-4-carboxamide;-   6-(4-(2-(dimethylamino)ethyl)phenyl)-1-isopropyl-3-methyl-N-((6-methyl-2-oxo-4-propyl-1,2-dihydropyridin-3-yl)methyl)-1H-indole-4-carboxamide;-   3,6-dibromo-N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-1-(1-methylethyl)-1H-indole-4-carboxamide;-   N-{[(1,1-dimethylethyl)oxy]carbonyl}-4-[4-({[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]amino}carbonyl)-3-methyl-1-(1-methylethyl)-1H-indol-6-yl]-L-phenylalanine;-   N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-6-[6-(1H-imidazol-1-ylmethyl)-3-pyridinyl]-3-methyl-1-(1-methylethyl)-1H-indole-4-carboxamide;-   N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-3-methyl-1-(1-methylethyl)-6-(5,6,7,8-tetrahydro-1,6-naphthyridin-3-yl)-1H-indole-4-carboxamide;-   N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-3-methyl-1-(1-methylethyl)-6-[2-(4-methyl-1-piperazinyl)-1,3-thiazol-5-yl]-1H-indole-4-carboxamide;-   N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-6-{6-[(9aS)-hexahydropyrazino[2,1-c][1,4]oxazin-8(1H)-yl]-3-pyridinyl}-3-methyl-1-(1-methylethyl)-1H-indole-4-carboxamide;-   3-methyl-1-(1-methylethyl)-N-[(6-methyl-2-oxo-4-propyl-1,2-dihydro-3-pyridinyl)methyl]-6-(5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)-1H-indole-4-carboxamide;-   6-[6-(4-ethyl-1-piperazinyl)-3-pyridinyl]-3-methyl-1-(1-methylethyl)-N-[(6-methyl-2-oxo-4-propyl-1,2-dihydro-3-pyridinyl)methyl]-1H-indole-4-carboxamide;-   N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-3-methyl-6-[6-(4-methyl-1-piperazinyl)-3-pyridinyl]-1-(1-methylpropyl)-1H-indole-4-carboxamide;-   3-methyl-1-(1-methyl    ethyl)-6-{6-[4-(1-methylethyl)-1-piperazinyl]-3-pyridinyl}-N-[(6-methyl-2-oxo-4-propyl-1,2-dihydro-3-pyridinyl)methyl]-1H-indole-4-carboxamide;-   N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-3-methyl-1-(1-methylethyl)-6-[6-(4-morpholinylmethyl)-2-pyridinyl]-1H-indole-4-carboxamide;-   N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-3-methyl-1-(1-methylethyl)-6-[6-(4-morpholinyl)-2-pyridinyl]-1H-indole-4-carboxamide;-   N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-3-methyl-1-(1-methylethyl)-6-(6-methyl-2-pyridinyl)-1H-indole-4-carboxamide;-   N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-3-methyl-1-(1-methylethyl)-6-[2-(4-morpholinyl)-4-pyrimidinyl]-1H-indole-4-carboxamide;-   N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-3-methyl-1-(1-methylethyl)-6-(2-pyrimidinyl)-1H-indole-4-carboxamide;-   6-{6-[(dimethylamino)methyl]-2-pyridinyl}-N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-3-methyl-1-(1-methylethyl)-1H-indole-4-carboxamide;-   6-(6-amino-2-pyridinyl)-N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-3-methyl-1-(1-methylethyl)-1H-indole-4-carboxamide;-   6-[2-amino-6-(4-morpholinyl)-4-pyrimidinyl]-N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-3-methyl-1-(1-methylethyl)-1H-indole-4-carboxamide;-   N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-3-methyl-6-[2-(methylamino)-4-pyrimidinyl]-1-(1-methylethyl)-1H-indole-4-carboxamide;-   N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-3-methyl-1-(1-methylethyl)-6-(4-pyrimidinyl)-1H-indole-4-carboxamide;-   N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-6-[2-(ethylamino)-4-pyrimidinyl]-3-methyl-1-(1-methylethyl)-1H-indole-4-carboxamide;-   6-(2-amino-4-pyrimidinyl)-N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-3-methyl-1-(1-methylethyl)-1H-indole-4-carboxamide;-   6-(1H-benzimidazol-5-yl)-N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-3-methyl-1-(1-methylethyl)-1H-indole-4-carboxamide;-   6-(3-amino-1H-indazol-6-yl)-N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-3-methyl-1-(1-methylethyl)-1H-indole-4-carboxamide;-   N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-3-methyl-1-(1-methylethyl)-6-(1-methyl-1H-indazol-6-yl)-1H-indole-4-carboxamide;-   N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-3-methyl-1-(1-methylethyl)-6-(5-methyl-1H-indazol-6-yl)-1H-indole-4-carboxamide;-   N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-6-[6-(4-ethyl-1-piperazinyl)-3-pyridinyl]-3-methyl-1-(1-methylethyl)-1H-indole-4-carboxamide;-   N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-3-methyl-1-(1-methylethyl)-6-{6-[4-(1-methylethyl)-1-piperazinyl]-3-pyridinyl}-1H-indole-4-carboxamide;-   6-chloro-3-methyl-1-(1-methylethyl)-N-{[6-methyl-4-(1-methylpropyl)-2-oxo-1,2-dihydro-3-pyridinyl]methyl}-1H-indole-4-carboxamide;-   6-bromo-3-methyl-1-(1-methylethyl)-N-{[6-methyl-4-(1-methylpropyl)-2-oxo-1,2-dihydro-3-pyridinyl]methyl}-1H-indole-4-carboxamide;-   3-methyl-1-(1-methylethyl)-N-{[6-methyl-4-(1-methylpropyl)-2-oxo-1,2-dihydro-3-pyridinyl]methyl}-6-[6-(4-methyl-1-piperazinyl)-3-pyridinyl]-1H-indole-4-carboxamide;-   6-(6-chloro-3-pyridinyl)-N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-3-methyl-1-(1-methylethyl)-1H-indole-4-carboxamide;-   N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-6-[6-(1H-imidazol-1-yl)-3-pyridinyl]-3-methyl-1-(1-methylethyl)-1H-indole-4-carboxamide;-   6-[6-(4-cyclopropyl-1-piperazinyl)-3-pyridinyl]-N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-3-methyl-1-(1-methylethyl)-1H-indole-4-carboxamide;-   6-bromo-N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-3-methyl-1-(1-methylpropyl)-1H-indole-4-carboxamide;-   6-{6-[2-(dimethylamino)ethyl]-3-pyridinyl}-N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-3-methyl-1-(1-methylethyl)-1H-indole-4-carboxamide;-   6-{3-[(dimethylamino)methyl]phenyl}-N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-3-methyl-1-(1-methylpropyl)-1H-indole-4-carboxamide;-   N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-3-methyl-6-[6-(4-methyl-1-piperazinyl)-3-pyridinyl]-1-(1-methylpropyl)-1H-indole-4-carboxamide;-   N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-6-{6-[(3R,5S)-3,5-dimethyl-1-piperazinyl]-3-pyridinyl}-3-methyl-1-(1-methylethyl)-1H-indole-4-carboxamide;-   6-{6-[3-(dimethylamino)-1-pyrrolidinyl]-3-pyridinyl}-N-[(4,6-di    methyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-3-methyl-1-(1-methylethyl)-1H-indole-4-carboxamide;-   N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-3-methyl-1-(1-methylpropyl)-6-[6-(1-piperazinyl)-3-pyridinyl]-1H-indole-4-carboxamide;-   N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-3-methyl-1-(1-methylethyl)-6-[6-(4-methylhexahydro-1H-1,4-diazepin-1-yl)-3-pyridinyl]-1H-indole-4-carboxamide;-   N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-3-methyl-1-(1-methylethyl)-6-[6-(4-piperidinyl)-3-pyridinyl]-1H-indole-4-carboxamide;-   6-bromo-1-isopropyl-N-((6-methyl-2-oxo-4-((6-(trifluoromethyl)pyridin-2-yl)methyl)-1,2-dihydropyridin-3-yl)methyl)-1H-indole-4-carboxamide;-   N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-3-methyl-6-(pyridazin-4-yl)-1H-indole-4-carboxamide;-   N-[(6-amino-4-methyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-6-chloro-3-methyl-1-(1-methylethyl)-1H-indole-4-carboxamide;-   N-[(6-amino-4-methyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-6-bromo-3-methyl-1-(1-methylethyl)-1H-indole-4-carboxamide;-   6-bromo-N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-3-methyl-1-[(3R)-tetrahydro-3-furanyl]-1H-indole-4-carboxamide;-   6-bromo-3-methyl-1-(1-methylethyl)-N-{[6-methyl-2-oxo-4-(1H-pyrazol-1-ylmethyl)-1,2-dihydro-3-pyridinyl]methyl}-1H-indole-4-carboxamide;-   6-bromo-1-(1-methylethyl)-N-{[6-methyl-2-oxo-4-(1H-pyrazol-1-ylmethyl)-1,2-dihydro-3-pyridinyl]methyl}-1H-indole-4-carboxamide;-   3-methyl-1-(1-methylethyl)-N-[(6-methyl-2-oxo-4-propyl-1,2-dihydro-3-pyridinyl)methyl]-6-(3-pyridinyl)-1H-indole-4-carboxamide;-   6-[(aminocarbonyl)amino]-N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-3-methyl-1-(1-methylethyl)-1H-indole-4-carboxamide;-   1-cyclopentyl-N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-3-methyl-6-[6-(4-methyl-1-piperazinyl)-3-pyridinyl]-1H-indole-4-carboxamide;-   N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-3-methyl-1-(1-methylpropyl)-6-[6-(1-piperazinyl)-3-pyridinyl]-1H-indole-4-carboxamide;-   N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-3-methyl-1-(1-methylpropyl)-6-[6-(1-piperazinyl)-3-pyridinyl]-1H-indole-4-carboxamide;-   1-cyclopentyl-N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-3-methyl-6-[6-(1-piperazinyl)-3-pyridinyl]-1H-indole-4-carboxamide;-   6-bromo-N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-3-methyl-1-[(1R)-1-methyl-2-(methyloxy)ethyl]-1H-indole-4-carboxamide;-   N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-3-methyl-1-[(1S)-1-methyl-2-(methyloxy)ethyl]-6-[6-(1-piperazinyl)-3-pyridinyl]-1H-indole-4-carboxamide;-   N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-3-methyl-1-[(1S)-1-methyl-2-(methyloxy)ethyl]-6-[6-(4-methyl-1-piperazinyl)-3-pyridinyl]-1H-indole-4-carboxamide;-   6-bromo-N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-3-methyl-1-[(1S)-1-methyl-2-(methyloxy)ethyl]-1H-indole-4-carboxamide;-   N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-3-methyl-6-{6-[(methylamino)methyl]-3-pyridinyl}-1-(1-methylethyl)-1H-indole-4-carboxamide;-   6-[6-(2,6-dimethyl-4-morpholinyl)-3-pyridinyl]-N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-3-methyl-1-(1-methylethyl)-1H-indole-4-carboxamide;-   N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-3-methyl-1-(1-methylethyl)-6-[6-(2-methyl-4-morpholinyl)-3-pyridinyl]-1H-indole-4-carboxamide;-   3-methyl-1-(1-methylethyl)-N-[(6-methyl-2-oxo-4-propyl-1,2-dihydro-3-pyridinyl)methyl]-6-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)-1H-indole-4-carboxamide;-   N-[(6-amino-4-methyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-3-methyl-6-[6-(4-methyl-1-piperazinyl)-3-pyridinyl]-1-(1-methylpropyl)-1H-indole-4-carboxamide;-   N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-3-methyl-6-(pyridazin-4-yl)-1H-indole-4-carboxamide;-   N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-3-fluoro-1-isopropyl-6-(6-(4-methylpiperazin-1-yl)pyridin-3-yl)-1H-indole-4-carboxamide;-   (R)—N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-3-methyl-6-(6-(4-methylpiperazin-1-yl)pyridin-3-yl)-1-(tetrahydrofuran-3-yl)-1H-indole-4-carboxamide;-   (S)—N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-(1-methoxypropan-2-yl)-3-methyl-6-(6-(piperazin-1-yl)pyridin-3-yl)-1H-indole-4-carboxamide;-   6-bromo-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-(1-(dimethylamino)propan-2-yl)-3-methyl-1H-indole-4-carboxamide;-   N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-3-methyl-6-(1H-pyrazolo[3,4-b]pyridin-5-yl)-1H-indole-4-carboxamide;-   N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-(2-(dimethylamino)propyl)-3-methyl-6-(6-(piperazin-1-yl)pyridin-3-yl)-1H-indole-4-carboxamide;-   6-bromo-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-3-methyl-1-(pentan-2-yl)-1H-indole-4-carboxamide;-   N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-6-(2-methoxypyrimidin-4-yl)-3-methyl-1H-indole-4-carboxamide;-   N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-3-methyl-6-(1H-pyrazolo[4,3-c]pyridin-6-yl)-1H-indole-4-carboxamide;-   6-methyl-3-({2-[3-methyl-1-(1-methylethyl)-6-(1,2,3,6-tetrahydro-4-pyridinyl)-1H-indol-4-yl]-2-oxoethyl}amino)-4-propyl-2(1H)-pyridinone;-   6-(1H-benzo[d]imidazol-2-yl)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-3-methyl-1H-indole-4-carboxamide;-   N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-(2-(dimethylamino)propyl)-3-methyl-6-(6-(4-methylpiperazin-1-yl)pyridin-3-yl)-1H-indole-4-carboxamide;-   N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-3-methyl-6-(2-methylpyrimidin-4-yl)-1H-indole-4-carboxamide;-   6-bromo-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-3-methyl-1-(tetrahydro-2H-pyran-4-yl)-1H-indole-4-carboxamide;-   6-bromo-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-(2-(dimethylamino)propyl)-3-methyl-1H-indole-4-carboxamide;-   N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-3-methyl-6-(6-(4-methylpiperazin-1-yl)pyridin-3-yl)-1H-indole-4-carboxamide;-   N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-3-methyl-1-(1-methylethyl)-6-[6-(1-piperazinyl)-3-pyridinyl]-1H-indole-4-carboxamide;-   6-bromo-1-(sec-butyl)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-3-methyl-1H-indole-4-carboxamide;-   (R)-6-Bromo-1-(sec-butyl)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-3-methyl-1H-indole-4-carboxamide;    and    (S)-6-bromo-1-(sec-butyl)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-3-methyl-1H-indole-4-carboxamide;-   1-(sec-butyl)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-3-methyl-6-(6-(piperazin-1-yl)pyridin-3-yl)-1H-indole-4-carboxamide;-   N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-3-methyl-1-[(1S)-1-methylpropyl]-6-[6-(1-piperazinyl)-3-pyridinyl]-1H-indole-4-carboxamide;-   N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-3-methyl-1-[(1R)-1-methylpropyl]-6-[6-(1-piperazinyl)-3-pyridinyl]-1H-indole-4-carboxamide;-   1-(sec-Butyl)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-6-(3-((dimethylamino)methyl)phenyl)-3-methyl-1H-indole-4-carboxamide;-   6-{3-[(Dimethylamino)methyl]phenyl}-N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-3-methyl-1-[(1S)-1-methylpropyl]-1H-indole-4-carboxamide;-   6-{3-[(dimethylamino)methyl]phenyl}-N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-3-methyl-1-[(1R)-1-methylpropyl]-1H-indole-4-carboxamide;-   1-cyclopentyl-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-3-methyl-6-(6-(piperazin-1-yl)pyridin-3-yl)-1H-indole-4-carboxamide;-   1-isopropyl-N-((6-methyl-2-oxo-4-propyl-1,2-dihydropyridin-3-yl)methyl)-6-(6-(piperazin-1-yl)pyridin-3-yl)-1H-indole-4-carboxamide;-   1-isopropyl-3-methyl-N-((6-methyl-2-oxo-4-propyl-1,2-dihydropyridin-3-yl)methyl)-6-(4-(2-oxopiperazin-1-yl)phenyl)-1H-indole-4-carboxamide;-   N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-3-methyl-6-(6-(piperazin-1-yl)pyridin-3-yl)-1H-indole-4-carboxamide;-   N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-3-methyl-6-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)-1H-indole-4-carboxamide;-   6-methyl-3-[(2-{3-methyl-1-(1-methylethyl)-6-[6-(1-piperazinyl)-3-pyridinyl]-1H-indol-4-yl}-2-oxoethyl)amino]-4-propyl-2(1H)-pyridinone;-   N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-3-methyl-6-(2-(piperazin-1-yl)pyrimidin-5-yl)-1H-indole-4-carboxamide;-   3-methyl-1-(1-methylethyl)-N-[(6-methyl-2-oxo-4-propyl-1,2-dihydro-3-pyridinyl)methyl]-6-(1H-pyrazol-4-yl)-1H-indole-4-carboxamide;-   N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-3-methyl-6-(5-(piperazin-1-yl)pyridin-3-yl)-1H-indole-4-carboxamide;-   4-[4-({[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]amino}carbonyl)-3-methyl-1-(1-methylethyl)-1H-indol-6-yl]-L-phenylalanine;-   6-[6-(aminomethyl)-3-pyridinyl]-N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-3-methyl-1-(1-methylethyl)-1H-indole-4-carboxamide;-   N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-3-methyl-1-(1-methylethyl)-6-[6-(3-methyl-1-piperazinyl)-3-pyridinyl]-1H-indole-4-carboxamide;-   4-[4-({[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]amino}carbonyl)-3-methyl-1-(1-methylethyl)-1H-indol-6-yl]benzoic    acid;-   3-[3-methyl-1-(1-methylethyl)-4-({[(6-methyl-2-oxo-4-propyl-1,2-dihydro-3-pyridinyl)methyl]amino}carbonyl)-1H-indol-6-yl]benzoic    acid;-   5-[3-methyl-1-(1-methylethyl)-4-({[(6-methyl-2-oxo-4-propyl-1,2-dihydro-3-pyridinyl)methyl]amino}carbonyl)-1H-indol-6-yl]-2-pyridinecarboxylic    acid;-   N-[(4,6-Dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-1-(1-methylethyl)-1H-indole-4-carboxamide;-   N-((4-benzyl-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-1H-indole-4-carboxamide;-   N-((4-benzyl-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-3-methyl-1H-indole-4-carboxamide;-   1-cyclopentyl-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-3-methyl-1H-indole-4-carboxamide;-   6-methyl-3-({2-[3-methyl-1-(1-methylethyl)-6-(4-piperidinyl)-1H-indol-4-yl]-2-oxoethyl}amino)-4-propyl-2(1H)-pyridinone;-   N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-3-methyl-1-(1-methylethyl)-6-[6-(2-piperidinyl)-3-pyridinyl]-1H-indole-4-carboxamide;-   N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-3-methyl-1-(1-methylethyl)-1H-indole-4-carboxamide;-   1-cyclopropyl-N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-3-methyl-6-(methylsulfonyl)-1H-indole-4-carboxamide;-   1-cyclopentyl-6-(cyclopropylsulfonyl)-N-[(4,6-di    methyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-3-methyl-1H-indole-4-carboxamide;-   1-cyclopentyl-N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-3-methyl-6-(methylsulfonyl)-1H-indole-4-carboxamide;-   3-({2-[6-(cyclopropylsulfonyl)-3-methyl-1-(1-methylethyl)-1H-indol-4-yl]-2-oxoethyl}amino)-4,6-dimethyl-2(1H)-pyridinone;-   3-({2-[6-(cyclopropylsulfonyl)-3-methyl-1-(1-methylethyl)-1H-indol-4-yl]-2-oxoethyl}amino)-4,6-dimethyl-2(1H)-pyridinone;-   1-cyclopentyl-6-(cyclopropylsulfonyl)-N-[(4,6-di    methyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-3-methyl-1H-indole-4-carboxamide;-   1-cyclopentyl-N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-3-methyl-6-(methylsulfonyl)-1H-indole-4-carboxamide;-   N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-1-(1-methylethyl)-6-(trifluoromethyl)-1H-indole-4-carboxamide;-   1-Isopropyl-N-((6-methyl-2-oxo-4-propyl-1,2-dihydropyridin-3-yl)methyl)-6-(trifluoromethyl)-1H-indole-4-carboxamide;-   N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-6-(4-((dimethylamino)methyl)piperidin-1-yl)-1-isopropyl-3-methyl-1H-indole-4-carboxamide;-   N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-6-(3-((dimethylamino)methyl)pyrrolidin-1-yl)-1-isopropyl-3-methyl-1H-indole-4-carboxamide;-   1-cyclopentyl-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-6-(pyrrolidin-1-yl)-1H-indole-4-carboxamide;-   6-(1,1-dioxidothiomorpholino)-1-isopropyl-3-methyl-N-((6-methyl-2-oxo-4-propyl-1,2-dihydropyridin-3-yl)methyl)-1H-indole-4-carboxamide;-   N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-3-methyl-6-(pyridin-3-ylamino)-1H-indole-4-carboxamide;-   N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-6-(4-(4-fluorophenyl)piperidin-1-yl)-1-isopropyl-3-methyl-1H-indole-4-carboxamide;-   N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-3-methyl-6-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)-1H-indole-4-carboxamide;-   N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-3-methyl-6-(4-(1-methylpiperidin-4-yl)piperazin-1-yl)-1H-indole-4-carboxamide;-   N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-6-(4-fluoropiperidin-1-yl)-1-isopropyl-3-methyl-1H-indole-4-carboxamide;-   N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-6-(4-(3-fluorophenyl)piperidin-1-yl)-1-isopropyl-3-methyl-1H-indole-4-carboxamide;-   N-[(4-ethyl-6-methyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-3-methyl-1-(1-methylethyl)-6-(4-morpholinyl)-1H-indole-4-carboxamide;-   N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-3-methyl-1-(1-methylethyl)-6-(4-morpholinyl)-1H-indole-4-carboxamide;-   N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-3-methyl-1-(1-methylethyl)-6-{[3-methyl-1-(1-methylethyl)-1H-pyrazol-5-yl]amino}-1H-indole-4-carboxamide;-   6-(2-dimethylamino-ethoxy)-1-isopropyl-1H-indole-4-carboxylic acid    (6-methyl-2-oxo-4-propyl-1,2-dihydro-pyridin-3-ylmethyl)-amide;-   1-isopropyl-6-[2-(4-methyl-piperazin-1-yl)-ethoxy]-1H-indole-4-carboxylic    acid (6-methyl-2-oxo-4-propyl-1,2-dihydro-pyridin-3-ylmethyl)-amide;-   1-isopropyl-6-(2-morpholin-4-yl-ethoxy)-1H-indole-4-carboxylic acid    (6-methyl-2-oxo-4-propyl-1,2-dihydro-pyridin-3-ylmethyl)-amide;-   1-Isopropyl-6-(2-piperazin-1-yl-ethoxy)-1H-indole-4-carboxylic acid    (6-methyl-2-oxo-4-propyl-1,2-dihydro-pyridin-3-ylmethyl)-amide;-   N-{[4-(ethylamino)-6-methyl-2-oxo-1,2-dihydro-3-pyridinyl]methyl}-1-(1-methylethyl)-6-[6-(4-methyl-1-piperazinyl)-3-pyridinyl]-1H-indole-4-carboxamide;-   6-bromo-N-{[4-(ethylamino)-6-methyl-2-oxo-1,2-dihydro-3-pyridinyl]methyl}-1-(1-methylethyl)-1H-indole-4-carboxamide;-   6-bromo-1-(1-methylethyl)-N-{[6-methyl-2-oxo-4-(1-pyrrolidinyl)-1,2-dihydro-3-pyridinyl]methyl}-1H-indole-4-carboxamide;-   6-bromo-1-(1-methylethyl)-N-{[6-methyl-2-oxo-4-(phenylamino)-1,2-dihydro-3-pyridinyl]methyl}-1H-indole-4-carboxamide;-   N-((6-amino-4-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-6-bromo-1-isopropyl-3-methyl-1H-indole-4-carboxamide;-   N-((6-amino-4-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-6-chloro-1-isopropyl-3-methyl-1H-indole-4-carboxamide;-   N-[(6-amino-4-methyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-3-methyl-1-(1-methylethyl)-6-[6-(4-methyl-1-piperazinyl)-3-pyridinyl]-1H-indole-4-carboxamide;-   N-[(6-amino-4-methyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-6-{3-[(di    methylamino)methyl]phenyl}-3-methyl-1-(1-methylethyl)-1H-indole-4-carboxamide;-   N-[(6-amino-4-methyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-6-bromo-3-methyl-1-(1-methylpropyl)-1H-indole-4-carboxamide;-   N-[(6-amino-4-methyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-6-bromo-3-methyl-1-(1-methylpropyl)-1H-indole-4-carboxamide;-   N-[(6-amino-4-methyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-6-bromo-3-methyl-1-(1-methylpropyl)-1H-indole-4-carboxamide;-   N-[(6-amino-4-methyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-3-methyl-6-[6-(4-methyl-1-piperazinyl)-3-pyridinyl]-1-(1-methylpropyl)-1H-indole-4-carboxamide;-   N-((6-amino-2-oxo-4-propyl-1,2-dihydropyridin-3-yl)methyl)-6-bromo-1-isopropyl-3-methyl-1H-indole-4-carboxamide;-   6-bromo-1-isopropyl-3-methyl-N-((4-methyl-6-(methylamino)-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1H-indole-4-carboxamide;-   N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-3-methyl-1-(1-methylethyl)-6-{6-[(2R)-2-methyl-1-piperazinyl]-3-pyridinyl}-1H-indole-4-carboxamide;-   N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-6-[6-(3,4-dimethyl-1-piperazinyl)-3-pyridinyl]-3-methyl-1-(1-methylethyl)-1H-indole-4-carboxamide;-   N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-6-[6-(hexahydropyrrolo[3,4-b]pyrrol-5(1H)-yl)-3-pyridinyl]-3-methyl-1-(1-methylethyl)-1H-indole-4-carboxamide;-   N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-6-[6-(hexahydropyrrolo[3,4-b]pyrrol-5(1H)-yl)-3-pyridinyl]-3-methyl-1-(1-methylethyl)-1H-indole-4-carboxamide;-   N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-6-[6-(3,3-dimethyl-1-piperazinyl)-3-pyridinyl]-3-methyl-1-(1-methylethyl)-1H-indole-4-carboxamide;-   N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-3-methyl-1-(1-methylethyl)-6-{6-[(2S)-2-methyl-1-piperazinyl]-3-pyridinyl}-1H-indole-4-carboxamide;-   N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-6-[6-(hexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl)-3-pyridinyl]-3-methyl-1-(1-methylethyl)-1H-indole-4-carboxamide;-   6-{6-[(1S,4S)-2,5-diazabicyclo[2.2.1]hept-2-yl]-3-pyridinyl}-N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-3-methyl-1-(1-methylethyl)-1H-indole-4-carboxamide;-   6-{6-[(1R,4R)-2,5-diazabicyclo[2.2.1]hept-2-yl]-3-pyridinyl}-N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-3-methyl-1-(1-methylethyl)-1H-indole-4-carboxamide;-   N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-6-{6-[(2S,5S)-2,5-dimethyl-1-piperazinyl]-3-pyridinyl}-3-methyl-1-(1-methylethyl)-1H-indole-4-carboxamide;-   6-[6-(3,8-diazabicyclo[3.2.1]oct-3-yl)-3-pyridinyl]-N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-3-methyl-1-(1-methylethyl)-1H-indole-4-carboxamide;-   N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-6-(6-((2R,5R)-2,5-dimethylpiperazin-1-yl)pyridin-3-yl)-1-isopropyl-3-methyl-1H-indole-4-carboxamide;-   N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-3-methyl-6-(6-(pyrrolidin-1-ylmethyl)pyridin-3-yl)-1H-indole-4-carboxamide;-   6-(6-{[(2R,6S)-2,6-dimethyl-4-morpholinyl]methyl}-3-pyridinyl)-N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-3-methyl-1-(1-methylethyl)-1H-indole-4-carboxamide;-   N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-3-methyl-1-(1-methylethyl)-6-{6-[(4-methyl-1-piperazinyl)methyl]-3-pyridinyl}-1H-indole-4-carboxamide;-   N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-3-methyl-1-(1-methylethyl)-6-[6-(4-morpholinylmethyl)-3-pyridinyl]-1H-indole-4-carboxamide;-   6-Bromo-N-((6-(hydroxymethyl)-4-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-3-methyl-1H-indole-4-carboxamide;-   N-((6-(aminomethyl)-4-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-6-bromo-1-isopropyl-3-methyl-1H-indole-4-carboxamide;-   3-Methyl-1-(1-methylethyl)-4-({[(6-methyl-2-oxo-4-propyl-1,2-dihydro-3-pyridinyl)methyl]amino}carbonyl)-1H-indole-6-carboxylic    acid;-   3-[3-methyl-1-(1-methylethyl)-4-({[(6-methyl-2-oxo-4-propyl-1,2-dihydro-3-pyridinyl)methyl]amino}carbonyl)-1H-indol-6-yl]propanoic    acid;-   6-(2-Aminoethyl)-N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-3-methyl-1-(1-methylethyl)-1H-indole-4-carboxamide;-   6-{3-[(dimethylamino)methyl]-4-fluorophenyl}-N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-3-methyl-1-(1-methylethyl)-1H-indole-4-carboxamide;-   6-(4,5-Dihydro-1H-imidazol-2-yl)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-3-methyl-1H-indole-4-carboxamide;-   [4-({[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]amino}carbonyl)-3-methyl-1-(1-methylethyl)-1H-indol-6-yl]boronic    acid;-   N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-6-[6-(hydroxymethyl)-3-pyridinyl]-3-methyl-1-(1-methylethyl)-1H-indole-4-carboxamide;-   N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-3-methyl-1-(1-methylethyl)-6-(3-oxetanyl)-1H-indole-4-carboxamide;-   N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-3-methyl-1-(1-methylethyl)-6-{[6-(4-methyl-1-piperazinyl)-3-pyridinyl]amino}-1H-indole-4-carboxamide;-   N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-3-methyl-1-(1-methylethyl)-6-{[(4-methyl-1-piperazinyl)carbonyl]amino}-1H-indole-4-carboxamide;-   6-{[3-(dimethylamino)propyl]thio}-N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-3-methyl-1-(1-methylethyl)-1H-indole-4-carboxamide;-   N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-6-(3-hydroxy-3-methyl-1-butyn-1-yl)-3-methyl-1-(1-methylethyl)-1H-indole-4-carboxamide;-   6-(3-hydroxy-3-methyl-1-butyn-1-yl)-3-methyl-1-(1-methyl    ethyl)-N-[(6-methyl-2-oxo-4-propyl-1,2-dihydro-3-pyridinyl)methyl]-1H-indole-4-carboxamide;-   6-(cyclopropylethynyl)-3-methyl-1-(1-methylethyl)-N-[(6-methyl-2-oxo-4-propyl-1,2-dihydro-3-pyridinyl)methyl]-1H-indole-4-carboxamide;-   N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-7-methyl-1-(1-methylethyl)-1H-indole-4-carboxamide;-   7-Methyl-1-(1-methylethyl)-N-[(6-methyl-2-oxo-4-propyl-1,2-dihydro-3-pyridinyl)methyl]-1H-indole-4-carboxamide;-   1-(1-Methylethyl)-N-[(6-methyl-2-oxo-4-propyl-1,2-dihydro-3-pyridinyl)methyl]-7-(methyloxy)-1H-indole-4-carboxamide;-   N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-1-(1-methylethyl)-7-(methyloxy)-1H-indole-4-carboxamide;-   6-chloro-1-isopropyl-2,3-dimethyl-N-((6-methyl-2-oxo-4-propyl-1,2-dihydropyridin-3-yl)methyl)-1H-indole-4-carboxamide;-   6-Chloro-2-((dimethylamino)methyl)-1-isopropyl-3-methyl-N-((6-methyl-2-oxo-4-propyl-1,2-dihydropyridin-3-yl)methyl)-1H-indole-4-carboxamide;    and-   2-(2-aminoethyl)-6-chloro-1-isopropyl-3-methyl-N-((6-methyl-2-oxo-4-propyl-1,2-dihydropyridin-3-yl)methyl)-1H-indole-4-carboxamide,    or a pharmaceutically acceptable salt thereof

As used herein, the term “optionally” means that the subsequentlydescribed event(s) may or may not occur, and includes both event(s) thatoccur and event(s) that do not occur.

As used herein, unless otherwise defined, the phrase “optionallysubstituted” or variations thereof denote an optional substitution,including multiple degrees of substitution, with one or moresubstitutent group. The phrase should not be interpreted as duplicativeof the substitutions herein described and depicted. Exemplary optionalsubstituent groups include acyl, C₁-C₆alkyl, C₁-C₃alkylsulfonyl,C₁-C₃alkoxy, C₁-C₃alkoxycarbonyl, cyano, halogen, haloalkyl, hydroxyl,oxo, and nitro.

The term “independently” means that where more than one substituent isselected from a number of possible substituents, those substituents maybe the same or different.

An “effective amount” means that amount of a drug or pharmaceuticalagent that will elicit the biological or medical response of a tissue,system, animal or human that is being sought, for instance, by aresearcher or clinician. Furthermore, the term “therapeuticallyeffective amount” means any amount which, as compared to a correspondingsubject who has not received such amount, results in improved treatment,healing, prevention, or amelioration of a disease, disorder, or sideeffect, or a decrease in the rate of advancement of a disease ordisorder. The term also includes within its scope amounts effective toenhance normal physiological function.

As used herein the term “alkyl” refers to a straight- or branched-chainhydrocarbon radical having the specified number of carbon atoms, so forexample, as used herein, the terms “C₁-C₈alkyl” refers to an alkyl grouphaving at least 1 and up to 8 carbon atoms respectively. Examples ofsuch branched or straight-chained alkyl groups useful in the presentinvention include, but are not limited to, methyl, ethyl, n-propyl,isopropyl, isobutyl, n-butyl, t-butyl, n-pentyl, isopentyl, n-hexyl,n-heptyl, and n-octyl and branched analogs of the latter 5 normalalkanes.

The term “alkoxy” as used herein means —O(C₁-C₈alkyl) including —OCH₃,—OCH₂CH₃ and —OC(CH₃)₃ and the like per the definition of alkyl above.

The term “alkylthio” as used herein is meant —S(C₁-C₈alkyl) including—SCH₃, —SCH₂CH₃ and the like per the definition of alkyl above.

The term “acyloxy” means —OC(O)C₁-C₈alkyl and the like per thedefinition of alkyl above.

“Acylamino” means-N(H)C(O)C₁-C₈alkyl and the like per the definition ofalkyl above.

“Aryloxy” means —O(aryl), —O(substituted aryl), —O(heteroaryl) or—O(substituted heteroaryl).

“Arylamino” means —NH(aryl), —NH(substituted aryl), —NH(heteroaryl) or—NH(substituted heteroaryl), and the like.

When the term “alkenyl” (or “alkenylene”) is used it refers to straightor branched hydrocarbon chains containing the specified number of carbonatoms and at least 1 and up to 5 carbon-carbon double bonds. Examplesinclude ethenyl (or ethenylene) and propenyl (or propenylene).

When the term “alkynyl” (or “alkynylene”) is used it refers to straightor branched hydrocarbon chains containing the specified number of carbonatoms and at least 1 and up to 5 carbon-carbon triple bonds. Examplesinclude ethynyl (or ethynylene) and propynyl (or propynylene).

“Haloalkyl” refers to an alkyl group that is substituted with one ormore halo substituents, suitably from 1 to 6 substituents. Haloalkylincludes trifluoromethyl.

When “cycloalkyl” is used it refers to a non-aromatic, saturated, cyclichydrocarbon ring containing the specified number of carbon atoms. So,for example, the term “C₃-C₈cycloalkyl” refers to a non-aromatic cyclichydrocarbon ring having from three to eight carbon atoms. Exemplary“C₃-C₈cycloalkyl” groups useful in the present invention include, butare not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl,cycloheptyl and cyclooctyl.

The term “C₅-C₈cycloalkenyl” refers to a non-aromatic monocycliccarboxycyclic ring having the specified number of carbon atoms and up to3 carbon-carbon double bonds. “Cycloalkenyl” includes by way of examplecyclopentenyl and cyclohexenyl.

Where “C₃-C₈heterocycloalkyl” is used, it means a non-aromaticheterocyclic ring containing the specified number of ring atoms being,saturated or having one or more degrees of unsaturation and containingone or more heteroatom substitutions independently selected from O, Sand N. Such a ring may be optionally fused to one or more other“heterocyclic” ring(s) or cycloalkyl ring(s). Examples are given hereinbelow.

As used herein, the term “aryl”, unless otherwise defined, is meantaromatic, hydrocarbon, ring system. The ring system may be monocyclic orfused polycyclic (e.g., bicyclic, tricyclic, etc.), substituted orunsubstituted. In various embodiments, the monocyclic aryl ring isC5-C10, or C5-C7, or C5-C6, where these carbon numbers refer to thenumber of carbon atoms that form the ring system. A C6 ring system, i.e.a phenyl ring, is a suitable aryl group. In various embodiments, thepolycyclic ring is a bicyclic aryl group, where suitable bicyclic arylgroups are C8-C12, or C9-C10. A naphthyl ring, which has 10 carbonatoms, is a suitable polycyclic aryl group. Suitable substituents foraryl, unless otherwise defined, are described below in the definition of“optionally substituted”.

As used herein, the term “heteroaryl”, unless otherwise defined, ismeant an aromatic ring system containing carbon(s) and at least oneheteroatom. Heteroaryl may be monocyclic or polycyclic, substituted orunsubstituted. A monocyclic heteroaryl group may have 1 to 4 heteroatomsin the ring, while a polycyclic heteroaryl may contain 1 to 10 heteroatoms. A polycyclic heteroaryl ring may contain fused, spiro or bridgedring junctions, for example, bicyclic heteroaryl is a polycyclicheteroaryl. Bicyclic heteroaryl rings may contain from 8 to 12 memberatoms. Monocyclic heteroaryl rings may contain from 5 to 8 member atoms(carbons and heteroatoms). Exemplary heteroaryl groups includebenzofuran, benzothiophene, furan, imidazole, indole, isothiazole,oxazole, pyrazine, pyrazole, pyridazine, pyridine, pyrimidine, pyrrole,quinoline, quinazoline, quinoxaline, thiazole, and thiophene. Suitablesubstituents for heteroaryl, unless otherwise defined are describedbelow in the definition of “optionally substituted”

Provided herein are methods of treatment or prevention of autoimmune andinflammatory conditions and diseases that can be improved by inhibitingEZH1 and/or EZH2 and thereby, e.g., modulate the level of expression ofmethylation activated and methylation repressed target genes, ormodulate the activity of signalling proteins. A method may compriseadministering to a human, e.g. a human in need thereof, atherapeutically effective amount of an agent described herein.

Thus in one aspect there is provided the use of use of a compound or apharmaceutically acceptable salt thereof which inhibits EZH2 and/or EZH1(i.e. an EZH2 and/or EZH1 inhibitor) in the manufacture of a medicamentfor treating T cell mediated inflammatory immune diseases or T cellmediated hypersensitivity diseases.

In a further aspect there is provided a method of treatment of T cellmediated inflammatory immune diseases or T cell mediatedhypersensitivity diseases in a human comprising administering atherapeutically effective amount of an EZH1 and/EZH2 inhibitor.

Inflammation represents a group of vascular, cellular and neurologicalresponses to trauma. Inflammation can be characterised as the movementof inflammatory cells such as monocytes, neutrophils and granulocytesinto the tissues. This is usually associated with reduced endothelialbarrier function and oedema into the tissues. Inflammation can beclassified as either acute or chronic. Acute inflammation is the initialresponse of the body to harmful stimuli and is achieved by the increasedmovement of plasma and leukocytes from the blood into the injuredtissues. A cascade of biochemical event propagates and matures theinflammatory response, involving the local vascular system, the immunesystem, and various cells within the injured tissue. Prolongedinflammation, known as chronic inflammation, leads to a progressiveshift in the type of cells which are present at the site of inflammationand is characterised by simultaneous destruction and healing of thetissue from the inflammatory process.

When occurring as part of an immune response to infection or as an acuteresponse to trauma, inflammation can be beneficial and is normallyself-limiting. However, inflammation can be detrimental under variousconditions. This includes the production of excessive inflammation inresponse to infectious agents, which can lead to significant organdamage and death (for example, in the setting of sepsis). Moreover,chronic inflammation is generally deleterious and is at the root ofnumerous chronic diseases, causing severe and irreversible damage totissues. In such settings, the immune response is often directed againstself-tissues (autoimmunity), although chronic responses to foreignentities can also lead to bystander damage to self tissues.

The aim of anti-inflammatory therapy is therefore to reduce thisinflammation, to inhibit autoimmunity when present and to allow for thephysiological process or healing and tissue repair to progress.

The agents may be used to treat inflammation of any tissue and organs ofthe body, including musculoskeletal inflammation, vascular inflammation,neural inflammation, digestive system inflammation, ocular inflammation,inflammation of the reproductive system, and other inflammation, asexemplified below.

Musculoskeletal inflammation refers to any inflammatory condition of themusculoskeletal system, particularly those conditions affecting skeletaljoints, including joints of the hand, wrist, elbow, shoulder, jaw,spine, neck, hip, knew, ankle, and foot, and conditions affectingtissues connecting muscles to bones such as tendons. Examples ofmusculoskeletal inflammation which may be treated with compounds of theinvention include arthritis (including, for example, osteoarthritis,psoriatic arthritis, ankylosing spondylitis, acute and chronicinfectious arthritis, arthritis associated with gout and pseudogout, andjuvenile idiopathic arthritis), tendonitis, synovitis, tenosynovitis,bursitis, fibrositis (fibromyalgia), epicondylitis, myositis, andosteitis (including, for example, Paget's disease, osteitis pubis, andosteitis fibrosa cystic).

Ocular inflammation refers to inflammation of any structure of the eye,including the eye lids. Examples of ocular inflammation which may betreated in this invention include blepharitis, blepharochalasis,conjunctivitis, dacryoadenitis, keratitis, keratoconjunctivitis sicca(dry eye), scleritis, trichiasis, and uveitis.

Examples of inflammation of the nervous system which may be treated inthis invention include encephalitis, Guillain-Barre syndrome,meningitis, neuromyotonia, narcolepsy, multiple sclerosis, myelitis andschizophrenia.

Examples of inflammation of the vasculature or lymphatic system whichmay be treated in this invention include arterosclerosis, arthritis,phlebitis, vasculitis, and lymphangitis.

Examples of inflammatory conditions of the digestive system which may betreated in this invention include cholangitis, cholecystitis, enteritis,enterocolitis, gastritis, gastroenteritis, ileitis, and proctitis.

Examples of inflammatory conditions of the reproductive system which maybe treated in this invention include cervicitis, chorioamnionitis,endometritis, epididymitis, omphalitis, oophoritis, orchitis,salpingitis, tubo-ovarian abscess, urethritis, vaginitis, vulvitis, andvulvodynia.

The agents may be used to treat autoimmune conditions having aninflammatory component. Such conditions include acute disseminatedalopecia universalise, Behcet's disease, Chagas' disease, chronicfatigue syndrome, dysautonomia, encephalomyelitis, ankylosingspondylitis, aplastic anemia, hidradenitis suppurativa, autoimmunehepatitis, autoimmune oophoritis, celiac disease, Crohn's disease,diabetes mellitus type 1, giant cell arteritis, goodpasture's syndrome,Grave's disease, Guillain-Barre syndrome, Hashimoto's disease,Henoch-Schönlein purpura, Kawasaki's disease, lupus erythematosus,microscopic colitis, microscopic polyarteritis, mixed connective tissuedisease, multiple sclerosis, myasthenia gravis, opsocionus myoclonussyndrome, optic neuritis, ord's thyroiditis, pemphigus, polyarteritisnodosa, polymyalgia, Reiter's syndrome, Sjogren's syndrome, temporalarteritis, Wegener's granulomatosis, warm autoimmune haemolytic anemia,interstitial cystitis, lyme disease, morphea, sarcoidosis, scleroderma,ulcerative colitis, and vitiligo.

The agents may be used to treat T-cell mediated hypersensitivitydiseases having an inflammatory component. Such conditions includecontact hypersensitivity, contact dermatitis (including that due topoison ivy), uticaria, skin allergies, respiratory allergies (hayfever,allergic rhinitis) and gluten-sensitive enteropathy (Celliac disease).

Other inflammatory conditions which may be treated in this inventioninclude, for example, appendicitis, dermatitis, dermatomyositis,endocarditis, fibrositis, gingivitis, glossitis, hepatitis, hidradenitissuppurativa, iritis, laryngitis, mastitis, myocarditis, nephritis,otitis, pancreatitis, parotitis, percarditis, peritonoitis, pharyngitis,pleuritis, pneumonitis, prostatistis, pyelonephritis, and stomatisi,transplant rejection (involving organs such as kidney, liver, heart,lung, pancreas (e.g., islet cells), bone marrow, cornea, small bowel,skin allografts, skin homografts, and heart valve xengrafts, sewrumsickness, and graft vs host disease), acute pancreatitis, chronicpancreatitis, acute respiratory distress syndrome, Sexary's syndrome,congenital adrenal hyperplasis, nonsuppurative thyroiditis,hypercalcemia associated with cancer, pemphigus, bullous dermatitisherpetiformis, severe erythema multiforme, exfoliative dermatitis,seborrheic dermatitis, seasonal or perennial allergic rhinitis,bronchial asthma, contact dermatitis, astopic dermatitis, drughypersensistivity reactions, allergic conjunctivitis, keratitis, herpeszoster ophthalmicus, iritis and oiridocyclitis, chorioretinitis, opticneuritis, symptomatic sarcoidosis, fulminating or disseminated pulmonarytuberculosis chemotherapy, idiopathic thrombocytopenic purpura inadults, secondary thrombocytopenia in adults, acquired (autoimmune)haemolytic anemia, leukaemia and lymphomas in adults, acute leukaemia ofchildhood, regional enteritis, autoimmune vasculitis, multiplesclerosis, chronic obstructive pulmonary disease, solid organ transplantrejection, sepsis.

Preferred treatments include any one of treatment of transplantrejection, psoriatic arthritis, multiple sclerosis, Type 1 diabetes,asthma, systemic lupus erythematosis, chronic pulmonary disease, andinflammation accompanying infectious conditions (e.g., sepsis).

Typically, but not absolutely, the salts of the compounds for use in theinvention are pharmaceutically acceptable salts. Salts encompassedwithin the term “pharmaceutically acceptable salts” refer to non-toxicsalts of the compounds of this invention. Salts of the compounds of thepresent invention may comprise acid addition salts. In general, thesalts are formed from pharmaceutically acceptable inorganic and organicacids. More specific examples of suitable acid salts include maleic,hydrochloric, hydrobromic, sulphuric, phosphoric, nitric, perchloric,fumic, acetic, propionic, succinic, glycolic, formic, lactic, aleic,tartaric, citric, palmoic, malonic, hydroxymaleic, phenylacetic,glutamic, benzoic, salicylic, fumaric, toluenesulfonic, methansulfonic(mesylate), naphthalene-2-sulfonic, benzenesulfonic, hydroxynaphthoic,hydroiodic, malic, teroic, tannic, and the like.

Other representative salts include acetate, benzenesulfonate, benzoate,bicarbonate, bisulfate, bitartrate, borate, calcium edetate, camsylate,carbonate, clavulanate, citrate, dihydrochloride, edisylate, estolate,esylate, fumarate, gluceptate, gluconate, glutamate,glycollylarsanilate, hexylresorcinate, hydrobromide, hydrochloride,hydroxynaphthoate, iodide, isethionate, lactate, lactobionate, laurate,malate, maleate, mandelate, mesylate, methylsulfate, monopotassiummaleate, mucate, napsylate, nitrate, oxalate, pamoate (embonate),palmitate, pantothenate, phosphate/diphosphate, polygalacturonate,salicylate, stearate, subacetate, succinate, sulfate, tannate, tartrate,teoclate, tosylate, triethiodide, and valerate salts.

Other salts, which are not pharmaceutically acceptable, may be useful inthe preparation of compounds for use in this invention. These salts,such as oxalic or trifluoroacetate, while not in themselvespharmaceutically acceptable, may be useful in the preparation of saltsuseful as intermediates in obtaining the compounds of the invention andtheir pharmaceutically acceptable salts.

Pharmaceutical compositions may be adapted for administration by anyappropriate route, for example by the oral (including buccal orsublingual), rectal, nasal, topical (including buccal, sublingual ortransdermal), vaginal or parenteral (including subcutaneous,intramuscular, intravenous or intradermal) route. Such compositions maybe prepared by any method known in the art of pharmacy, for example bybringing into association a compound of formal (I) with the carrier(s)or excipient(s).

Pharmaceutical compositions adapted for oral administration may bepresented as discrete units such as capsules or tablets; powders orgranules; solutions or suspensions in aqueous or non-aqueous liquids;edible foams or whips; or oil-in-water liquid emulsions or water-in-oilliquid emulsions.

Capsules are made by preparing a powder mixture, as described above, andfilling formed gelatin sheaths. Glidants and lubricants such ascolloidal silica, talc, magnesium stearate, calcium stearate or solidpolyethylene glycol can be added to the powder mixture before thefilling operation. A disintegrating or solubilizing agent such asagar-agar, calcium carbonate or sodium carbonate can also be added toimprove the availability of the medicament when the capsule is ingested.

Moreover, when desired or necessary, suitable binders, lubricants,disintegrating agents and coloring agents can also be incorporated intothe mixture. Suitable binders include starch, gelatin, natural sugarssuch as glucose or beta-lactose, corn sweeteners, natural and syntheticgums such as acacia, tragacanth or sodium alginate,carboxymethylcellulose, polyethylene glycol, waxes and the like.Lubricants used in these dosage forms include sodium oleate, sodiumstearate, magnesium stearate, sodium benzoate, sodium acetate, sodiumchloride and the like. Disintegrators include, without limitation,starch, methyl cellulose, agar, bentonite, xanthan gum and the like.Tablets are formulated, for example, by preparing a powder mixture,granulating or slugging, adding a lubricant and disintegrant andpressing into tablets. A powder mixture is prepared by mixing thecompound, suitably comminuted, with a diluent or base as describedabove, and optionally, with a binder such as carboxymethylcellulose, analiginate, gelatin, or polyvinyl pyrrolidone, a solution retardant suchas paraffin, a resorption accelerator such as a quaternary salt and/oran absorption agent such as bentonite, kaolin or dicalcium phosphate.The powder mixture can be granulated by tablet forming dies by means ofthe addition of stearic acid, a stearate salt, talc or mineral oil. Thelubricated mixture is then compressed into tablets. The compounds foruse in this invention can also be combined with a free flowing inertcarrier and compressed into tablets directly without going through thegranulating or slugging steps. A clear or opaque protective coatingconsisting of a sealing coat of shellac, a coating of sugar or polymericmaterial and a polish coating of wax can be provided. Dyestuffs can beadded to these coatings to distinguish different unit dosages.

Oral fluids such as solution, syrups and elixirs can be prepared indosage unit form so that a given quantity contains a predeterminedamount of a compound of formula (I). Syrups can be prepared bydissolving the compound in a suitably flavored aqueous solution, whileelixirs are prepared through the use of a non-toxic alcoholic vehicle.Suspensions can be formulated by dispersing the compound in a non-toxicvehicle. Solubilizers and emulsifiers such as ethoxylated isostearylalcohols and polyoxy ethylene sorbitol ethers, preservatives, flavoradditive such as peppermint oil or natural sweeteners or saccharin orother artificial sweeteners, and the like can also be added.

Where appropriate, dosage unit pharmaceutical compositions for oraladministration can be microencapsulated. The formulation can also beprepared to prolong or sustain the release as for example by coating orembedding particulate material in polymers, wax or the like.

Pharmaceutical compositions adapted for rectal administration may bepresented as suppositories or as enemas.

Pharmaceutical compositions adapted for vaginal administration may bepresented as pessaries, tampons, creams, gels, pastes, foams or sprayformulations.

Pharmaceutical formulations adapted for parenteral administrationinclude aqueous and non-aqueous sterile injection solutions which maycontain anti-oxidants, buffers, bacteriostats and solutes which renderthe composition isotonic with the blood of the intended recipient; andaqueous and non-aqueous sterile suspensions which may include suspendingagents and thickening agents. The pharmaceutical compositions may bepresented in unit-dose or multi-dose containers, for example sealedampoules and vials, and may be stored in a freeze-dried (lyophilized)condition requiring only the addition of the sterile liquid carrier, forexample water for injections, immediately prior to use. Extemporaneousinjection solutions and suspensions may be prepared from sterilepowders, granules and tablets.

It should be understood that in addition to the ingredients particularlymentioned above, the pharmaceutical compositions may include otheragents conventional in the art having regard to the type of formulationin question, for example those suitable for oral administration mayinclude flavouring agents.

A therapeutically effective amount of a compound for use in thisinvention will depend upon a number of factors including, for example,the age and weight of the intended recipient, the precise conditionrequiring treatment and its severity, the nature of the formulation, andthe route of administration, and will ultimately be at the discretion ofthe attendant prescribing the medication. However, an effective amountof a compound of formula (I) for the treatment of anemia will generallybe in the range of 0.001 to 100 mg/kg body weight of recipient per day,suitably in the range of 0.01 to 10 mg/kg body weight per day. For a 70kg adult mammal, the actual amount per day would suitably be from 7 to700 mg and this amount may be given in a single dose per day or in anumber (such as two, three, four, five or six) of sub-doses per day suchthat the total daily dose is the same. An effective amount of a salt orsolvate, etc., may be determined as a proportion of the effective amountof the compound of formula (I) per se. It is envisaged that similardosages would be appropriate for treatment of the other conditionsreferred to above.

Experimentals Chemical Background

The present compounds are automatically named by computer software, eg.ISISdraw, ChemDraw, or eLNB. A person skilled in the art understandsthat there might be slight differences in the chemical names generatedby different software. The compounds of this invention may be made by avariety of methods, including standard chemistry. Any previously definedvariable will continue to have the previously defined meaning unlessotherwise indicated. Illustrative general synthetic methods are set outbelow and then specific compounds of the invention as prepared are givenin the examples.

Compounds of general formula (I) may be prepared by methods known in theart of organic synthesis as set forth in part by the following synthesisschemes. In all of the schemes described below, it is well understoodthat protecting groups for sensitive or reactive groups are employedwhere necessary in accordance with general principles of chemistry.Protecting groups are manipulated according to standard methods oforganic synthesis (T. W. Green and P. G. M. Wuts (1991) ProtectingGroups in Organic Synthesis, John Wiley & Sons). These groups areremoved at a convenient stage of the compound synthesis using methodsthat are readily apparent to those skilled in the art. The selection ofprocesses as well as the reaction conditions and order of theirexecution shall be consistent with the preparation of compounds offormula (I). Those skilled in the art will recognize if a stereocenterexists in compounds of formula (I). Accordingly, the present inventionincludes both possible stereoisomers and includes not only racemiccompounds but the individual enantiomers as well. Also included in thepresent invention are fully or partially deuterated forms of the presentcompounds. When a compound is desired as a single enantiomer, it may beobtained by stereospecific synthesis or by resolution of the finalproduct or any convenient intermediate. Resolution of the final product,an intermediate, or a starting material may be effected by any suitablemethod known in the art. See, for example, Stereochemistry of OrganicCompounds by E. L. Eliel, S. H. Wilen, and L. N. Mander(Wiley-Interscience, 1994).

Examples General Experimental Methods

The following abbreviations are used throughout the experimental andhave the following meaning:

aq aqueousBINAP 2,2′-bis(diphenylphosphino)-1,1′-binapthylca. circaCDCl₃-d chloroform-dCD₃OD-d₄ methanol-d₄Cs₂CO₃ cesium carbonateCHCl₃ chloroformACN acetonitrileCH₃CN acetonitrileCelite® registered trademark of Celite Corp. brand of diatomaceous earthDBU 1,8-diazabicyclo[5.4.0]undeca-7-eneDCE dichloroethaneDCM methylene chlorideDME 1,2 dimethoxyethane

DMF N,N-dimethylformamide

DIEA diisopropyl ethylamineDMSO-d₆ dimethylsulfoxide-d₆EtOAc ethyl acetateEDC 1-(3-dimethylaminopropyl)-3-ethylcarbodimide hydrochlorideh hour(s)¹H NMR proton nuclear magnetic resonanceHCl hydrochloric acidHOAT 1-hydroxy-7-azabenzotriazoleHPLC high performance liquid chromatographyIPA 2-propanolK₂CO₃ potassium carbonateKOH potassium hydroxideLC/MS liquid chromatography/mass spectroscopyMgSO₄ magnesium sulfateMeOH methanolmin minute(s)MTBE methyl tert-butyl etherMS mass spectrometryNaOH sodium hydroxideNa₂SO₄ sodium sulfateNH₄OH ammonium hydroxideNMM 4-methylmorpholineNMP N-Methyl-2-pyrrolidonePd/C Palladium (10% by wt) on carbonPdCl₂(dppf)-CH₂Cl₂1,1′-Bis(diphenylphosphino)ferrocene-palladium(II)dichloridedichloromethane complexPd(Ph₃P)₄ tetrakis(triphenylphosphine)palladium(0)SOCl₂ thionyl chlorideSPhos 2-Dicyclohexylphosphino-2′,6′-dimethoxybiphenylTFA trifluoroacetic acidTHF tetrahydrofuranTLC thin layer chromatography

The following guidelines apply to all experimental procedures describedherein. All reactions were conducted under a positive pressure ofnitrogen using oven-dried glassware, unless otherwise indicated.Temperatures designated are external (i.e. bath temperatures), and areapproximate. Air and moisture-sensitive liquids were transferred viasyringe. Reagents were used as received. Solvents utilized were thoselisted as “anhydrous” by vendors. Molarities listed for reagents insolutions are approximate, and were used without prior titration againsta corresponding standard. All reactions were agitated by stir bar,unless otherwise indicated. Heating was conducted using heating bathscontaining silicon oil, unless otherwise indicated. Reactions conductedby microwave irradiation (0-400 W at 2.45 GHz) were done so using aBiotage Initiator™ 2.0 instrument with Biotage microwave EXP vials(0.2-20 mL) and septa and caps. Irradiation levels utilized (i.e. high,normal, low) based on solvent and ionic charge were based on vendorspecifications. Cooling to temperatures below −70° C. was conductedusing dry ice/acetone or dry ice/2-propanol. Magnesium sulfate andsodium sulfate used as drying agents were of anhydrous grade, and wereused interchangeably. Solvents described as being removed “in vacuo” or“under reduced pressure” were done so by rotary evaporation.

Preparative normal phase silica gel chromatography was carried out usingeither a Teledyne ISCO CombiFlash Companion instrument with RediSep orISCO Gold silica gel cartridges (4 g-330 g), or an Analogix IF280instrument with SF25 silica gel cartridges (4 g-3-00 g), or a BiotageSP1 instrument with HP silica gel cartridges (10 g-100 g). Purificationby reverse phase HPLC was conducted using a YMC-pack column (ODS-A 75×30mm) as solid phase, unless otherwise noted. A mobile phase of 25 mL/minA (acetonitrile-0.1% TFA): B (water-0.1% TFA), 10-80% gradient A (10min) was utilized with UV detection at 214 nM, unless otherwise noted.

A PE Sciex API 150 single quadrupole mass spectrometer (PE Sciex,Thornhill, Ontario, Canada) was operated using electrospray ionizationin the positive ion detection mode. The nebulizing gas was generatedfrom a zero air generator (Balston Inc., Haverhill, Mass., USA) anddelivered at 65 psi and the curtain gas was high purity nitrogendelivered from a Dewar liquid nitrogen vessel at 50 psi. The voltageapplied to the electrospray needle was 4.8 kV. The orifice was set at 25V and mass spectrometer was scanned at a rate of 0.5 scan/sec using astep mass of 0.2 amu and collecting profile data.

Method A LCMS. Samples were introduced into the mass spectrometer usinga CTC PAL autosampler (LEAP Technologies, Carrboro, N.C.) equipped witha hamilton 10 uL syringe which performed the injection into a Valco10-port injection valve. The HPLC pump was a Shimadzu LC-10ADvp(Shimadzu Scientific Instruments, Columbia, Md.) operated at 0.3 mL/minand a linear gradient 4.5% A to 90% B in 3.2 min. with a 0.4 min. hold.The mobile phase was composed of 100% (H₂O 0.02% TFA) in vessel A and100% (CH₃CN 0.018% TFA) in vessel B. The stationary phase is Aquasil(C18) and the column dimensions were 1 mm×40 mm. Detection was by UV at214 nm, evaporative light-scattering (ELSD) and MS.

Method B, LCMS. Alternatively, an Agilent 1100 analytical HPLC systemwith an LC/MS was used and operated at 1 mL/min and a linear gradient 5%A to 100% B in 2.2 min with a 0.4 min hold. The mobile phase wascomposed of 100% (H₂O 0.02% TFA) in vessel A and 100% (CH₃CN 0.018% TFA)in vessel B. The stationary phase was Zobax (C8) with a 3.5 um particlesize and the column dimensions were 2.1 mm×50 mm. Detection was by UV at214 nm, evaporative light-scattering (ELSD) and MS.

Method C, LCMS. Alternatively, an MDSSCIEX API 2000 equipped with acapillary column of (50×4.6 mm, 5 μm) was used. HPLC was done onAgilent-1200 series UPLC system equipped with column Zorbax SB-C18(50×4.6 mm, 1.8 μm) eluting with CH₃CN: ammonium acetate buffer. Thereactions were performed in the microwave (CEM, Discover).

¹H-NMR spectra were recorded at 400 MHz using a Bruker AVANCE 400 MHzinstrument, with ACD Spect manager v. 10 used for reprocessing.Multiplicities indicated are: s=singlet, d=doublet, t=triplet,q=quartet, quint=quintet, sxt=sextet, m=multiplet, dd=doublet ofdoublets, dt=doublet of triplets etc. and br indicates a broad signal.All NMRs in DMSO unless otherwise noted.

Analytical HPLC: Products were analyzed by Agilent 1100 AnalyticalChromatography system, with 4.5×75 mm Zorbax XDB-C18 column (3.5 um) at2 mL/min with a 4 min gradient from 5% CH₃CN (0.1% formic acid) to 95%CH₃CN (0.1% formic acid) in H₂O (0.1% formic acid) and a 1 min hold.

The compounds of formula (I) can be made according to Scheme 1 or byanalogous methods. Methyl 6-bromo-1H-indole-4-carboxylate (I) isalkylated with an alkyl halide in the presence of base (e.g. sodiumhydride) or with an alcohol in the presence of(cyanomethyl)trimethylphosphonium chloride and base (e.g. sodiumhydride) to give compounds of Formula II. Saponification of the esterwith aqueous base provides compounds of Formula III, which are coupledto various aminomethylpyridones IV utilizing standard peptide couplingreagents (e.g. EDC, HOAT, NMM) to furnish compounds of Formula V.Palladium-mediated cross-coupling of various boronic acids (orboronates) with V provides compounds of Formula VI.

The following examples are for illustrative purposes only and are notintended to limit the scope of the present invention. The compounds werenamed using ACD Name software [Advanced Chemistry Development, Inc.,(ACD/Labs), Toronto, Canada.(http://www.acdlabs.com/products/name_lab/)].

Example 16-Bromo-N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-1-(1-methylethyl)-1H-indole-4-carboxamide

1a) Methyl 6-bromo-1-(1-methylethyl)-1H-indole-4-carboxylate

To a cooled (0° C.) solution of methyl 6-bromo-1H-indole-4-carboxylate(1.0 g, 3.94 mmol) solid in N,N-dimethylformamide (25 mL) was addedsodium hydride (0.173 g, 4.33 mmol). The reaction was stirred for 15min, at which time 2-bromopropane (0.554 mL, 5.90 mmol) was added. Thereaction was then allowed to warm to RT and was maintained overnight.LCMS showed about 25% starting material remaining. The reaction washeated at 45° C. for 4 h, but no further conversion was noted. Thereaction vessel was put back into an ice bath and stirred for 15 min.Then excess NaH (60%) was added, stirred for 10 min, and then2-bromopropane (excess) was added. The ice bath was removed and thereaction stirred for 1 h. Approximately half of the reaction volume wasremoved in vacuo and poured into saturated NH₄Cl (200 mL). This wasextracted with ether (2×) and the combined organics were washed withbrine, dried (MgSO₄), and concentrated. Purification by columnchromatography (80 g Isco silica column; Gradient B: 5-25%, A: hexane,B: ethyl acetate) gave methyl6-bromo-1-(1-methylethyl)-1H-indole-4-carboxylate (0.53 g, 1.718 mmol,43.7% yield).

1b) 6-Bromo-1-(1-methylethyl)-1H-indole-4-carboxylic acid

To a solution of methyl6-bromo-1-(1-methylethyl)-1H-indole-4-carboxylate (0.52 g, 1.756 mmol)in methanol (15 mL) and tetrahydrofuran (3 mL) was added 3 M NaOH (1.756mL, 5.27 mmol) via syringe drop wise (over 2 min). The solution wasmaintained at RT for 2 h, at which time LCMS showed only 12% conversionto product. Then 1.5 mL 3 M NaOH was added and the solution wasmaintained at RT overnight. LCMS showed complete conversion to product.Removed volatiles in vacuo and dissolved the residue in water and slowlyacidified with 1 M HCl (solids precipitated). Extracted with EtOAc (2×),combined organics and dried over MgSO₄. Filtered and concentrated invacuo to give 6-bromo-1-(1-methylethyl)-1H-indole-4-carboxylic acid(0.50 g, 1.737 mmol, 99% yield) as a white solid.

1c)6-Bromo-N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-1-(1-methylethyl)-1H-indole-4-carboxamide

To a mixture of 6-bromo-1-(1-methylethyl)-1H-indole-4-carboxylic acid(0.71 g, 2.52 mmol), 3-(aminomethyl)-4,6-dimethyl-2(1H)-pyridinone(0.575 g, 3.77 mmol), 1-hydroxy-7-azabenzotriazole (0.514 g, 3.77 mmol),and EDC (0.724 g, 3.77 mmol) in dimethylsulfoxide (20 mL) was addedquickly N-methylmorpholine (1.107 mL, 10.07 mmol) via syringe. Thesolids slowly dissolved and the reaction was maintained at RT overnight.The reaction was slowly poured into ice-water (300 mL), stirred for 10min, then allowed to sit for 10 min. The solids were filtered and washedwith water (100 mL), airdried for 15 min, then dried in vacuum oven at45° C. for 4 h to give6-bromo-N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-1-(1-methylethyl)-1H-indole-4-carboxamide(0.82 g, 1.871 mmol, 74.4% yield). ¹H NMR (400 MHz, DMSO-d₆) δ ppm1.39-1.46 (m, 6H) 2.09-2.15 (m, 3H) 2.21 (s, 3H) 4.32 (d, J=5.05 Hz, 2H)4.82 (quin, J=6.63 Hz, 1H) 5.88 (s, 1H) 6.86 (d, J=3.28 Hz, 1H) 7.51 (d,J=1.77 Hz, 1H) 7.62 (d, J=3.28 Hz, 1H) 7.92 (s, 1H) 8.31 (t, J=4.93 Hz,1H) 11.55 (br. s., 1H). MS(ES) [M+H]⁺ 416.0.

Example 2N-[(4,6-Dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-1-(1-methylethyl)-6-[6-(4-methyl-1-piperazinyl)-3-pyridinyl]-1H-indole-4-carboxamide

A mixture of6-bromo-N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-1-(1-methylethyl)-1H-indole-4-carboxamide(0.10 g, 0.240 mmol),1-methyl-4-[5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2-pyridinyl]piperazine(0.087 g, 0.288 mmol) and potassium phosphate (tribasic) (0.153 g, 0.721mmol) in 1,4-dioxane (2 mL) and water (0.5 mL) was degassed with N₂ for10 min, at which time PdCl₂(dppf)-CH₂Cl₂ (0.029 g, 0.036 mmol) wasadded. The reaction was sealed and heated at 100° C. for 2 h. Thereaction was then allowed to cool to RT and sat overnight, at which timeit was diluted with EtOAc, filtered through Celite, washed with EtOAc,and concentrated in vacuo. Purification of the residue by columnchromatography (12 g Isco GOLD silica column; Gradient B: 5-90%; A:dichloromethane, B: 10% chloroform containing 2 M ammonia in methanol)gaveN-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-1-(1-methylethyl)-6-[6-(4-methyl-1-piperazinyl)-3-pyridinyl]-1H-indole-4-carboxamide(94 mg, 0.180 mmol, 74.8% yield). ¹H NMR (400 MHz, DMSO-d₆) δ ppm 1.46(d, J=6.57 Hz, 6H) 2.12 (s, 3H) 2.17-2.28 (m, 6H) 2.38-2.46 (m, 4H)3.49-3.57 (m, 4H) 4.37 (d, J=5.05 Hz, 2H) 4.86-4.98 (m, 1H) 5.88 (s, 1H)6.87 (d, J=3.03 Hz, 1H) 6.93 (d, J=8.84 Hz, 1H) 7.58 (d, J=3.28 Hz, 1H)7.65 (d, J=1.26 Hz, 1H) 7.87 (s, 1H) 7.98 (dd, J=8.97, 2.65 Hz, 1H) 8.28(t, J=5.05 Hz, 1H) 8.57 (d, J=2.27 Hz, 1H) 11.55 (s, 1H). MS(ES) [M+H]⁺513.3.

Examples 3-xx were prepared by the methods described above for Examples1 and 2 or routine variations thereof, starting from the requisite4-aminomethylpyridones and 6-substituted-4-indolecarboxylates. Routinevariations include, but are not limited to, reversing the bromide andboronate coupling partners for the Suzuki type couplings or using a onepot procedure in which the boroate is formed in situ.

¹H NMR MS(ES) Ex Structure Name (400 MHz, DMSO-d₆) δ ppm [M + H]⁺ 3

N-[(4,6-Dimethyl-2- oxo-1,2-dihydro-3- pyridinyl)methyl]-1-(1-methylethyl)-6-phenyl- 1H-indole-4- carboxamide 1.45-1.51 (m, 6 H) 2.12(s, 3 H) 2.23 (s, 3 H) 4.37 (d, J = 5.05 Hz, 2 H) 4.89-5.02 (m, 1 H)5.88 (s, 1 H) 6.88 (d, J = 3.28 Hz, 1 H) 7.30- 7.37 (m, 1 H) 7.47 (t, J= 7.71 Hz, 2 H) 7.62 (d, J = 3.28 Hz, 1 H) 7.71 (d, J = 1.52 Hz, 1 H)7.76-7.84 (m, 2 H) 7.92 (s, 1 H) 8.32 (t, J = 5.05 Hz, 1 H) 11.55 (s, 1H) 414.1 4

N-[(4,6-Dimethyl-2- oxo-1,2-dihydro-3- pyridinyl)methyl]-1-(1-methylethyl)-6-(2-oxo- 2,3-dihydro-1H- benzimidazol-5-yl)-1H-indole-4-carboxamide 1.47 (d, J = 6.57 Hz, 6 H) 2.12 (s, 3 H) 2.23 (s, 3H) 4.38 (d, J = 5.05 Hz, 2 H) 4.86-5.01 (m, 1 H) 5.89 (s, 1 H) 6.86 (d,J = 3.03 Hz, 1 H) 7.00 (d, J = 8.08 Hz, 1 H) 7.30 (s, 1 H) 7.36 (dd, J =8.08, 1.77 Hz, 1 H) 7.59 (d, J = 3.28 Hz, 1 H) 7.65 (d, J = 1.26 Hz, 1H) 7.83 (s, 1 H) 8.30 (t, J = 5.18 Hz, 1 H) 10.70 (s, 1 H) 10.66 (s, 1H) 11.55 (s, 1 H) 469.2 5

1-(1-methylethyl)-N- [(6-methyl-2-oxo-4- propyl-1,2-dihydro-3-pyridinyl)methyl]-6-[2- (4-methyl-1- piperazinyl)-4-pyridinyl]-1H-indole-4- carboxamide 0.91 (t, J = 7.33 Hz, 3 H) 1.48 (d,J = 6.57 Hz, 6 H) 1.51- 1.59 (m, 2 H) 2.13 (s, 3 H) 2.23 (s, 3 H) 2.43(t, J = 4.93 Hz, 4 H) 2.52-2.59 (m, 2 H) 3.50-3.65 (m, 4 H) 4.41 (d, J =5.05 Hz, 2 H) 4.91-5.09 (m, 1 H) 5.91 (s, 1 H) 6.89 (d, J = 3.03 Hz, 1H) 7.05- 7.21 (m, 2 H) 7.66-7.78 (m, 2 H) 8.05 (s, 1 H) 8.16 (d, J =5.31 Hz, 1 H) 8.32 (t, J = 5.05 Hz, 1 H) 11.56 (s, 1 H) 541.3 6

1-(1-Methylethyl)-N- [(6-methyl-2-oxo-4- propyl-1,2-dihydro-3-pyridinyl)methyl]-6-(2- oxo-2,3-dihydro-1H- benzimidazol-5-yl)-1H-indole-4-carboxamide 0.91 (t, J = 7.33 Hz, 3 H) 1.47 (d, J = 6.57 Hz, 6H) 1.50- 1.60 (m, 2 H) 2.13 (s, 3 H) 2.55 (d, J = 7.07 Hz, 2 H) 4.41 (d,J = 5.05 Hz, 2 H) 4.94 (quin, J = 6.63 Hz, 1 H) 5.91 (s, 1 H) 6.85 (d, J= 3.28 Hz, 1 H) 7.00 (d, J = 7.83 Hz, 1 H) 7.29 (s, 1 H) 7.35 (dd, J =8.08, 1.77 Hz, 1 H) 7.57- 7.69 (m, 2 H) 7.83 (s, 1 H) 8.30 (t, J = 5.05Hz, 1 H) 10.70 (s, 1 H) 10.66 (s, 1 H) 11.56 (s, 1 H) 498.3 7

6-Bromo-1- cyclopentyl-N-[(4,6- dimethyl-2-oxo-1,2- dihydro-3-pyridinyl)methyl]-1H- indole-4-carboxamide 1.64-1.87 (m, 6 H) 2.08- 2.18(m, 5 H) 2.21 (s, 3 H) 4.32 (d, J = 5.05 Hz, 2 H) 4.86- 5.02 (m, 1 H)5.88 (s, 1 H) 6.86 (d, J = 3.03 Hz, 1 H) 7.52 (d, J = 1.77 Hz, 1 H) 7.58(d, J = 3.28 Hz, 1 H) 7.92 (s, 1 H) 8.24-8.38 (m, 1 H) 11.54 (s, 1 H) 442.0, 444.2 8

1-(1-Methylethyl)-N- [(6-methyl-2-oxo-4- propyl-1,2-dihydro-3-pyridinyl)methyl]-6-(3- pyridinyl)-1H-indole-4- carboxamide 0.90 (t, J =7.33 Hz, 3 H) 1.44- 1.59 (m, 8 H) 2.13 (s, 3 H) 2.54 (dd, J = 8.59, 6.82Hz, 2 H) 4.41 (d, J = 5.05 Hz, 2 H) 4.98 (quin, J = 6.63 Hz, 1 H) 5.91(s, 1 H) 6.92 (d, J = 3.28 Hz, 1 H) 7.49 (dd, J = 7.33, 4.80 Hz, 1 H)7.66 (d, J = 3.03 Hz, 1 H) 7.75 (d, J = 1.26 Hz, 1 H) 8.04 (s, 1 H) 8.20(dt, J = 8.27, 1.80 Hz, 1 H) 8.34 (t, J = 5.05 Hz, 1 H) 8.54 (dd, J =4.67, 1.64 Hz, 1 H) 9.04 (d, J = 1.77 Hz, 1 H) 11.56 (s, 1 H) 443.2 9

6-Bromo-1-(1- methylethyl)-N-[(6- methyl-2-oxo-4-propyl- 1,2-dihydro-3-pyridinyl)methyl]-1H- indole-4-carboxamide 0.90 (t, J = 7.33 Hz, 3 H)1.43 (d, J = 6.57 Hz, 6 H) 1.47- 1.62 (m, 2 H) 2.13 (s, 3 H) 2.53 (d, J= 7.83 Hz, 2 H) 4.35 (d, J = 5.05 Hz, 2 H) 4.76- 4.88 (m, 1 H) 5.91 (s,1 H) 6.86 (d, J = 3.03 Hz, 1 H) 7.51 (d, J = 1.52 Hz, 1 H) 7.63 (d, J =3.28 Hz, 1 H) 7.92 (s, 1 H) 8.29 (t, J = 5.05 Hz, 1 H) 11.56 (br.s., 1H)  444.2, 446.0 10

1-(1-Methylethyl)-N- [(6-methyl-2-oxo-4- propyl-1,2-dihydro-3-pyridinyl)methyl]-6- phenyl-1H-indole-4- carboxamide 0.91 (t, J = 7.33Hz, 3 H) 1.48 (d, J = 6.57 Hz, 6 H) 1.50- 1.60 (m, 2 H) 2.13 (s, 3 H)2.54 (dd, J = 8.59, 6.82 Hz, 2 H) 4.41 (d, J = 5.05 Hz, 2 H) 4.88-5.02(m, 1 H) 5.91 (s, 1 H) 6.88 (d, J = 3.03 Hz, 1 H) 7.28-7.38 (m, 1 H)7.43- 7.51 (m, 2 H) 7.63 (d, J = 3.28 Hz, 1 H) 7.71 (d, J = 1.26 Hz, 1H) 7.75-7.83 (m, 2 H) 7.93 (s, 1 H) 8.32 (t, J = 5.05 Hz, 1 H) 11.57 (s,1 H) 442.1 11

6-Bromo-N-[(4- cyclopropyl-6-methyl- 2-oxo-1,2-dihydro-3-pyridinyl)methyl]-1-(1- methylethyl)-1H- indole-4-carboxamide 11.48 (s,1 H) 8.36 (t, J = 4.93 Hz, 1 H) 7.92 (s, 1 H) 7.63 (d, J = 3.28 Hz, 1 H)7.52 (d, J = 1.52 Hz, 1 H) 6.84 (d, J = 3.28 Hz, 1 H) 5.52 (s, 1 H)4.80-4.86 (m, 1 H) 4.52 (d, J = 5.05 Hz, 2 H) 2.14-2.19 (m, 1 H) 2.10(s, 3 H) 1.43 (d, J = 6.57 Hz, 6 H) 0.91- 0.98 (m, 2 H) 0.70-0.77 (m, 2H)  442.0, 444.1 12

6-Bromo-1-(1- methylethyl)-N-{[6- methyl-4-(1- methylethyl)-2-oxo-1,2-dihydro-3- pyridinyl]methyl}-1H- indole-4-carboxamide 11.54 (s, 1 H)8.31 (t, J = 5.05 Hz, 1 H) 7.92 (s, 1 H) 7.63 (d, J = 3.28 Hz, 1 H) 7.51(d, J = 1.52 Hz, 1 H) 6.86 (d, J = 3.25 Hz, 1 H) 6.02 (s, 1 H) 4.78-4.87(m, 1 H) 4.40 (d, J = 4.80 Hz, 2 H) 3.36-3.40 (m, 1 H) 3.24-3.28 (m, 1H) 2.16 (s, 3 H) 1.43 (d, J = 6.57 Hz, 6 H) 1.09-1.15 (m, 6 H)  444.1,446.0 13

6-Bromo-N-[(4- cyclobutyl-6-methyl-2- oxo-1,2-dihydro-3-pyridinyl)methyl]-1-(1- methylethyl)-1H- indole-4-carboxamide 11.60 (s,1 H) 8.26 (t, J = 4.80 Hz, 1 H) 7.92 (s, 1 H) 7.63 (d, J = 3.28 Hz, 1 H)7.50 (d, J = 1.52 Hz, 1 H) 6.87 (d, J = 3.28 Hz, 1 H) 6.12 (s, 1 H) (d,4.78-4.86 (m, 1 H) 4.31 (d, J = 4.80 Hz, 2 H) 3.80 (m, 1 H) 2.21-2.26(m, 2 H) 2.18 (s, 3 H) 2.05-2.13 (m, 2 H) 1.93-2.03 (m, 1 H) 1.78 (m, 1H) 1.43 (d, J = 6.57 Hz, 6 H)  455.9, 458.1 14

6-Bromo-1-(1- methylethyl)-N-[(4- methyl-2-oxo-6-propyl- 1,2-dihydro-3-pyridinyl)methyl]-1H- indole-4-carboxamide 8.33 (br.s., 1H), 7.92 (s,1H), 7.63 (d, J = 3.28 Hz, 1H), 7.52 (d, J = 1.52 Hz, 1H), 6.87 (d, J =3.28 Hz, 1H), 5.90 (s, 1H), 4.78-4.87 (m, 1H), 4.33 (d, J = 5.05 Hz 2H),2.37 (t, J = 7.58 Hz, 2H), 2.23 (s, 3H), 1.58 (sxt, J = 7.43 Hz, 2H),1.43 (d, J = 6.57 Hz, 6H), 0.88 (t, J = 7.33 Hz, 3H)  444.2, 446.0 15

6-Bromo-1-(1- methylethyl)-N-[(6- methyl-2-oxo-4-phenyl- 1,2-dihydro-3-pyridinyl)methyl]-1H- indole-4-carboxamide 11.88 (s, 1 H) 8.35 (t, J =4.42 Hz, 1 H) 7.93 (s, 1 H) 7.63 (d, J = 3.28 Hz, 1 H) 7.40- 7.50 (m, 6H) 6.86 (d, J = 3.03 Hz, 1 H) 6.00 (s, 1 H) 4.78- 4.87 (m, 1 H) 4.19 (d,J = 4.29 Hz, 2 H) 2.22 (s, 3 H) 1.44 (d, J = 6.57 Hz, 6 H)  447.9, 479.716

N-((4,6-dimethyl-2- oxo-1,2-dihydropyridin- 3-yl)methyl)-1-isopropyl-6-(6-(2- oxopyrrolidin-1- yl)pyridin-3-yl)-1H-indole-4-carboxamide 1.49 (d, J = 4.00 Hz 6 H), 2.03- 2.15 (m, 5 H),2.24 (s, 3 H), 2.61 (t, J = 8.08 Hz, 2 H), 4.06 (t, J = 7.20 Hz, 2 H),4.38 (d, J = 5.05 Hz, 2 H), 4.96 (quin, J = 6.69 Hz, 1 H), 5.89 (s, 1H), 6.91 (d, J = 3.28 Hz, 1 H), 7.65 (d, J = 3.28 Hz, 1 H), 7.75 (d, J =1.26 Hz, 1 H), 8.01 (s, 1 H), 8.25 (dd, J = 8.59, 2.53 Hz, 1 H), 8.32(t, J = 5.05 Hz, 1 H), 8.39 (d, J = 8.84 Hz, 1 H), 8.85 (d, J = 2.02 Hz,1 H), 11.55 (s, 1 H) 498.3 17

1-isopropyl-N-((6- methyl-2-oxo-4-propyl- 1,2-dihydropyridin-3-yl)methyl)-6-(2- methylpyridin-3-yl)-1H- indole-4-carboxamide 0.86-0.94(m, 3 H), 1.46 (d, J = 6.57 Hz, 6 H), 1.50-1.59 (m, 2 H) 2.12 (s, 3 H),4.38 (d, J = 5.31 Hz, 2 H), 4.80- 4.94 (m, 1 H), 5.90 (s, 1 H), 6.92 (d,J = 3.03 Hz, 1 H), 7.31 (dd, J = 7.71, 4.93 Hz, 1 H), 7.42 (d, J = 1.26Hz, 1 H), 7.66 (d, J = 3.28 Hz, 1 H), 7.67-7.72 (m, 3 H), 8.17 (s, 1 H),8.24 (t, J = 5.18 Hz, 1 H), 8.46 (dd, J = 4.80, 1.77 Hz, 1 H) 457.1 18

1-isopropyl-N-((6- methyl-2-oxo-4-propyl- 1,2-dihydropyridin-3-yl)methyl)-6-(2- methylpyrimidin-5-yl)- 1H-indole-4- carboxamide0.85-0.95 (m, 3 H), 1.44- 1.60 (m, 8 H), 2.13 (s, 3 H), 3.33 (br.s., 2H), 2.67 (s, 3H), 4.41 (d, J = 5.31 Hz, 2 H), 4.97 (quin, J = 6.63 Hz, 1H), 5.92 (s, 1 H), 6.90 (d, J = 3.03 Hz, 1 H), 7.65 (d, J = 3.28 Hz, 1H), 7.78 (d, J = 1.26 Hz, 2 H), 8.11 (s, 1 H), 8.32 (m, 1 H) 458.2 19

1-isopropyl-N-((6- methyl-2-oxo-4-propyl- 1,2-dihydropyridin-3-yl)methyl)-6-(6- methylpyridin-3-yl)-1H- indole-4-carboxamide 0.85-0.96(m, 3 H), 1.48 (d, J = 8.00 Hz, 6 H), 1.55 (m, 2 H), 2.13 (s, 3 H), 3.33(br.s., 1 H), 4.41 (d, J = 5.31 Hz, 2 H), 4.97 (quin, J = 6.63 Hz, 1 H),5.92 (s, 1 H), 6.90 (d, J = 3.03 Hz, 1 H), 7.35 (d, J = 8.08 Hz, 1 H),7.65 (d, J = 3.28 Hz, 1 H), 7.72 (d, J = 1.26 Hz, 1 H), 7.99 (s, 1 H),8.09 (dd, J = 8.08, 2.53 Hz, 1 H), 8.15 (s, 1 H), 8.33 (t, J = 5.05 Hz,1 H), 8.89 (d, J = 2.02 Hz, 1 H) 457.1 20

N-((4,6-dimethyl-2- oxo-1,2-dihydropyridin- 3-yl)methyl)-6-(4-((dimethylamino)methyl) phenyl)-1-isopropyl-3- methyl-1H-indole-4-carboxamide 1.44 (m, 6 H), 1.73-1.80 (m, 2 H), 2.11 (s, 3 H), 2.17 (s, 3H), 2.22-2.26 (m, 9 H), 3.58- 3.65 (m, 2 H), 4.36 (d, J = 5.05 Hz, 2 H),4.87 (quin, J = 6.69 Hz, 1 H), 5.87 (s, 1 H), 7.25 (d, J = 1.26 Hz, 1H), 7.32 (d, J = 1.01 Hz, 1 H), 7.38 (d, J = 8.08 Hz, 2 H), 7.71 (d, J =8.34 Hz, 2 H), 7.78 (d, J = 1.26 Hz, 1 H), 8.12-8.23 (m, 1 H) 485.3 21

N-((4,6-dimethyl-2- oxo-1,2-dihydropyridin- 3-yl)methyl)-1-isopropyl-6-(6- methoxypyridin-3-yl)-3- methyl-1H-indole-4- carboxamide1.38-1.47 (m, 6 H), 2.11 (s, 3 H), 2.17 (s, 3 H), 2.24 (s, 3 H) 3.90 (s,3 H), 4.35 (d, J = 5.05 Hz, 2 H), 4.86 (quin, J = 6.57 Hz, 1 H), 5.87(s, 1 H), 6.88-6.96 (m, 1 H), 7.22 (d, J = 1.26 Hz, 1 H), 7.33 (d, J =1.01 Hz, 1 H), 7.79 (d, J = 1.52 Hz, 1 H), 8.09 (dd, J = 8.59, 2.53 Hz,1 H), 8.17 (t, J = 5.05 Hz, 1 H), 8.54 (d, J = 2.02 Hz, 1 H) 459.3 22

N-((4,6-dimethyl-2- oxo-1,2-dihydropyridin- 3-yl)methyl)-1-isopropyl-3-methyl-6- (6-morpholinopyridin- 3-yl)-1H-indole-4-carboxamide 1.43 (m, 6 H), 2.11 (s, 3 H), 2.16 (s, 3 H), 2.24 (s, 3 H),3.45-3.54 (m, 4 H), 3.70- 3.79 (m, 4 H), 4.35 (d, J = 5.05 Hz, 2 H),4.85 (quin, J = 6.63 Hz, 1 H), 5.87 (s, 1 H), 6.93 (d, J = 8.84 Hz, 1H), 7.20 (d, J = 1.26 Hz, 1 H), 7.29 (s, 1 H), 7.69-7.77 (m, 1 H), 7.96(dd, J = 8.97, 2.65 Hz, 1 H), 8.15 (t, J = 5.05 Hz, 1 H), 8.54 (d, J =2.27 Hz, 1 H), 11.48 (s, 1 H) 514.3 23

N-((4,6-dimethyl-2- oxo-1,2-dihydropyridin- 3-yl)methyl)-1-isopropyl-3-methyl-6- (4-(4-methylpiperazin- 1-yl)phenyl)-1H-indole-4-carboxamide 1.43 (m, 6 H), 2.11 (s, 3 H), 2.16 (s, 3 H), 2.24 (s, 3H), 2.29 (s, 3 H), 2.53-2.58 (m, 4 H), 3.15-3.28 (m, 4 H), 4.35 (d, J =5.05 Hz, 2 H), 4.84 (quin, J = 6.69 Hz, 1 H), 5.87 (s, 1 H), 7.02 (d, J= 8.84 Hz, 2 H), 7.19 (d, J = 1.26 Hz, 1 H), 7.27 (s, 1 H), 7.60 (d, J =8.84 Hz, 2 H), 7.67 (d, J = 1.26 Hz, 1 H), 8.09-8.21 (m, 2 H) 526.3 24

N-((4,6-dimethyl-2- oxo-1,2-dihydropyridin- 3-yl)methyl)-1-isopropyl-3-methyl-6- (3- ((methylsulfonyl)methyl) phenyl)-1H-indole-4-carboxamide 1.45 (m, 6 H), 2.11 (s, 3 H), 2.17 (s, 3 H), 2.24 (s, 3 H),2.95 (s, 3 H), 4.36 (d, J = 5.05 Hz, 2 H), 4.57 (s, 2 H), 4.85 (quin, J= 6.63 Hz, 1 H), 5.87 (s, 1 H), 7.25 (d, J = 1.52 Hz, 1 H), 7.33-7.40(m, 2 H), 7.49 (t, J = 7.71 Hz, 1 H), 7.72- 7.82 (m, 3 H), 8.19 (t, J =5.05 Hz, 1 H), 11.47 (s, 1 H) 520.0 25

N-((4,6-dimethyl-2- oxo-1,2-dihydropyridin- 3-yl)methyl)-1-isopropyl-3-methyl-6- (2-methylpyrimidin-5- yl)-1H-indole-4- carboxamide1.44 (m, 6 H), 2.11 (s, 3 H), 2.17 (s, 3 H), 2.25 (s, 3 H), 2.67 (s, 3H), 4.36 (d, J = 5.05 Hz, 2 H), 4.90 (quin, J = 6.63 Hz, 1 H), 5.87 (s,1 H), 7.33 (d, J = 1.52 Hz, 1 H), 7.39 (d, J = 1.01 Hz, 1 H), 7.96 (d, J= 1.26 Hz, 1 H), 8.20 (t, J = 5.05 Hz, 1 H), 9.09 (s, 2 H), 11.49 (s, 1H) 444.2 26

6-(2-aminopyrimidin-5- yl)-N-((4,6-dimethyl-2- oxo-1,2-dihydropyridin-3-yl)methyl)-1- isopropyl-3-methyl-1H- indole-4-carboxamide 1.43 (d, 6H), 2.11 (s, 3 H), 2.15-2.20 (m, 3 H), 2.24 (s, 3 H), 4.35 (d, J = 5.05Hz, 2 H), 4.85 (quin, J = 6.69 Hz, 1 H), 5.87 (s, 1 H), 6.70 (s, 2 H),7.18 (d, J = 1.26 Hz, 1 H), 7.30 (s, 1 H), 7.75 (d, J = 1.26 Hz, 1 H),8.10-8.19 (m, 1 H), 8.61-8.68 (m, 2H), 11.49 (br.s., 1 H) 445.2 27

6-(6-aminopyridin-3- yl)-N-((4,6-dimethyl-2- oxo-1,2-dihydropyridin-3-yl)methyl)-1- isopropyl-3-methyl-1H- indole-4-carboxamide 1.42 (d, J =8.00 Hz, 6 H), 2.11 (s, 3 H), 2.16 (s, 3 H), 2.24 (s, 3 H), 4.35 (d, J =5.05 Hz, 2 H), 4.83 (quin, J = 6.63 Hz, 1 H), 5.87 (s, 1 H), 6.02 (s, 2H), 6.54 (d, J = 8.59 Hz, 1 H), 7.14 (d, J = 1.52 Hz, 1 H), 7.27 (s, 1H), 7.66 (d, J = 1.26 Hz, 1 H), 7.78 (dd, J = 8.59, 2.53 Hz, 1 H), 8.11-8.18 (m, 1 H), 8.30 (d, J = 2.02 Hz, 1 H) 444.2 28

N-((4,6-dimethyl-2- oxo-1,2-dihydropyridin- 3-yl)methyl)-6-(6-(dimethylamino)pyridin- 3-yl)-1-isopropyl-3- methyl-1H-indole-4-carboxamide 1.43 (d, J = 8.00 Hz, 6 H), 2.11 (s, 3 H), 2.16 (s, 3 H),2.24 (s, 3 H), 3.07 (s, 6 H), 4.35 (d, J = 5.05 Hz, 2 H), 4.84 (quin, J= 6.57 Hz, 1 H), 5.87 (s, 1 H), 6.73 (d, J = 8.59 Hz, 1 H), 7.17 (d, J =1.52 Hz, 1 H), 7.28 (d, J = 1.01 Hz, 1 H), 7.68-7.74 (m, 1 H), 7.90 (dd,J = 8.84, 2.53 Hz, 1 H), 8.11-8.18 (m, 1 H), 8.48 (d, J = 2.02 Hz, 1 H)472.5 29

N-((4,6-dimethyl-2- oxo-1,2-dihydropyridin- 3-yl)methyl)-1-isopropyl-3-methyl-6- (6-(pyrrolidin-1- yl)pyridin-3-yl)-1H-indole-4-carboxamide 1.39-1.47 (d, J = 8.00 Hz, 6 H), 1.93-2.01 (m, 4H), 2.11 (s, 3 H), 2.16 (s, 3 H), 2.24 (s, 3 H), 3.41-3.48 (m, 4 H),4.35 (d, J = 5.05 Hz, 2 H), 4.84 (quin, J = 6.63 Hz, 1 H), 5.87 (s, 1H), 6.56 (d, J = 8.59 Hz, 1 H), 7.17 (d, J = 1.52 Hz, 1 H), 7.27 (d, J =1.01 Hz, 1 H), 7.69 (d, J = 1.26 Hz, 1 H), 7.91 (dd, J = 8.72, 2.15 Hz,1 H), 8.10-8.17 (m, 1 H), 8.45 (d, J = 2.27 Hz, 1 H) 498.4 30

N-((4,6-dimethyl-2- oxo-1,2-dihydropyridin- 3-yl)methyl)-6-(4-fluorophenyl)-1- isopropyl-3-methyl-1 indole-4-carboxamide 1.43 (m, 6H), 2.11 (s, 3 H), 2.17 (s, 3 H), 2.24 (s, 3 H), 4.31-4.41 (m, 2 H),4.80- 4.93 (m, 1 H), 5.87 (s, 1 H), 7.17-7.36 (m, 4 H), 7.74- 7.84 (m, 3H), 8.16-8.24 (m, 1 H), 11.43-11.55 (m, 1 H) 446.0 31

N-((4,6-dimethyl-2- oxo-1,2-dihydropyridin- 3-yl)methyl)-1-isopropyl-6-(4-(4- isopropylpiperazin-1- yl)phenyl)-3-methyl-1H-indole-4- carboxamide 1.01-1.11 (m, 6 H), 1.43 (d, J = 6.57 Hz, 6 H),2.11 (s, 3 H), 2.16 (s, 3 H), 2.24 (s, 3 H), 2.68 (br.s., 4 H), 2.74-2.84 (m, 1 H), 3.15-3.26 (m, 4 H), 4.35 (d, J = 5.05 Hz, 2 H), 4.83(quin, J = 6.57 Hz, 1 H), 5.87 (s, 1 H), 7.02 (d, J = 8.84 Hz, 2 H),7.19 (d, J = 1.52 Hz, 1 H), 7.27 (s, 1 H), 7.60 (d, J = 8.84 Hz, 2 H),7.67 (d, J = 1.26 Hz, 1 H), 8.11-8.21 (m, 2 H) 554.2 32

N-((4,6-dimethyl-2- oxo-1,2-dihydropyridin- 3-yl)methyl)-6-(1H-indazol-6-yl)-1- isopropyl-3-methyl-1H- indole-4-carboxamide 1.40-1.51(m, 6 H), 2.11 (s, 3 H), 2.19 (s, 3 H), 2.25 (s, 3 H), 4.33-4.46 (m, 2H), 4.90 (quin, J = 6.63 Hz, 1 H), 5.87 (s, 1 H), 7.33 (dd, J = 12.76,1.14 Hz, 2 H), 7.54 (dd, J = 8.46, 1.39 Hz, 1 H) , 7.76- 7.89 (m, 3 H),8.09 (s, 1 H), 8.24 (t, J = 5.05 Hz, 1 H), 11.48 (br.s., 1 H), 13.07(br. s., 1 H) 468.3 33

6-bromo-N-[(4-ethyl-6- methyl-2-oxo-1,2- dihydro-3- pyridinyl)methyl]-3-methyl-1-(1- methylethyl)-1H- indole-4-carboxamide 11.49 (s, 1 H) 8.23(t, J = 5.05 Hz, 1 H) 7.77 (d, J = 1.77 Hz, 1 H) 7.33 (s, 1 H) 7.00 (d,J = 1.77 Hz, 1 H) 5.91 (s, 1 H) 4.74 (quin, J = 6.63 Hz, 1 H) 4.33 (s, 1H) 4.32 (s, 1 H) 2.56 (q, J = 7.58 Hz, 2 H) 2.13 (s, 6 H) 1.40 (s, 3 H)1.38 (s, 3 H) 1.13 (t, J = 7.58 Hz, 3 H)  444.1/ 446.0 34

N-[(4-ethyl-6-methyl-2- oxo-1,2-dihydro-3- pyridinyl)methyl]-3-methyl-1-(1- methylethyl)-6-[6-(4- methyl-1-piperazinyl)-3-pyridinyl]-1H-indole- 4-carboxamide 11.46 (br.s., 1 H) 8.50 (d, J =2.27 Hz, 1 H) 8.10-8.18 (m, 1 H) 7.92 (dd, J = 8.84, 2.53 Hz, 1 H) 7.72(d, J = 1.26 Hz, 1 H) 7.29 (s, 1 H) 7.18 (d, J = 1.52 Hz, 1 H) 6.92 (d,J = 8.84 Hz, 1 H) 5.92 (s, 1 H) 4.84 (quin, J = 6.57 Hz, 1 H) 4.37 (d, J= 4.80 Hz, 2 H) 3.49- 3.55 (m, 4 H) 2.59 (q, J = 7.41 Hz, 2 H) 2.40-2.44(m, 4 H) 2.23 (s, 3 H) 2.17 (s, 3 H) 2.13 (s, 3 H) 1.44 (s, 3 H) 1.42(s, 3 H) 1.14 (t, J = 7.58 Hz, 3 H) 541.5 35

6-{3- [(dimethylamino)methyl] phenyl}-N-[(4-ethyl-6- methyl-2-oxo-1,2-dihydro-3- pyridinyl)methyl]-3- methyl-1-(1- methylethyl)-1H-indole-4-carboxamide 11.48 (br.s., 1 H) 8.18 (t, J = 5.05 Hz, 1 H) 7.76(d, J = 1.26 Hz, 1 H) 7.59-7.65 (m, 2 H) 7.40 (t, J = 7.58 Hz, 1 H) 7.33(s, 1 H) 7.22-7.26 (m, 2 H) 5.92 (s, 1 H) 4.88 (dt, J = 13.33, 6.60 Hz,1 H) 4.38 (s, 1 H) 4.37 (s, 1 H) 3.46 (s, 2 H) 2.59 (q, J = 7.58 Hz, 2H) 2.18 (s, 9 H) 2.13 (s, 3 H) 1.45 (s, 3 H) 1.43 (s, 3 H) 1.15 (t, J =7.58 Hz, 3 H) 499.3 36

6-{4- [(dimethylamino)methyl] phenyl}-N-[(4-ethyl-6- methyl-2-oxo-1,2-dihydro-3- pyridinyl)methyl]-3- methyl-1-(1- methylethyl)-1H-indole-4-carboxamide 11.48 (br.s., 1 H) 8.16 (t, J = 4.93 Hz, 1 H) 7.77(s, 1 H) 7.70 (s, 1 H) 7.68 (s, 1 H) 7.37 (s, 1 H) 7.35 (s, 1 H) 7.32(s, 1 H) 7.25 (s, 1 H) 5.92 (s, 1 H) 4.87 (dt, J = 13.14, 6.57 Hz, 1 H)4.38 (br.s., 1 H) 4.37 (br.s., 1 H) 3.42 (s, 2 H) 2.59 (q, J = 7.58 Hz,2 H) 2.17 (s, 9 H) 2.13 (s, 3 H) 1.44 (s, 3 H) 1.43 (s, 3 H) 1.15 (t, J= 7.45 Hz, 3 H) 499.4 37

N-[(4-ethyl-6-methyl-2- oxo-1,2-dihydro-3- pyridinyl)methyl]-3-methyl-1-(1- methylethyl)-6-[6- (methyloxy)-3- pyridinyl]-1H-indole-4-carboxamide 11.49 (s, 1 H) 8.53 (d, J = 2.02 Hz, 1 H) 8.16 (t, J = 5.05Hz, 1 H) 8.09 (dd, J = 8.59, 2.53 Hz, 1 H) 7.79 (d, J = 1.26 Hz, 1 H)7.33 (s, 1 H) 7.22 (d, J = 1.26 Hz, 1 H) 6.91 (d, J = 8.59 Hz, 1 H) 5.92(s, 1 H) 4.86 (quin, J = 6.63 Hz, 1 H) 4.38 (s, 1 H) 4.36 (s, 1 H) 3.90(s, 3 H) 2.59 (q, J = 7.58 Hz, 2 H) 2.17 (s, 3 H) 2.13 (s, 3 H) 1.44 (s,3 H) 1.43 (s, 3 H) 1.14 (t, J = 7.58 Hz, 3 H) 473.1 38

N-[(4-ethyl-6-methyl-2- oxo-1,2-dihydro-3- pyridinyl)methyl]-3-methyl-1-(1- methylethyl)-6-(2- methyl-5-pyrimidinyl)- 1H-indole-4-carboxamide 11.50 (s, 1 H) 9.09 (s, 2 H) 8.18 (t, J = 5.05 Hz, 1 H) 7.96(d, J = 1.26 Hz, 1 H) 7.39 (s, 1 H) 7.32 (d, J = 1.52 Hz, 1 H) 5.92 (s,1 H) 4.90 (quin, J = 6.69 Hz, 1 H) 4.38 (s, 1 H) 4.37 (s, 1 H) 2.65-2.68(m, 3 H) 2.60 (q, J = 7.58 Hz, 2 H) 2.18 (s, 3 H) 2.13 (s, 3 H) 1.45 (s,3 H) 1.43 (s, 3 H) 1.14 (t, J = 7.58 Hz, 3 H) 458.3 39

6-(6-amino-3- pyridinyl)-N-[(4-ethyl-6- methyl-2-oxo-1,2- dihydro-3-pyridinyl)methyl]-3- methyl-1-(1- methylethyl)-1H- indole-4-carboxamide11.50 (s, 1 H) 8.30 (d, J = 2.02 Hz, 1 H) 8.12 (t, J = 5.05 Hz, 1 H)7.76 (dd, J = 8.59, 2.53 Hz, 1 H) 7.66 (d, J = 1.26 Hz, 1 H) 7.27 (s, 1H) 7.14 (d, J = 1.52 Hz, 1 H) 6.53 (d, J = 8.59 Hz, 1 H) 5.98 (s, 2 H)5.92 (s, 1 H) 4.83 (quin, J = 6.63 Hz, 1 H) 4.37 (s, 1 H) 4.36 (s, 1 H)2.59 (q, J = 7.58 Hz, 2 H) 2.16 (s, 3 H) 2.13 (s, 3 H) 1.43 (s, 3 H)1.41 (s, 3 H) 1.14 (t, J = 7.45 Hz, 3 H) 458.2 40

6-[6-(dimethylamino)- 3-pyridinyl]-N-[(4-ethyl- 6-methyl-2-oxo-1,2-dihydro-3- pyridinyl)methyl]-3- methyl-1-(1- methylethyl)-1H-indole-4-carboxamide 11.47 (br.s., 1 H) 8.48 (d, J = 2.27 Hz, 1 H) 8.14(t, J = 4.67 Hz, 1 H) 7.89 (dd, J = 8.72, 2.65 Hz, 1 H) 7.70 (d, J =1.26 Hz, 1 H) 7.28 (s, 1 H) 7.17 (d, J = 1.52 Hz, 1 H) 6.73 (d, J = 8.84Hz, 1 H) 5.92 (s, 1 H) 4.84 (quin, J = 6.57 Hz, 1 H) 4.37 (s, 1 H) 4.36(s, 1 H) 3.07 (s, 6 H) 2.59 (q, J = 7.58 Hz, 2 H) 2.16 (s, 3 H) 2.13 (s,3 H) 1.44 (s, 3 H) 1.42 (s, 3 H) 1.15 (t, J = 7.58 Hz, 3 H) 486.3 41

N-[(4-ethyl-6-methyl-2- oxo-1,2-dihydro-3- pyridinyl)methyl]-3-methyl-1-(1- methylethyl)-6-(6- methyl-3-pyridinyl)-1H-indole-4-carboxamide 11.44 (br.s., 1 H) 8.83 (d, J = 2.02 Hz, 1 H) 8.20(t, J = 4.93 Hz, 1 H) 8.03 (dd, J = 8.08, 2.53 Hz, 1 H) 7.84 (d, J =1.52 Hz, 1 H) 7.31- 7.36 (m, 2 H) 7.26 (d, J = 1.52 Hz, 1 H) 5.92 (s, 1H) 4.88 (quin, J = 6.63 Hz, 1 H) 4.38 (s, 1 H) 4.37 (s, 1 H) 2.59 (q, J= 7.58 Hz, 2 H) 2.18 (s, 3 H) 2.13 (s, 3 H) 1.44 (s, 3 H) 1.43 (s, 3 H)1.14 (t, J = 7.58 Hz, 3 H) 457.2 42

N-[(4,6-dimethyl-2-oxo- 1,2-dihydro-3- pyridinyl)methyl]-3- methyl-1-(1-methylethyl)-6-(1H- pyrazol-3-yl)-1H- indole-4-carboxamide 12.77 (br.s.,1 H) 11.48 (br. s., 1 H) 8.10 (br.s., 1 H) 7.89 (s, 1 H) 7.76 (br.s., 1H) 7.46 (br.s., 1 H) 7.29 (br. s., 1 H) 6.75 (br.s., 1 H) 5.87 (s, 1 H)4.79 (br.s., 1 H) 4.36 (s, 1 H) 4.35 (s, 1 H) 2.25 (s, 3 H) 2.15 (s, 3H) 2.11 (s, 3 H) 1.45 (s, 3 H) 1.43 (s, 3 H) 418.2 43

N-[(4,6-dimethyl-2-oxo- 1,2-dihydro-3- pyridinyl)methyl]-3- methyl-1-(1-methylethyl)-6-(1- methyl-1H-pyrazol-4- yl)-1H-indole-4- carboxamide11.47 (s, 1 H) 8.14 (s, 1 H) 8.05 (t, J = 5.18 Hz, 1 H) 7.89 (s, 1 H)7.69 (d, J = 1.26 Hz, 1 H) 7.23 (s, 1 H) 7.15 (d, J = 1.52 Hz, 1 H) 5.87(s, 1 H) 4.77 (quin, J = 6.69 Hz, 1 H) 4.35 (s, 1 H) 4.34 (s, 1 H) 3.86(s, 3 H) 2.24 (s, 3 H) 2.13 (s, 3 H) 2.11 (s, 3 H) 1.43 (s, 3 H) 1.41(s, 3 H) 432.2 44

N-[(4,6-dimethyl-2-oxo- 1,2-dihydro-3- pyridinyl)methyl]-3- methyl-1-(1-methylethyl)-6-(1H- pyrazol-4-yl)-1H- indole-4-carboxamide 11.50 (br.s.,1 H) 7.95-8.17 (m, 3 H) 7.72 (d, J = 1.01 Hz, 1 H) 7.23 (s, 1 H) 7.20(d, J = 1.52 Hz, 1 H) 5.87 (s, 1 H) 4.79 (quin, J = 6.63 Hz, 1 H) 4.35(s, 1 H) 4.34 (s, 1 H) 2.24 (s, 3 H) 2.13 (s, 3 H) 2.11 (s, 3 H) 1.43(s, 3 H) 1.42 (s, 3 H) 418.2 45

N-[(4,6-dimethyl-2-oxo- 1,2-dihydro-3- pyridinyl)methyl]-3- methyl-1-(1-methylethyl)-6-[1-(2- pyridinylmethyl)-1H- pyrazol-4-yl]-1H-indole-4-carboxamide 11.47 (s, 1 H) 8.56 (d, J = 4.04 Hz, 1 H) 8.33 (s,1 H) 8.07 (t, J = 5.05 Hz, 1 H) 7.99 (s, 1 H) 7.76-7.81 (m, 1 H) 7.73(s, 1 H) 7.33 (dd, J = 6.69, 4.93 Hz, 1 H) 7.24 (s, 1 H) 7.18 (d, J =1.26 Hz, 1 H) 7.10 (d, J = 7.83 Hz, 1 H) 5.87 (s, 1 H) 5.45 (s, 2 H)4.79 (dt, J = 13.14, 6.57 Hz, 1 H) 4.35 (s, 1 H) 4.34 (s, 1 H) 2.24 (s,3 H) 2.13 (s, 3 H) 2.11 (s, 3 H) 1.43 (s, 3 H) 1.41 (s, 3 H) 509.0 46

N-[(4,6-dimethyl-2-oxo- 1,2-dihydro-3- pyridinyl)methyl]-3- methyl-1-(1-methylethyl)-6-(1H- pyrrolo[2,3-b]pyridin-5- yl)-1H-indole-4-carboxamide 11.67 (br.s., 1 H) 11.48 (s, 1 H) 8.60 (d, J = 2.27 Hz, 1 H)8.27 (d, J = 2.02 Hz, 1 H) 8.20 (t, J = 5.05 Hz, 1 H) 7.82 (d, J = 1.26Hz, 1 H) 7.49-7.52 (m, 1 H) 7.32 (s, 1 H) 7.29 (d, J = 1.52 Hz, 1 H)6.51 (dd, J = 3.28, 1.77 Hz, 1 H) 5.87 (s, 1 H) 4.89 (dt, J = 13.33,6.60 Hz, 1 H) 4.38 (s, 1 H) 4.36 (s, 1 H) 2.25 (s, 3 H) 2.19 (s, 3 H)2.11 (s, 3 H) 1.45 (s, 3 H) 1.44 (s, 3 H) 468.0 47

N-[(4,6-dimethyl-2-oxo- 1,2-dihydro-3- pyridinyl)methyl]-3- methyl-1-(1-methylethyl)-6-[1-(2- thienylmethyl)-1H- pyrazol-4-yl]-1H-indole-4-carboxamide 11.38 (br.s., 1 H) 8.26 (s, 1 H) 8.08 (t, J = 4.93Hz, 1 H) 7.96 (s, 1 H) 7.70 (d, J = 1.26 Hz, 1 H) 7.48 (dd, J = 5.05,1.26 Hz, 1 H) 7.23 (s, 1 H) 7.16 (s, 2 H) 7.01 (dd, J = 5.05, 3.28 Hz, 1H) 5.87 (s, 1 H) 5.53 (s, 2 H) 4.78 (quin, J = 6.63 Hz, 1 H) 4.35 (s, 1H) 4.33 (s, 1 H) 2.24 (s, 3 H) 2.13 (s, 3 H) 2.11 (s, 3 H) 1.42 (s, 3 H)1.41 (s, 3 H) 514.2 48

N-((4,6-dimethyl-2- oxo-1,2-dihydropyridin- 3-yl)methyl)-1-isopropyl-3-methyl-6- (3- (methylsulfonamido- methyl)phenyl)-1H-indole-4-carboxamide 11.47 (s, 1 H) 8.18 (t, J = 4.93 Hz, 1 H) 7.70-7.78(m, 2 H) 7.61-7.68 (m, 2 H) 7.44 (t, J = 7.71 Hz, 1 H) 7.30-7.35 (m, 2H) 7.26 (d, J = 1.52 Hz, 1 H) 5.87 (s, 1 H) 4.86 (quin, J = 6.69 Hz, 1H) 4.37 (br.s., 1 H) 4.35 (br.s., 1 H) 4.26 (s, 1 H) 4.24 (s, 1 H) 2.87-2.90 (m, 3 H) 2.22-2.26 (m, 3 H) 2.17 (s, 3 H) 2.11 (s, 3 H) 1.45 (s, 3H) 1.41-1.45 (m, 3 H) 534.9 49

N-((4-benzyl-6-methyl- 2-oxo-1,2- dihydropyridin-3-yl)methyl)-6-bromo-1- isopropyl-3-methyl-1H- indole-4-carboxamide 11.56(s, 1 H) 8.34 (t, J = 5.05 Hz, 1 H) 7.76 (d, J = 1.52 Hz, 1 H) 7.29-7.34(m, 3 H) 7.20-7.26 (m, 3 H) 6.97 (d, J = 1.77 Hz, 1 H) 5.78 (s, 1 H)4.74 (quin, J = 6.63 Hz, 1 H) 4.40 (s, 1 H) 4.39 (s, 1 H) 3.97 (s, 2 H)2.13 (s, 3 H) 2.09 (s, 3 H) 1.40 (s, 3 H) 1.38 (s, 3 H)  505.8/ 507.9 50

6-(6-acetamidopyridin- 3-yl)-N-((4,6-dimethyl- 2-oxo-1,2-dihydropyridin-3- yl)methyl)-1-isopropyl- 3-methyl-1H-indole-4-carboxamide 11.48 (br.s., 1 H) 10.58 (s, 1 H) 8.71 (t, J = 1.64 Hz, 1 H)8.12-8.21 (m, 3 H) 7.85 (d, J = 1.26 Hz, 1 H) 7.34 (s, 1 H) 7.27 (d, J =1.52 Hz, 1 H) 5.87 (s, 1 H) 4.89 (quin, J = 6.57 Hz, 1 H) 4.36 (s, 1 H)4.35 (s, 1 H) 2.25 (s, 3 H) 2.17 (s, 3 H) 2.12 (s, 3 H) 2.11 (s, 3 H)1.45 (s, 3 H) 1.43 (s, 3 H) 486.2 51

6-(6-acetamidopyridin- 3-yl)-1-isopropyl-3- methyl-N-((6-methyl-2-oxo-4-propyl-1,2- dihydropyridin-3- yl)methyl)-1H-indole-4- carboxamide11.49 (s, 1 H) 10.58 (s, 1 H) 8.70 (s, 1 H) 8.13-8.18 (m, 3 H) 7.83-7.87(m, 1 H) 7.35 (s, 1 H) 7.26 (d, J = 1.26 Hz, 1 H) 5.90 (s, 1 H) 4.89(dt, J = 13.20, 6.66 Hz, 1 H) 4.38 (br.s., 1 H) 4.36 (br.s., 1 H)2.53-2.58 (m, 2 H) 2.18 (s, 3 H) 2.12 (s, 5 H) 1.54-1.62 (m, 2 H) 1.45(s, 3 H) 1.43 (s, 3 H) 0.94 (t, J = 7.33 Hz, 3 H) 514.2 52

1-isopropyl-3-methyl- N-((6-methyl-2-oxo-4- propyl-1,2-dihydropyridin-3- yl)methyl)-6-(1-(2- morpholinoethyl)-1H-pyrazol-4-yl)-1H- indole-4-carboxamide 11.47 (br.s., 1 H) 8.18 (s, 1 H)8.03 (t, J = 5.05 Hz, 1 H) 7.89 (s, 1 H) 7.69 (d, J = 1.01 Hz, 1 H) 7.24(d, J = 1.01 Hz, 1 H) 7.15 (d, J = 1.26 Hz, 1 H) 5.90 (s, 1 H) 4.78(quin, J = 6.63 Hz, 1 H) 4.37 (s, 1 H) 4.35 (s, 1 H) 4.24 (t, J = 6.69Hz, 2 H) 3.52-3.58 (m, 4 H) 2.75 (t, J = 6.69 Hz, 2 H) 2.52- 2.58 (m, 2H) 2.39-2.47 (m, 4 H) 2.13 (s, 3 H) 2.12 (s, 3 H) 1.53-1.62 (m, 2 H)1.43 (s, 3 H) 1.42 (s, 3 H) 0.95 (t, J = 7.33 Hz, 3 H) 559.0 53

N-[(4,6-dimethyl-2-oxo- 1,2-dihydro-3- pyridinyl)methyl]-3- methyl-1-(1-methylethyl)-6-(3- pyridinyl)-1H-indole-4- carboxamide 1.44 (d, J = 6.57Hz, 6 H), 2.10 (s, 3 H), 2.17 (s, 3 H), 2.24 (s, 3 H), 4.36 (d, J = 5.05Hz, 2 H), 4.89 (dt, J = 13.14, 6.57 Hz, 1 H), 5.87 (s, 1 H), 7.35 (s, 1H), 7.40 (s, 1 H), 7.73 (dd, J = 7.83, 5.31 Hz, 1 H), 7.98 (s, 1 H),8.21 (t, J = 5.05 Hz, 1 H), 8.49 (d, J = 8.08 Hz, 1 H), 8.65 (d, J =4.55 Hz, 1 H), 9.13 (s, 1 H), 11.48 (br.s., 1 H) 429.0 54

6-bromo-3-methyl-1- (1-methylethyl)-N-[(6- methyl-2-oxo-4-propyl-1,2-dihydro-3- pyridinyl)methyl]-1H- indole-4-carboxamide 0.93 (t, 3 H),1.38 (d, J = 6.57 Hz, 6 H), 1.44-1.67 (m, 2 H), 2.12 (d, J = 5.31 Hz, 6H), 4.31 (d, J = 5.05 Hz, 2 H), 4.73 (dt, J = 13.14, 6.57 Hz, 1 H), 5.89(s, 1 H), 6.99 (d, J = 1.52 Hz, 1 H), 7.33 (s, 1 H), 7.76 (d, J = 1.52Hz, 1 H), 8.20 (t, J = 4.80 Hz, 1 H), 11.48 (s, 1 H)  458.2/ 460.1 55

6-(1H- benzo[d]imidazol-2-yl)- N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin- 3-yl)methyl)-1- isopropyl-3-methyl-1H-indole-4-carboxamide 1.50 (d, J = 6.82 Hz, 6 H), 2.12 (s, 3 H), 2.19 (s,3 H), 2.26 (s, 3 H), 4.39 (d, J = 5.05 Hz, 2 H), 4.82 (spt, J = 6.44 Hz,1 H), 5.88 (s, 1 H), 7.12-7.24 (m, 2 H), 7.44 (s, 1 H), 7.51 (d, J =6.82 Hz, 1 H), 7.64 (d, J = 7.07 Hz, 1 H), 7.82 (d, J = 1.52 Hz, 1 H),8.22 (t, J = 5.05 Hz, 1 H), 8.33 (d, J = 1.26 Hz, 1 H), 11.49 (br.s., 1H), 12.83 (s, 1 H) 468.4 56

3-methyl-1-(1- methylethyl)-N-[(6- methyl-2-oxo-4-propyl- 1,2-dihydro-3-pyridinyl)methyl]-6-(2- methyl-3-pyridinyl)-1H- indole-4-carboxamide0.87-0.97 (m, 3 H), 1.41 (d, J = 6.57 Hz, 6 H), 1.55 (m, J = 15.16,7.52, 7.36, 7.36 Hz, 2 H), 2.11 (s, 3 H), 2.19 (s, 3 H), 2.48 (s, 3 H),3.17 (d, J = 5.31 Hz, 5 H), 4.34 (d, J = 5.05 Hz, 2 H), 4.78 (dt, J =13.20, 6.66 Hz, 1 H), 5.88 (s, 1 H), 6.91 (d, J = 1.52 Hz, 1 H), 7.29(dd, J = 7.58, 4.80 Hz, 2 H), 7.35 (s, 1 H), 7.54 (d, J = 1.26 Hz, 1 H),7.65 (dd, J = 7.58, 1.52 Hz, 1 H), 8.11 (t, J = 5.05 Hz, 1 H), 8.44 (dd,J = 4.80, 1.52 Hz, 1 H), 11.47 (br.s., 1 H) 471.4 57

3-methyl-1-(1- methylethyl)-N-[(6- methyl-2-oxo-4-propyl- 1,2-dihydro-3-pyridinyl)methyl]-6-[6- (4-methyl-1- piperazinyl)-3-pyridinyl]-1H-indole-4- carboxamide 0.93 (t, J = 7.33 Hz, 3 H), 1.42 (d,J = 6.57 Hz, 5 H), 1.56 (m, J = 7.60, 7.60, 7.60, 7.39, 7.20 Hz, 2 H),2.12 (s, 3 H), 2.16 (s, 3 H), 2.23 (s, 3 H), 2.43 (t, J = 4.93 Hz, 4 H),3.44- 3.61 (m, 5 H), 4.36 (d, J = 5.05 Hz, 2 H), 4.84 (ddd, J = 13.26,6.57, 6.44 Hz, 1 H), 5.89 (s, 1 H), 6.92 (d, J = 8.84 Hz, 1 H), 7.17 (d,J = 1.52 Hz, 1 H), 7.28 (s, 1 H), 7.72 (d, J = 1.26 Hz, 1 H), 7.91 (dd,J = 8.84, 2.53 Hz, 1 H), 8.11 (t, J = 4.93 Hz, 1 H), 8.17 (s, 1 H), 8.49(d, J = 2.53 Hz, 1 H), 11.49 (br.s., 1 H) 555.1 58

3-methyl-1-(1- methylethyl)-N-[(6- methyl-2-oxo-4-propyl- 1,2-dihydro-3-pyridinyl)methyl]-6-[5- (4-methyl-1- piperazinyl)-3-pyridinyl]-1H-indole-4- carboxamide 0.93 (t, J = 7.33 Hz, 3 H), 1.43 (d,J = 6.57 Hz, 6 H), 1.57 (m, J = 7.54, 7.54, 7.54, 7.33, 7.20 Hz, 2 H),2.12 (s, 3 H), 2.17 (s, 3 H), 2.24 (s, 3 H), 2.44 (t, J = 4.80 Hz, 4 H),2.52- 2.58 (m, 2 H), 3.52-3.61 (m, 4 H), 4.36 (d, J = 4.80 Hz, 2 H),4.92 (dt, J = 13.14, 6.57 Hz, 1 H), 5.90 (s, 1 H), 7.03 (d, J = 5.31 Hz,1 H), 7.11 (s, 1 H), 7.30 (d, J = 1.26 Hz, 1 H), 7.38 (s, 1 H), 7.90 (d,J = 1.26 Hz, 1 H), 8.09-8.31 (m, 3 H) 555.1 59

3-methyl-1-(1- methylethyl)-N-[(6- methyl-2-oxo-4-propyl- 1,2-dihydro-3-pyridinyl)methyl]-6-(6- methyl-3-pyridinyl)-1H- indole-4-carboxamide0.93 (t, J = 7.33 Hz, 3 H), 1.45 (d, J = 6.57 Hz, 6 H), 1.57 (m, J =15.16, 7.52, 7.36, 7.36 Hz, 2 H), 2.12 (s, 3 H), 2.17 (s, 3 H),2.53-2.59 (m, 2 H), 2.68 (s, 3 H), 4.37 (d, J = 5.05 Hz, 2 H), 4.90 (dt,J = 13.33, 6.60 Hz, 1 H), 5.91 (s, 1 H), 7.11 (s, 1 H), 7.37 (d, J =1.26 Hz, 1 H), 7.43 (s, 6 H), 7.81 (d, J = 8.34 Hz, 6 H), 8.02 (d, J =1.26 Hz, 6 H), 8.17 (t, J = 5.05 Hz, 6 H), 8.66 (br.s., 6 H), 9.09 (d, J= 1.77 Hz, 1 H), 11.50 (br.s., 1 H) 471.4 60

6-{4- [(dimethylamino)methyl] phenyl}-3-methyl-1- (1-methylethyl)-N-[(6-methyl-2-oxo-4-propyl- 1,2-dihydro-3- pyridinyl)methyl]-1H-indole-4-carboxamide 0.93 (t, J = 7.33 Hz, 3 H), 1.43 (d, J = 6.82 Hz, 6H), 1.57 (dq, J = 15.06, 7.44 Hz, 2H), 2.12 (s, 3 H), 2.15-2.20 (m, 9H), 2.53(1H), 3.41 (s, 2 H), 4.36 (d, J = 5.05 Hz, 2 H), 4.86 (quin, J =6.63 Hz, 1 H), 5.89 (s, 1 H), 7.24 (d, J = 1.26 Hz, 1 H), 7.32 (s, 1 H),7.35 (d, J = 8.34 Hz, 2 H), 7.68 (d, J = 8.08 Hz, 2 H), 7.76 (d, J =1.26 Hz, 1 H), 8.15 (t, J = 4.93 Hz, 1 H), 11.47 (br. s., 1 H) 513.4 61

6-methyl-3-({2-[3- methyl-1-(1- methylethyl)-6- (1,2,3,6-tetrahydro-4-pyridinyl)-1H-indol-4- yl]-2-oxoethyl}amino)- 4-propyl-2(1H)- pyridinone0.93 (t, J = 7.33 Hz, 3 H), 1.40 (d, J = 6.57 Hz, 6 H), 1.50- 1.65 (m, 2H), 2.12 (d, J = 6.06 Hz, 6 H), 3.08 (br.s., 2 H), 3.52 (br.s., 2 H),4.34 (d, J = 5.05 Hz, 2 H), 4.78 (dt, J = 13.20, 6.66 Hz, 1 H), 5.89 (s,1 H), 6.18 (br.s., 1 H), 7.05 (d, J = 1.26 Hz, 1 H), 7.27 (s, 1 H), 7.50(s, 3 H), 8.03 (t, J = 5.05 Hz, 1 H), 11.49 (br.s., 1 H) 461.2 62

N-[(4,6-dimethyl-2-oxo- 1,2-dihydro-3- pyridinyl)methyl]-1-(1-methylethyl)-6-(3- pyridinyl)-1H-indole-4- carboxamide 11.55 (br.s., 1H), 9.11 (d, J = 1.8 Hz, 1 H), 8.60 (dd, J = 5.1, 1.5 Hz, 1 H), 8.36 (m,2 H), 8.08 (s, 1 H), 7.78 (d, J = 1.5 Hz, 1 H), 7.68 (d, J = 3.3 Hz, 1H), 7.61 (dd, J = 8.0, 4.9 Hz, 1 H), 6.93 (d, J = 3.3 Hz, 1 H), 5.89 (s,1 H), 4.98 (quin, J = 6.6 Hz, 1 H), 4.38 (d, J = 5.1 Hz, 2 H), 2.23 (s,3 H), 2.12 (s, 3 H), 1.49 (d, J = 6.8 Hz, 6 H) 415.0 63

6-bromo-1-cyclopentyl- N-[(6-methyl-2-oxo-4- propyl-1,2-dihydro-3-pyridinyl)methyl]-1H- indole-4-carboxamide 11.56 (s, 1 H), 8.30 (t, J =5.2 Hz, 1 H), 7.93 (s, 1 H), 7.59 (d, J = 3.3 Hz, 1 H), 7.52 (d, J = 1.5Hz, 1 H), 6.85 (d, J = 3.3 Hz, 1 H), 5.91 (s, 1 H), 4.94 (m, 1 H), 4.35(d, J = 5.1 Hz, 2 H), 2.53 (d, J = 7.8 Hz, 2 H), 2.12 (m, 5 H), 1.80 (m,4 H), 1.71 (m, 2 H), 1.52 (m, 2 H), 0.90 (t, J = 7.3 Hz, 3 H) 470.1 64

1-(1-methylethyl)-N- [(6-methyl-2-oxo-4- propyl-1,2-dihydro-3-pyridinyl)methyl]-6-[6- (4-methyl-1- piperazinyl)-3-pyridinyl]-1H-indole-4- carboxamide 11.56 (s, 1 H), 8.56 (d, J = 2.5 Hz,1 H), 8.27 (t, J = 5.2 Hz, 1 H), 7.97 (dd, J = 9.0, 2.7 Hz, 1 H), 7.87(s, 1 H), 7.65 (d, J = 1.3 Hz, 1 H), 7.58 (d, J = 3.3 Hz, 1 H), 6.93 (d,J = 9.1 Hz, 1 H), 6.86 (d, J = 3.0 Hz, 1 H), 5.91 (s, 1 H), 4.92 (m, 1H), 4.39 (d, J = 5.1 Hz, 2 H), 3.52 (m, 4 H), 2.54 (m, 2 H), 2.41 (m, 4H), 2.22 (m, 3 H), 2.13 (s, 3 H), 1.53 (m, 2 H), 1.47 (d, J = 6.6 Hz, 6H), 0.90 (t, J = 7.3 Hz, 3 H) 541.5 65

6-bromo-1-cyclobutyl- N-[(6-methyl-2-oxo-4- propyl-1,2-dihydro-3-pyridinyl)methyl]-1H- indole-4-carboxamide 11.56 (s, 1 H), 8.31 (t, J =5.1 Hz, 1 H), 7.87 (s, 1 H), 7.73 (d, J = 3.3 Hz, 1 H), 7.53 (d, J = 1.5Hz, 1 H), 6.88 (d, J = 3.3 Hz, 1 H), 5.91 (s, 1 H), 5.04 (t, J = 8.3 Hz,1 H), 4.35 (d, J = 5.1 Hz, 2 H), 2.54 (s, 1 H), 2.41 (m, 4 H), 2.13 (s,3 H), 1.83 (m, 2 H), 1.52 (m, 2 H), 0.90 (t, J = 7.3 Hz, 3 H) 445.9 66

1-cyclobutyl-6-{4- [(dimethylamino)methyl] phenyl}-N-[(6-methyl-2-oxo-4-propyl-1,2- dihydro-3- pyridinyl)methyl]-1H-indole-4-carboxamide 11.55 (s, 1 H), 8.32 (t, J = 5.1 Hz, 1 H), 7.89 (s,1 H), 7.73 (m, 4 H), 7.37 (d, J = 8.1 Hz, 2 H), 6.90 (d, J = 3.0 Hz, 1H), 5.91 (s, 1 H), 5.16 (t, J = 8.5 Hz, 1 H), 4.40 (d, J = 5.1 Hz, 2 H),3.42 (s, 2 H), 2.55 (m, 3 H), 2.43 (m, 2 H), 2.15 (m, 9 H), 1.85 (dt, J= 9.8, 4.8 Hz, 2 H), 1.54 (m, 2 H), 0.90 (t, J = 7.3 Hz, 3 H) 511.3 67

1-cyclopropyl-6-{4- [(dimethylamino)methyl] phenyl}-N-[(4,6-dimethyl-2-oxo-1,2- dihydro-3- pyridinyl)methyl]-3- methyl-1H-indole-4-carboxamide 11.46 (s, 1 H), 8.19 (t, J = 5.1 Hz, 1 H), 7.76 (d, J = 1.5Hz, 1 H), 7.67 (m, J = 8.1 Hz, 2 H), 7.37 (m, J = 8.1 Hz, 2 H), 7.28 (d,J = 1.5 Hz, 1 H), 7.14 (d, J = 1.0 Hz, 1 H), 5.86 (s, 1 H), 4.34 (d, J =5.1 Hz, 2 H), 3.43 (m, 3 H), 2.23 (s, 3 H), 2.14 (m, 12 H), 1.06 (m, 2H), 0.92 (m, 2 H) 483.1 68

1-cyclopropyl-N-[(4,6- dimethyl-2-oxo-1,2- dihydro-3-pyridinyl)methyl]-3- methyl-6-[6- (methyloxy)-3- pyridinyl]-1H-indole-4-carboxamide 11.46 (br.s., 1 H), 8.52 (d, J = 2.3 Hz, 1 H), 8.19 (t, J =4.9 Hz, 1 H), 8.07 (dd, J = 8.6, 2.5 Hz, 1 H), 7.76 (d, J = 1.5 Hz, 1H), 7.25 (d, J = 1.5 Hz, 1 H), 7.15 (d, J = 1.0 Hz, 1 H), 6.92 (d, J =8.6 Hz, 1 H), 5.86 (s, 1 H), 4.34 (d, J = 5.1 Hz, 2 H), 3.90 (s, 3 H),3.42 (m, 1 H), 2.22 (m, 3 H), 2.10 (s, 3 H), 2.13 (s, 3 H), 1.06 (m, 2H), 0.92 (m, 2 H) 457.1 69

N-[(4,6-dimethyl-2-oxo- 1,2-dihydro-3- pyridinyl)methyl]-3- methyl-1-(1-methylethyl)-6-[3- (methylsulfonyl)phenyl]- 1H-indole-4- carboxamide11.47 (s, 1 H), 8.23 (m, 2 H), 8.12 (d, J = 7.8 Hz, 1 H), 7.89 (m, 2 H),7.73 (m, 1 H), 7.39 (s, 1 H), 7.32 (d, J = 1.5 Hz, 1 H), 5.87 (s, 1 H),4.92 (m, 1 H), 4.36 (d, J = 4.8 Hz, 2 H), 3.31 (s, 3 H), 2.23 (m, 3 H),2.18 (m, 3 H), 2.11 (s, 3 H), 1.42 (m, 6 H) 505.9 70

6-bromo-1-cyclopentyl- N-[(4,6-dimethyl-2-oxo- 1,2-dihydro-3-pyridinyl)methyl]-3- methyl-1H-indole-4- carboxamide 11.48 (s, 1 H),8.24 (t, J = 4.9 Hz, 1 H), 7.77 (d, J = 1.8 Hz, 1 H), 7.29 (s, 1 H),7.00 (d, J = 1.8 Hz, 1 H), 5.86 (s, 1 H), 4.86 (t, J = 7.1 Hz, 1 H),4.30 (d, J = 4.8 Hz, 2 H), 2.21 (s, 3 H), 2.08 (m, 8 H), 1.74 (m, 6 H)455.9 71

1-cyclopentyl-6-{4- [(dimethylamino)methyl] phenyl}-N-[(4,6-dimethyl-2-oxo-1,2- dihydro-3- pyridinyl)methyl]-3- methyl-1H-indole-4-carboxamide 11.47 (s, 1 H), 8.18 (t, J = 5.1 Hz, 1 H), 7.78 (d, J = 1.5Hz, 1 H), 7.69 (m, J = 8.1 Hz, 2 H), 7.36 (m, J = 8.3 Hz, 2 H), 7.26 (m,2 H), 5.86 (s, 1 H), 5.00 (d, J = 7.1 Hz, 1 H), 4.35 (d, J = 5.1 Hz, 2H), 3.41 (s, 2 H), 2.23 (s, 3 H), 2.14 (m, 14 H), 1.78 (m, 6 H) 511.3 72

3-methyl-1-(1- methylethyl)-N-[(6- methyl-2-oxo-4-propyl- 1,2-dihydro-3-pyridinyl)methyl]-6-(1- methyl-1H-pyrazol-4- yl)-1H-indole-4-carboxamide 11.49 (s, 1 H), 8.12 (s, 1 H), 8.01 (t, J = 5.1 Hz, 1 H),7.87 (s, 1 H), 7.69 (d, J = 1.3 Hz, 1 H), 7.23 (s, 1 H), 7.14 (d, J =1.5 Hz, 1 H), 5.90 (s, 1 H), 4.77 (quin, J = 6.6 Hz, 1 H), 4.35 (d, J =5.1 Hz, 2 H), 3.86 (s, 3 H), 2.54 (m, 2 H), 2.11 (m, 6 H), 1.57 (sxt, J= 7.5 Hz, 2 H), 1.42 (d, J = 6.6 Hz, 6 H), 0.94 (t, J = 7.3 Hz, 3 H)460.1 73

N-((4,6-dimethyl-2- oxo-1,2-dihydropyridin- 3-yl)methyl)-1-isopropyl-3-methyl-6- (2-(4-methylpiperazin- 1-yl)pyrimidin-5-yl)-1H-indole-4-carboxamide 11.48 (s, 1 H), 8.76 (s, 2 H), 8.13 (t, J = 5.2 Hz,1 H), 7.77 (d, J = 1.5 Hz, 1 H), 7.30 (s, 1 H), 7.19 (d, J = 1.3 Hz, 1H), 5.87 (s, 1 H), 4.83 (quin, J = 6.6 Hz, 1 H), 4.35 (d, J = 5.1 Hz, 2H), 3.77 (m, 4 H), 2.38 (t, J = 5.1 Hz, 4 H), 2.23 (d, J = 6.3 Hz, 6 H),2.16 (s, 3 H), 2.11 (s, 3 H), 1.42 (d, J = 6.6 Hz, 6 H) 528.0 74

6-bromo-1-(1- methylethyl)-N-[(6- methyl-2-oxo-1,2-dihydro-4,4′-bipyridin- 3-yl)methyl]-1H-indole- 4-carboxamide 11.99(br.s., 1 H) 8.66 (d, J = 6.06 Hz, 2 H) 8.33 (t, J = 4.42 Hz, 1 H) 7.93(s, 1 H) 7.63 (d, J = 3.28 Hz, 1 H) 7.42- 7.48 (m, 3 H) 6.84 (d, J =3.03 Hz, 1 H) 6.00 (s, 1 H) 4.76-4.88 (m, 1 H) 4.16 (d, J = 4.29 Hz, 2H) 2.23 (s, 3 H) 1.43 (d, J = 6.57 Hz, 6 H) 480.7 75

N-((4,6-dimethyl-2- oxo-1,2-dihydropyridin- 3-yl)methyl)-1-(2-(dimethylamino)propyl)- 3-methyl-6-(6-(4- methylpiperazin-1-yl)pyridin-3-yl)-1H- indole-4-carboxamide 0.82 (d, J = 6.57 Hz, 3 H),2.10 (s, 3 H), 2.14 (s, 3 H), 2.20 (s, 6 H), 2.23 (d, J = 5.05 Hz, 6 H),2.37-2.46 (m, 4 H), 2.98 (q, J = 6.82 Hz, 1 H), 3.48-3.58 (m, 4 H),3.95- 4.27 (m, 1 H), 4.34 (d, J = 5.05 Hz, 2 H), 5.86 (s, 1 H), 6.92 (d,J = 9.09 Hz, 1 H), 7.14 (s, 1 H), 7.17 (d, J = 1.26 Hz, 1 H), 7.68 (d, J= 1.26 Hz, 1 H), 7.90 (dd, J = 8.84, 2.78 Hz, 1 H), 8.17 (t, J = 5.05Hz, 1 H), 8.50 (d, J = 2.27 Hz, 1 H), 11.47 (br.s., 1 H) 570.6 76

N-((4,6-dimethyl-2- oxo-1,2-dihydropyridin- 3-yl)methyl)-1-isopropyl-3-methyl-6- (2-methylpyrimidin-4- yl)-1H-indole-4- carboxamide1.46 (d, J = 6.57 Hz, 6 H), 2.12 (s, 3 H), 2.18 (s, 3 H), 2.25 (s, 3 H),2.68 (s, 3 H), 4.37 (d, J = 4.80 Hz, 2 H), 4.92 (spt, J = 6.57 Hz, 1 H),5.88 (s, 1 H), 7.48 (s, 1 H), 7.84 (d, J = 1.26 Hz, 1 H), 7.98 (d, J =5.56 Hz, 1 H), 8.22 (t, J = 4.93 Hz, 1 H), 8.37 (d, J = 1.26 Hz, 1 H),8.68 (d, J = 5.56 Hz, 1 H), 11.48 (s, 1 H) 444.4 77

6-bromo-N-((4,6- dimethyl-2-oxo-1,2- dihydropyridin-3-yl)methyl)-3-methyl-1- (tetrahydro-2H-pyran- 4-yl)-1H-indole-4-carboxamide 1.76-1.86 (m, 2 H), 1.93 (dd, J = 12.00, 4.17 Hz, 2 H), 2.12(d, J = 5.81 Hz, 6 H), 2.22 (s, 3 H), 3.49-3.62 (m, 2 H), 3.97 (dd, J =11.12, 3.79 Hz, 2 H), 4.31 (d, J = 5.05 Hz, 2 H), 4.64 (br.s., 1 H),5.86 (s, 1 H), 7.02 (d, J = 1.52 Hz, 1 H), 7.36 (s, 1 H), 7.88 (d, J =1.52 Hz, 1 H), 8.24 (t, J = 4.93 Hz, 1 H), 11.47 (br. s., 1 H) 472, 474   78

6-bromo-N-((4,6- dimethyl-2-oxo-1,2- dihydropyridin-3- yl)methyl)-1-(2-(dimethylamino)propyl)- 3-methyl-1H-indole-4- carboxamide (CHLOROFORM-d)0.90 (d, J = 6.57 Hz, 3 H), 2.15 (s, 3 H), 2.22 (s, 3 H), 2.34 (s, 6 H),2.39 (s, 3 H), 2.88-3.11 (m, 1 H), 3.81 (dd, J = 14.27, 8.46 Hz, 1 H),4.19 (dd, J = 14.02, 4.42 Hz, 1 H), 4.57 (d, J = 5.56 Hz, 2 H), 5.93 (s,1 H), 6.86 (s, 1 H), 7.20 (d, J = 1.52 Hz, 1 H), 7.45 (d, J = 1.52 Hz, 1H), 12.52 (br. s., 1 H)  473.2, 475.2 79

6-bromo-N-[(4-ethyl-6- methyl-2-oxo-1,2- dihydro-3-pyridinyl)methyl]-1-(1- methylethyl)-1H- indole-4-carboxamide 11.56 (s,1 H) 8.31 (t, J = 5.18 Hz, 1 H) 7.92 (s, 1 H) 7.63 (d, J = 3.03 Hz, 1 H)7.52 (d, J = 1.52 Hz, 1 H) 6.86 (d, J = 3.28 Hz, 1 H) 5.93 (s, 1 H)4.75-4.90 (m, 1 H) 4.35 (d, J = 5.05 Hz, 2 H) 2.54-2.60 (m, 2 H) 2.14(s, 3 H) 1.43 (d, J = 6.57 Hz, 6 H) 1.11 (t, J = 7.33 Hz, 3 H) 80

6-{4- [(dimethylamino)methyl] phenyl}-N-[(4-ethyl-6- methyl-2-oxo-1,2-dihydro-3- pyridinyl)methyl]-1-(1- methylethyl)-1H- indole-4-carboxamide11.56 (s, 1 H) 8.33 (t, J = 5.05 Hz, 1 H) 7.92 (s, 1 H) 7.70- 7.78 (m, 3H) 7.62 (d, J = 3.28 Hz, 1 H) 7.37 (d, J = 8.34 Hz, 2 H) 6.88 (d, J =3.28 Hz, 1 H) 5.93 (s, 1 H) 4.87-5.04 (m, 1 H) 4.41 (d, J = 5.31 Hz, 2H) 3.42 (s, 2 H) 2.59 (q, J = 7.58 Hz, 2 H) 2.17 (s, 6 H) 2.14 (s, 3 H)1.48 (d, J = 6.82 Hz, 6 H) 1.12 (t, J = 7.33 Hz, 3 H) 485.3 81

N-[(4-ethyl-6-methyl-2- oxo-1,2-dihydro-3- pyridinyl)methyl]-1-(1-methylethyl)-6-[6-(4- methyl-1-piperazinyl)- 3-pyridinyl]-1H-indole-4-carboxamide 11.57 (br.s., 1 H) 8.57 (d, J = 2.27 Hz, 1 H) 8.30 (t, J =5.05 Hz, 1 H) 7.98 (dd, J = 8.97, 2.65 Hz, 1 H) 7.88 (s, 1 H) 7.66 (d, J= 1.26 Hz, 1 H) 7.59 (d, J = 3.28 Hz, 1 H) 6.93 (d, J = 9.09 Hz, 1 H)6.87 (d, J = 3.03 Hz, 1 H) 5.93 (s, 1 H) 4.88-4.98 (m, 1 H) 4.40 (d, J =5.05 Hz, 2 H) 3.49- 3.59 (m, 4 H) 2.58 (q, J = 7.58 Hz, 2 H) 2.37-2.45(m, 4 H) 2.23 (s, 3 H) 2.14 (s, 3 H) 1.47 (d, J = 6.82 Hz, 6 H) 1.12 (t,J = 7.33 Hz, 3 H) 527.2 82

N-[(4-ethyl-6-methyl-2- oxo-1,2-dihydro-3- pyridinyl)methyl]-1-(1-methylethyl)-6-[6- (methyloxy)-3- pyridinyl]-1H-indole-4- carboxamide11.57 (br.s., 1 H) 8.60 (br. s., 1 H) 8.31 (br.s., 1 H) 8.11-8.19 (m, 1H) 7.94 (s, 1 H) 7.58-7.73 (m, 2 H) 6.85-6.99 (m, 2 H) 5.93 (s, 1 H)4.87-5.02 (m, 1 H) 4.40 (d, J = 4.29 Hz, 2 H) 3.91 (s, 3 H) 2.55-2.64(m, 2 H) 2.14 (s, 3 H) 1.48 (d, J = 6.57 Hz, 6 H) 1.12 (t, J = 7.33 Hz,3 H) 459.2 83

6-[6-(acetylamino)-3- pyridinyl]-1-(1- methylethyl)-N-[(6-methyl-2-oxo-4-propyl- 1,2-dihydro-3- pyridinyl)methyl]-1H-indole-4-carboxamide 11.56 (s, 1 H) 10.58 (s, 1 H) 8.76 (d, J = 2.02 Hz,1 H) 8.32 (t, J = 4.93 Hz, 1 H) 8.14- 8.23 (m, 2 H) 8.00 (s, 1 H) 7.73(d, J = 1.26 Hz, 1 H) 7.65 (d, J = 3.03 Hz, 1 H) 6.90 (d, J = 3.28 Hz, 1H) 5.92 (s, 1 H) 4.92-5.03 (m, 1 H) 4.41 (d, J = 5.05 Hz, 2 H) 2.53-2.58(m, 2 H) 2.13 (d, J = 4.04 Hz, 6 H) 1.51-1.61 (m, 2 H) 1.48 (d, J = 6.57Hz, 6 H) 0.91 (t, J = 7.33, 3 H) 500.1 84

6-(4-fluorophenyl)-1- (1-methylethyl)-N-[(6- methyl-2-oxo-4-propyl-1,2-dihydro-3- pyridinyl)methyl]-1H- indole-4-carboxamide 11.56 (s, 1 H)8.31 (t, J = 5.05 Hz, 1 H) 7.92 (s, 1 H) 7.80- 7.86 (m, 2 H) 7.68 (d, J= 1.52 Hz, 1 H) 7.63 (d, J = 3.28 Hz, 1 H) 7.27-7.34 (m, 2 H) 6.88 (d, J= 3.03 Hz, 1 H) 5.92 (s, 1 H) 4.91-5.00 (m, 1 H) 4.41 (d, J = 5.05 Hz, 2H) 2.53- 2.58 (m, 2 H) 2.13 (s, 3 H) 1.51-1.59 (m, 2 H) 1.48 (d, J =6.82 Hz, 6 H) 0.91 (t, J = 7.33 Hz, 3 H) 460.1 85

6-[4- (acetylamino)phenyl]- 1-(1-methylethyl)-N- [(6-methyl-2-oxo-4-propyl-1,2-dihydro-3- pyridinyl)methyl]-1H- indole-4-carboxamide 11.56(br.s., 1 H) 10.02 (s, 1 H) 8.29 (t, J = 5.05 Hz, 1 H) 7.89 (s, 1 H)7.57-7.75 (m, 6 H) 6.86 (d, J = 3.28 Hz, 1 H) 5.92 (s, 1 H) 4.94 (quin,J = 6.57 Hz, 1 H) 4.41 (d, J = 5.05 Hz, 2 H) 2.57-2.53 (m, 2 H) 2.13 (s,3 H) 2.07 (s, 3 H) 1.51-1.60 (m, 2 H) 1.48 (d, J = 6.57 Hz, 6 H) 0.91(t, J = 7.33 Hz, 3 H) 499.4 86

methyl 4-[4-({[(4,6- dimethyl-2-oxo-1,2- dihydro-3-pyridinyl)methyl]amino} carbonyl)-3-methyl-1- (1-methylethyl)-1H-indol-6-yl]benzoate 11.48 (s, 1 H) 8.23 (t, J = 5.05 Hz, 1 H) 8.01-8.07(m, 2 H) 7.90-7.96 (m, 3 H) 7.39 (s, 1 H) 7.33 (d, J = 1.26 Hz, 1 H)5.87 (s, 1 H) 4.91 (t, J = 6.69 Hz, 1 H) 4.36 (d,J = 4.80 Hz, 2 H)3.88(s, 3 H) 2.24 (s, 3 H) 2.18 (s, 3 H) 2.11 (s, 3 H) 1.44 (d, J = 6.57Hz, 6 H) 486.1 87

methyl 5-[3-methyl-1- (1-methylethyl)-4-({[(6- methyl-2-oxo-4-propyl-1,2-dihydro-3- pyridinyl)methyl]amino} carbonyl)-1H-indol-6- yl]-2-pyridinecarboxylate 11.50 (s, 1 H) 9.13 (d, J = 1.77 Hz, 1 H) 8.36 (dd,J = 8.34, 2.27 Hz, 1 H) 8.23 (t, J = 5.05 Hz, 1 H) 8.13 (d, J = 8.34 Hz,1 H) 8.02 (d, J = 1.52 Hz, 1 H) 7.43 (s, 1 H) 7.37 (d, J = 1.52 Hz, 1 H)5.91 (s, 1 H) 4.88-4.99 (m, 1 H) 4.38 (d, J = 5.05 Hz, 2 H) 3.91 (s, 3H) 2.53-2.59 (m, 2 H) 2.19 (s, 3 H) 2.13 (s, 3 H) 1.52-1.64 (m, 2 H)1.45 (d, J = 6.57 Hz, 6 H) 0.94 (t, J = 7.33 Hz, 3 H) 515.1 88

methyl 3-[3-methyl-1- (1-methylethyl)-4-({[(6- methyl-2-oxo-4-propyl-1,2-dihydro-3- pyridinyl)methyl]amino} carbonyl)-1H-indol-6- yl]benzoate11.49 (br.s., 1 H) 8.19-8.31 (m, 2 H) 8.01-8.08 (m, 1 H) 7.95-7.90 (m, 1H) 7.85 (s, 1 H) 7.59-7.65 (m, 1 H) 7.37 (s, 1 H) 7.26 (s, 1 H) 5.91(br.s., 1 H) 4.87-4.97 (m, 1 H) 4.38 (d, J = 4.29 Hz, 2 H) 3.91 (s, 3 H)2.55-2.62 (m, 2 H) 2.19 (s, 3 H) 2.12 (s, 3 H) 1.55-1.65 (m, 2 H) 1.44(d, J = 6.57 Hz, 6 H) 0.94 (t, J = 7.2 Hz, 3 H) 514.2 89

6-bromo-N-((6-ethyl-4- methyl-2-oxo-1,2- dihydropyridin-3-yl)methyl)-1-isopropyl- 1H-indole-4- carboxamide 8.36 (br.s., 1H), 7.92(s, 1H), 7.63 (d, J = 3.28 Hz, 1H), 7.53 (d, J = 1.77 Hz, 1H), 6.88 (d,J = 3.28 Hz, 1H), 5.91 (s, 1H), 4.82 (dt, J = 6.60, 13.33 Hz, 1H), 4.33(d, J = 5.05 Hz, 2H), 2.42 (q, J = 7.58 Hz, 2H), 2.23 (s, 3H), 1.43 (d,J = 6.57 Hz, 6H), 1.14 (t, J = 7.58 Hz, 3H) 432.2 90

N-((6-benzyl-4-methyl- 2-oxo-1,2- dihydropyridin-3-yl)methyl)-6-bromo-1- isopropyl-1H-indole-4- carboxamide 7.62 (d, J =3.28 Hz, 1H), 7.51 (d, J = 1.52 Hz, 1H), 7.32 (s, 4H), 7.23 (td, J =2.78, 5.56 Hz, 1H), 6.87 (d, J = 3.28 Hz, 1H), 5.89 (s, 1H), 4.82 (ddd,J = 6.44, 6.57, 13.26 Hz, 1H), 4.31 (d, J = 5.05 Hz, 2H), 3.74 (s, 2H),2.19 (s, 3H), 1.43 (d, J = 6.82 Hz, 6H) 494.2 91

6-bromo-N-((6- cyclobutyl-4-methyl-2- oxo-1,2-dihydropyridin-3-yl)methyl)-1- isopropyl-1H-indole-4- carboxamide 8.40 (br.s., 1H),7.92 (s, 1H), 7.63 (d, J = 3.28 Hz, 1H), 7.53 (d, J = 1.77 Hz, 1H), 6.88(d, J = 3.28 Hz, 1H), 5.96 (s, 1H), 4.82 (quin, J = 6.63 Hz, 1H), 4.33(d, J = 4.80 Hz, 2H), 3.25-3.38 (m, 2H), 2.25 (s, 3H), 2.06-2.22 (m,4H), 1.84-1.99 (m, 1H), 1.70-1.82 (m, 1H), 1.43 (d, J = 6.57 Hz, 6H)455.9 92

6-bromo-1-(1- methylethyl)-N-({6- methyl-4- [(methyloxy)methyl]-2-oxo-1,2-dihydro-3- pyridinyl}methyl)-1H- indole-4-carboxamide 11.70 (s,1H), 8.32 (t, J = 5.05 Hz, 1H), 7.93 (s, 1H), 7.63 (d, J = 3.28 Hz, 1H),7.51 (d, J = 1.52 Hz, 1H), 6.87 (d, J = 3.03 Hz, 1H), 6.09 (s, 1H), 4.82(quin, J = 6.63 Hz, 1H), 4.49 (s, 2H), 4.30 (d, J = 5.05 Hz, 2H), 3.32(s, 3H), 2.17 (s, 3H), 1.43 (d, J = 6.57 Hz, 6H) 447.8 93

1-(1-methylethyl)-N- ({6-methyl-4- [(methyloxy)methyl]-2-oxo-1,2-dihydro-3- pyridinyl}methyl)-6-[6- (4-methyl-1- piperazinyl)-3-pyridinyl]-1H-indole-4- carboxamide 8.58 (d, J = 2.53 Hz, 1H), 8.31 (t,J = 5.05 Hz, 1H), 8.17 (s, 1H), 7.99 (dd, J = 2.53, 8.84 Hz, 1H), 7.88(s, 1H), 7.66 (d, J = 1.26 Hz, 1H), 7.59 (d, J = 3.28 Hz, 1H), 6.94 (d,J = 8.84 Hz, 1H), 6.87 (d, J = 3.28 Hz, 1H), 6.10 (s, 1H), 4.93 (dq, J =6.65, 6.82 Hz, 1H), 4.52 (s, 2H), 4.35 (d, J = 5.05 Hz, 2H), 3.50-3.58(m, 4H), 3.32 (s, 3H), 2.45 (t, J = 4.93 Hz, 4H), 2.25 (s, 3H), 2.17 (s,3H), 1.47 (d, J = 6.57 Hz, 6H) 543.1 94

1-(1-methylethyl)-N- ({6-methyl-4- [(methyloxy)methyl]-2-oxo-1,2-dihydro-3- pyridinyl}methyl)-6-[2- (4-methyl-1- piperazinyl)-4-pyridinyl]-1H-indole-4- carboxamide 8.35 (t, J = 5.18 Hz, 1H), 8.18 (s,1H), 8.16 (s, 2H), 8.05 (s, 1H), 7.74 (d, J = 1.26 Hz, 1H), 7.69 (d, J =3.28 Hz, 1H), 7.17 (s, 1H), 7.11 (dd, J = 1.01, 5.31 Hz, 1H), 6.90 (d, J= 3.28 Hz, 1H), 6.10 (s, 1H), 5.01 (quin, J = 6.57 Hz, 1H), 4.53 (s,2H), 4.35 (d, J = 5.31 Hz, 2H), 3.54-3.68 (m, 4H), 3.32 (s, 3H),2.51-2.54 (m, 4H), 2.30 (s, 3H), 2.17 (s, 3H), 1.48 (d, J = 6.57 Hz, 6H)543.2 95

1-(1-methylethyl)-N- ({6-methyl-4- [(methyloxy)methyl]-2-oxo-1,2-dihydro-3- pyridinyl}methyl)-6-(3- pyridinyl)-1H-indole-4-carboxamide 11.75 (s, 1H), 9.05 (d, J = 2.02 Hz, 1H), 8.55 (dd, J =1.52, 4.80 Hz, 1H), 8.39 (t, J = 5.18 Hz, 1H), 8.21 (dddd, J = 1.17,1.52, 8.02 Hz, 1H), 8.15 (s, 1H), 8.05 (s, 1H), 7.76 (d, J = 1.52 Hz,1H), 7.66 (d, J = 3.28 Hz, 1H), 7.49 (qd, 1H), 6.93 (d, J = 3.28 Hz,1H), 6.10 (s, 1H), 4.98 (quin, J = 6.63 Hz, 1H), 4.52 (s, 2H), 4.36 (d,J = 5.05 Hz, 2H), 3.32 (s, 3H), 2.17 (s, 3H), 1.48 (d, J = 6.57 Hz, 6H)445.2 96

1-(1-methylethyl)-N- ({6-methyl-4- [(methyloxy)methyl]-2-oxo-1,2-dihydro-3- pyridinyl}methyl)-6-[6- (4-morpholinyl)-3-pyridinyl]-1H-indole-4- carboxamide 11.71 (br.s., 1H), 8.60 (d, J = 2.53Hz, 1H), 8.31 (t, J = 5.05 Hz, 1H), 8.15 (s, 1H), 8.02 (dd, J = 2.53,8.84 Hz, 1H), 7.89 (s, 1H), 7.67 (d, J = 1.26 Hz, 1H), 7.59 (d, J = 3.28Hz, 1H), 6.95 (d, J = 8.59 Hz, 1H), 6.88 (d, J = 3.28 Hz, 1H), 6.10 (s,1H), 4.93 (quin, J = 6.63 Hz, 1H), 4.52 (s, 2H), 4.35 (d, J = 5.05 Hz,2H), 3.70-3.77 (m, 4H), 3.46-3.52 (m, 4H), 3.32 (s, 3H), 2.17 (s, 3H),1.47 (d, J = 6.57 Hz, 6H) 530.9 97

6-bromo-1-cyclopropyl- N-[(6-methyl-2-oxo-4- propyl-1,2-dihydro-3-pyridinyl)methyl]-1H- indole-4-carboxamide 11.56 (s, 1 H), 8.32 (t, J =4.9 Hz, 1 H), 7.85 (s, 1 H), 7.56 (d, J = 1.8 Hz, 1 H), 7.45 (d, J = 3.3Hz, 1 H), 6.78 (d, J = 3.0 Hz, 1 H), 5.90 (s, 1 H), 4.34 (d, J = 5.1 Hz,2 H), 3.47 (dt, J = 7.0, 3.4 Hz, 1 H), 2.53 (br.s., 1 H), 2.13 (s, 3 H),1.52 (m, 2 H), 1.07 (m, 2 H), 0.92 (m, 5 H) 442.0 98

1-cyclopropyl-N-[(6- methyl-2-oxo-4-propyl- 1,2-dihydro-3-pyridinyl)methyl]-6-[6- (4-methyl-1- piperazinyl)-3-pyridinyl]-1H-indole-4- carboxamide 11.56 (s, 1 H), 8.54 (d, J = 2.5 Hz,1 H), 8.30 (t, J = 5.1 Hz, 1 H), 7.95 (dd, J = 9.0, 2.7 Hz, 1 H), 7.85(s, 1 H), 7.68 (d, J = 1.5 Hz, 1 H), 7.41 (d, J = 3.0 Hz, 1 H), 6.94 (d,J = 8.8 Hz, 1 H), 6.80 (d, J = 3.3 Hz, 1 H), 5.91 (s, 1 H), 4.39 (d, J =5.1 Hz, 2 H), 3.51 (m, 5 H), 2.54 (m, 2 H), 2.41 (m, 4 H), 2.21 (m, 3H), 2.13 (s, 3 H), 1.53 (m, 2 H), 1.09 (m, 2 H), 0.98 (m, 2 H), 0.89 (t,J = 7.3 Hz, 3 H) 539.4 99

1-cyclopropyl-N-[(6- methyl-2-oxo-4-propyl- 1,2-dihydro-3-pyridinyl)methyl]-6-(3- pyridinyl)-1H-indole-4- carboxamide 11.56 (s, 1H), 9.02 (d, J = 1.8 Hz, 1 H), 8.56 (dd, J = 4.8, 1.5 Hz, 1 H), 8.37 (t,J = 5.1 Hz, 1 H), 8.18 (dt, J = 8.3, 1.9 Hz, 1 H), 7.99 (s, 1 H), 7.78(d, J = 1.5 Hz, 1 H), 7.50 (m, 2 H), 6.85 (d, J = 3.3 Hz, 1 H), 5.91 (s,1 H), 4.40 (d, J = 5.1 Hz, 2 H), 3.55 (tt, J = 7.0, 3.6 Hz, 1 H), 2.54(m, 2 H), 2.13 (s, 3 H), 1.53 (m, 2 H), 1.11 (m, 2 H), 1.00 (m, 2 H),0.89 (t, J = 7.3 Hz, 3 H) 441.0 100

N-((4,6-dimethyl-2- oxo-1,2-dihydropyridin- 3-yl)methyl)-1-isopropyl-3-methyl-6- (4-(piperazin-1- yl)phenyl)-1H-indole-4-carboxamide 1.43 (d, J = 6.57 Hz, 6 H), 2.11 (s, 3 H), 2.16 (s, 3 H),2.24 (s, 3 H), 2.82-2.90 (m, 4 H), 3.04-3.12 (m, 4 H), 4.35 (d, J = 5.05Hz, 2 H), 4.84 (quin, J = 6.63 Hz, 1 H), 5.87 (s, 1 H), 7.00 (d, J =8.84 Hz, 2 H), 7.19 (d, J = 1.52 Hz, 1 H), 7.25-7.31 (m, 1 H), 7.59 (d,J = 8.84 Hz, 2 H), 7.67 (d, J = 1.26 Hz, 1 H), 8.14 (t, J = 5.05 Hz, 1H) 512.4 101

N-[(4-ethyl-6-methyl-2- oxo-1,2-dihydro-3- pyridinyl)methyl]-3-methyl-1-(1- methylethyl)-6-[6-(1- piperazinyl)-3-pyridinyl]-1H-indole-4- carboxamide 11.50 (br.s., 1 H) 8.50 (d, J = 2.53Hz, 1 H) 8.13 (t, J = 4.80 Hz, 1 H) 7.91 (dd, J = 8.84, 2.53 Hz, 1 H)7.69- 7.76 (m, 1 H) 7.29 (s, 1 H) 7.18 (d, J = 1.26 Hz, 1 H) 6.88 (d, J= 8.84 Hz, 1 H) 5.92 (s, 1 H) 4.80-4.89 (m, 1 H) 4.38 (br.s., 1 H) 4.36(br.s., 1 H) 3.39-3.51 (m, 4 H) 2.71- 2.85 (m, 4 H) 2.53-2.63 (m, 3 H)2.16 (s, 3 H) 2.13 (s, 3 H) 1.44 (s, 3 H) 1.42 (s, 3 H) 1.14 (t, J =7.58 Hz, 3 H) 527.2 102

1-isopropyl-3-methyl- N-((6-methyl-2-oxo-4- propyl-1,2-dihydropyridin-3- yl)methyl)-6-(2- (piperazin-1-yl)pyridin-4-yl)-1H-indole-4- carboxamide 11.51 (br.s., 1 H) 8.18 (t, J = 5.05 Hz,1 H) 8.11-8.16 (m, 1 H) 7.90 (d, J = 1.52 Hz, 1 H) 7.39 (s, 1 H) 7.30(d, J = 1.52 Hz, 1 H) 6.99-7.12 (m, 2 H) 5.90 (s, 1 H) 4.93 (quin, J =6.63 Hz, 1 H) 4.38 (br.s., 1 H) 4.36 (br.s., 1 H) 3.42-3.61 (m, 4 H)2.79- 2.83 (m, 3 H) 2.53-2.58 (m, 2 H) 2.17 (s, 3 H) 2.12 (s, 3 H)1.53-1.62 (m, 2 H) 1.45 (s, 3 H) 1.43 (s, 3 H) 0.94 (t, J = 7.33 Hz, 3H) 541.4 103

N-((4,6-dimethyl-2- oxo-1,2-dihydropyridin- 3-yl)methyl)-1-isopropyl-3-methyl-6- (2-(piperazin-1- yl)pyridin-4-yl)-1H-indole-4-carboxamide 11.51 (br.s., 1 H) 8.21 (t, J = 4.93 Hz, 1 H) 8.14(d, J = 5.05 Hz, 1 H) 7.90 (d, J = 1.52 Hz, 1 H) 7.38 (s, 1 H) 7.31 (d,J = 1.52 Hz, 1 H) 7.08 (s, 1 H) 7.02 (d, J = 4.80 Hz, 1 H) 5.87 (s, 1 H)4.93 (quin, J = 6.57 Hz, 1 H) 4.36 (s, 1 H) 4.35 (s, 1 H) 3.43-3.52 (m,4 H) 3.35 (br.s., 2 H) 2.79- 2.84 (m, 3 H) 2.25 (s, 3 H) 2.16 (s, 3 H)2.11 (s, 3 H) 1.44 (s, 3 H) 1.43 (s, 3 H) 513.3 104

1-cyclopropyl-N-[(4,6- dimethyl-2-oxo-1,2- dihydro-3-pyridinyl)methyl]-3- methyl-6-[6-(1- piperazinyl)-3-pyridinyl]-1H-indole-4- carboxamide 11.46 (br.s., 1 H), 8.48 (d, J = 2.3Hz, 1 H), 8.16 (t, J = 5.1 Hz, 1 H), 7.89 (dd, J = 9.0, 2.7 Hz, 1 H),7.70 (d, J = 1.5 Hz, 1 H), 7.22 (d, J = 1.5 Hz, 1 H), 7.11 (d, J = 1.0Hz, 1 H), 6.89 (d, J = 8.8 Hz, 1 H), 5.86 (s, 1 H), 4.34 (d, J = 5.1 Hz,2 H), 3.42 (m, 5 H), 2.80 (m, 4 H), 2.23 (s, 3 H), 2.12 (d, J = 7.1 Hz,6 H), 1.05 (m, 2 H), 0.91 (m, 2 H) 511.3 105

methyl 4-[4-({[(4,6- dimethyl-2-oxo-1,2- dihydro-3-pyridinyl)methyl]amino} carbonyl)-3-methyl-1- (1-methylethyl)-1H-indol-6-yl]benzoate 11.48 (s, 1 H) 8.23 (t, J = 5.05 Hz, 1 H) 8.01-8.07(m, 2 H) 7.90-7.96 (m, 3 H) 7.39 (s, 1 H) 7.33 (d, J = 1.26 Hz, 1 H)5.87 (s, 1 H) 4.91 (t, J = 6.69 Hz, 1 H) 4.36 (d, J = 4.80 Hz, 2 H)3.88(s, 3 H) 2.24 (s, 3 H) 2.18 (s, 3 H) 2.11 (s, 3 H) 1.44 (d, J = 6.57Hz, 6 H) 486.1 106

methyl 3-[3-methyl-1- (1-methylethyl)-4-({[(6- methyl-2-oxo-4-propyl-1,2-dihydro-3- pyridinyl)methyl]amino} carbonyl)-1H-indol-6- yl]benzoate11.49 (br.s., 1 H) 8.19-8.31 (m, 2 H) 8.01-8.08 (m, 1 H) 7.95-7.90 (m, 1H) 7.85 (s, 1 H) 7.59-7.65 (m, 1 H) 7.37 (s, 1 H) 7.26 (s, 1 H) 5.91(br.s., 1 H) 4.87-4.97 (m, 1 H) 4.38 (d, J = 4.29 Hz, 2 H) 3.91 (s, 3 H)2.55-2.62 (m, 2 H) 2.19 (s, 3 H) 2.12 (s, 3 H) 1.55-1.65 (m, 2 H) 1.44(d, J = 6.57 Hz, 6 H) 0.94 (t, J = 7.2 Hz, 3 H) 514.2 107

methyl 5-[3-methyl-1- (1-methylethyl)-4-({[(6- methyl-2-oxo-4-propyl-1,2-dihydro-3- pyridinyl)methyl]amino} carbonyl)-1H-indol-6- yl]-2-pyridinecarboxylate 11.50 (s, 1 H) 9.13 (d, J = 1.77 Hz, 1 H) 8.36 (dd,J = 8.34, 2.27 Hz, 1 H) 8.23 (t, J = 5.05 Hz, 1 H) 8.13 (d, J = 8.34 Hz,1 H) 8.02 (d, J = 1.52 Hz, 1 H) 7.43 (s, 1 H) 7.37 (d, J = 1.52 Hz, 1 H)5.91 (s, 1 H) 4.88-4.99 (m, 1 H) 4.38 (d, J = 5.05 Hz, 2 H) 3.91 (s, 3H) 2.53-2.59 (m, 2 H) 2.19 (s, 3 H) 2.13 (s, 3 H) 1.52-1.64 (m, 2 H)1.45 (d, J = 6.57 Hz, 6 H) 0.94 (t, J = 7.33 Hz, 3 H) 515.1 108

1-isopropyl-N-((6- methyl-2-oxo-4-propyl- 1,2-dihydropyridin-3-yl)methyl)-6- (methylsulfonyl)-1H- indole-4-carboxamide 0.91 (t, J =8.00 Hz, 3 H), 1.45- 1.60 (m, 8 H), 2.14 (s, 3 H), 3.23 (s, 3 H), 4.40(d, J = 4.80 Hz, 2 H), 4.92-5.04 (m, 1 H), 5.92 (s, 1 H), 6.99 (d, J =3.03 Hz, 1 H), 7.86 (d, J = 1.26 Hz, 1 H), 7.94 (d, J = 3.28 Hz, 1 H),8.20 (s, 1 H), 8.44 (t, J = 4.80 Hz, 1 H), 11.58 (s, 1 H) 444.2 109

N-((4,6-dimethyl-2- oxo-1,2-dihydropyridin- 3-yl)methyl)-1-isopropyl-3-methyl-6- (methylsulfonyl)-1H- indole-4-carboxamide1.42-1.51 (d, J = 8.00 Hz, 6 H), 2.12 (s, 3 H), 2.19 (s, 3 H), 2.24 (s,3 H), 3.20 (s, 3 H), 4.35 (d, J = 5.05 Hz, 2 H), 4.89 (quin, J = 6.69Hz, 1 H), 5.88 (s, 1 H), 7.41 (s, 1 H) 7.66 (s, 1 H), 8.07 (d, J = 1.52Hz, 1 H), 8.37 (t, J = 4.93 Hz, 1 H), 11.50 (s, 1 H) 430.0 110

N-((4-ethyl-6-methyl-2- oxo-1,2-dihydropyridin- 3-yl)methyl)-1-isopropyl-3-methyl-6- (methylsulfonyl)-1H- indole-4-carboxamide 1.14 (m,3 H), 1.45 (d, J = 6.57 Hz, 6 H), 2.13 (s, 3 H), 2.19 (s, 3 H),2.54-2.65 (m, 3 H), 3.20 (s, 3 H), 4.37 (d, J = 5.05 Hz, 2 H), 4.89(quin, J = 6.69 Hz, 1 H), 5.93 (s, 1 H), 7.40 (d, J = 1.52 Hz, 1 H),7.66 (s, 1 H), 8.07 (d, J = 1.52 Hz, 1 H), 8.36 (t, J = 5.05 Hz, 1 H),11.51 (s, 1 H) 444.2 111

N-((4-benzyl-6-methyl- 2-oxo-1,2- dihydropyridin-3-yl)methyl)-1-isopropyl- 3-methyl-6- (methylsulfonyl)-1H-indole-4-carboxamide 1.45 (m, 6 H), 2.09 (s, 3 H), 2.18 (s, 3 H), 3.20(s, 3 H), 3.99 (s, 2 H), 4.44 (d, J = 5.05 Hz, 2 H), 4.89 (quin, J =6.69 Hz, 1 H), 5.79 (s, 1 H), 7.16- 7.28 (m, 3 H), 7.30-7.36 (m, 2 H),7.42 (d, J = 1.52 Hz, 1 H), 7.66 (s, 1 H), 8.08 (d, J = 1.52 Hz, 1 H),8.50 (t, J = 5.05 Hz, 1 H), 11.58 (s, 1 H) 505.9 112

1-isopropyl-3-methyl- N-((6-methyl-2-oxo-4- propyl-1,2-dihydropyridin-3- yl)methyl)-6- (methylsulfonyl)-1H-indole-4-carboxamide 0.94 (m, 3 H), 1.45 (d, J = 6.57 Hz, 6 H), 1.56(sxt, J = 7.53 Hz, 2 H), 2.13 (s, 3 H), 2.19 (s, 3 H), 3.19 (s, 3 H),4.37 (d, J = 4.80 Hz, 2 H), 4.89 (dt, J = 13.33, 6.60 Hz, 1 H), 5.91 (s,1 H), 7.40 (d, J = 1.52 Hz, 1 H), 7.66 (s, 1 H), 8.08 (d, J = 1.26 Hz, 1H), 8.35 (t, J = 4.67 Hz, 1 H), 11.51 (s, 1 H) 458.2 113

3-({2-[6- (cyclopropylsulfonyl)-3- methyl-1-(1- methylethyl)-1H-indol-4-yl]-2- oxoethyl}amino)-4,6- dimethyl-2(1H)- pyridinone 0.93-1.06 (m, 2H), 1.11- 1.25 (m, 2 H), 1.49 (d, J = 6.57 Hz, 6 H), 2.13 (s, 3 H), 2.24(s, 3 H), 2.81-2.98 (m, 1 H), 4.37 (d, J = 5.05 Hz, 2 H), 4.99 (dt, J =13.33, 6.60 Hz, 1 H), 5.90 (s, 1 H), 6.99 (d, J = 3.28 Hz, 1 H), 7.85(d, J = 1.52 Hz, 1 H), 7.93 (d, J = 3.28 Hz, 1 H), 8.16 (s, 1 H), 8.49(t, J = 4.93 Hz, 1 H), 11.57 (br.s., 1 H) 442.0 114

3-({2-[6- (cyclopropylsulfonyl)-3- methyl-1-(1- methylethyl)-1H-indol-4-yl]-2- oxoethyl}amino)-4,6- dimethyl-2(1H)- pyridinone 1.00 (dd, J =7.71, 2.65 Hz, 2 H), 1.13 (dd, J = 4.67, 2.40 Hz, 2 H), 1.45 (d, J =6.57 Hz, 6 H), 2.12 (s, 3 H), 2.19 (s, 3 H), 2.23 (s, 3 H), 2.76-2.95(m, 1 H), 4.35 (d, J = 5.05 Hz, 2 H), 4.91 (quin, J = 6.63 Hz, 1 H),5.88 (s, 1 H), 7.36 (d, J = 1.52 Hz, 1 H), 7.66 (s, 1 H), 8.03 (d, J =1.52 Hz, 1 H), 8.40 (t, J = 4.93 Hz, 1 H), 11.51 (s, 1 H) 455.9 115

3-methyl-1-(1- methylethyl)-N-{[6- methyl-2-oxo-4- (phenylmethyl)-1,2-dihydro-3- pyridinyl]methyl}-6- (methyloxy)-1H-indole- 4-carboxamide11.54 (br.s., 1 H) 8.13 (t, J = 5.18 Hz, 1 H) 7.29-7.33 (m, 2 H)7.19-7.26 (m, 3 H) 7.12 (d, J = 1.01 Hz, 1 H) 7.03 (d, J = 2.27 Hz, 1 H)6.58 (d, J = 2.27 Hz, 1 H) 5.78 (s, 1 H) 4.67 (quin, J = 6.63 Hz, 1 H)4.40 (s, 1 H) 4.39 (s, 1 H) 3.98 (s, 2 H) 3.78-3.81 (m, 3 H) 2.10 (s, 3H) 2.08 (s, 3 H) 1.40 (s, 3 H) 1.38 (s, 3 H) 458.2 116

N-[(4-ethyl-6-methyl-2- oxo-1,2-dihydro-3- pyridinyl)methyl]-3-methyl-1-(1- methylethyl)-6- (methyloxy)-1H-indole- 4-carboxamide 11.47(br.s., 1 H) 8.00 (t, J = 4.93 Hz, 1 H) 7.12 (s, 1 H) 7.02 (d, J = 2.02Hz, 1 H) 6.57 (d, J = 2.27 Hz, 1 H) 5.91 (s, 1 H) 4.67 (quin, J = 6.63Hz, 1 H) 4.33 (s, 1 H) 4.32 (s, 1 H) 3.79 (s, 3 H) 2.53-2.60 (m, 2 H)2.13 (s, 3 H) 2.10 (s, 3 H) 1.39 (s, 3 H) 1.38 (s, 3 H) 1.13 (t, J =7.45 Hz, 3 H) 395.8 117

3-methyl-1-(1- methylethyl)-N-[(6- methyl-2-oxo-4-propyl- 1,2-dihydro-3-pyridinyl)methyl]-6- (methyloxy)-1H-indole- 4-carboxamide 11.48 (br.s.,1 H) 7.98 (t, J = 5.05 Hz, 1 H) 7.10-7.13 (m, 1 H) 7.02 (d, J = 2.02 Hz,1 H) 6.57 (d, J = 2.02 Hz, 1 H) 5.90 (s, 1 H) 4.66 (quin, J = 6.63 Hz, 1H) 4.33 (s, 1 H) 4.32 (s, 1 H) 3.79 (s, 3 H) 2.55 (m, 2 H) 2.12 (s, 3 H)2.10 (s, 3 H) 1.51-1.59 (m, 2 H) 1.39 (s, 3 H) 1.38 (s, 3 H) 0.93 (t, J= 7.33 Hz, 3 H) 410.3 118

6-bromo-N-[(4,6- dimethyl-2-oxo-1,2- dihydro-3- pyridinyl)methyl]-3-methyl-1-(1- methylethyl)-1H- indole-4-carboxamide 11.48 (br.s., 1H),8.24 (t, J = 4.93 Hz, 1H), 7.76 (d, J = 1.52 Hz, 1H), 7.33 (d, J = 0.76Hz, 1H), 7.00 (d, J = 1.77 Hz, 1H), 5.86 (s, 1H), 4.74 (quin, J = 6.63Hz, 1H), 4.31 (d, J = 4.80 Hz, 2H), 2.22 (s, 3H), 2.12 (d, J = 7.07 Hz,6H), 1.39 (d, J = 6.57 Hz, 6H) 429.9 119

N-[(4,6-dimethyl-2-oxo- 1,2-dihydro-3- pyridinyl)methyl]-1-(1-methylethyl)-6- (methyloxy)-1H-indole- 4-carboxamide 11.55 (s, 1H), 8.12(t, J = 5.18 Hz, 1H), 7.43 (d, J = 3.28 Hz, 1H), 7.19 (d, J = 2.02 Hz,1H), 7.06 (d, J = 2.27 Hz, 1H), 6.74 (d, J = 3.28 Hz, 1H), 5.89 (s, 1H),4.75 (quin, J = 6.63 Hz, 1H), 4.34 (d, J = 5.31 Hz, 2H), 3.82 (s, 3H),2.23 (s, 3H), 2.12 (s, 3H), 1.43 (d, J = 6.57 Hz, 6H) 368.1 120

N-[(4,6-dimethyl-2-oxo- 1,2-dihydro-3- pyridinyl)methyl]-3- methyl-1-(1-methylethyl)-6- (methyloxy)-1H-indole- 4-carboxamide 11.47 (s, 1H), 8.02(t, J = 5.05 Hz, 1H), 7.11 (s, 1H), 7.02 (d, J = 2.02 Hz, 1H), 6.57 (d,J = 2.02 Hz, 1H), 5.86 (s, 1H), 4.66 (quin, J = 6.63 Hz, 1H), 4.31 (d, J= 5.05 Hz, 2H), 3.79 (s, 3H), 2.22 (s, 3H), 2.10 (d, J = 4.80 Hz, 6H),1.38 (d, J = 6.57 Hz, 6H) 382.2 121

6-chloro-N-[(4,6- dimethyl-2-oxo-1,2- dihydro-3- pyridinyl)methyl]-3-methyl-1-(1- methylethyl)-1H- indole-4-carboxamide 11.48 (br.s., 1H),8.23 (t, J = 4.93 Hz, 1H), 7.63 (d, J = 1.77 Hz, 1H), 7.34 (d, J = 0.76Hz, 1H), 6.90 (d, J = 2.02 Hz, 1H), 5.87 (s, 1H), 4.73 (quin, J = 6.63Hz, 1H), 4.31 (d, J = 5.05 Hz, 2H), 2.22 (s, 3H), 2.12 (d, J = 7.07 Hz,6H), 1.39 (d, J = 6.82 Hz, 6H) 386.0 122

6-{3- [(dimethylamino)methyl] phenyl}-N-[(4,6- dimethyl-2-oxo-1,2-dihydro-3- pyridinyl)methyl]-3- methyl-1-(1- methylethyl)-1H-indole-4-carboxamide 11.48 (s, 1H), 8.19 (t, J = 4.93 Hz, 1H), 7.77 (d,J = 1.26 Hz, 1H), 7.62-7.72 (m, 2H), 7.43 (t, J = 7.58 Hz, 1H), 7.33 (d,J = 0.76 Hz, 1H), 7.28 (d, J = 7.58 Hz, 1H), 7.24 (d, J = 1.52 Hz, 1H),5.87 (s, 1H), 4.88 (quin, J = 6.63 Hz, 1H), 4.36 (d, J = 5.05 Hz, 2H),3.62 (br.s., 2H), 2.28 (br.s., 6H), 2.24 (s, 3H), 2.17 (d, J = 1.01 Hz,3H), 2.11 (s, 3H), 1.44 (d, J = 6.82 Hz, 6H) 485.3 123

6-bromo-3-methyl-1- (1-methylethyl)-N-{[6- methyl-4-(4-morpholinylmethyl)-2- oxo-1,2-dihydro-3- pyridinyl]methyl}-1H-indole-4-carboxamide 11.64 (br.s., 1 H), 8.43 (br. s., 1 H), 7.78 (d, J= 1.3 Hz, 1 H), 7.33 (s, 1 H), 7.02 (d, J = 1.5 Hz, 1 H), 6.04 (s, 1 H),4.75 (dt, J = 6.6, 13.0 Hz, 1 H), 4.41 (d, J = 4.8 Hz, 2 H), 3.40 (s, 2H), 2.33 (br.s., 4 H), 2.25 (br.s., 4 H), 2.15 (s, 3 H), 2.11 (s, 3 H),1.39 (d, J = 6.6 Hz, 6 H) 515.2 124

N-[(4,6-dimethyl-2-oxo- 1,2-dihydro-3- pyridinyl)methyl]-6-iodo-1-(1-methylethyl)- 1H-indole-4- carboxamide 11.54 (s, 1 H), 8.27(t, J = 5.1 Hz, 1 H), 8.05 (s, 1 H), 7.65 (d, J = 1.3 Hz, 1 H), 7.57 (d,J = 3.3 Hz, 1 H), 6.85 (d, J = 3.3 Hz, 1 H), 5.89 (s, 1 H), 4.81 (quin,J = 6.6 Hz, 1 H), 4.32 (d, J = 5.1 Hz, 2 H), 2.22 (s, 3 H), 2.12 (s, 3H), 1.43 (d, J = 6.6 Hz, 6 H) 464.0 125

6-iodo-1-(1- methylethyl)-N-[(6- methyl-2-oxo-4-propyl- 1,2-dihydro-3-pyridinyl)methyl]-1H- indole-4-carboxamide 11.56 (s, 1 H), 8.27 (t, J =5.1 Hz, 1 H), 8.05 (s, 1 H), 7.65 (d, J = 1.3 Hz, 1 H), 7.58 (d, J = 3.3Hz, 1 H), 6.84 (d, J = 3.3 Hz, 1 H), 5.91 (s, 1 H), 4.82 (dt, J = 6.6,13.3 Hz, 1 H), 4.35 (d, J = 5.3 Hz, 2 H), 2.52 (2 H under DMSO), 2.13(s, 3 H), 1.53 (dq, J = 7.4, 15.1 Hz, 2 H), 0.91 (t, J = 7.3 Hz, 3 H)491.9 126

6-bromo-1-ethyl-N-[(6- methyl-2-oxo-4-propyl- 1,2-dihydro-3-pyridinyl)methyl]-1H- indole-4-carboxamide 0.92-0.88 (t, 3H), 1.34-1.31(t, 3H), 1.53-1.49 (m, 2H), 2.13 (s, 3H), 2.54-2.49 (m, 2H), 4.25-4.20(m, 2H), 4.35 (d, J = 4.8 Hz, 2H), 5.90 (s, 1H), 6.83 (d, J = 3.2 Hz,1H), 7.51 (d, J = 3.2 Hz, 2H), 7.89 (s, 1H), 8.29-8.27 (t, 1H), 11.54(s, 1H)  432.15 127

6-bromo-N-[(6-methyl- 2-oxo-4-propyl-1,2- dihydro-3-pyridinyl)methyl]-1- propyl-1H-indole-4- carboxamide 0.83-0.79 δ (t,3H), 0.92-0.88 (t, 3H), 1.55-1.51 (m, 2H), 1.74-1.71 (m, 2H), 1.76 (s,3H), 2.54-2.45 (m, 2H), 4.17- 4.14 (t, 2H), 4.35-4.34 (d, J = 5.2 Hz,2H), 5.75 (s, 1H), 5.90 (s, 1H), 6.82 (d, J = 2.8 Hz), 7.51-7.49 (m,2H), 7.90 (s, 1H), 8.28 (s, 1H), 11.54 (s, 1H)  446.04 128

3-({2-[6-chloro-1-(1- methylethyl)-1H-indol- 4-yl]-2-oxoethyl}amino)-4,6- dimethyl-2(1H)- pyridinone 1.43 (d, 6 H), 2.12 (s,3 H), 2.21 (s, 3 H), 4.32 (d, J = 4.80 Hz, 2 H), 4.81 (dt, J = 13.33,6.60 Hz, 1 H), 5.88 (s, 1 H), 6.86 (d, J = 3.03 Hz, 1 H), 7.40 (d, J =1.52 Hz, 1 H), 7.63 (d, J = 3.28 Hz, 1 H), 7.79 (s, 1 H), 8.29 (t, J =4.80 Hz, 1 H), 11.53 (br.s., 1 H) 371.9 129

3-({2-[6-chloro-1-(1- methylethyl)-1H-indol- 4-yl]-2- oxoethyl}amino)-6-methyl-4-propyl-2(1H)- pyridinone 0.90 (t, J = 7.20 Hz, 3 H), 1.43 (d, J= 6.57 Hz, 6 H), 1.48- 1.57 (m, 3 H), 2.13 (s, 3 H), 4.35 (d, J = 4.80Hz, 2 H), 4.69-4.93 (m, 1 H), 5.90 (s, 1 H), 6.86 (d, J = 2.78 Hz, 1 H),7.40 (s, 1 H), 7.64 (d, J = 3.28 Hz, 1 H), 7.79 (s, 1 H), 8.28 (br.s., 1H), 11.55 (br.s., 1 H) 399.8 130

3-({2-[6-chloro-3- methyl-1-(1- methylethyl)-1H-indol- 4-yl]-2-oxoethyl}amino)-6- methyl-4-propyl-2(1H)- pyridinone 0.93 (t, J = 7.33Hz, 3 H), 1.39 (d, J = 6.57 Hz, 6 H), 1.47- 1.67 (m, 2 H), 2.12 (d, J =4.80 Hz, 6 H), 4.32 (d, J = 4.55 Hz, 2 H), 4.54-4.90 (m, 1 H), 5.89 (s,1 H), 6.88 (s, 1 H), 7.34 (s, 1 H), 7.63 (s, 1 H), 8.20 (br.s., 1 H),11.48 (br.s., 1 H) 414.0 131

N-[(4,6-dimethyl-2-oxo- 1,2-dihydro-3- pyridinyl)methyl]-6- fluoro-1-(1-methylethyl)-1H- indole-4-carboxamide 1.42 (d, 6 H), 2.12 (s, 3 H), 2.22(s, 3 H), 4.33 (d, J = 5.05 Hz, 2 H), 4.74 (dt, J = 13.14, 6.57 Hz, 1H), 5.88 (s, 1 H), 6.85 (d, J = 3.03 Hz, 2 H), 7.25 (dd, J = 10.36, 1.77Hz, 2 H), 7.51-7.67 (m, 4 H), 8.24 (t, J = 4.55 Hz, 2 H), 11.55 (br.s.,1 H) 356.2 132

3-({2-[6-fluoro-1-(1- methylethyl)-1H-indol- 4-yl]-2- oxoethyl}amino)-6-methyl-4-propyl-2(1H)- pyridinone 0.90 (t, J = 7.20 Hz, 3 H), 1.43 (d, 6H), 1.47-1.61 (m, 2 H), 2.13 (s, 3 H), 4.36 (d, J = 5.05 Hz, 2 H), 2.53(2H), 4.75 (ddd, J = 13.20, 6.51, 6.32 Hz, 1 H), 5.91 (s, 1 H), 6.84 (d,J = 3.03 Hz, 1 H), 7.25 (dd, J = 10.36, 2.02 Hz, 1 H), 7.49- 7.69 (m, 2H), 8.23 (t, J = 4.93 Hz, 1 H), 11.57 (br. s., 1 H) 384.0 133

N-((4,6-dimethyl-2- oxo-1,2-dihydropyridin- 3-yl)methyl)-1-isopropyl-3-methyl-6- (1H-tetrazol-5-yl)-1H- indole-4-carboxamide 11.50(br.s., 1 H), 8.29 (t, J = 4.9 Hz, 1 H), 8.21 (s, 1 H), 7.62 (d, J = 1.3Hz, 1 H), 7.51 (s, 1 H), 5.88 (s, 1 H), 4.80 (dt, J = 6.6, 13.1 Hz, 1H), 4.37 (d, J = 5.1 Hz, 2 H), 2.25 (s, 3 H), 2.19 (s, 3 H), 2.12 (s, 3H), 1.48 (d, J = 6.6 Hz, 6 H) 419.9 134

1-isopropyl-3-methyl- N-((6-methyl-2-oxo-4- propyl-1,2-dihydropyridin-3- yl)methyl)-6-(2H- tetrazol-5-yl)-1H-indole-4-carboxamide 11.50 (br.s., 1H), 8.25 (t, J = 4.93 Hz, 1H), 8.21(d, J = 1.26 Hz, 1H), 7.63 (d, J = 0.76 Hz, 1H), 7.52 (s, 1H), 5.91 (s,1H), 4.80 (qd, J = 6.19, 6.44 Hz, 1H), 4.38 (d, J = 5.05 Hz, 2H), 2.19(s, 3H), 2.13 (s, 3H), 1.51-1.63 (m, 2H), 1.48 (d, J = 6.57 Hz, 6H),1.10 (t, J = 6.95 Hz, 2H), 0.95 (t, J = 7.33 Hz, 3H) 447.8 135

6-cyano-3-methyl-1-(1- methylethyl)-N-[(6- methyl-2-oxo-4-propyl-1,2-dihydro-3- pyridinyl)methyl]-1H- indole-4-carboxamide 11.50 (br.s.,1 H) 8.31 (t, J = 4.80 Hz, 1 H) 8.16 (d, J = 1.26 Hz, 1 H) 7.65 (s, 1 H)7.19 (d, J = 1.26 Hz, 1 H) 5.90 (s, 1 H) 4.79-4.93 (m, 1 H) 4.33 (d, J =5.05 Hz, 2 H) 2.55 (d, J = 1.52 Hz, 1 H) 2.17 (s, 3 H) 2.13 (s, 3 H)1.51-1.61 (m, 2 H) 1.43 (d, J = 6.57 Hz, 6 H) 0.94 (t, J = 7.33 Hz, 3 H)405.1 136

6-bromo-3-chloro-1- isopropyl-N-((6-methyl- 2-oxo-4-propyl-1,2-dihydropyridin-3- yl)methyl)-1H-indole-4- carboxamide 11.48 (s, 1H),8.23 (t, J = 5.05 Hz, 1H), 7.93 (d, J = 1.52 Hz, 1H), 7.78 (s, 1H), 7.06(d, J = 1.52 Hz, 1H), 5.89 (s, 1H), 4.84 (quin, J = 6.63 Hz, 1H), 4.33(d, J = 5.05 Hz, 2H), 2.52-2.57 (m, 2H), 2.12 (s, 3H), 1.49-1.61 (m, J =7.33, 7.52, 7.52, 7.52, 7.52 Hz, 2H), 1.41 (d, J = 6.82 Hz, 6H), 0.94(t, J = 7.33 Hz, 3H) 479.7 137

6-bromo-3-chloro-1-(1- methylethyl)-N-({6- methyl-4-[(methyloxy)methyl]-2- oxo-1,2-dihydro-3- pyridinyl}methyl)-1H-indole-4-carboxamide 8.32 (t, J = 4.80 Hz, 1H), 7.93 (s, 1H), 7.78 (s,1H), 7.08 (s, 1H), 6.07 (s, 1H), 4.84 (q, J = 6.19, 6.38, 12.95 Hz, 1H),4.48 (s, 2H), 4.29 (d, J = 5.05 Hz, 2H), 3.33 (br.s., 3H), 2.16 (s, 3H),1.41 (d, J = 6.57 Hz, 6H) 481.8 138

6-bromo-3-chloro-N- [(4,6-dimethyl-2-oxo- 1,2-dihydro-3-pyridinyl)methyl]-1-(1- methylethyl)-1H- indole-4-carboxamide 8.27 (t, J= 4.93 Hz, 1H), 7.93 (d, J = 1.52 Hz, 1H), 7.78 (s, 1H), 7.07 (d, J =1.77 Hz, 1H), 5.86 (s, 1H), 4.84 (quin, J = 6.63 Hz, 1H), 4.32 (d, J =5.05 Hz, 2H), 2.21 (s, 3H), 2.11 (s, 3H), 1.41 (d, J = 6.57 Hz, 6H)451.8 139

3-chloro-N-((4,6- dimethyl-2-oxo-1,2- dihydropyridin-3-yl)methyl)-1-isopropyl- 6-(4- (morpholinomethyl) phenyl)-1H-indole-4-carboxamide 8.17 (t, J = 5.05 Hz, 1H), 8.15 (s, 1H), 7.90 (d, J = 1.26Hz, 1H), 7.75 (s, 1H), 7.71 (d, J = 8.08 Hz, 2H), 7.40 (d, J = 8.34 Hz,2H), 7.30 (d, J = 1.26 Hz, 1H), 5.87 (s, 1H), 4.96 (quin, J = 6.63 Hz,1H), 4.37 (d, J = 5.05 Hz, 2H), 3.59 (t, J = 4.55 Hz, 4H), 3.51 (s, 2H),2.39 (br.s., 4H), 2.24 (s, 3H), 2.11 (s, 3H), 1.46 (d, J = 6.82 Hz, 6H)547.0 140

3-chloro-N-((4,6- dimethyl-2-oxo-1,2- dihydropyridin-3-yl)methyl)-6-(3-fluoro- 4- (morpholinomethyl) phenyl)-1-isopropyl-1H-indole-4-carboxamide 8.18 (t, J = 5.05 Hz, 1H), 8.14 (s, 1H), 7.98 (d, J= 1.26 Hz, 1H), 7.78 (s, 1H), 7.57-7.66 (m, 2H), 7.45- 7.51 (m, 1H),7.33 (d, J = 1.26 Hz, 1H), 5.87 (s, 1H), 4.99 (quin, J = 6.63 Hz, 1H),4.37 (d, J = 5.05 Hz, 2H), 3.58 (dd, J = 4.04, 8.84 Hz, 6H), 2.42(br.s., 4H), 2.24 (s, 3H), 2.11 (s, 3H), 1.46 (d, J = 6.57 Hz, 6H) 565.3141

6-(4-((1H-pyrazol-1- yl)methyl)phenyl)-3- chloro-N-((4,6-dimethyl-2-oxo-1,2- dihydropyridin-3- yl)methyl)-1-isopropyl-1H-indole-4- carboxamide 8.15 (s, 1H), 7.97 (s, 1H), 7.77 (s, 1H), 7.44(s, 1H), 7.24-7.40 (m, 6H), 6.17 (br. s., 1H), 5.39 (s, 2H), 4.78- 4.89(m, 1H), 4.57 (br.s., 2H), 2.45 (s, 3H), 2.26 (br. s., 3H), 1.51 (d, J =6.57 Hz, 6H) 528.0 142

3-chloro-N-((4,6- dimethyl-2-oxo-1,2- dihydropyridin-3- yl)methyl)-6-(2-fluorophenyl)-1- isopropyl-1H-indole-4- carboxamide 11.49 (br.s., 1H),8.19 (t, J = 5.05 Hz, 1H), 7.76-7.83 (m, 2H), 7.56-7.68 (m, 1H),7.38-7.46 (m, 1H), 7.29- 7.36 (m, 2H), 7.17 (t, J = 1.39 Hz, 1H), 5.87(s, 1H), 4.90 (quin, J = 6.63 Hz, 1H), 4.36 (d, J = 5.05 Hz, 2H), 2.23(s, 3H), 2.11 (s, 3H), 1.45 (d, J = 6.82 Hz, 6H) 465.9 143

3-chloro-6-{4- [(dimethylamino)methyl] phenyl}-N-[(4,6-dimethyl-2-oxo-1,2- dihydro-3- pyridinyl)methyl]-1-(1- methylethyl)-1H-indole-4-carboxamide 8.19 (s, 1H), 8.14-8.18 (m, 1H), 7.91 (d, J = 1.26Hz, 1H), 7.75 (s, 1H), 7.73 (s, 1H), 7.71 (s, 1H), 7.39 (d, J = 8.08 Hz,2H), 7.30 (d, J = 1.52 Hz, 1H), 5.87 (s, 1H), 4.97 (quin, J = 6.57 Hz,1H), 4.37 (d, J = 5.05 Hz, 2H), 3.49 (s, 2H), 2.24 (s, 3H), 2.21 (s,6H), 2.11 (s, 3H), 1.46 (d, J = 6.57 Hz, 6H) 506.0 144

3-chloro-N-[(4,6- dimethyl-2-oxo-1,2- dihydro-3- pyridinyl)methyl]-1-(1-methylethyl)-6-[6- (methyloxy)-3- pyridinyl]-1H-indole-4- carboxamide11.46 (s, 1H), 8.56 (d, J = 2.02 Hz, 1H), 8.16 (t, J = 5.05 Hz, 1H),8.11 (dd, J = 2.78, 8.59 Hz, 1H), 7.92 (d, J = 1.26 Hz, 1H), 7.75 (s,1H), 7.28 (d, J = 1.26 Hz, 1H), 6.92 (d, J = 8.59 Hz, 1H), 5.87 (s, 1H),4.96 (quin, J = 6.63 Hz, 1H), 4.36 (d, J = 5.05 Hz, 2H), 3.91 (s, 3H),2.24 (s, 3H), 2.11 (s, 3H), 1.46 (d, J = 6.57 Hz, 6H) 478.9 145

3-chloro-N-[(4,6- dimethyl-2-oxo-1,2- dihydro-3- pyridinyl)methyl]-1-(1-methylethyl)-6-(3- pyridinyl)-1H-indole-4- carboxamide 11.47 (br.s.,1H), 8.99 (d, J = 2.27 Hz, 1H), 8.56 (dd, J = 1.64, 4.67 Hz, 1H), 8.14-8.22 (m, 2H), 8.03 (d, J = 1.52 Hz, 1H), 7.80 (s, 1H), 7.49 (dd, J =4.67, 7.96 Hz, 1H), 7.35 (d, J = 1.52 Hz, 1H), 5.87 (s, 1H), 4.94-5.05(m, 1H), 4.37 (d, J = 5.05 Hz, 2H), 2.25 (s, 3H), 2.11 (s, 3H), 1.46 (d,J = 6.82 Hz, 6H) 450.9 146

3-chloro-6-{4- [(dimethylamino)methyl] phenyl}-1-(1- methylethyl)-N-[(6-methyl-2-oxo-4-propyl- 1,2-dihydro-3- pyridinyl)methyl]-1H-indole-4-carboxamide 11.48 (br.s., 1H), 8.14 (t, J = 4.80 Hz, 1H), 7.91(d, J = 1.01 Hz, 1H), 7.75 (s, 1H), 7.71 (s, 1H), 7.69 (s, 1H), 7.39 (s,1H), 7.37 (s, 1H), 7.29 (d, J = 1.01 Hz, 1H), 5.90 (s, 1H), 4.97 (qd, J= 6.44, 6.61 Hz, 1H), 4.38 (d, J = 5.05 Hz, 2H), 3.44 (s, 2H), 2.55 (dd,J = 6.95, 8.72 Hz, 2H), 2.18 (s, 6H), 2.12 (s, 3H), 1.57 (dq, J = 7.48,15.19 Hz, 2H), 1.46 (d, J = 6.57 Hz, 6H), 0.95 (t, J = 7.33 Hz, 3H)534.4 147

3-chloro-1-(1- methylethyl)-N-[(6- methyl-2-oxo-4-propyl- 1,2-dihydro-3-pyridinyl)methyl]-6-[6- (methyloxy)-3- pyridinyl]-1H-indole-4-carboxamide 11.48 (s, 1H), 8.55 (d, J = 2.02 Hz, 1H), 8.13 (t, J = 5.05Hz, 1H), 8.10 (dd, J = 2.53, 8.59 Hz, 1H), 7.93 (d, J = 1.52 Hz, 1H),7.76 (s, 1H), 7.27 (d, J = 1.52 Hz, 1H), 6.93 (d, J = 8.59 Hz, 1H), 5.90(s, 1H), 4.96 (quin, J = 6.63 Hz, 1H), 4.38 (d, J = 5.05 Hz, 2H), 3.91(s, 3H), 2.55 (dd, J = 6.82, 8.84 Hz, 2H), 2.12 (s, 3H), 1.51-1.63 (m,2H), 1.46 (d, J = 6.82 Hz, 6H), 0.94 (t, J = 7.33 Hz, 3H) 509.0 148

3-chloro-6-{4- [(dimethylamino)methyl] phenyl}-1-(1- methylethyl)-N-({6-methyl-4- [(methyloxy)methyl]-2- oxo-1,2-dihydro-3-pyridinyl}methyl)-1H- indole-4-carboxamide 11.62 (br.s., 1H), 8.22 (t, J= 5.05 Hz, 1H), 8.16 (s, 1H), 7.90 (s, 1H), 7.74 (s, 1H), 7.72 (s, 1H),7.70 (s, 1H), 7.39 (d, J = 8.34 Hz, 2H), 7.30 (s, 1H), 6.07 (s, 1H),4.97 (dt, J = 6.69, 13.39 Hz, 1H), 4.51 (s, 2H), 4.33 (d, J = 5.05 Hz,2H), 3.48 (s, 2H), 3.33 (s, 3H), 2.21 (s, 6H), 2.15 (s, 3H), 1.45 (d, J= 6.57 Hz, 6H) 534.9 149

3-chloro-1-(1- methylethyl)-N-({6- methyl-4- [(methyloxy)methyl]-2-oxo-1,2-dihydro-3- pyridinyl}methyl)-6-[6- (methyloxy)-3-pyridinyl]-1H-indole-4- carboxamide 11.63 (br.s., 1H), 8.56 (d, J = 2.02Hz, 1H), 8.22 (t, J = 5.05 Hz, 1H), 8.11 (dd, J = 2.65, 8.72 Hz, 1H),7.93 (d, J = 1.26 Hz, 1H), 7.75 (s, 1H), 7.29 (d, J = 1.52 Hz, 1H), 6.93(d, J = 8.08 Hz, 1H), 6.08 (s, 1H), 4.96 (quin, J = 6.57 Hz, 1H), 4.52(s, 2H), 4.34 (d, J = 5.31 Hz, 2H), 3.91 (s, 3H), 3.33 (br.s., 3H), 2.16(s, 3H), 1.46 (d, J = 6.57 Hz, 6H) 510.0 150

3-chloro-1-isopropyl-N- ((4-(methoxymethyl)-6- methyl-2-oxo-1,2-dihydropyridin-3- yl)methyl)-6-(pyridin-3- yl)-1H-indole-4- carboxamide11.63 (br.s., 1H), 9.00 (d, J = 1.77 Hz, 1H), 8.56 (dd, J = 1.52, 4.80Hz, 1H), 8.26 (t, J = 5.18 Hz, 1H), 8.17 (ddd, J = 1.77, 2.02, 8.34 Hz,1H), 8.04 (d, J = 1.52 Hz, 1H), 7.80 (s, 1H), 7.49 (ddd, J = 0.76, 4.74,7.89 Hz, 1H), 7.36 (d, J = 1.26 Hz, 1H), 6.08 (s, 1H), 5.00 (quin, J =6.63 Hz, 1H), 4.53 (s, 2H), 4.34 (d, J = 5.05 Hz, 2H), 3.33 (s, 3H),2.16 (s, 3H), 1.46 (d, J = 6.57 Hz, 6H) 479.0 151

3-chloro-1-isopropyl-N- ((6-methyl-2-oxo-4- propyl-1,2-dihydropyridin-3- yl)methyl)-6-(6-(4- methylpiperazin-1-yl)pyridin-3-yl)-1H- indole-4-carboxamide 8.51 (d, J = 2.53 Hz, 1H),8.13 (t, J = 4.55 Hz, 1H), 7.93 (dd, J = 2.53, 8.84 Hz, 1H), 7.86 (d, J= 1.26 Hz, 1H), 7.71 (s, 1H), 7.24 (d, J = 1.26 Hz, 1H), 6.93 (d, J =9.09 Hz, 1H), 5.89 (s, 1H), 4.95 (quin, J = 6.63 Hz, 1H), 4.37 (d, J =4.80 Hz, 2H), 3.51-3.57 (m, 4H), 2.52- 2.58 (m, 2H), 2.37-2.45 (m, 4H),2.23 (s, 3H), 2.12 (s, 3H), 1.57 (dddd, J = 7.20, 7.33, 7.48, 15.13 Hz,2H), 1.45 (d, J = 6.57 Hz, 6H), 0.94 (t, J = 7.33 Hz, 3H) 575.3 152

3-chloro-N-((4-ethyl-6- methyl-2-oxo-1,2- dihydropyridin-3-yl)methyl)-1-isopropyl- 6-(6-(4- methylpiperazin-1- yl)pyridin-3-yl)-1H-indole-4-carboxamide 8.52 (d, J = 2.53 Hz, 1H), 8.13 (t, J = 5.05 Hz,1H), 7.94 (dd, J = 2.65, 8.97 Hz, 1H), 7.86 (d, J = 1.52 Hz, 1H), 7.71(s, 1H), 7.24 (d, J = 1.52 Hz, 1H), 6.93 (d, J = 8.84 Hz, 1H), 5.91 (s,1H), 4.94 (quin, J = 6.57 Hz, 1H), 4.38 (d, J = 5.05 Hz, 2H), 3.50-3.57(m, 4H), 2.59 (q, J = 7.58 Hz, 2H), 2.39-2.45 (m, 4H), 2.23 (s, 3H),2.13 (s, 3H), 1.45 (d, J = 6.82 Hz, 6H), 1.14 (t, J = 7.58 Hz, 3H) 561.1153

3-chloro-N-((4,6- dimethyl-2-oxo-1,2- dihydropyridin-3-yl)methyl)-1-isopropyl- 6-(6-(4- methylpiperazin-1- yl)pyridin-3-yl)-1H-indole-4-carboxamide 8.52 (d, J = 2.27 Hz, 1H), 8.15 (t, J = 4.55 Hz,1H), 7.94 (dd, J = 2.53, 8.84 Hz, 1H), 7.85 (d, J = 1.26 Hz, 1H), 7.71(s, 1H), 7.25 (d, J = 1.26 Hz, 1H), 6.93 (d, J = 8.84 Hz, 1H), 5.86 (s,1H), 4.94 (quin, J = 6.63 Hz, 1H), 4.36 (d, J = 5.05 Hz, 2H), 3.50-3.57(m, 4H), 2.38- 2.45 (m, 4H), 2.23 (d, J = 3.03 Hz, 6H), 2.11 (s, 3H),1.45 (d, J = 6.57 Hz, 6H) 547.0 154

3-chloro-N-((4,6- dimethyl-2-oxo-1,2- dihydropyridin-3-yl)methyl)-1-isopropyl- 6-(4- (trifluoromethyl)phenyl)- 1H-indole-4-carboxamide 11.47 (s, 1H), 8.23 (t, J = 4.93 Hz, 1H), 7.98-8.05 (m, 3H),7.79-7.86 (m, 3H), 7.37 (d, J = 1.26 Hz, 1H), 5.87 (s, 1H), 5.00 (qd, J= 6.44, 6.61 Hz, 1H), 4.37 (d, J = 4.80 Hz, 2H), 2.24 (s, 3H), 2.11 (s,3H), 1.47 (d, J = 6.57 Hz, 6H) 516.0 155

3-chloro-N-((4,6- dimethyl-2-oxo-1,2- dihydropyridin-3-yl)methyl)-1-isopropyl- 6-(6- (trifluoromethyl)pyridin-3-yl)-1H-indole-4- carboxamide 11.49 (br.s., 1H), 9.20 (d, J = 2.02 Hz,1H), 8.47 (dd, J = 2.02, 8.08 Hz, 1H), 8.24 (t, J = 5.05 Hz, 1H), 8.16(d, J = 1.26 Hz, 1H), 7.99 (d, J = 8.34 Hz, 1H), 7.86 (s, 1H), 7.45 (d,J = 1.52 Hz, 1H), 5.88 (s, 1H), 5.01 (quin, J = 6.63 Hz, 1H), 4.38 (d, J= 4.80 Hz, 2H), 2.25 (s, 3H), 2.11 (s, 3H), 1.47 (d, J = 6.57 Hz, 6H)517.0 156

3-chloro-N-((4,6- dimethyl-2-oxo-1,2- dihydropyridin-3- yl)methyl)-6-(3-fluorophenyl)-1- isopropyl-1H-indole-4- carboxamide 11.47 (br.s., 1H),8.19 (t, J = 4.93 Hz, 1H), 7.99 (s, 1H), 7.79 (s, 1H), 7.44-7.69 (m,4H), 7.34 (s, 1H), 7.18 (t, J = 7.33 Hz, 1H), 5.87 (s, 1H), 5.00 (dt, J= 6.66, 13.20 Hz, 1H), 4.37 (d, J = 4.80 Hz, 2H), 2.25 (s, 3H), 2.11 (s,3H), 1.46 (d, J = 6.57 Hz, 6H) 466.0 157

3-chloro-6-(3,5- difluorophenyl)-N- ((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3- yl)methyl)-1-isopropyl- 1H-indole-4- carboxamide11.47 (s, 1H), 8.19 (t, J = 5.05 Hz, 1H), 8.06 (d, J = 1.52 Hz, 1H),7.81 (s, 1H), 7.52-7.63 (m, 2H), 7.38 (d, J = 1.26 Hz, 1H), 7.20 (tt, J= 2.27, 9.35 Hz, 1H), 5.87 (s, 1H), 5.02 (quin, J = 6.63 Hz, 1H), 4.37(d, J = 5.05 Hz, 2H), 2.25 (s, 3H), 2.11 (s, 3H), 1.46 (d, J = 6.57 Hz,6H) 484.0 158

3-chloro-6-(3,4- difluorophenyl)-N- ((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3- yl)methyl)-1-isopropyl- 1H-indole-4- carboxamide11.46 (s, 1H), 8.17 (t, J = 5.05 Hz, 1H), 7.98 (d, J = 1.52 Hz, 1H),7.90 (ddd, J = 2.27, 7.83, 12.63 Hz, 1H), 7.78 (s, 1H), 7.59-7.69 (m,1H), 7.52 (dt, J = 8.59, 10.61 Hz, 1H), 7.32 (d, J = 1.52 Hz, 1H), 5.87(s, 1H), 4.99 (qd, J = 6.44, 6.61 Hz, 1H), 4.37 (d, J = 5.05 Hz, 2H),2.24 (s, 3H), 2.11 (s, 3H), 1.46 (d, J = 6.57 Hz, 6H) 484.0 159

3-chloro-N-((4,6- dimethyl-2-oxo-1,2- dihydropyridin-3-yl)methyl)-6-(4-fluoro- 3-hydroxyphenyl)-1- isopropyl-1H-indole-4-carboxamide 11.46 (br.s., 1H), 9.94 (br. s., 1H), 8.18 (t, J = 5.05 Hz,1H), 7.82 (d, J = 1.26 Hz, 1H), 7.74 (s, 1H), 7.29 (dd, J = 2.27, 8.59Hz, 1H), 7.13- 7.25 (m, 3H), 5.87 (s, 1H), 4.95 (quin, J = 6.63 Hz, 1H),4.36 (d, J = 5.05 Hz, 2H), 2.24 (s, 3H), 2.11 (s, 3H), 1.45 (d, J = 6.82Hz, 6H) 481.8 160

3-chloro-N-((4,6- dimethyl-2-oxo-1,2- dihydropyridin-3-yl)methyl)-6-(4-fluoro- 3-methoxyphenyl)-1- isopropyl-1H-indole-4-carboxamide 11.46 (br.s., 1H), 8.16 (t, J = 5.05 Hz, 1H), 7.90 (s, 1H),7.76 (s, 1H), 7.46 (d, J = 8.59 Hz, 1H), 7.24-7.34 (m, 3H), 5.87 (s, 1H)4.98 (ddd J = 6.44, 6.57, 13.26 Hz, 1H), 4.37 (d, J = 5.05 Hz, 2H), 3.97(s, 3H), 2.25 (s, 3H), 2.11 (s, 3H), 1.46 (d, J = 6.57 Hz, 6H) 496.1 161

3-chloro-N-((4,6- dimethyl-2-oxo-1,2- dihydropyridin-3-yl)methyl)-1-isopropyl- 6-(4-methoxyphenyl)- 1H-indole-4- carboxamide11.48 (br.s., 1H), 8.16 (t, J = 5.05 Hz, 1H), 7.84 (d, J = 1.01 Hz, 1H),7.64-7.75 (m, 3H), 7.26 (d, J = 1.01 Hz, 1H), 7.03 (d, J = 8.59 Hz, 2H),5.87 (s, 1H), 4.95 (quin, J = 6.63 Hz, 1H), 4.36 (d, J = 5.05 Hz, 2H),3.81 (s, 3H), 2.24 (s, 3H), 2.11 (s, 3H), 1.45 (d, J = 6.57 Hz, 6H)477.9 162

3-chloro-N-((4,6- dimethyl-2-oxo-1,2- dihydropyridin-3-yl)methyl)-1-isopropyl- 6-(3-methoxyphenyl)- 1H-indole-4- carboxamide11.47 (br.s., 1H), 8.18 (t, J = 5.05 Hz, 1H), 7.91 (d, J = 1.01 Hz, 1H),7.76 (s, 1H), 7.35-7.42 (m, 1H), 7.25- 7.34 (m, 3H), 6.93 (dd, J = 1.77,8.08 Hz, 1H), 5.87 (s, 1H), 4.99 (dt, J = 6.60, 13.33 Hz, 1H), 4.37 (d,J = 5.05 Hz, 2H), 3.85 (s, 3H), 2.24 (s, 3H), 2.11 (s, 3H), 1.46 (d, J =6.57 Hz, 6H) 477.9 163

3-chloro-6-(3-cyano-4- fluorophenyl)-N-((4,6- dimethyl-2-oxo-1,2-dihydropyridin-3- yl)methyl)-1-isopropyl- 1H-indole-4- carboxamide 11.47(s, 1H), 8.40 (dd, J = 2.40, 6.19 Hz, 1H), 8.15- 8.24 (m, 2H), 8.06 (d,J = 1.52 Hz, 1H), 7.81 (s, 1H), 7.63 (t, J = 9.09 Hz, 1H), 7.38 (d, J =1.52 Hz, 1H), 5.87 (s, 1H), 4.99 (quin, J = 6.63 Hz, 1H), 4.37 (d, J =5.05 Hz, 2H), 2.25 (s, 3H), 2.11 (s, 3H), 1.47 (d, J = 6.57 Hz, 6H)491.0 164

3-chloro-N-((4,6- dimethyl-2-oxo-1,2- dihydropyridin-3-yl)methyl)-1-isopropyl- 6-phenyl-1H-indole-4- carboxamide 11.48 (br.s.,1H), 8.19 (t, J = 5.05 Hz, 1H), 7.91 (s, 1H), 7.72-7.80 (m, 3H), 7.47(t, J = 7.58 Hz, 2H), 7.33-7.39 (m, 1H), 7.30 (d, J = 1.26 Hz, 1H), 5.87(s, 1H), 4.97 (dt, J = 6.60, 13.33 Hz, 1H), 4.37 (d, J = 4.80 Hz, 2H),2.24 (s, 3H), 2.11 (s, 3H), 1.46 (d, J = 6.82 Hz, 6H) 447.8 165

3-chloro-N-((4,6- dimethyl-2-oxo-1,2- dihydropyridin-3- yl)methyl)-6-(4-fluorophenyl)-1- isopropyl-1H-indole-4- carboxamide 11.47 (s, 1H), 8.18(t, J = 5.05 Hz, 1H), 7.90 (d, J = 1.26 Hz, 1H), 7.80 (dd, J = 5.31,8.84 Hz, 2H), 7.76 (s, 1H), 7.26-7.34 (m, 3H), 5.87 (s, 1H), 4.97 (quin,J = 6.57 Hz, 1H), 4.36 (d, J = 5.05 Hz, 2H), 2.24 (s, 3H), 2.11 (s, 3H),1.45 (d, J = 6.57 Hz, 6H) 466.0 166

3-chloro-N-((4,6- dimethyl-2-oxo-1,2- dihydropyridin-3-yl)methyl)-6-(3-fluoro- 4-morpholinophenyl)- 1-isopropyl-1H-indole-4-carboxamide 11.48 (br.s., 1H), 8.16 (t, J = 4.93 Hz, 1H), 7.91 (d, J =1.26 Hz, 1H), 7.74 (s, 1H), 7.63 (dd, J = 2.02, 14.65 Hz, 1H), 7.54 (dd,J = 1.77, 8.34 Hz, 1H), 7.30 (d, J = 1.01 Hz, 1H), 7.11 (t, J = 8.84 Hz,1H), 5.87 (s, 1H), 4.98 (quin, J = 6.63 Hz, 1H), 4.36 (d, J = 5.05 Hz,2H), 3.70-3.82 (m, 4H), 2.99-3.12 (m, 4H), 2.24 (s, 3H), 2.11 (s, 3H),1.45 (d, J = 6.57 Hz, 6H) 551.2 167

3-chloro-N-((4,6- dimethyl-2-oxo-1,2- dihydropyridin-3- yl)methyl)-6-(6-fluoropyridin-3-yl)-1- isopropyl-1H-indole-4- carboxamide 11.47 (s, 1H),8.64 (d, J = 2.53 Hz, 1H), 8.39 (td, J = 2.53, 8.21 Hz, 1H), 8.19 (t, J= 4.93 Hz, 1H), 8.03 (d, J = 1.52 Hz, 1H), 7.80 (s, 1H), 7.34 (d, J =1.52 Hz, 1H), 7.30 (dd, J = 2.78, 8.59 Hz, 1H), 5.87 (s, 1H), 4.98 (ddd,J = 6.69, 6.82, 13.26 Hz, 1H), 4.37 (d, J = 5.05 Hz, 2H), 2.25 (s, 3H),2.11 (s, 3H), 1.46 (d, J = 6.82 Hz, 6H) 467.3 168

3-chloro-N-[(4,6- dimethyl-2-oxo-1,2- dihydro-3- pyridinyl)methyl]-1-(1-methylethyl)-6-(1H- pyrrolo[2,3-b]pyridin-5- yl)-1H-indole-4-carboxamide 11.70 (br.s., 1 H) 11.42 (br. s., 1 H) 8.61 (d, J = 2.02 Hz,1 H) 8.30 (d, J = 2.27 Hz, 1 H) 8.20 (t, J = 5.05 Hz, 1 H) 7.96 (d, J =1.26 Hz, 1 H) 7.74 (s, 1 H) 7.52 (d, J = 3.54 Hz, 1 H) 7.35 (d, J = 1.26Hz, 1 H) 6.51 (d, J = 3.54 Hz, 1 H) 5.87 (s, 1 H) 5.00 (quin, J = 6.63Hz, 1 H) 4.38 (s, 1 H) 4.37 (s, 1 H) 2.25 (s, 3 H) 2.11 (s, 3 H) 1.48(s, 3 H) 1.46 (s, 3 H) 488.0 169

3-chloro-1-(1- methylethyl)-N-[(6- methyl-2-oxo-4-propyl- 1,2-dihydro-3-pyridinyl)methyl]-6-(1- methyl-1H-pyrazol-4- yl)-1H-indole-4-carboxamide 11.47 (s, 1 H) 8.19 (s, 1 H) 8.02 (t, J = 5.05 Hz, 1 H) 7.92(s, 1 H) 7.81-7.84 (m, 1 H) 7.66 (s, 1 H) 7.21 (d, J = 1.26 Hz, 1 H)5.90 (s, 1 H) 4.87 (quin, J = 6.63 Hz, 1 H) 4.37 (s, 1 H) 4.36 (s, 1 H)3.87 (s, 3 H) 2.53-2.58 (m, 2 H) 2.12 (s, 3 H) 1.53-1.61 (m, 2 H) 1.45(s, 3 H) 1.44 (s, 3 H) 0.95 (t, J = 7.33 Hz, 3 H)  479.8/ 481.9 170

6-bromo-1-cyclopropyl- N-[(4,6-dimethyl-2-oxo- 1,2-dihydro-3-pyridinyl)methyl]-3- methyl-1H-indole-4- carboxamide 11.48 (s, 1 H) 8.27(t, J = 4.93 Hz, 1 H) 7.71 (d, J = 1.77 Hz, 1 H) 7.15 (s, 1 H) 7.06 (d,J = 1.52 Hz, 1 H) 5.86 (s, 1 H) 4.31 (s, 1 H) 4.29 (s, 1 H) 3.36-3.41(m, 1 H) 2.21 (s, 3 H) 2.11 (s, 3 H) 2.10 (s, 3 H) 1.01-1.07 (m, 2 H)0.86- 0.91 (m, 2 H)  427.7/ 429.9 171

6-bromo-3-chloro-1- cyclopentyl-N-((4,6- dimethyl-2-oxo-1,2-dihydropyridin-3- yl)methyl)-1H-indole-4- carboxamide 1.62-1.90 (m, 6H), 2.08- 2.15 (m, 5 H), 2.22 (s, 3 H), 2.22 (s, 3 H), 4.32 (d, J = 4.80Hz, 2 H), 4.87-5.04 (m, 1 H), 5.86 (s, 1 H), 7.08 (m, 1 H), 7.72 (m, 1H), 7.93 (d, J = 1.52 Hz, H), 8.25 (t, J = 4.93 Hz, 1 H), 11.47 (br. s.,1 H) 475.7 172

6-cyano-N-((4,6- dimethyl-2-oxo-1,2- dihydropyridin-3-yl)methyl)-1-isopropyl- 3-methyl-1H-indole-4- carboxamide 1.39-1.47 (m,6 H), 2.12 (s, 3 H), 2.16 (s, 3 H), 2.22- 2.26 (m, 3 H), 4.32 (d, J =5.05 Hz, 2 H), 4.85 (quin, J = 6.63 Hz, 1 H), 5.87 (s, 1 H), 7.21 (d, J= 1.26 Hz, 1 H), 7.64 (s, 1 H), 8.16 (d, J = 1.26 Hz, 1 H), 8.33 (t, J =5.05 Hz, 1 H), 11.48 (br.s., 1 H) 377.2 173

3-methyl-1-(1- methylethyl)-N-{[6- methyl-4-(1- methylethyl)-2-oxo-1,2-dihydro-3- pyridinyl]methyl}-6-[6- (4-methyl-1- piperazinyl)-3-pyridinyl]-1H-indole-4- carboxamide 11.44 (br.s., 1 H) 8.50 (d, J = 2.27Hz, 1 H) 8.18 (t, J = 4.80 Hz, 1 H) 7.92 (dd, J = 8.84, 2.53 Hz, 1 H)7.72 (d, J = 1.26 Hz, 1 H) 7.29 (s, 1 H) 7.18 (d, J = 1.26 Hz, 1 H) 6.92(d, J = 9.09 Hz, 1 H) 6.01 (s, 1 H) 4.84 (quin, J = 6.63 Hz, 1 H) 4.41(br.s., 1 H) 4.40 (br.s., 1 H) 3.48-3.56 (m, 4 H) 3.24-3.31 (m, 1 H)2.39-2.44 (m, 4 H) 2.23 (s, 3 H) 2.17 (s, 3 H) 2.14 (s, 3 H) 1.44 (s, 3H) 1.42 (s, 3 H) 1.15 (s, 3 H) 1.13 (s, 3 H) 555.4 174

6-(4-{[2- (dimethylamino)ethyl] oxy}phenyl)-N-[(4,6- dimethyl-2-oxo-1,2-dihydro-3- pyridinyl)methyl]-3- methyl-1-(1- methylethyl)-1H-indole-4-carboxamide 11.43 (br.s., 1 H) 8.09-8.27 (m, 1 H) 7.70 (d, J =1.52 Hz, 1 H) 7.66-7.68 (m, 1 H) 7.63-7.66 (m, 1 H) 7.29 (d, J = 1.01Hz, 1 H) 7.19 (d, J = 1.52 Hz, 1 H) 7.02-7.04 (m, 1 H) 7.00-7.02 (m, 1H) 5.87 (s, 1 H) 4.85 (dt, J = 13.39, 6.69 Hz, 1 H) 4.36 (s, 1 H) 4.34(s, 1 H) 4.09 (t, J = 5.81 Hz, 2 H) 2.61-2.67 (m, 2 H) 2.23 (s, 9 H)2.17 (s, 3 H) 2.11 (s, 3 H) 1.44 (s, 3 H) 1.42 (s, 3 H) 515.1 175

6-bromo-N-[(4,6- dimethyl-2-oxo-1,2- dihydro-3- pyridinyl)methyl]-3-fluoro-1-(1- methylethyl)-1H- indole-4-carboxamide 1H NMR (400 MHz,METHANOL-d4) δ 7.81 (t, J = 1.77 Hz, 1H), 7.40 (d, J = 1.52 Hz, 1H),7.38 (d, J = 2.27 Hz, 1H), 6.13 (s, 1H), 4.71-4.81 (m, J = 1.52, 6.63,6.63, 13.26 Hz, 1H), 4.54 (s, 2H), 2.40 (s, 3H), 2.26 (s, 3H), 1.47 (d,J = 6.82 Hz, 6H) 434.1 176

6-bromo-3-fluoro-1-(1- methylethyl)-N-[(6- methyl-2-oxo-4-propyl-1,2-dihydro-3- pyridinyl)methyl]-1H- indole-4-carboxamide 11.49 (s, 1H),8.20-8.28 (m, 1H), 7.94 (t, J = 1.77 Hz, 1H), 7.66 (d, J = 2.27 Hz, 1H),7.24 (d, J = 1.52 Hz, 1H), 5.90 (s, 1H), 4.82 (dd, J = 1.52, 6.82 Hz,1H), 4.33 (d, J = 5.05 Hz, 2H), 2.13 (s, 3H), 1.48-1.59 (m, 2H), 1.39(d, J = 6.57 Hz, 6H), 0.92 (t, 3H) 462.2 177

N-[(4,6-dimethyl-2-oxo- 1,2-dihydro-3- pyridinyl)methyl]-3- fluoro-1-(1-methylethyl)-6-[6-(4- methyl-1-piperazinyl)- 3-pyridinyl]-1H-indole-4-carboxamide 11.48 (d, J = 11.87 Hz, 1H), 8.54 (d, J = 2.53 Hz, 1H),8.19 (t, J = 5.05 Hz, 1H), 8.16 (s, 1H), 7.96 (dd, J = 2.53, 8.84 Hz,1H), 7.86 (s, 1H), 7.58 (d, J = 2.27 Hz, 1H), 7.43 (d, J = 1.01 Hz, 1H),6.94 (d, J = 8.84 Hz, 1H), 5.88 (s, 1H), 4.86-5.03 (m, J = 7.07 Hz, 1H),4.36 (d, J = 4.80 Hz, 2H), 3.48-3.59 (m, 4H), 2.44 (t, J = 4.93 Hz, 4H),2.23 (d, J = 10.36 Hz, 6H), 2.12 (s, 3H), 1.42 (d, 6H) 531.4 178

3-bromo-N-[(4,6- dimethyl-2-oxo-1,2- dihydro-3- pyridinyl)methyl]-1-(1-methylethyl)-6-[6-(4- methyl-1-piperazinyl)- 3-pyridinyl]-1H-indole-4-carboxamide 1H NMR (400 MHz, METHANOL-d4) δ 8.49 (d, J = 2.27 Hz, 1H),7.97 (dd, J = 2.53, 8.84 Hz, 1H), 7.77 (d, J = 1.26 Hz, 1H), 7.55 (s,1H), 7.37 (d, J = 1.26 Hz, 1H), 6.99 (d, J = 8.84 Hz, 1H), 6.14 (s, 1H),4.60 (s, 2H), 3.74 (br.s., 4H), 2.96 (t, J = 4.55 Hz, 4H), 2.65 (s, 3H),2.47 (s, 3H), 2.26 (s, 3H), 1.54 (d, J = 6.57 Hz, 6H) 592.2 179

3-fluoro-1-(1- methylethyl)-N-[(6- methyl-2-oxo-4-propyl- 1,2-dihydro-3-pyridinyl)methyl]-6-[6- (4-methyl-1- piperazinyl)-3-pyridinyl]-1H-indole-4- carboxamide 11.50 (br.s., 1H), 8.53 (d, J = 2.53Hz, 1H), 8.12-8.21 (m, 1H), 7.95 (dd, J = 2.53, 8.84 Hz, 1H), 7.86 (s,1H), 7.59 (d, J = 2.27 Hz, 1H), 7.43 (d, J = 1.26 Hz, 1H), 6.94 (d, J =8.84 Hz, 1H), 5.90 (s, 1H), 4.86-5.03 (m, 1H), 4.37 (d, J = 5.05 Hz,2H), 3.49-3.58 (m, 4H), 2.37-2.47 (m, 4H), 2.24 (s, 3H), 2.13 (s, 3H),1.55 (sxt, J = 7.53 Hz, 2H), 1.42 (d, J = 6.57 Hz, 6H), 0.92 (t, J =7.33 Hz, 3H) 559.7 180

3-methyl-1-(1- methylethyl)-N-[(6- methyl-2-oxo-4-propyl- 1,2-dihydro-3-pyridinyl)methyl]-6-(4- pyridazinyl)-1H-indole- 4-carboxamide11.00-11.70 (bs, 1H), 9.70- 9.79 (m, 1H), 9.16-9.27 (m, 1H), 8.25 (t, J= 4.80 Hz, 1H), 8.19 (d, J = 1.52 Hz, 1H), 8.08 (dd, J = 2.53, 5.56 Hz,1H), 7.48 (s, 2H), 5.91 (s, 1H), 4.96 (quin, J = 6.63 Hz, 1H), 4.38 (d,J = 4.80 Hz, 2H), 2.53-2.59 (m, 2H), 2.19 (s, 3H), 2.12 (s, 3H), 1.58(sxt, J = 7.43 Hz, 2H), 1.46 (d, J = 6.82 Hz, 6H), 0.94 (t, J = 7.45 Hz,3H) 458.3 181

N-[(4,6-dimethyl-2-oxo- 1,2-dihydro-3- pyridinyl)methyl]-3- methyl-1-(1-methylethyl)-6-(6- phenyl-3-pyridinyl)-1H- indole-4-carboxamide 11.52(br.s., 1 H) 9.10 (d, J = 2.27 Hz, 1 H) 8.31 (dd, J = 8.21, 2.15 Hz, 1H) 8.25 (t, J = 5.05 Hz, 1 H) 8.16 (d, J = 7.33 Hz, 2 H) 8.09 (d, J =8.34 Hz, 1 H) 7.98 (d, J = 1.26 Hz, 1 H) 7.51-7.56 (m, 2 H) 7.45-7.49(m, 1 H) 7.37-7.40 (m, 2 H) 5.89 (s, 1 H) 4.89-4.96 (m, 1 H) 4.37 (d, J= 5.05 Hz, 2 H) 2.26 (s, 3 H) 2.19 (s, 3 H) 2.12 (s, 3 H) 1.46 (d, J =6.57 Hz, 6 H) 182

6-[3- (aminomethyl)phenyl]- N-[(4,6-dimethyl-2-oxo- 1,2-dihydro-3-pyridinyl)methyl]-3- methyl-1-(1- methylethyl)-1H- indole-4-carboxamide8.17 (br.s., 1 H) 7.78 (br.s., 2 H) 7.65 (br.s., 1 H) 7.43 (t, J = 7.83Hz, 1 H) 7.33 (br.s., 2 H) 7.20-7.31 (m, 1 H) 5.87 (s, 1 H) 4.85 (d, J =6.57 Hz, 1 H) 4.36 (br.s., 1 H) 4.35 (br.s., 1 H) 3.92 (s, 1 H) 2.24 (s,3 H) 2.17 (s, 3 H) 2.11 (s, 3 H) 1.45 (br.s., 3 H) 1.44 (br.s., 3 H)457.3 183

N-[(4,6-dimethyl-2-oxo- 1,2-dihydro-3- pyridinyl)methyl]-3- methyl-1-(1-methylethyl)-6-[5-(4- morpholinylcarbonyl)- 3-pyridinyl]-1H-indole-4-carboxamide 11.48 (s, 1 H) 9.07 (d, J = 2.27 Hz, 1 H) 8.56 (d, J =1.77 Hz, 1 H) 8.18-8.25 (m, 2 H) 7.96 (d, J = 1.26 Hz, 1 H) 7.39 (s, 1H) 7.34 (d, J = 1.52 Hz, 1 H) 5.87 (s, 1 H) 4.92 (quin, J = 6.63 Hz, 1H) 4.36 (d, J = 5.05 Hz, 2 H) 3.69 (br.s., 4 H) 3.54-3.62 (m, 2 H) 3.43(br.s., 2 H) 2.25 (s, 3 H) 2.18 (s, 3 H) 2.11 (s, 3 H) 1.44 (d, J = 6.57Hz, 6 H) 542.4 184

3-methyl-1-(1- methylethyl)-N-{[6- methyl-4-(1- methylethyl)-2-oxo-1,2-dihydro-3- pyridinyl]methyl}-6-[6- (1-piperazinyl)-3-pyridinyl]-1H-indole-4- carboxamide 11.49 (br.s., 1 H) 8.49 (d, J = 2.27Hz, 1 H) 8.18 (t, J = 4.67 Hz, 1 H) 7.90 (dd, J = 8.84, 2.27 Hz, 1 H)7.72 (s, 1 H) 7.29 (s, 1 H) 7.18 (s, 1 H) 6.88 (d, J = 8.84 Hz, 1 H)6.01 (s, 1 H) 4.79-4.90 (m, 1 H) 4.41 (br.s., 1 H) 4.40 (br.s., 1 H)3.41-3.57 (m, 4 H) 3.22-3.30 (m, 1 H) 2.62- 2.90 (m, 4 H) 2.55 (s, 1 H)2.17 (s, 3 H) 2.14 (s, 3 H) 1.43 (s, 3 H) 1.42 (s, 3 H) 1.15 (s, 3 H)1.13 (s, 3 H) 541.3 185

N-[(4,6-dimethyl-2-oxo- 1,2-dihydro-3- pyridinyl)methyl]-6-(6-formyl-3-pyridinyl)-3- methyl-1-(1- methylethyl)-1H-indole-4-carboxamide 11.50 (br.s., 1 H) 10.04 (s, 1 H) 9.27 (d, J = 1.52Hz, 1 H) 8.44 (dd, J = 8.08, 1.77 Hz, 1 H) 8.27 (t, J = 5.05 Hz, 1 H)8.07 (d, J = 1.26 Hz, 1 H) 8.01 (d, J = 8.08 Hz, 1 H) 7.42- 7.45 (m, 2H) 5.88 (s, 1 H) 4.89-4.99 (m, 1 H) 4.37 (d, J = 5.05 Hz, 2 H) 2.25 (s,3 H) 2.18 (s, 3 H) 2.11 (s, 3 H) 1.45 (d, J = 6.57 Hz, 6 H) 457.2 186

N-[(4-cyclopropyl-6- methyl-2-oxo-1,2- dihydro-3- pyridinyl)methyl]-3-methyl-1-(1- methylethyl)-6-[6-(1- piperazinyl)-3-pyridinyl]-1H-indole-4- carboxamide 11.42 (br.s., 1 H) 8.50 (d, J = 2.02Hz, 1 H) 8.23 (t, J = 4.93 Hz, 1 H) 7.91 (dd, J = 8.84, 2.53 Hz, 1 H)7.72 (s, 1 H) 7.29 (s, 1 H) 7.20 (s, 1 H) 6.88 (d, J = 9.09 Hz, 1 H)5.49 (s, 1 H) 4.79-4.89 (m, 1 H) 4.54 (br.s., 1 H) 4.53 (br.s., 1 H)3.42-3.50 (m, 4 H) 2.74-2.88 (m, 4 H) 2.15- 2.23 (m, 4 H) 2.09 (s, 3 H)1.44 (s, 3 H) 1.42 (s, 3 H) 0.94-1.01 (m, 2 H) 0.76 (d, J = 3.54 Hz, 2H) 539.3 187

N-[(4,6-dimethyl-2-oxo- 1,2-dihydro-3- pyridinyl)methyl]-3-methyl-6-[6-(4-methyl- 1-piperazinyl)-3- pyridinyl]-1-(1-methylpropyl)-1H- indole-4-carboxamide 11.47 (s, 1 H) 8.50 (d, J = 2.53Hz, 1 H) 8.16 (t, J = 5.05 Hz, 1 H) 7.92 (dd, J = 8.84, 2.53 Hz, 1 H)7.73 (d, J = 1.26 Hz, 1 H) 7.26 (s, 1 H) 7.17 (d, J = 1.52 Hz, 1 H) 6.92(d, J = 9.09 Hz, 1 H) 5.87 (s, 1 H) 4.56-4.65 (m, 1 H) 4.36 (s, 1 H)4.34 (s, 1 H) 3.49-3.55 (m, 4 H) 2.40- 2.44 (m, 4 H) 2.24 (s, 3 H) 2.23(s, 3 H) 2.16 (s, 3 H) 2.11 (s, 3 H) 1.76-1.87 (m, 2 H) 1.41 (d, J =6.57 Hz, 3 H) 0.73 (t, J = 7.33 Hz, 3 H) 541.6 188

6-(4-(2- (dimethylamino)ethyl) phenyl)-1-isopropyl-3-methyl-N-((6-methyl-2- oxo-4-propyl-1,2- dihydropyridin-3-yl)methyl)-1H-indole-4- carboxamide 11.50 (br.s., 1 H) 8.15 (t, J = 4.93Hz, 1 H) 7.73-7.76 (m, 1 H) 7.61-7.66 (m, 2 H) 7.31 (d, J = 2.78 Hz, 2H) 7.29 (s, 1 H) 7.22 (d, J = 1.26 Hz, 1 H) 5.90 (s, 1 H) 4.86 (quin, J= 6.63 Hz, 1 H) 4.37 (s, 1 H) 4.36 (br.s., 1 H) 2.72-2.78 (m, 2 H) 2.55(d, J = 7.33 Hz, 2 H) 2.47 (d, J = 7.07 Hz, 2 H) 2.14-2.23 (m, 9 H) 2.12(s, 3 H) 1.53-1.62 (m, 2 H) 1.44 (s, 3 H) 1.43 (s, 3 H) 0.94 (t, J =7.45 Hz, 3 H) 527.1 189

3,6-dibromo-N-[(4,6- dimethyl-2-oxo-1,2- dihydro-3-pyridinyl)methyl]-1-(1- methylethyl)-1H- indole-4-carboxamide 1H NMR(400 MHz, METHANOL-d4) δ 7.81 (d, J = 1.52 Hz, 1H), 7.54 (s, 1H), 7.23(d, J = 1.52 Hz, 1H), 6.12 (s, 1H), 4.77 (quin, J = 6.69 Hz, 1H), 4.55(s, 2H), 2.44 (s, 3H), 2.25 (s, 3H), 1.50 (d, J = 6.57 Hz, 6H) 495.8 190

N-{[(1,1- dimethylethyl)oxy]car- bonyl}-4-[4-({[(4,6-dimethyl-2-oxo-1,2- dihydro-3- pyridinyl)methyl]amino}carbonyl)-3-methyl-1- (1-methylethyl)-1H- indol-6-yl]-L- phenylalanine12.61 (br.s., 1 H) 11.49 (br. s., 1 H) 8.18 (t, J = 5.05 Hz, 1 H) 7.75(s, 1 H) 7.65 (d, J = 8.34 Hz, 2 H) 7.34 (s, 1 H) 7.32 (s, 2 H) 7.23 (s,1 H) 7.15 (s, 1 H) 5.87 (s, 1 H) 4.82-4.90 (m, 1 H) 4.35 (d, J = 5.31Hz, 2 H) 4.12-4.08 (m, 1 H) 3.08-2.88 (m, 2 H) 2.24 (s, 3 H) 2.17 (s, 3H) 2.11 (s, 3 H) 1.43 (d, J = 6.57 Hz, 6H 615.4 191

N-[(4,6-dimethyl-2-oxo- 1,2-dihydro-3- pyridinyl)methyl]-6-[6-(1H-imidazol-1- ylmethyl)-3-pyridinyl]- 3-methyl-1-(1- methylethyl)-1H-indole-4-carboxamide 9.31 (br.s., 1 H) 9.04 (br.s., 1 H) 8.39 (d, J =2.53 Hz, 1 H) 7.97 (br.s., 1 H) 7.70-7.86 (m, 3 H) 7.39 (br.s., 2 H)6.25 (br.s., 1 H) 5.68 (br.s., 2 H) 4.80-4.95 (m, 1 H) 4.42 (br.s., 2 H)2.34 (br.s., 3 H) 2.22 (br.s., 3 H) 2.15 (br.s., 3 H) 1.44 (br.s., 6 H);spiked with d-TFA 509.6 192

N-[(4,6-dimethyl-2-oxo- 1,2-dihydro-3- pyridinyl)methyl]-3- methyl-1-(1-methylethyl)-6- (5,6,7,8-tetrahydro-1,6- naphthyridin-3-yl)-1H-indole-4-carboxamide 11.49 (br.s., 1 H) 8.71 (d, J = 2.02 Hz, 1 H) 8.19(t, J = 5.05 Hz, 1 H) 7.82 (dd, J = 11.49, 1.64 Hz, 2 H) 7.34 (s, 1 H)7.26 (d, J = 1.52 Hz, 1 H) 5.87 (s, 1 H) 4.88 (quin, J = 6.63 Hz, 1 H)4.36 (d, J = 5.05 Hz, 2 H) 3.94 (s, 2 H) 3.05 (t, J = 5.81 Hz, 2 H)2.75- 2.86 (m, 2 H) 2.24 (s, 3 H) 2.17 (s, 3 H) 2.11 (s, 3 H) 1.43 (d, J= 6.57 Hz, 6 H) 484.3 193

N-[(4,6-dimethyl-2-oxo- 1,2-dihydro-3- pyridinyl)methyl]-3- methyl-1-(1-methylethyl)-6-[2-(4- methyl-1-piperazinyl)- 1,3-thiazol-5-yl]-1H-indole-4-carboxamide 11.47 (s, 1 H) 8.15 (t, J = 5.05 Hz, 1 H) 7.57 (s,1 H) 7.56 (d, J = 1.26 Hz, 1 H) 7.28 (d, J = 1.01 Hz, 1 H) 7.05 (d, J =1.26 Hz, 1 H) 5.87 (s, 1 H) 4.77 (quin, J = 6.63 Hz, 1 H) 4.34 (s, 1 H)4.33 (s, 1 H) 3.41-3.47 (m, 4 H) 2.41- 2.47 (m, 4 H) 2.23 (s, 6 H) 2.13(s, 3 H) 2.11 (s, 3 H) 1.42 (s, 3 H) 1.40 (s, 3 H) 533.6 194

N-[(4,6-dimethyl-2-oxo- 1,2-dihydro-3- pyridinyl)methyl]-6-{6- [(9aS)-hexahydropyrazino[2,1- c][1,4]oxazin-8(1H)- yl]-3-pyridinyl}-3-methyl-1-(1- methylethyl)-1H- indole-4-carboxamide 11.44 (br.s., 1 H)8.50 (d, J = 2.53 Hz, 1 H) 8.16 (t, J = 5.05 Hz, 1 H) 7.94 (dd, J =8.84, 2.53 Hz, 1 H) 7.72 (d, J = 1.26 Hz, 1 H) 7.29 (s, 1 H) 7.18 (d, J= 1.52 Hz, 1 H) 6.93 (d, J = 8.84 Hz, 1 H) 5.87 (s, 1 H) 4.84 (quin, J =6.63 Hz, 1 H) 4.35 (s, 1 H) 4.34 (s, 1 H) 4.24 (d, J = 12.63 Hz, 1 H)4.14 (d, J = 11.62 Hz, 1 H) 3.78-3.82 (m, 1 H) 3.77 (br.s., 1 H) 3.56(td, J = 11.37, 2.27 Hz, 1 H) 3.19 (t, J = 10.48 Hz, 1 H) 2.80- 2.95 (m,2 H) 2.69 (d, J = 11.87 Hz, 1 H) 2.39-2.46 (m, 1 H) 2.14-2.27 (m, 9 H)2.11 (s, 3 H) 1.43 (s, 3 H) 1.42 (s, 3 H) 569.5 195

3-methyl-1-(1- methylethyl)-N-[(6- methyl-2-oxo-4-propyl- 1,2-dihydro-3-pyridinyl)methyl]-6- (5,6,7,8-tetrahydro-1,8- naphthyridin-3-yl)-1H-indole-4-carboxamide 11.49 (s, 1 H) 8.14 (d, J = 2.27 Hz, 1 H) 8.09 (t,J = 5.05 Hz, 1 H) 7.64 (d, J = 1.26 Hz, 1 H) 7.56 (d, J = 1.77 Hz, 1 H)7.26 (s, 1 H) 7.14 (d, J = 1.26 Hz, 1 H) 6.51 (s, 1 H) 5.90 (s, 1 H)4.83 (quin, J = 6.57 Hz, 1 H) 4.37 (br.s., 1 H) 4.35 (br.s., 1 H) 3.30(br.s., 2 H) 2.76 (t, J = 6.06 Hz, 2 H) 2.56 (d, J = 7.33 Hz, 2 H) 2.16(s, 3 H) 2.12 (s, 3 H) 1.78-1.85 (m, 2 H) 1.53-1.62 (m, 2 H) 1.43 (s, 3H) 1.41 (s, 3 H) 0.94 (t, J = 7.33 Hz, 3 H) 512.4 196

6-[6-(4-ethyl-1- piperazinyl)-3- pyridinyl]-3-methyl-1-(1-methylethyl)-N-[(6- methyl-2-oxo-4-propyl- 1,2-dihydro-3-pyridinyl)methyl]-1H- indole-4-carboxamide 11.49 (s, 1 H) 8.50 (d, J =2.53 Hz, 1 H) 8.12 (t, J = 5.05 Hz, 1 H) 7.91 (dd, J = 8.84, 2.53 Hz, 1H) 7.72 (d, J = 1.26 Hz, 1 H) 7.29 (s, 1 H) 7.18 (d, J = 1.52 Hz, 1 H)6.92 (d, J = 8.84 Hz, 1 H) 5.90 (s, 1 H) 4.84 (quin, J = 6.63 Hz, 1 H)4.37 (s, 1 H) 4.36 (s, 1 H) 3.48-3.56 (m, 4 H) 2.55 (dd, J = 8.72, 6.95Hz, 2 H) 2.44-2.49 (m, 4 H) 2.38 (q, J = 7.24 Hz, 2 H) 2.17 (s, 3 H)2.12 (s, 3 H) 1.53-1.62 (m, 2 H) 1.44 (s, 3 H) 1.42 (s, 3 H) 1.05 (t, J= 7.07 Hz, 3 H) 0.94 (t, J = 7.33 Hz, 3 H) 569.8 197

N-[(4,6-dimethyl-2-oxo- 1,2-dihydro-3- pyridinyl)methyl]-3-methyl-6-[6-(4-methyl- 1-piperazinyl)-3- pyridinyl]-1-(1-methylpropyl)-1H- indole-4-carboxamide 11.47 (s, 1 H) 8.50 (d, J = 2.53Hz, 1 H) 8.16 (t, J = 5.05 Hz, 1 H) 7.92 (dd, J = 8.84, 2.53 Hz, 1 H)7.72- 7.75 (m, 1 H) 7.26 (s, 1 H) 7.17 (d, J = 1.26 Hz, 1 H) 6.92 (d, J= 8.84 Hz, 1 H) 5.87 (s, 1 H) 4.56-4.65 (m, 1 H) 4.36 (s, 1 H) 4.34 (s,1 H) 3.50- 3.55 (m, 4 H) 2.40-2.44 (m, 4 H) 2.24 (s, 3 H) 2.23 (s, 3 H)2.16 (s, 3 H) 2.11 (s, 3 H) 1.81 (dq, J = 9.85, 7.16 Hz, 2 H) 1.41 (d, J= 6.57 Hz, 3 H) 0.73 (t, J = 7.33 Hz, 3 H) 541.8 198

3-methyl-1-(1- methylethyl)-6-{6-[4-(1- methylethyl)-1- piperazinyl]-3-pyridinyl}-N-[(6-methyl- 2-oxo-4-propyl-1,2- dihydro-3-pyridinyl)methyl]-1H- indole-4-carboxamide 11.49 (br.s., 1 H) 8.50 (d, J= 2.53 Hz, 1 H) 8.12 (t, J = 5.05 Hz, 1 H) 7.91 (dd, J = 8.84, 2.53 Hz,1 H) 7.72 (d, J = 1.26 Hz, 1 H) 7.29 (s, 1 H) 7.18 (d, J = 1.26 Hz, 1 H)5.90 (s, 1 H) 4.84 (quin, J = 6.69 Hz, 1 H) 4.37 (br.s., 1 H) 4.36(br.s., 1 H) 3.46- 3.55 (m, 4 H) 2.66-2.73 (m, 1 H) 2.52-2.57 (m, 6 H)2.17 (s, 3 H) 2.12 (s, 3 H) 1.53-1.62 (m, 2 H) 1.44 (s, 3 H) 1.42 (s, 3H) 1.02 (s, 3 H) 1.01 (s, 3 H) 0.99 (d, J = 6.57 Hz, 1 H) 0.94 (t, J =7.33 Hz, 3 H) 583.6 199

N-[(4,6-dimethyl-2-oxo- 1,2-dihydro-3- pyridinyl)methyl]-3- methyl-1-(1-methylethyl)-6-[6-(4- morpholinylmethyl)-2- pyridinyl]-1H-indole-4-carboxamide 1.45 (d, J = 6.82 Hz, 6 H), 2.11 (s, 3 H), 2.18 (s, 3 H),2.25 (s, 3 H), 3.57-3.66 (m, 4 H), 3.69 (s, 2 H), 4.37 (d, J = 5.05 Hz,2 H), 4.87 (spt, J = 6.40 Hz, 1 H), 5.87 (s, 1 H), 7.33-7.41 (m, 2 H),7.74 (d, J = 1.52 Hz, 1 H), 7.83 (t, J = 7.71 Hz, 1 H), 7.93 (d, J =7.83 Hz, 1 H), 8.15 (t, J = 5.05 Hz, 1 H), 8.19 (d, J = 1.26 Hz, 1 H),11.47 (s, 1 H) 528.4 200

N-[(4,6-dimethyl-2-oxo- 1,2-dihydro-3- pyridinyl)methyl]-3- methyl-1-(1-methylethyl)-6-[6-(4- morpholinyl)-2- pyridinyl]-1H-indole-4-carboxamide 1.45 (d, J = 6.57 Hz, 6 H), 2.12 (s, 3 H), 2.17 (s, 3 H),2.25 (s, 3 H), 3.48-3.61 (m, 4 H), 3.70-3.83 (m, 4 H), 4.36 (d, J = 5.05Hz, 2 H), 4.86 (spt, J = 6.57 Hz, 1 H), 5.88 (s, 1 H), 6.75 (d, J = 8.59Hz, 1 H), 7.30-7.43 (m, 2 H), 7.63 (t, J = 7.95 Hz, 1 H), 7.71 (d, J =1.52 Hz, 1 H), 8.09-8.21 (m, 2 H), 11.46 (s, 1 H) 514   201

N-[(4,6-dimethyl-2-oxo- 1,2-dihydro-3- pyridinyl)methyl]-3- methyl-1-(1-methylethyl)-6-(6- methyl-2-pyridinyl)-1H- indole-4-carboxamide 1.45 (d,J = 6.82 Hz, 6 H), 2.11 (s, 3 H), 2.18 (s, 3 H), 2 25 (s, 3 H), 2 55 (s,3 H), 4.37 (d, J = 5.05 Hz, 2 H), 4.87 (spt, J = 6.57 Hz, 1 H), 5.87 (s,1 H), 7.16 (d, J = 7.33 Hz, 1 H), 7.37 (d, J = 1.01 Hz, 1 H), 7.70-7.78(m, 2 H), 7.85 (d, J = 8.08 Hz, 1 H), 8.15 (t, J = 4.93 Hz, 1 H), 8.19(d, J = 1.52 Hz, 1 H), 11.48 (s, 1 H) 443   202

N-[(4,6-dimethyl-2-oxo- 1,2-dihydro-3- pyridinyl)methyl]-3- methyl-1-(1-methylethyl)-6-[2-(4- morpholinyl)-4- pyrimidinyl]-1H-indole-4-carboxamide 1.45 (d, J = 6.57 Hz, 6 H), 2.12 (s, 3 H), 2.17 (s, 3 H),2.25 (s, 3 H), 3.68-3.76 (m, 4 H), 3.76-3.86 (m, 4 H), 4.36 (d, J = 5.05Hz, 2 H), 4.92 (spt, J = 6.48 Hz, 1 H), 5.88 (s, 1 H), 7.38 (d, J = 5.31Hz, 1 H), 7.45 (s, 1 H), 7.79 (d, J = 1.26 Hz, 1 H), 8.20 (t, J = 5.05Hz, 1 H), 8.29 (d, J = 1.26 Hz, 1 H), 8.41 (d, J = 5.31 Hz, 1 H), 11.46(s, 1 H) 515   203

N-[(4,6-dimethyl-2-oxo- 1,2-dihydro-3- pyridinyl)methyl]-3- methyl-1-(1-methylethyl)-6-(2- pyrimidinyl)-1H-indole- 4-carboxamide 1.47 (d, J =6.57 Hz, 6 H), 2.12 (s, 3 H), 2.19 (s, 3 H), 2.25 (s, 3 H), 4.37 (d, J =5.05 Hz, 2 H), 4.84 (spt, J = 6.61 Hz, 1 H), 5.88 (s, 1 H), 7.38 (t, J =4.80 Hz, 1 H), 7.46 (s, 1 H), 8.06 (d, J = 1.26 Hz, 1 H), 8.18 (t, J =5.05 Hz, 1 H), 8.52 (d, J = 1.26 Hz, 1 H), 8.87 (d, J = 4.80 Hz, 2 H),11.48 (s, 1 H) 204

6-{6- (dimethylamino)methyl]- 2-pyridinyl}-N-[(4,6- dimethyl-2-oxo-1,2-dihydro-3- pyridinyl)methyl]-3- methyl-1-(1- methylethyl)-1H-indole-4-carboxamide 1.45 (d, J = 6.82 Hz, 6 H), 2.11 (s, 3 H), 2.17 (s,3 H), 2.25 (s, 9 H), 3.62 (s, 2 H), 4.37 (d, J = 4.80 Hz, 2 H), 4.87(spt, J = 6.36 Hz, 1 H), 5.87 (s, 1 H), 7.33 (d, J = 7.58 Hz, 1 H), 7.37(s, 1 H), 7.75 (d, J = 1.26 Hz, 1 H), 7.83 (t, J = 7.71 Hz, 1 H), 7.92(d, J = 7.83 Hz, 1 H), 8.15 (t, J = 4.93 Hz, 1 H), 8.19 (d, J = 1.26 Hz,1 H), 11.47 (s, 1 H) 205

6-(6-amino-2- pyridinyl)-N-[(4,6- dimethyl-2-oxo-1,2- dihydro-3-pyridinyl)methyl]-3- methyl-1-(1- methylethyl)-1H- indole-4-carboxamide1.44 (d, J = 6.57 Hz, 6 H), 2.11 (s, 3 H), 2.16 (s, 3 H), 2.24 (s, 3 H),4.35 (d, J = 5.05 Hz, 2 H), 4.74-4.87 (m, 1 H), 5.87 (s, 1 H), 5.96 (s,2 H), 6.37 (d, J = 7.83 Hz, 1 H), 7.14 (d, J = 7.33 Hz, 1 H), 7.34 (s, 1H), 7.44 (t, J = 7.83 Hz, 1 H), 7.65 (d, J = 1.26 Hz, 1 H), 8.04-8.13(m, 2 H), 11.47 (s, 1 H). 444   206

6-[2-amino-6-(4- morpholinyl)-4- pyrimidinyl]-N-[(4,6-dimethyl-2-oxo-1,2- dihydro-3- pyridinyl)methyl]-3- methyl-1-(1-methylethyl)-1H- indole-4-carboxamide 1.44 (d, 6 H), 2.11 (s, 3 H), 2.15(s, 3 H), 2.24 (s, 3 H), 3.53-3.79 (m, 8 H), 4.35 (d, J = 4.29 Hz, 2 H),4.80-4.95 (m, 1 H), 5.87 (s, 1 H), 6.10 (br.s., 2 H), 6.68 (s, 1 H),7.38 (s, 1 H), 7.76 (s, 1 H), 8.06 (br.s., 1 H), 8.18 (s, 1 H), 11.46(br.s., 1 H). 530   207

N-[(4,6-dimethyl-2-oxo- 1,2-dihydro-3- pyridinyl)methyl]-3- methyl-6-[2-(methylamino)-4- pyrimidinyl]-1-(1- methylethyl)-1H-indole-4-carboxamide 1.45 (d, J = 6.82 Hz, 6 H), 2.11 (s, 3 H), 2.17 (s,3 H), 2.25 (s, 3 H), 2.88 (br.s., 3 H), 4.36 (d, J = 5.05 Hz, 2 H),4.81-4.94 (spt, J = 6.57 Hz, 1 H), 5.87 (s, 1 H), 7.07 (br.s., 1 H),7.25 (d, J = 5.31 Hz, 1 H), 7.44 (s, 1 H), 7.78 (s, 1 H), 8.16 (t, J =4.93 Hz, 1 H), 8.26 (s, 1 H), 8.31 (d, J = 4.80 Hz, 1 H), 11.47 (s, 1 H)459.1 208

N-[(4,6-dimethyl-2-oxo- 1,2-dihydro-3- pyridinyl)methyl]-3- methyl-1-(1-methylethyl)-6-(4- pyrimidinyl)-1H-indole- 4-carboxamide 1.46 (d, J =6.57 Hz, 6 H), 2.12 (s, 3 H), 2.19 (s, 3 H), 2.25 (s, 3 H), 4.37 (d, J =5.05 Hz, 2 H), 4.92 (spt, J = 6.65 Hz, 1 H), 5.88 (s, 1 H), 7.49 (s, 1H), 7.85 (d, J = 1.26 Hz, 1 H), 8.17-8.27 (m, 2 H), 8.42 (d, J = 1.52Hz, 1 H), 8.80 (d, J = 5.31 Hz, 1 H), 9.19 (d, J = 1.01 Hz, 1 H), 11.48(s, 1 H) 430.0 209

N-[(4,6-dimethyl-2-oxo- 1,2-dihydro-3- pyridinyl)methyl]-6-[2-(ethylamino)-4- pyrimidinyl]-3-methyl- 1-(1-methylethyl)-1H-indole-4-carboxamide 1.17 (t, J = 7.07 Hz, 3 H), 1.45 (d, J = 6.57 Hz, 6H), 2.11 (s, 3 H), 2.17 (s, 3 H), 2.24 (s, 3 H), 3.34-3.45 (m, 2 H),4.36 (d, J = 5.05 Hz, 2 H), 4.86 (spt, J = 6.61 Hz, 1 H), 5.87 (s, 1 H),7.12 (br.s., 1 H), 7.23 (d, J = 5.31 Hz, 1 H), 7.43 (s, 1 H), 7.76 (d, J= 1.26 Hz, 1 H), 8.16 (t, J = 4.93 Hz, 1 H), 8.25 (s, 1 H), 8.30 (d, J =5.05 Hz, 1 H), 11.47 (s, 1 H) 473.0 210

6-(2-amino-4- pyrimidinyl)-N-[(4,6- dimethyl-2-oxo-1,2- dihydro-3-pyridinyl)methyl]-3- methyl-1-(1- methylethyl)-1H- indole-4-carboxamide1.45 (d, J = 6.57 Hz, 6 H), 2.11 (s, 3 H), 2.17 (s, 3 H), 2.24 (s, 3 H),4.35 (d, J = 5.05 Hz, 2 H), 4.80-4.92 (m, 1 H), 5.87 (s, 1 H), 6.61 (s,2 H), 7.25 (d, J = 5.31 Hz, 1 H), 7.44 (s, 1 H), 7.75 (d, J = 1.26 Hz, 1H), 8.15 (t, J = 5.05 Hz, 1 H), 8.23 (d, J = 1.01 Hz, 1 H), 8.27 (d, J =5.31 Hz, 1 H), 11.47 (s, 1 H) 445   211

6-(1H-benzimidazol-5- yl)-N-[(4,6-dimethyl-2- oxo-1,2-dihydro-3-pyridinyl)methyl]-3- methyl-1-(1- methylethyl)-1H- indole-4-carboxamide1.45 (d, J = 6.57 Hz, 6 H), 2.11 (s, 3 H), 2.19 (s, 3 H), 2.25 (s, 3 H),4.37 (d, J = 5.05 Hz, 2 H), 4.82-4.95 (m, 1 H), 5.87 (s, 1 H), 7.24-7.30 (m, 1 H), 7.30 (s, 1 H), 7.53-7.64 and 7.66-7.75 (m, 2 H), 7.79 (s,1 H), 7.80- 7.84 and 7.98-8.06 (m, 1 H), 8.20 (t, J = 5.05 Hz, 1 H),8.23 (s, 1 H), 11.47 (br.s., 1 H), 12.45 (br.s., 1 H) 212

6-(3-amino-1H-indazol- 6-yl)-N-[(4,6-dimethyl- 2-oxo-1,2-dihydro-3-pyridinyl)methyl]-3- methyl-1-(1- methylethyl)-1H- indole-4-carboxamide1.44 (d, J = 6.82 Hz, 6 H), 2.11 (s, 3 H), 2.18 (s, 3 H), 2.24 (s, 3 H),4.37 (d, J = 4.80 Hz, 2 H), 4.89 (spt, J = 6.48 Hz, 1 H), 5.35 (s, 2 H),5.87 (s, 1 H), 7.25-7.35 (m, 3 H), 7.50 (s, 1 H), 7.74 (d, J = 8.34 Hz,1 H), 7.80 (d, J = 1.26 Hz, 1 H), 8.21 (t, J = 5.05 Hz, 1 H), 11.37(br.s., 1 H), 11.47 (br.s., 1 H) 483   213

N-[(4,6-dimethyl-2-oxo- 1,2-dihydro-3- pyridinyl)methyl]-3- methyl-1-(1-methylethyl)-6-(1- methyl-1H-indazol-6- yl)-1H-indole-4- carboxamide1.46 (d, J = 6.57 Hz, 6 H), 2.11 (s, 3 H), 2.18 (s, 3 H), 2.26 (s, 3 H),4.13 (s, 3 H), 4.37 (d, J = 5.05 Hz, 2 H), 4.91 (spt, J = 6.57 Hz, 1 H),5.87 (s, 1 H), 7.35 (s, 1 H), 7.39 (d, J = 1.26 Hz, 1 H), 7.57 (dd, J =8.46, 1.39 Hz, 1 H), 7.81 (d, J = 8.59 Hz, 1 H), 7.90 (d, J = 1.52 Hz, 1H), 7.96 (s, 1 H), 8.04 (s, 1 H), 8.18 (t, J = 5.05 Hz, 1 H), 11.47 (s,1 H) 214

N-[(4,6-dimethyl-2-oxo- 1,2-dihydro-3- pyridinyl)methyl]-3- methyl-1-(1-methylethyl)-6-(5- methyl-1H-indazol-6- yl)-1H-indole-4- carboxamide1.42 (d, J = 6.57 Hz, 6 H), 2.09 (s, 3 H), 2.20 (s, 3 H), 2.22 (s, 3 H),2.31 (s, 3 H), 4.34 (d, J = 5.05 Hz, 2 H), 4.78 (spt, J = 6.53 Hz, 1 H),5.85 (s, 1 H), 6.93 (d, J = 1.52 Hz, 1 H), 7.33 (s, 1 H), 7.37 (s, 1 H),7.50 (d, J = 1.26 Hz, 1 H), 7.65 (s, 1 H), 8.01 (s, 1 H), 8.13 (t, J =5.05 Hz, 1 H), 11.45 (br.s., 1 H), 12.92 (br.s., 1 H) 215

N-[(4,6-dimethyl-2-oxo- 1,2-dihydro-3- pyridinyl)methyl]-6-[6-(4-ethyl-1-piperazinyl)- 3-pyridinyl]-3-methyl-1- (1-methylethyl)-1H-indole-4-carboxamide 1.05 (t, J = 7.20 Hz, 3 H) 1.43 (d, J = 6.57 Hz, 6H) 2.11 (s, 3 H) 2.16 (s, 3 H) 2.24 (s, 3 H) 2.37 (q, J = 7.07 Hz, 2 H)2.45- 2.49 (m, 4 H) 3.49-3.55 (m, 4 H) 4.35 (d, J = 5.05 Hz, 2 H)4.78-4.90 (m, 1 H) 5.87 (s, 1 H) 6.92 (d, J = 8.84 Hz, 1 H) 7.18 (d, J =1.52 Hz, 1 H) 7.29 (s, 1 H) 7.72 (d, J = 1.26 Hz, 1 H) 7.92 (dd, J =8.84, 2.78 Hz, 1 H) 8.15 (t, J = 5.05 Hz, 1 H) 8.51 (d, J = 2.53 Hz, 1H) 11.48 (br.s., 1 H) 541.6 216

N-[(4,6-dimethyl-2-oxo- 1,2-dihydro-3- pyridinyl)methyl]-3- methyl-1-(1-methylethyl)-6-{6-[4-(1- methylethyl)-1- piperazinyl]-3-pyridinyl}-1H-indole-4- carboxamide 1.01 (d, J = 6.57 Hz, 6 H) 1.43 (d,J = 6.57 Hz, 6 H) 2.11 (s, 3 H) 2.16 (s, 3 H) 2.24 (s, 3 H) 2.53-2.57(m, 4 H) 2.67- 2.73 (m, 1 H) 3.47-3.54 (m, 4 H) 4.35 (d, J = 5.31 Hz, 2H) 4.84 (s, 1 H) 5.87 (s, 1 H) 6.91 (d, J = 8.84 Hz, 1 H) 7.18 (d, J =1.26 Hz, 1 H) 7.29 (s, 1 H) 7.72 (d, J = 1.52 Hz, 1 H) 7.92 (dd, J =8.84, 2.53 Hz, 1 H) 8.14 (s, 1 H) 8.50 (d, J = 2.27 Hz, 1 H) 11.48 (s, 1H) 555.8 217

6-chloro-3-methyl-1-(1- methylethyl)-N-{[6- methyl-4-(1-methylpropyl)-2-oxo- 1,2-dihydro-3- pyridinyl]methyl}-1H-indole-4-carboxamide 0.79 (t, J = 7.33 Hz, 3 H) 1.11 (d, J = 6.82 Hz, 3H) 1.39 (d, J = 6.57 Hz, 6 H) 1.50 (quin, J = 7.33 Hz, 2 H) 2.14 (s, 6H) 2.98 (q, J = 6.91 Hz, 1 H) 4.36 (d, J = 5.05 Hz, 2 H) 4.73 (quin, J =6.63 Hz, 1 H) 5.95 (s, 1 H) 6.88 (d, J = 1.77 Hz, 1 H) 7.34 (s, 1 H)7.64 (d, J = 1.77 Hz, 1 H) 8.23 (t, J = 4.93 Hz, 1 H) 11.48 (s, 1 H)428.2 218

6-bromo-3-methyl-1- (1-methylethyl)-N-{[6- methyl-4-(1-methylpropyl)-2-oxo- 1,2-dihydro-3- pyridinyl]methyl}-1H-indole-4-carboxamide 0.79 (t, J = 7.33 Hz, 3 H) 1.11 (d, J = 6.82 Hz, 3H) 1.33- 1.44 (m, 6 H) 1.50 (quin, J = 7.33 Hz, 2 H) 2.07-2.20 (m, 6 H)2.91-3.05 (m, 1 H) 4.36 (d, J = 5.05 Hz, 2 H) 4.74 (dt, J = 13.33, 6.60Hz, 1 H) 5.95 (s, 1 H) 6.99 (d, J = 1.52 Hz, 1 H) 7.34 (s, 1 H) 7.76 (d,J = 1.52 Hz, 1 H) 8.24 (t, J = 4.80 Hz, 1 H) 11.48 (br.s., 1 H) 474.2219

3-methyl-1-(1- methylethyl)-N-{[6- methyl-4-(1- methylpropyl)-2-oxo-1,2-dihydro-3- pyridinyl]methyl}-6-[6- (4-methyl-1- piperazinyl)-3-pyridinyl]-1H-indole-4- carboxamide 0.80 (t, J = 7.33 Hz, 3 H) 1.10-1.15 (m, 3 H) 1.34-1.47 (m, 6 H) 1.51 (quin, J = 7.33 Hz, 2 H) 2.10-2.28(m, 9 H) 2.35-2.44 (m, 4 H) 3.01 (sxt, J = 6.92 Hz, 1 H) 3.45- 3.58 (m,4 H) 4.33-4.50 (m, 2 H) 4.84 (quin, J = 6.63 Hz, 1 H) 5.96 (s, 1 H) 6.92(d, J = 8.84 Hz, 1 H) 7.18 (d, J = 1.26 Hz, 1 H) 7.29 (s, 1 H) 7.72 (d,J = 1.26 Hz, 1 H) 7.90 (dd, J = 8.84, 2.53 Hz, 1 H) 8.16 (t, J = 4.93Hz, 1 H) 8.49 (d, J = 2.53 Hz, 1 H) 11.48 (br.s., 1 H) 569.4 220

6-(6-chloro-3- pyridinyl)-N-[(4,6- dimethyl-2-oxo-1,2- dihydro-3-pyridinyl)methyl]-3- methyl-1-(1- methylethyl)-1H- indole-4-carboxamide1.36-1.52 (m, 6 H) 2.11 (s, 3 H) 2.16-2.20 (m, 3 H) 2.21-2.28 (m, 3 H)4.35 (d, J = 5.05 Hz, 2 H) 4.89 (quin, J = 6.63 Hz, 1 H) 5.87 (s, 1 H)7.30 (d, J = 1.26 Hz, 1 H) 7.39 (s, 1 H) 7.59 (d, J = 8.34 Hz, 1 H) 7.92(d, J = 1.52 Hz, 1 H) 8.18-8.29 (m, 2 H) 8.83 (d, J = 2.27 Hz, 1 H)11.49 (s, 1 H) 463.2 221

N-[(4,6-dimethyl-2-oxo- 1,2-dihydro-3- pyridinyl)methyl]-6-[6-(1H-imidazol-1-yl)-3- pyridinyl]-3-methyl-1- (1-methylethyl)-1H-indole-4-carboxamide 1.42-1.48 (m, 6 H) 2.11 (s, 3 H) 2.18 (s, 3 H)2.22-2.30 (m, 3 H) 4.36 (d, J = 5.05 Hz, 2 H) 4.84-4.97 (m, 1 H) 5.87(s, 1 H) 7.16 (s, 1 H) 7.33-7.41 (m, 2 H) 7.91 (d, J = 8.34 Hz, 1 H)7.95 (d, J = 1.26 Hz, 1 H) 8.02 (s, 1 H) 8.22 (t, J = 5.05 Hz, 1 H) 8.39(dd, J = 8.59, 2.53 Hz, 1 H) 8.60 (s, 1 H) 8.90 (d, J = 2.27 Hz, 1 H)11.49 (s, 1 H) 495.2 222

6-[6-(4-cyclopropyl-1- piperazinyl)-3- pyridinyl]-N-[(4,6-dimethyl-2-oxo-1,2- dihydro-3- pyridinyl)methyl]-3- methyl-1-(1-methylethyl)-1H- indole-4-carboxamide 0.34-0.49 (m, 4 H) 1.42 (d, J =6.57 Hz, 6 H) 1.65 (tt, J = 6.57, 3.41 Hz, 1 H) 2.11 (s, 3 H) 2.16 (s, 3H) 2.24 (s, 3 H) 2.59-2.69 (m, 4 H) 3.42-3.56 (m, 4 H) 4.34 (d, J = 5.05Hz, 2 H) 4.84 (quin, J = 6.63 Hz, 1 H) 5.87 (s, 1 H) 6.91 (d, J = 8.84Hz, 1 H) 7.18 (d, J = 1.26 Hz, 1 H) 7.28 (s, 1 H) 7.71 (d, J = 1.26 Hz,1 H) 7.92 (dd, J = 8.84, 2.53 Hz, 1 H) 8.15 (t, J = 5.05 Hz, 1 H) 8.50(d, J = 2.27 Hz, 1 H) 11.48 (s, 1 H) 553.8 223

6-{6-[2- (dimethylamino)ethyl]- 3-pyridinyl}-N-[(4,6-dimethyl-2-oxo-1,2- dihydro-3- pyridinyl)methyl]-3- methyl-1-(1-methylethyl)-1H- indole-4-carboxamide 1.43 (d, J = 6.57 Hz, 6 H) 2.11(s, 3 H) 2.14-2.22 (m, 9 H) 2.24 (s, 3 H) 2.61 (t, J = 7.58 Hz, 2 H)2.89 (t, J = 7.45 Hz, 2 H) 4.35 (d, J = 5.05 Hz, 2 H) 4.81-4.94 (m, 1 H)5.87 (s, 1 H) 7.25 (d, J = 1.26 Hz, 1 H) 7.32- 7.40 (m, 2 H) 7.84 (d, J= 1.26 Hz, 1 H) 8.03 (dd, J = 8.08, 2.53 Hz, 1 H) 8.19 (t, J = 5.05 Hz,1 H) 8.84 (d, J = 2.02 Hz, 1 H) 11.48 (s, 1 H) 500.3 224

N-[(4,6-dimethyl-2-oxo- 1,2-dihydro-3- pyridinyl)methyl]-3-methyl-6-[6-(4-methyl- 1-piperazinyl)-3- pyridinyl]-1-(1-methylpropyl)-1H- indole-4-carboxamide 0.72 (t, J = 7.33 Hz, 3 H) 1.40(d, J = 6.82 Hz, 3 H) 1.80 (td, J = 7.26, 2.91 Hz, 2 H) 2.11 (s, 3 H)2.16 (s, 3 H) 2.23 (d, J = 5.31 Hz, 6 H) 2.37-2.46 (m, 4 H) 3.46-3.56(m, 4 H) 4.35 (d, J = 5.05 Hz, 2 H) 4.60 (d, J = 7.07 Hz, 1 H) 5.86 (s,1 H) 6.91 (d, J = 8.84 Hz, 1 H) 7.17 (d, J = 1.26 Hz, 1 H) 7.26 (s, 1 H)7.73 (d, J = 1.26 Hz, 1 H) 7.91 (dd, J = 8.84, 2.53 Hz, 1 H) 8.16 (t, J= 4.93 Hz, 1 H) 8.50 (d, J = 2.53 Hz, 1 H) 11.48 (s, 1 H) 541.7 225

N-[(4,6-dimethyl-2-oxo- 1,2-dihydro-3- pyridinyl)methyl]-6-{6-[(3R,5S)-3,5-dimethyl- 1-piperazinyl]-3- pyridinyl}-3-methyl-1-(1-methylethyl)-1H- indole-4-carboxamide 1.00-1.07 (m, 6 H) 1.39- 1.46(m, 6 H) 2.11 (s, 3 H) 2.16 (s, 3 H) 2.21-2.34 (m, 6 H) 2.70-2.82 (m, 2H) 4.17 (dd, J = 12.25, 2.15 Hz, 2 H) 4.35 (d, J = 5.05 Hz, 2 H) 4.83(quin, J = 6.57 Hz, 1 H) 5.87 (s, 1 H) 6.89 (d, J = 9.09 Hz, 1 H) 7.17(d, J = 1.26 Hz, 1 H) 7.28 (s, 1 H) 7.70 (d, J = 1.52 Hz, 1 H) 7.89 (dd,J = 8.84, 2.53 Hz, 1 H) 8.15 (t, J = 5.18 Hz, 1 H) 8.47 (d, J = 2.27 Hz,1 H) 11.48 (br.s., 1 H) 541.4 226

6-{6-[3- (dimethylamino)-1- pyrrolidinyl]-3- pyridinyl}-N-[(4,6-dimethyl-2-oxo-1,2- dihydro-3- pyridinyl)methyl]-3- methyl-1-(1-methylethyl)-1H- indole-4-carboxamide 1.35-1.49 (m, 6 H) 1.75- 1.88 (m,1 H) 2.11 (s, 3 H) 2.13-2.19 (m, 4 H) 2.20- 2.27 (m, 9 H) 2.72-2.84 (m,1 H) 3.14 (dd, J = 9.85, 8.34 Hz, 1 H) 3.34-3.41 (m, 1 H) 3.61 (t, J =8.59 Hz, 1 H) 3.71 (dd, J = 10.11, 7.07 Hz, 1 H) 4.35 (d, J = 5.05 Hz, 2H) 4.83 (quin, J = 6.63 Hz, 1 H) 5.87 (s, 1 H) 6.54 (d, J = 8.84 Hz, 1H) 7.16 (d, J = 1.52 Hz, 1 H) 7.27 (s, 1 H) 7.68 (d, J = 1.26 Hz, 1 H)7.88 (dd, J = 8.59, 2.53 Hz, 1 H) 8.14 (t, J = 5.05 Hz, 1 H) 8.45 (d, J= 2.27 Hz, 1 H) 11.48 (s, 1 H) 541.7 227

N-[(4,6-dimethyl-2-oxo- 1,2-dihydro-3- pyridinyl)methyl]-3- methyl-1-(1-methylethyl)-6-[6-(4- methylhexahydro-1H- 1,4-diazepin-1-yl)-3-pyridinyl]-1H-indole-4- carboxamide 1.42 (d, J = 6.57 Hz, 6 H) 1.87-1.97 (m, 2 H) 2.16 (s, 3 H) 2.11 (s, 3 H) 2.20-2.32 (m, 6 H) 2.59-2.72(m, 2 H) 3.63 (t, J = 6.19 Hz, 2 H) 3.78 (br.s., 2 H) 4.34 (d, J = 5.05Hz, 2 H) 4.76-4.89 (m, 1 H) 5.87 (s, 1 H) 6.70 (d, J = 8.84 Hz, 1 H)7.16 (d, J = 1.52 Hz, 1 H) 7.27 (s, 1 H) 7.69 (d, J = 1.26 Hz, 1 H) 7.87(dd, J = 8.84, 2.53 Hz, 1 H) 8.14 (t, J = 5.05 Hz, 1 H) 8.45 (d, J =2.27 Hz, 1 H) 11.48 (s, 1 H) 541.3 228

N-[(4,6-dimethyl-2-oxo- 1,2-dihydro-3- pyridinyl)methyl]-3- methyl-1-(1-methylethyl)-6-[6-(4- piperidinyl)-3- pyridinyl]-1H-indole-4-carboxamide 1H NMR (400 MHz, MeOH- d4) 1.55 (d, J = 6.82 Hz, 6 H)2.14-2.29 (m, 5 H) 2.35 (br. s., 2 H) 2.47 (s, 3 H) 2.60 (s, 3 H)3.23-3.31 (m, 1 H) 3.47-3.59 (m, 1 H) 3.64 (br. s., 2 H) 4.68 (s, 2 H)6.77 (br.s., 1 H) 7.45 (s, 1 H) 7.65 (s, 1 H) 8.08-8.17 (m, 2 H) 9.03(d, J = 8.34 Hz, 1 H) 9.22 (d, J = 1.77 Hz, 1 H) 585   229

6-bromo-1-isopropyl- N-((6-methyl-2-oxo-4- ((6-(trifluoromethyl)pyridin- 2-yl)methyl)-1,2- dihydropyridin-3-yl)methyl)-1H-indole-4- carboxamide 1.42 (s, 3 H), 1.44 (s, 3 H), 2.11(s, 3 H), 4.27 (s, 2 H), 4.44 (d, J = 5.05 Hz, 2 H), 4.74-4.88 (m, 1 H),5.88 (s, 1 H), 6.84 (d, J = 3.03 Hz, 1 H), 7.45 (d, J = 1.77 Hz, 1 H),7.54-7.64 (m, 2 H), 7.71 (d, J = 7.58 Hz, 1 H), 7.91 (s, 1 H), 7.93-8.00(m, 1 H), 8.35 (t, J = 5.05 Hz, 1 H), 11.68 (s, 1 H) 461,  463   230

N-((4,6-dimethyl-2- oxo-1,2-dihydropyridin- 3-yl)methyl)-1-isopropyl-3-methyl-6- (pyridazin-4-yl)-1H- indole-4-carboxamide11.10-11.70 (br.s, 1H), 9.77 (dd, J = 1.26, 2.53 Hz, 1H), 9.22 (dd, J =1.14, 5.43 Hz, 1H), 8.30 (br.s., 1H), 8.19 (d, J = 1.52 Hz, 1H), 8.09(dd, J = 2.53, 5.56 Hz, 1H), 7.42-7.54 (m, 2H), 5.87 (s, 1H), 4.96(quin, J = 6.63 Hz, 1H), 4.36 (d, J = 5.05 Hz, 2H), 2.25 (s, 3H), 2.18(s, 3H), 2.11 (s, 3H), 1.45 (d, 6H) 430.3 231

N-[(6-amino-4-methyl- 2-oxo-1,2-dihydro-3- pyridinyl)methyl]-6-chloro-3-methyl-1-(1- methylethyl)-1H- indole-4-carboxamide 10.62(br.s., 1 H), 8.14 (t, J = 4.4 Hz, 1 H), 7.63 (d, J = 1.8 Hz, 1 H), 7.34(s, 1 H), 6.89 (d, J = 1.8 Hz, 1 H), 5.85 (br.s., 2 H), 5.20 (s, 1 H),4.73 (dt, J = 6.7, 13.2 Hz, 1 H), 4.22 (d, J = 4.8 Hz, 2 H), 2.14 (s, 3H), 2.12 (s, 3 H), 1.39 (d, J = 6.6 Hz, 6 H) 387.2 232

N-[(6-amino-4-methyl- 2-oxo-1,2-dihydro-3- pyridinyl)methyl]-6-bromo-3-methyl-1-(1- methylethyl)-1H- indole-4-carboxamide 10.59 (br.s.,1 H), 8.13 (t, J = 4.4 Hz, 1 H), 7.76 (d, J = 1.5 Hz, 1 H), 7.33 (s, 1H), 6.99 (d, J = 1.5 Hz, 1 H), 5.83 (br.s., 2 H), 5.19 (s, 1 H), 4.74(dt, J = 6.6, 13.3 Hz, 1 H), 4.22 (d, J = 4.8 Hz, 2 H), 2.14 (s, 3 H),2.11 (s, 3 H), 1.39 (d, J = 6.6 Hz, 6 H) 431.1 233

6-bromo-N-[(4,6- dimethyl-2-oxo-1,2- dihydro-3- pyridinyl)methyl]-3-methyl-1-[(3R)- tetrahydro-3-furanyl]- 1H-indole-4- carboxamide1.94-2.07 (m, 1 H), 2.11, (s, 3 H), 2.12 (s, 3 H), 2.22 (s, 3 H),2.40-2.48 (m, 1 H), 3.75- 3.87 (m, 2 H), 3.88-3.96 (m, 1 H), 3.98-4.11(m, 1 H), 4.31 (d, J = 5.05 Hz, 2 H), 5.17-5.32 (m, 1 H), 5.86 (s, 1 H),7.04 (d, J = 1.52 Hz, 1 H), 7.23 (s, 1 H), 7.84 (d, J = 1.77 Hz, 1 H),8.25 (t, J = 4.93 Hz, 1 H), 11.47 (s, 1 H) 458,  460   234

6-bromo-3-methyl-1- (1-methylethyl)-N-{[6- methyl-2-oxo-4-(1H-pyrazol-1-ylmethyl)- 1,2-dihydro-3- pyridinyl]methyl}-1H-indole-4-carboxamide 1.39 (d, J = 6.8 Hz, 6 H), 2.06 (s, 3 H), 2.11 (s,3 H), 4.44 (d, J = 5.3 Hz, 2 H), 4.75 (dt, J = 13.3, 6.6 Hz, 1 H), 5.41(s, 1 H), 5.44 (s, 2 H), 7.07 (d, J = 1.8 Hz, 1 H), 7.33 (s, 1 H), 7.47(d, J = 1.3 Hz, 1 H), 7.78 (d, J = 1.5 Hz, 1 H), 7.84 (d, J = 1.8 Hz, 1H), 8.52 (t, J = 5.2 Hz, 1 H), 11.67 (br.s., 1 H) 496.3 235

6-bromo-1-(1- methylethyl)-N-{[6- methyl-2-oxo-4-(1H-pyrazol-1-ylmethyl)- 1,2-dihydro-3- pyridinyl]methyl}-1H-indole-4-carboxamide 1.44 (d, J = 6.6 Hz, 6 H), 2.06 (s, 3 H), 4.46 (d,J = 5.3 Hz, 2 H), 4.83 (dt, J = 13.2, 6.7 Hz, 1 H), 5.45 (s, 3 H), 6.31(t, J = 2.0 Hz, 1 H), 6.90 (d, J = 3.0 Hz, 1 H), 7.51 (d, J = 1.8 Hz, 1H), 7.57 (d, J = 1.5 Hz, 1 H), 7.64 (d, J = 3.3 Hz, 1 H), 7.87 (d, J =2.3 Hz, 1 H), 7.94 (s, 1 H), 8.56 (t, J = 5.1 Hz, 1 H), 11.73 (br.s., 1H) 484.2 236

3-methyl-1-(1- methylethyl)-N-[(6- methyl-2-oxo-4-propyl- 1,2-dihydro-3-pyridinyl)methyl]-6-(3- pyridinyl)-1H-indole-4- carboxamide 0.94 (t, J =7.3 Hz, 3 H), 1.44 (d, J = 6.6 Hz, 6 H), 1.51- 1.67 (m, 2 H), 2.12 (s, 3H), 2.19 (s, 3 H), 2.52-2.59 (m, 2 H), 4.38 (d, J = 4.0 Hz, 2 H),4.81-4.98 (m, 1 H), 5.90 (s, 1 H), 7.28 (s, 1 H), 7.37 (s, 1 H), 7.47(dd, J = 7.8, 4.5 Hz, 1 H), 7.89 (s, 1 H), 8.14 (d, J = 8.1 Hz, 1 H),8.18 (br.s., 1 H), 8.53 (dd, J = 4.8, 1.3 Hz, 1 H), 8.97 (d, J = 1.8 Hz,1 H), 11.49 (s, 1 H) 457.3 237

6- [(aminocarbonyl)amino]- N-[(4,6-dimethyl-2- oxo-1,2-dihydro-3-pyridinyl)methyl]-3- methyl-1-(1- methylethyl)-1H- indole-4-carboxamide1.39 (m, 6 H), 2.08-2.12 (m, 6 H), 2.22 (s, 3 H), 4.32 (d, J = 5.05 Hz,2 H), 4.44- 4.59 (m, 1 H), 5.76 (s, 2 H), 5.87 (s, 1 H), 6.79 (d, J =1.77 Hz, 1 H), 7.11 (s, 1 H), 7.71 (d, J = 1.52 Hz, 1 H), 7.98 (t, J =5.05 Hz, 1 H), 8.47 (s, 1 H), 11.46 (s, 1 H) 410.3 238

1-cyclopentyl-N-[(4,6- dimethyl-2-oxo-1,2- dihydro-3-pyridinyl)methyl]-3- methyl-6-[6-(4-methyl- 1-piperazinyl)-3-pyridinyl]-1H-indole-4- carboxamide 1.66-1.89 (m, 6 H), 2.05- 2.20 (m, 8H), 2.25 (d, J = 7.07 Hz, 6 H), 3.49-3.58 (m, 4 H), 2.47 (m, 4 H), 4.35(d, J = 5.05 Hz, 2 H), 4.97 (quin, J = 6.88 Hz, 1 H), 5.87 (s, 1 H),6.93 (d, J = 8.84 Hz, 1 H), 7.19 (d, J = 1.26 Hz, 1 H), 7.25 (s, 1 H),7.74 (d, J = 1.26 Hz, 1 H), 7.93 (dd, J = 8.84, 2.53 Hz, 1 H), 8.14-8.21(m, 1 H), 8.51 (d, J = 2.53 Hz, 1 H) 553.8 239

6-bromo-N-((4,6- dimethyl-2-oxo-1,2- dihydropyridin-3- yl)methyl)-1-(1-(dimethylamino)propan- 2-yl)-3-methyl-1H- indole-4-carboxamide (600 MHz,CHLOROFORM- d) 1.44 (d, J = 6.42 Hz, 3 H) 2.14 (s, 3 H) 2.22 (br.s., 9H) 2.38 (s, 3 H) 2.55-2.60 (m, 1 H) 2.65-2.74 (m, 1 H) 4.45-4.54 (m, 1H) 4.57 (d, J = 5.29 Hz, 2 H) 5.92 (s, 1 H) 6.93 (s, 1 H) 7.19 (s, 1 H)7.23 (br.s., 1 H) 7.48 (s, 1 H) 12.53 (br.s., 1 H)  473.2, 475.2 240

N-((4,6-dimethyl-2- oxo-1,2-dihydropyridin- 3-yl)methyl)-1-isopropyl-3-methyl-6- (1H-pyrazolo[3,4- b]pyridin-5-yl)-1H-indole-4-carboxamide 1.45 (d, J = 6.82 Hz, 6 H), 2.11 (s, 3 H), 2.19 (s,3 H), 2.25 (s, 3 H), 4.37 (d, J = 5.05 Hz, 2 H), 4.84-4.96 (m, J =13.29, 6.59, 6.59, 6.59, 6.59 Hz, 1 H), 5.87 (s, 1 H), 7.32 (d, J = 1.52Hz, 1 H), 7.35 (s, 1 H), 7.90 (d, J = 1.26 Hz, 1 H), 8.16-8.25 (m, 2 H),8.53 (d, J = 2.02 Hz, 1 H), 8.94 (d, J = 2.02 Hz, 1 H), 11.47 (s, 1 H),13.67 (s, 1 H) 469   241

N-((4,6-dimethyl-2- oxo-1,2-dihydropyridin- 3-yl)methyl)-1-(2-(dimethylamino)propyl)- 3-methyl-6-(6- (piperazin-1-yl)pyridin-3-yl)-1H-indole-4- carboxamide 0.82 (d, 3 H), 2.10 (s, 3 H), 2.14 (s, 3H), 2.20 (s, 6 H), 2.23 (s, 3 H), 2.75-2.84 (m, 4 H), 2.91-3.04 (m, 1H), 3.39-3.50 (m, 4 H), 4.03 (dd, J = 14.40, 7.07 Hz, 1 H), 4.20 (dd, J= 14.15, 7.07 Hz, 1 H), 4.34 (d, J = 5.05 Hz, 2 H), 5.86 (s, 1 H), 6.88(d, J = 8.84 Hz, 1 H), 7.14 (s, 1 H), 7.17 (d, J = 1.26 Hz, 1 H), 7.67(d, J = 1.26 Hz, 1 H), 7.89 (dd, J = 8.84, 2.53 Hz, 1 H), 8.17 (t, J =4.93 Hz, 1 H), 8.49 (d, J = 2.27 Hz, 1 H), 11.48 (br. s., 1 H) 556.7 242

6-bromo-N-((4,6- dimethyl-2-oxo-1,2- dihydropyridin-3-yl)methyl)-3-methyl-1- (pentan-2-yl)-1H- indole-4-carboxamide 0.76-0.86(m, 3 H), 0.92- 1.20 (m, 2 H), 1.36 (d, J = 6.82 Hz, 3 H), 1.63-1.86 (m,2 H), 2.08-2.15 (m, 6 H), 2.19-2.26 (m, 3 H), 4.30 (d, J = 5.05 Hz, 2H), 4.51- 4.68 (m, 1 H), 5.86 (s, 1 H), 6.99 (d, J = 1.52 Hz, 1 H), 7.31(s, 1 H), 7.78 (d, J = 1.77 Hz, 1 H), 8.25 (t, J = 4.93 Hz, 1 H), 11.48(s, 1 H) 243

N-((4,6-dimethyl-2- oxo-1,2-dihydropyridin- 3-yl)methyl)-1-isopropyl-6-(2- methoxypyrimidin-4- yl)-3-methyl-1H-indole-4-carboxamide 1.46 (d, J = 6.57 Hz, 6 H), 2.12 (s, 3 H), 2.18 (s, 3 H),2.25 (s, 3 H), 4.00 (s, 3 H), 4.37 (d, J = 4.80 Hz, 2 H), 4.92 (spt, J =6.61 Hz, 1 H), 5.87 (s, 1 H), 7.49 (s, 1 H), 7.79-7.86 (m, 2 H), 8.22(t, J = 5.05 Hz, 1 H), 8.38 (d, J = 1.26 Hz, 1 H), 8.60 (d, J = 5.30 Hz,1 H), 11.48 (s, 1 H) 460.4 244

N-((4,6-dimethyl-2- oxo-1,2-dihydropyridin- 3-yl)methyl)-1-isopropyl-3-methyl-6- (1H-pyrazolo[4,3- c]pyridin-6-yl)-1H-indole-4-carboxamide 1.46 (d, J = 6.57 Hz, 6 H), 2.12 (s, 3 H), 2.19 (s,3 H), 2.26 (s, 3 H), 4.38 (d, J = 5.05 Hz, 2 H), 4.90 (spt, J = 6.61 Hz,1 H), 5.88 (s, 1 H), 7.37 (s, 1 H), 7.79 (d, J = 1.26 Hz, 1 H), 8.08 (s,1 H), 8.19 (t, J = 4.93 Hz, 1 H), 8.27-8.35 (m, 2 H), 9.18 (d, J = 1.01Hz, 1 H), 11.48 (br. s., 1 H), 13.45 (br.s., 1 H) 469.4 245

6-bromo-N-[(4,6- dimethyl-2-oxo-1,2- dihydro-3- pyridinyl)methyl]-3-methyl-1-[(1R)-1- methyl-2- (methyloxy)ethyl]-1H- indole-4-carboxamide1.33-1.40 (m, 3 H), 2.12 (d, J = 4.80 Hz, 6 H), 2.22 (s, 3 H), 3.15-3.21(m, 3 H), 3.49- 3.65 (m, 2 H), 4.31 (d, J = 5.05 Hz, 2 H), 4.73-4.90 (m,1 H), 5.87 (s, 1 H), 6.97- 7.06 (m, 1 H), 7.31 (s, 1 H), 7.78 (d, J =1.52 Hz, 1 H), 8.26 (t, J = 4.93 Hz, 1 H), 11.48 (s, 1 H) 460.2 246

N-[(4,6-dimethyl-2-oxo- 1,2-dihydro-3- pyridinyl)methyl]-3-methyl-1-[(1S)-1- methyl-2- (methyloxy)ethyl]-6-[6- (1-piperazinyl)-3-pyridinyl]-1H-indole-4- carboxamide 1.41 (m, 3 H), 2.11 (s, 3 H), 2.15(s, 3 H), 2.24 (s, 3 H), 2.77-2.83 (m, 3 H), 3.13- 3.26 (m, 3 H),3.41-3.48 (m, 3 H), 3.53-3.69 (m, 2 H), 4.35 (d, J = 5.05 Hz, 2 H),4.85-4.99 (m, 1 H), 5.87 (s, 1 H), 6.85-6.93 (m, 1 H), 7.18 (d, J = 1.26Hz, 1 H), 7.27 (s, 1 H), 7.74 (d, J = 1.26 Hz, 1 H), 7.88-7.96 (m, 1 H),8.17 (t, J = 4.93 Hz, 1 H), 8.45-8.54 (m, 1 H) 543.7 247

N-[(4,6-dimethyl-2-oxo- 1,2-dihydro-3- pyridinyl)methyl]-3-methyl-1-[(1S)-1- methyl-2- (methyloxy)ethyl]-6-[6- (4-methyl-1-piperazinyl)-3- pyridinyl]-1H-indole-4- carboxamide 1.41 (d, J = 6.82Hz, 3 H), 2.11 (s, 3 H), 2.16 (s, 3 H), 2.23 (d, J = 4.04 Hz, 5 H),2.39-2.45 (m, 4 H), 3.31- 3.38 (m, 1 H), 3.47-3.70 (m, 6 H), 4.35 (d, J= 5.05 Hz, 2 H), 4.84-4.99 (m, 1 H), 5.87 (s, 1 H), 6.92 (d, J = 8.84Hz, 1 H), 7.19 (d, J = 1.52 Hz, 1 H), 7.27 (s, 1 H), 7.75 (d, J = 1.26Hz, 1 H), 7.92 (dd, J = 8.84, 2.78 Hz, 1 H), 8.19 (t, J = 4.93 Hz, 1 H),8.51 (d, J = 2.53 Hz, 1 H) 557.8 248

6-bromo-N-[(4,6- dimethyl-2-oxo-1,2- dihydro-3- pyridinyl)methyl]-3-methyl-1-[(1S)-1- methyl-2- (methyloxy)ethyl]-1H- indole-4-carboxamide1.37 (m, 3 H), 2.12 (d, J = 4.55 Hz, 6 H), 2.22 (s, 3 H), 3.18 (s, 3 H),3.50-3.66 (m, 2 H), 4.30 (d, J = 5.05 Hz, 2 H), 4.72-4.87 (m, 1 H),5.80-5.92 (m, 1 H), 7.00 (d, J = 1.52 Hz, 1 H), 7.31 (s, 1 H), 7.78 (d,J = 1.52 Hz, 1 H), 8.26 (t, J = 4.80 Hz, 1 H), 11.48 (s, 1 H) 460.2 249

N-[(4,6-dimethyl-2-oxo- 1,2-dihydro-3- pyridinyl)methyl]-3- methyl-6-{6-[(methylamino)methyl]- 3-pyridinyl}-1-(1- methylethyl)-1H-indole-4-carboxamide 11.52 (s, 1H) 8.87 (d, J = 2.27 Hz, 1 H) 8.21 (t, J= 5.05 Hz, 1 H) 8.08-8.14 (m, 1 H) 7.86 (d, J = 1.26 Hz, 1 H) 7.49 (d, J= 8.08 Hz, 1 H) 7.36 (s, 1 H) 7.28 (d, J = 1.26 Hz, 1 H) 5.87 (s, 1 H)4.89 (dt, J = 13.33, 6.60 Hz, 1 H) 4.36 (s, 1 H) 4.35 (s, 1 H) 3.78 (s,2 H) 2.29-2.38 (m, 3 H) 2.24 (s, 3 H) 2.18 (s, 3 H) 2.11 (s, 3 H) 1.45(s, 3 H) 1.43 (s, 3 H) 472.3 250

6-[6-(2,6-dimethyl-4- morpholinyl)-3- pyridinyl]-N-[(4,6-dimethyl-2-oxo-1 2- dihydro-3- pyridinyl)methyl]-3- methyl-1-(1-methylethyl)-1H- indole-4-carboxamide 11.47 (s, 1 H) 8.51 (d, J = 2.27Hz, 1 H) 8.15 (t, J = 4.93 Hz, 1 H) 7.94 (dd, J = 8.84, 2.53 Hz, 1 H)7.72 (d, J = 1.26 Hz, 1 H) 7.27- 7.31 (m, 1 H) 7.19 (d, J = 1.26 Hz, 1H) 6.94 (d, J = 8.84 Hz, 1 H) 5.87 (s, 1 H) 4.85 (quin, J = 6.63 Hz, 1H) 4.36 (s, 1 H) 4.34 (s, 1 H) 4.19-4.22 (m, 1 H) 4.17 (s, 1 H)3.60-3.68 (m, 2 H) 2.42 (dd, J = 12.63, 10.61 Hz, 2 H) 2.24 (s, 3 H)2.16 (s, 3 H) 2.11 (s, 3 H) 1.44 (s, 3 H) 1.42 (s, 3 H) 1.19 (s, 3 H)1.18 (s, 3 H) 542.5 251

N-[(4,6-dimethyl-2-oxo- 1,2-dihydro-3- pyridinyl)methyl]-3- methyl-1-(1-methylethyl)-6-[6-(2- methyl-4-morpholinyl)- 3-pyridinyl]-1H-indole-4-carboxamide 11.48 (s, 1 H) 8.52 (d, J = 2.53 Hz, 1 H) 8.16 (t, J =5.05 Hz, 1 H) 7.95 (dd, J = 8.84, 2.53 Hz, 1 H) 7.73 (d, J = 1.26 Hz, 1H) 7.29 (s, 1 H) 7.19 (d, J = 1.26 Hz, 1 H) 6.93 (d, J = 8.84 Hz, 1 H)5.87 (s, 1 H) 4.85 (dt, J = 13.20, 6.66 Hz, 1 H) 4.35 (s, 1 H) 4.34 (s,1 H) 4.18 (d, J = 12.38 Hz, 1 H) 4.07 (s, 1 H) 3.93 (dd, J = 11.37, 2.27Hz, 1 H) 3.54-3.64 (m, 2 H) 2.82 (td, J = 12.25, 3.54 Hz, 1 H) 2.52-2.56(m, 1 H) 2.22- 2.26 (m, 3 H) 2.16 (s, 3 H) 2.11 (s, 3 H) 1.44 (s, 3 H)1.42 (s, 3 H) 1.18 (d, J = 6.32 Hz, 3 H) 528.3 252

3-methyl-1-(1- methylethyl)-N-[(6- methyl-2-oxo-4-propyl- 1,2-dihydro-3-pyridinyl)methyl]-6-(7- oxo-5,6,7,8-tetrahydro- 1,8-naphthyridin-3-yl)-1H-indole-4- carboxamide 11.44 (br.s., 1 H) 10.53 (br. s., 1 H) 8.48 (d,J = 2.27 Hz, 1 H) 8.11-8.22 (m, 1 H) 8.01 (d, J = 2.27 Hz, 1 H) 7.82 (d,J = 1.26 Hz, 1 H) 7.34 (s, 1 H) 7.25 (d, J = 1.26 Hz, 1 H) 5.90 (s, 1 H)4.88 (quin, J = 6.69 Hz, 1 H) 4.37 (br.s., 1 H) 4.36 (br.s., 1 H) 2.98(t, J = 7.58 Hz, 2 H) 2.53-2.57 (m, 4 H) 2.17 (s, 3 H) 2.12 (s, 3 H)1.53-1.62 (m, 2 H) 1.45 (s, 3 H) 1.43 (s, 3 H) 0.94 (t, J = 7.45 Hz, 3H) 526.2 253

N-[(6-amino-4-methyl- 2-oxo-1,2-dihydro-3- pyridinyl)methyl]-3-methyl-6-[6-(4-methyl- 1-piperazinyl)-3- pyridinyl]-1-(1-methylpropyl)-1H- indole-4-carboxamide 10.47 (br.s., 1 H) 8.50 (d, J =2.53 Hz, 1 H) 7.98 (br.s., 1 H) 7.92 (dd, J = 8.84, 2.53 Hz, 1 H),7.71-7.74 (m, 1 H) 7.26 (s, 1 H) 7.16 (d, J = 1.26 Hz, 1 H) 6.92 (d, J =9.09 Hz, 1 H) 5.76 (s, 2 H) 5.16 (br. s., 1 H) 4.57-4.65 (m, 1 H) 4.26(br.s., 1 H) 4.25 (br.s., 1 H) 3.52 (br.s., 4 H) 2.42 (br.s., 4 H) 2.23(s, 3 H) 2.18 (s, 3 H) 2.13 (s, 3 H) 1.81 (td, J = 7.20, 3.03 Hz, 2 H)1.41 (d, J = 6.82 Hz, 3 H) 0.73 (t, J = 7.20 Hz, 3 H) 542.6 254

N-((4,6-dimethyl-2- oxo-1,2-dihydropyridin- 3-yl)methyl)-1-isopropyl-3-methyl-6- (pyridazin-4-yl)-1H- indole-4-carboxamide11.10-11.70 (br.s, 1H), 9.77 (dd, J = 1.26, 2.53 Hz, 1H), 9.22 (dd, J =1.14, 5.43 Hz, 1H), 8.30 (br.s., 1H), 8.19 (d, J = 1.52 Hz, 1H), 8.09(dd, J = 2.53, 5.56 Hz, 1H), 7.42-7.54 (m, 2H), 5.87 (s, 1H), 4.96(quin, J = 6.63 Hz, 1H), 4.36 (d, J = 5.05 Hz, 2H), 2.25 (s, 3H), 2.18(s, 3H), 2.11 (s, 3H), 1.45 (d, 6H) 430.3 255

N-((4,6-dimethyl-2- oxo-1,2-dihydropyridin- 3-yl)methyl)-3-fluoro-1-isopropyl-6-(6-(4- methylpiperazin-1- yl)pyridin-3-yl)-1H-indole-4-carboxamide 11.48 (d, J = 11.87 Hz, 1H), 8.54 (d, J = 2.53 Hz,1H), 8.19 (t, J = 5.05 Hz, 1H), 8.16 (s, 1H), 7.96 (dd, J = 2.53, 8.84Hz, 1H), 7.86 (s, 1H), 7.58 (d, J = 2.27 Hz, 1H), 7.43 (d, J = 1.01 Hz,1H), 6.94 (d, J = 8.84 Hz, 1H), 5.88 (s, 1H), 4.86-5.03 (m, J = 7.07 Hz,1H), 4.36 (d, J = 4.80 Hz, 2H), 3.48-3.59 (m, 4H), 2.44 (t, J = 4.93 Hz,4H), 2.23 (d, J = 10.36 Hz, 6H), 2.12 (s, 3H), 1.42 (d, 6H) 531.4 256

(R)-N-((4,6-dimethyl-2- oxo-1,2-dihydropyridin- 3-yl)methyl)-3-methyl-6-(6-(4- methylpiperazin-1- yl)pyridin-3-yl)-1- (tetrahydrofuran-3-yl)-1H-indole-4- carboxamide 2.02-2.13 (m, 4 H), 2.15 (s, 3 H), 2.19-2.28(m, 6 H), 2.37-2.49 (m, 5 H), 3.45- 3.59 (m, 4 H), 3.77-3.89 (m, 2 H),3.94-4.01 (m, 1 H), 4.01-4.11 (m, 1 H), 4.35 (d, J = 5.05 Hz, 2 H), 5.33(dd, J = 7.96, 5.68 Hz, 1 H), 5.87 (s, 1 H), 6.93 (d, J = 8.84 Hz, 1 H),7.15-7.26 (m, 2 H), 7.81 (d, J = 1.26 Hz, 1 H), 7.93 (dd, J = 8.84, 2.53Hz, 1 H), 8.16 (t, J = 5.05 Hz, 1 H), 8.52 (d, J = 2.53 Hz, 1 H), 11.47(s, 1 H) 555.6 257

(S)-N-((4,6-dimethyl-2- oxo-1,2-dihydropyridin- 3-yl)methyl)-1-(1-methoxypropan-2-yl)- 3-methyl-6-(6- (piperazin-1-yl)pyridin-3-yl)-1H-indole-4- carboxamide 1.34-1.48 (m, 3 H), 2.11 (s, 3 H), 2.16(s, 3 H), 2.24 (s, 3 H), 2.76-2.86 (m, 4 H), 3.34 (s, 3 H), 3.40-3.48(m, 4 H), 3.53-3.69 (m, 2 H), 4.35 (d, J = 5.05 Hz, 2 H) 4.84-4.98 (m, 1H), 5.87 (s, 1 H), 6.88 (d, J = 8.84 Hz, 1 H), 7.18 (d, J = 1.26 Hz, 1H), 7.27 (d, J = 1.01 Hz, 1 H), 7.74 (d, J = 1.26 Hz, 1 H), 7.87-7.96(m, 1 H), 8.17 (t, J = 5.05 Hz, 1 H), 8.44-8.54 (m, 1 H) 543.5 258

6-bromo-1-(1- ethylpropyl)-3-methyl- N-[(6-methyl-2-oxo-4-propyl-1,2-dihydro-3- pyridinyl)methyl]-1H- indole-4-carboxamide 11.48(br.s., 1 H) 8.24 (br. s., 1 H) 7.79 (s, 1 H) 7.28 (s, 1 H) 6.98 (s, 1H) 5.89 (s, 1 H) 4.33 (d, J = 4.29 Hz, 2 H) 4.21-4.29 (m, 1 H) 2.58-2.55 (m, 2 H) 2.14 (d, J = 9.85 Hz, 6 H) 1.74-1.82 (m, 4 H) 1.55 (br.s.,2 H) 0.94 (t, J = 7.07 Hz, 3 H) 0.64 (t, J = 7.07 Hz, 6 H) 486.3 259

6-bromo-N-[(4,6- dimethyl-2-oxo-1,2- dihydro-3- pyridinyl)methyl]-1-(1-ethylpropyl)-3-methyl- 1H-indole-4- carboxamide 11.47 (br.s., 1 H) 8.26(t, J = 4.80 Hz, 1 H) 7.79 (d, J = 1.26 Hz, 1 H) 7.27 (s, 1 H) 6.99 (d,J = 1.52 Hz, 1 H) 5.86 (s, 1 H) 4.31 (d, J = 4.80 Hz, 2 H) 4.23-4.29 (m,1 H) 2.22 (s, 3 H) 2.13 (d, J = 11.62 Hz, 6 H) 1.73-1.83 (m, 4 H) 0.64(t, J = 7.33 Hz, 6 H) 458.2 260

1-(1-ethylpropyl)-3- methyl-N-[(6-methyl-2- oxo-4-propyl-1,2- dihydro-3-pyridinyl)methyl]-6-[6- (4-methyl-1- piperazinyl)-3-pyridinyl]-1H-indole-4- carboxamide 11.49 (br.s., 1 H) 8.49 (br. s., 1H) 8.15 (br.s., 1 H) 7.90 (br.s., 1 H) 7.75 (br.s., 1 H) 7.11-7.26 (m, 2H) 6.93 (br.s., 1 H) 5.90 (br.s., 1 H) 4.37 (br.s., 3 H) 3.47-3.57 (m, 4H) 2.36-2.45 (m, 6 H) 2.10-2.25 (m, 9 H) 1.81 (br.s., 4 H) 1.58 (br.s.,2 H) 0.94 (br.s., 3 H) 0.67 (br.s., 6 H) 583.8 261

6-{3- [(dimethylamino)methyl] phenyl}-1-(1- ethylpropyl)-3-methyl-N-[(6-methyl-2-oxo-4- propyl-1,2-dihydro-3- pyridinyl)methyl]-1H-indole-4-carboxamide 11.37 (br.s., 1 H) 7.39-7.58 (m, 7 H) 6.95 (br.s.,1 H) 5.89 (br.s., 1 H) 4.66 (d, J = 5.31 Hz, 2 H) 4.16 (br.s., 1 H) 3.53(br.s., 2 H) 2.68- 2.18 (m, 2 H) 2.31 (br.s., 9 H) 2.09 (br.s., 3 H)1.80- 1.96 (m, 4 H) 1.60-1.72 (m, 2 H) 0.98-1.09 (m, 3 H) 0.79 (d, J =6.06 Hz, 6 H) 541.2 262

6-{3- [(dimethylamino)methyl] phenyl}-N-[(4,6- dimethyl-2-oxo-1,2-dihydro-3- pyridinyl)methyl]-1-(1- ethylpropyl)-3-methyl- 1H-indole-4-carboxamide 11.47 (br.s., 1 H) 8.23 (br. s., 1 H) 7.78 (br.s., 1 H) 7.61(br.s., 2 H) 7.40 (br.s., 1 H) 7.19-7.29 (m, 3 H) 5.87 (br.s., 1 H)4.33-4.45 (m, 3 H) 3.47 (br.s., 2 H) 2.24 (br.s., 3 H) 2.18 (br.s., 9 H)2.11 (br.s., 3 H) 1.75- 1.90 (m, 4 H) 0.68 (br.s., 6 H) 513.4 263

6-bromo-1-(1- ethylpropyl)-3-methyl- N-[(6-methyl-2-oxo-4-propyl-1,2-dihydro-3- pyridinyl)methyl]-1H- indole-4-carboxamide 11.48(br.s., 1 H) 8.24 (br. s., 1 H) 7.79 (s, 1 H) 7.28 (s, 1 H) 6.98 (s, 1H) 5.89 (s, 1 H) 4.33 (d, J = 4.29 Hz, 2 H) 4.21-4.29 (m, 1 H) 2.58-2.55 (m, 2 H) 2.14 (d, J = 9.85 Hz, 6 H) 1.74-1.82 (m, 4 H) 1.55 (br.s.,2 H) 0.94 (t, J = 7.07 Hz, 3 H) 0.64 (t, J = 7.07 Hz, 6 H) 486.3

Example 264N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-3-methyl-6-(6-(4-methylpiperazin-1-yl)pyridin-3-yl)-1H-indole-4-carboxamide

To a stirred solution of6-bromo-N-((1,2-dihydro-4,6-dimethyl-2-oxopyridin-3-yl)methyl)-1-isopropyl-3-methyl-1H-indole-4-carboxamide(2 g, 4.65 mmol) in DMF (100 mL) was added1-methyl-4-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl)piperazine(1.55 g, 5.12 mmol) followed by a solution of sodium carbonate (1.23 g,11.62 mmol) in water (10 mL) and the contents were degassed with argonfor 30 min. After that PdCl₂(PPh₃)₂(326 mg, 0.464 mmol) was added andthe contents again degassed with argon for 10 min. The reaction mixturewas stirred at reflux for 3 h. The reaction mixture was diluted withwater (100 mL) and extracted with ethyl acetate (3×150 mL). The combinedorganic layers were dried over anhydrous Na₂SO₄, filtered, andconcentrated to afford the crude product (2.8 g). The crude compound waspurified by column chromatography over silica gel (100-200 mesh, eluent:0-10% MeOH: DCM), and the obtained product was further triturated withdiethyl ether (100 mL) to afford the title compound as an off whitesolid (1.2 g, 50%). ¹H NMR (DMSO-d₆ 400 MHz): δ 1.493 (d, J=6.4 Hz, 6H),2.092 (s, 3H), 2.286 (s, 3H), 2.409 (s, 3H), 2.424 (s, 3H), 2.632 (s,4H), 3.621 (s, 4H), 4.603-4.685 (m, 3H), 5.880 (s, 1H), 6.606 (d, J=8.8Hz, 1H), 7.016 (s, 1H), 7.261 (s, 1H), 7.433 (s, 1H), 7.675-7.704 (dd,J=9 Hz, 2.4 Hz, 1H), 8.425 (d, J=2.0 Hz, 1H), 11.699 (brs, 1H); LCMS(ES+): 525.23 [M−H].

Example 265N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-3-methyl-1-(1-methylethyl)-6-[6-(1-piperazinyl)-3-pyridinyl]-1H-indole-4-carboxamide

6-Bromo-N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-3-methyl-1-(1-methylethyl)-1H-indole-4-carboxamide(1.9 g, 4.42 mmol),1-[5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2-pyridinyl]piperazine(1.277 g, 4.42 mmol) and potassium phosphate (tribasic) (2.81 g, 13.25mmol) were placed in a 150 mL pressure vessel followed by addition of1,4-dioxane (40 mL) and water (10.00 mL). The suspension was stirred anddegassed under N₂ for 15 min. (emulsion). Next added inPdCl₂(dppf)-CH₂Cl₂ adduct (0.361 g, 0.442 mmol) and degassed for 2 min.The reaction flask was sealed and the contents heated at reflux for 2 h.The suspension was filtered, and dioxane was removed in vacuo. Theresultant oil was partitioned between 300 mL of ethyl acetate and 100 mLof water, and the layers were separated. Decolorizing carbon was added,and after 10 min, the organic layer was filtered through short pad ofsilica. 300 mL of 1 M HCl was added and neutralized with NaOH (to pH˜9). The contents were extracted with ethyl acetate. The organic layerwas separated, washed with brine, dried over MgSO₄, filtered andconcentrated in vacuo. The product was suspended in diethyl ether andfiltered. The title compound was isolated as a yellow solid (950 mg, 41%yield). ¹H NMR (400 MHz, DMSO-d₆) δ 11.49 (br. s., 1H), 8.52 (d, J=2.27Hz, 1H), 8.15 (t, J=5.05 Hz, 1H), 7.95 (dd, J=2.53, 8.84 Hz, 1H), 7.73(d, J=1.26 Hz, 1H), 7.29 (s, 1H), 7.19 (d, J=1.52 Hz, 1H), 6.93 (d,J=9.09 Hz, 1H), 5.87 (s, 1H), 4.85 (quin, J=6.63 Hz, 1H), 4.35 (d,J=5.05 Hz, 2H), 3.49-3.63 (m, 4H), 2.81-3.02 (m, 4H), 2.24 (s, 3H), 2.16(s, 3H), 2.11 (s, 3H), 1.43 (d, J=6.57 Hz, 6H); LCMS=513.3 (MH+).

Example 2666-bromo-1-(sec-butyl)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-3-methyl-1H-indole-4-carboxamide

Added sequentially to a reaction flask were6-bromo-1-(sec-butyl)-3-methyl-1H-indole-4-carboxylic acid (1.33 g, 4.29mmol), 3-(aminomethyl)-4,6-dimethyl-2(1H)-pyridinone (1.213 g, 6.43mmol), 1-hydroxy-7-azabenzotriazole (0.875 g, 6.43 mmol), EDC (1.233 g,6.43 mmol), followed by DMSO (30 mL, via syringe) and thenN-methylmorpholine (1.886 mL, 17.15 mmol, via syringe). The contentswere sealed and stirred at room temperature and the solids graduallydissolved. The contents were stirred at room temperature for 32 h, andthen slowly diluted into 220 mL of ice-water with stirring. The contentswere stirred for 10 min, and then allowed to stand for an additional 10min. The contents were filtered and the filtered solid was washed withadditional water (50 mL). The solid was then air dried for 10 min, andthen in a vacuum oven at 50° C. for 23 h total. The product wascollected as 1.75 g (87%). ¹H NMR (400 MHz, DMSO-d6) δ ppm 0.69 (t,J=7.33 Hz, 3H), 1.36 (d, J=6.57 Hz, 3H), 1.77 (dq, J=10.29, 7.09 Hz,2H), 2.12 (d, J=9.09 Hz, 6H), 2.21 (s, 3H), 4.30 (d, J=5.05 Hz, 2H),4.43-4.56 (m, 1H), 5.86 (s, 1H), 6.99 (d, J=1.52 Hz, 1H), 7.30 (s, 1H),7.77 (d, J=1.77 Hz, 1H), 8.25 (t, J=4.93 Hz, 1H), 11.49 (br. s., 1H);LCMS=444.1 (MH+).

Examples 267 and 268(S)-6-bromo-1-(sec-butyl)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-3-methyl-1H-indole-4-carboxamide(Ex 267) and(R)-6-Bromo-1-(sec-butyl)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-3-methyl-1H-indole-4-carboxamide(Ex 268)

6-Bromo-1-(sec-butyl)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-3-methyl-1H-indole-4-carboxamide(racemic mixture, 1.9 g) was resolved by chiral HPLC (column: ChiralpakAD-H, 5 microns, 50 mm×250 mm, UV detection: 240 nM, flow rate: 100mL/min, T=20 deg C, eluent: 60:40:0.1 n-heptane:ethanol:isopropylamine(isocratic)). For each run, 100 mg of the racemic compound was dissolvedin 30 volumes (3.0 mL) of warm ethanol with a few drops ofisopropylamine added. A total of 19 runs were performed. Baselineresolution was observed for each run. The isomer that eluted at 8.3-10.1min was collected (following concentration) as a white solid, which wasdried at 50° C. (<5 mm Hg) to afford 901 mg, and was determined to bethe S isomer* (Ex. 267; chiral HPLC: >99.5% ee (no R isomer detected).The isomer that eluted at 10.8-13.0 min was collected as a white solid,which was dried at 50° C. (<5 mm Hg) to afford 865 mg, and wasdetermined to be the R isomer* (Ex. 268; chiral HPLC: 99.2% ee; 0.4% Sisomer detected). ¹H NMR and LCMS were consistent with the parentracemate. * The absolute configuration was determined by an independentsynthesis of each enantiomer from the corresponding commerciallyavailable homochiral alcohols via Mitsunobu reaction. The stereochemicalassignments were also consistent by vibrational circular dichroism (VCD)analysis.

Example 2691-(sec-butyl)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-3-methyl-6-(6-(piperazin-1-yl)pyridin-3-yl)-1H-indole-4-carboxamide

Added sequentially to a reaction vial were6-bromo-1-(sec-butyl)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-3-methyl-1H-indole-4-carboxamide(0.15 g, 0.338 mmol),1-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl)piperazine(0.127 g, 0.439 mmol), and potassium phosphate (tribasic) (0.287 g,1.350 mmol), followed by 1,4-Dioxane (3 mL) and water (0.75 mL). Thesuspension was stirred under N₂ degassing for 10 min., and then addedPdCl₂(dppf)-CH₂Cl₂ adduct (0.028 g, 0.034 mmol). The reaction vial wassealed, placed into a heat block at 95° C., and stirred for 1.5 h. Thecontents were removed from heating and allowed to cool to roomtemperature. The aq layer was removed from bottom of the reaction vialvia pipette. The reaction mixture was diluted into EtOAc (20 mL)followed by addition of 0.2 g each of Thiol-3 silicycle resin and silicagel. The volatiles were removed in vacuo and the residue dried on hi-vacfor 1 h. The contents were purified by silica gel chromatography (dryloaded, eluent: A: Dichloromethane, B: 10% (2M Ammonia in Methanol) inChloroform, Gradient B: 8-95%). The obtained solid was concentrated fromTBME and dried in vacuum oven at 45° C. for 18 h. The product wascollected as 129 mg (70%). ¹H NMR (400 MHz, DMSO-d6) δ ppm 0.73 (t,J=7.33 Hz, 3H), 1.40 (d, J=6.57 Hz, 3H), 1.80 (dq, J=10.07, 7.08 Hz,2H), 2.11 (s, 3H), 2.14-2.19 (m, 3H), 2.24 (s, 3H), 2.76-2.85 (m, 4H),3.41-3.49 (m, 4H), 4.35 (d, J=5.05 Hz, 2H), 4.54-4.67 (m, 1H), 5.87 (s,1H), 6.88 (d, J=8.84 Hz, 1H), 7.17 (d, J=1.26 Hz, 1H), 7.26 (s, 1H),7.73 (d, J=1.26 Hz, 1H), 7.91 (dd, J=8.84, 2.53 Hz, 1H), 8.16 (t, J=5.05Hz, 1H), 8.50 (d, J=2.53 Hz, 1H), 11.48 (br. s., 1H); LCMS MH+=527.3.

Example 270N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-3-methyl-1-[(1S)-1-methylpropyl]-6-[6-(1-piperazinyl)-3-pyridinyl]-1H-indole-4-carboxamide

To a 30 mL microwave vial were added(S)-6-bromo-1-(sec-butyl)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-3-methyl-1H-indole-4-carboxamide(100 mg, 0.225 mmol),1-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl)piperazine(85 mg, 0.293 mmol), 1,2-Dimethoxyethane (DME) (3 mL), water (1.000 mL)and sodium carbonate (0.338 mL, 0.675 mmol), and the mixture wasdegassed for 5 min by bubbling nitrogen. PdCl₂(dppf)-CH₂Cl₂ adduct(14.70 mg, 0.018 mmol) was added and the tube was sealed. The mixturewas irradiated (microwave) at 140° C. for 10 min. The mixture wasconcentrated and the residue was taken up into MeOH and filtered. Thefiltrate was purified using reverse-phase HPLC (eluent: 25% ACN/H₂O,0.1% NH₄OH to 60% ACN/H₂O, 0.1% NH₄OH) to give 91 mg of product asoff-white solid. ¹H NMR (400 MHz, DMSO-d6) δ ppm 0.70-0.78 (m, 3H),1.37-1.44 (m, 3H), 1.75-1.87 (m, 2H), 2.11 (s, 3H), 2.16 (s, 3H),2.22-2.27 (m, 3H), 2.77-2.85 (m, 4H), 3.41-3.49 (m, 4H), 4.35 (d, J=5.31Hz, 2H), 4.56-4.68 (m, 1H), 5.87 (s, 1H), 6.88 (d, J=8.84 Hz, 1H), 7.17(d, J=1.52 Hz, 1H), 7.26 (s, 1H), 7.73 (d, J=1.26 Hz, 1H), 7.91 (dd,J=8.84, 2.53 Hz, 1H), 8.16 (t, J=5.05 Hz, 1H), 8.50 (d, J=2.53 Hz, 1H);LCMS: 527.8 (MH+).

Example 271N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-3-methyl-1-[(1R)-1-methylpropyl]-6-[6-(1-piperazinyl)-3-pyridinyl]-1H-indole-4-carboxamide

To a 30 mL microwave vial were added(R)-6-bromo-1-(sec-butyl)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-3-methyl-1H-indole-4-carboxamide(100 mg, 0.225 mmol),1-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl)piperazine(85 mg, 0.293 mmol), 1,2-Dimethoxyethane (DME) (3 mL), water (1.000 mL)and sodium carbonate (0.338 mL, 0.675 mmol), and the mixture wasdegassed for 5 min by bubbling nitrogen. PdCl₂(dppf)-CH₂Cl₂ adduct(14.70 mg, 0.018 mmol) was added and the tube was sealed. The mixturewas irradiated (microwave) at 140° C. for 10 min. The mixture wasconcentrated and the residue was taken up into MeOH and filtered. Thefiltrate was purified using reverse-phase HPLC (eluent: 25% ACN/H₂O,0.1% NH₄OH to 60% ACN/H₂O, 0.1% NH₄OH) to give 90 mg of product asoff-white solid. ¹H NMR (400 MHz, DMSO-d6) δ ppm 0.73 (m, 3H), 1.41 (d,J=6.57 Hz, 3H), 1.81 (td, J=7.14, 2.91 Hz, 2H), 2.11 (s, 3H), 2.15-2.20(m, 3H), 2.24 (s, 3H), 2.77-2.83 (m, 4H), 3.41-3.49 (m, 4H), 4.35 (d,J=5.05 Hz, 2H), 4.54-4.68 (m, 1H), 5.87 (s, 1H), 6.88 (d, J=8.84 Hz,1H), 7.17 (d, J=1.52 Hz, 1H), 7.26 (s, 1H), 7.73 (d, J=1.26 Hz, 1H),7.91 (dd, J=8.84, 2.53 Hz, 1H), 8.16 (t, J=5.05 Hz, 1H), 8.50 (d, J=2.27Hz, 1H); LCMS: 527.7 (MH+).

Example 2721-(sec-Butyl)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-6-(3-((dimethylamino)methyl)phenyl)-3-methyl-1H-indole-4-carboxamide

Added sequentially to a reaction vial were6-bromo-1-(sec-butyl)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-3-methyl-1H-indole-4-carboxamide(0.15 g, 0.338 mmol), N,N-dimethyl-1-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)methanamine-hydrochloride(0.131 g, 0.439 mmol) and potassium phosphate (tribasic) (0.287 g, 1.350mmol), followed by 1,4-Dioxane (4 mL) and water (0.75 mL). Thesuspension was stirred under N₂ degassing for 10 min., and then addedPdCl₂(dppf)-CH₂Cl₂ adduct (0.028 g, 0.034 mmol). The reaction vial wassealed, placed into a heat block at 95° C., and stirred for 1.5 h. Thecontents were removed from heating and allowed to cool to roomtemperature. The aq layer was removed from bottom of the reaction vialvia pipette. The reaction mixture was diluted into EtOAc (20 mL)followed by addition of 0.2 g each of Thiol-3 silicycle resin and silicagel. The volatiles were removed in vacuo and the residue dried on hi-vacfor 1 h. The contents were purified by silica gel chromatography (dryloaded, eluent: A: Dichloromethane, B: 10% (2M Ammonia in Methanol) inChloroform; Gradient B: 8-95%). The obtained solid was concentrated fromTBME to afford a foam, and was dried in vacuum oven at 45° C. for 18 h.The product was collected as 116 mg (65%). ¹H NMR (400 MHz, DMSO-d6) δppm 0.73 (t, J=7.33 Hz, 3H), 1.41 (d, J=6.57 Hz, 3H), 1.82 (dq, J=9.85,7.16 Hz, 2H), 2.08-2.12 (m, 3H), 2.15-2.21 (m, 9H), 2.24 (s, 3H),3.44-3.49 (m, 2H), 4.35 (d, J=5.05 Hz, 2H), 4.57-4.70 (m, 1H), 5.86 (s,1H), 7.19-7.26 (m, 2H), 7.30 (s, 1H), 7.36-7.44 (m, 1H), 7.58-7.65 (m,2H), 7.76 (d, J=1.26 Hz, H), 8.21 (t, J=5.05 Hz, 1H), 11.47 (s, 1H);LCMS M+H=499.3.

Example 2736-{3-[(Dimethylamino)methyl]phenyl}-N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-3-methyl-1-[(1S)-1-methylpropyl]-1H-indole-4-carboxamide

(S)-6-bromo-1-(sec-butyl)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-3-methyl-1H-indole-4-carboxamide(100 mg, 0.23 mmol),N,N-dimethyl-1-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)methanamine,HCl (100 mg, 0.34 mmol) and Palladium Tetrakis (26 mg, 0.023 mmol) inDMF/water (3 ml:1 ml) were stirred for 10 min under nitrogen. Cesiumcarbonate (220 mg, 0.68 mmol) was added and the insoluble mixture wasirradiated (microwave) at 150° C. for 15 min. The contents wereevaporated, dissolved in DCM/MeOH (1:1), and pre-absorbed on silica geland purified using silica gel chromatography (eluent: DCM/MeOH/NH₄OH,gradient 0 to 80:20:2 in DCM). The isolated product was first treatedwith EtOAc along with some hexanes. The product was then dissolved inMeOH and purified by reverse-phase HPLC (30×100 Varian Polaris C18column, eluent: 10-80% gradient of MeCN in water with 0.1% TFA). Theproduct fractions were combined, most of the solvent was evaporated, anda sat. solution of NaHCO₃ was added. Solids that crashed out werefiltered, air-dried for 15 min, and dried in vacuum-oven overnight. Thesolid product was collected as 87 mg (75%). ¹H NMR (400 MHz, DMSO-d6) δppm 11.38 (br. s., 1H), 8.23 (t, J=4.67 Hz, 1H), 7.77 (d, J=1.01 Hz,1H), 7.60-7.64 (m, 2H), 7.40 (t, J=7.58 Hz, 1H), 7.30 (s, 1H), 7.20-7.26(m, 2H), 5.87 (s, 1H), 4.59-4.68 (m, 1H), 4.36 (s, 1H), 4.35 (s, 1H),3.46 (s, 2H), 2.24 (s, 3H), 2.18 (s, 9H), 2.11 (s, 3H), 1.76-1.88 (m,2H), 1.41 (d, J=6.57 Hz, 3H), 0.74 (t, J=7.33 Hz, 3H); LCMS: 499.4(MH+).

Example 2746-{3-[(dimethylamino)methyl]phenyl}-N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-3-methyl-1-[(1R)-1-methylpropyl]-1H-indole-4-carboxamide

(R)-6-bromo-1-(sec-butyl)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-3-methyl-1H-indole-4-carboxamide(100 mg, 0.23 mmol),N,N-dimethyl-1-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)methanamine,HCl (100 mg, 0.34 mmol) and Palladium Tetrakis (26 mg, 0.023 mmol) inDMF/water (3 mL:1 mL) were stirred for 10 min under nitrogen. Cesiumcarbonate (220 mg, 0.68 mmol) was added and the insoluble mixture wasirradiated (microwave) at 150° C. for 15 min. The contents wereevaporated, dissolved in DCM/MeOH (1:1), and pre-absorbed on silica geland purified using silica gel chromatography (eluent: DCM/MeOH/NH₄OH,gradient 0 to 80:20:2 in DCM). The isolated product was first treatedwith EtOAc along with some hexanes. The product was then dissolved inMeOH and purified by reversed-phase HPLC (30×100 Varian Polaris C18column, eluent: 10-80% gradient of MeCN in water with 0.1% TFA). Theproduct fractions were combined, most of the solvent was evaporated, anda sat. solution of NaHCO₃ was added. Solids that crashed out werefiltered, air-dried for 15 min, and dried in vacuum-oven overnight. Thesolid product was collected as 85 mg (75%). ¹H NMR (400 MHz, DMSO-d6) δppm 11.48 (s, 1H) 8.21 (t, J=5.05 Hz, 1H) 7.77 (d, J=1.26 Hz, 1H)7.60-7.66 (m, 2H) 7.41 (t, J=7.58 Hz, 1H) 7.30 (s, 1H) 7.25 (d, J=7.58Hz, 1H) 7.22 (d, J=1.52 Hz, 1H) 5.87 (s, 1H) 4.60-4.68 (m, 1H) 4.36 (s,1H) 4.35 (s, 1H) 3.49 (br. s., 2H) 2.24 (s, 3H) 2.19 (d, J=8.84 Hz, 9H)2.11 (s, 3H) 1.77-1.88 (m, 2H) 1.41 (d, J=6.57 Hz, 3H) 0.74 (t, J=7.33Hz, 3H); LCMS: 499.4 (MH+).

Example 2751-cyclopentyl-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-3-methyl-6-(6-(piperazin-1-yl)pyridin-3-yl)-1H-indole-4-carboxamide

To a 30 mL microwave vial were added6-bromo-1-cyclopentyl-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-3-methyl-1H-indole-4-carboxamide(80 mg, 0.175 mmol),1-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl)piperazine(65.9 mg, 0.228 mmol), 1,2-Dimethoxyethane (DME) (3 mL), Water (1.000mL) and sodium carbonate (0.263 mL, 0.526 mmol), and the mixture wasdegassed for 5 min by bubbling nitrogen. PdCl₂(dppf)-CH₂Cl₂ adduct(11.45 mg, 0.014 mmol) was added and the tube was sealed. The mixturewas irradiated (microwave) at 140° C. for 10 min. The mixture wasconcentrated and the residue was taken up into MeOH and filtered. Thefiltrate was purified using reverse-phase HPLC (eluent: 25% ACN/H₂O,0.1% NH₄OH to 60% ACN/H₂O, 0.1% NH₄OH) to give 72 mg of product asoff-white solid. ¹H NMR (400 MHz, DMSO-d6) δ ppm 1.65-1.89 (m, 6H),2.08-2.19 (m, 8H), 2.24 (s, 3H), 2.76-2.84 (m, 4H), 3.40-3.48 (m, 4H),4.35 (d, J=5.05 Hz, 2H), 4.92-5.04 (m, 1H), 5.87 (s, 1H), 6.88 (d,J=8.84 Hz, 1H), 7.19 (d, J=1.26 Hz, 1H), 7.25 (s, 1H), 7.74 (d, J=1.26Hz, 1H), 7.91 (dd, J=8.84, 2.53 Hz, 1H), 8.15 (t, J=5.05 Hz, 1H), 8.51(d, J=2.53 Hz, 1H); LCMS: 539.8 (MH+).

Some examples were prepared as above from a boronic acid (or boronate)containing a Boc-protected amine. These examples required removal of theBoc-protecting group to provide the title compounds.

Example 2761-isopropyl-N-((6-methyl-2-oxo-4-propyl-1,2-dihydropyridin-3-yl)methyl)-6-(6-(piperazin-1-yl)pyridin-3-yl)-1H-indole-4-carboxamide

To a suspension of 1,1-dimethylethyl4-{5-[1-(1-methylethyl)-4-({[(6-methyl-2-oxo-4-propyl-1,2-dihydro-3-pyridinyl)methyl]amino}carbonyl)-1H-indol-6-yl]-2-pyridinyl}-1-piperazinecarboxylate(70 mg, 0.112 mmol) in dichloromethane (2 mL) was added TFA (0.5 ml,6.49 mmol), and the mixture was stirred for 1 h. The mixture wasconcentrated and the residue was treated with saturated aqueous NaHCO3solution and filtered. The solid was purified using columnchromatography (silica gel, 0 to 15% (9:1 MeOH/NH4OH)/CH2Cl2) to give1-isopropyl-N-((6-methyl-2-oxo-4-propyl-1,2-dihydropyridin-3-yl)methyl)-6-(6-(piperazin-1-yl)pyridin-3-yl)-1H-indole-4-carboxamide(51 mg, 84%) as off-white solid. ¹H NMR (400 MHz, DMSO-d₆) δ ppm 0.91(m, 3H), 1.47 (d, J=4.00 Hz, 6H), 1.53-1.60 (m, 2H), 2.14 (s, 3H),2.89-2.98 (m, 4H), 3.51-3.59 (m, 4H), 4.40 (d, J=5.05 Hz, 2H), 4.93(quin, J=6.63 Hz, 1H), 5.92 (s, 1H), 6.87 (d, J=3.03 Hz, 1H), 6.94 (d,J=8.84 Hz, 1H), 7.60 (d, J=3.03 Hz, 1H), 7.66 (d, J=1.26 Hz, 1H), 7.88(s, 1H), 8.00 (dd, J=8.84, 2.53 Hz, 1H), 8.28 (t, J=5.05 Hz, 1H), 8.58(d, J=2.27 Hz, 1H). MS: (M+H)⁺=527.2.

Examples 277-285 were prepared by the methods described above forExamples 276 or routine variations thereof, starting from the requisiteN-Boc protected material:

¹H NMR MS(ES) Ex Structure Name (400 MHz, DMSO-d₆) δ ppm [M + H]⁺ 277

1-isopropyl-3- methyl-N-((6-methyl- 2-oxo-4-propyl-1,2-dihydropyridin-3- yl)methyl)-6-(4-(2- oxopiperazin-1- yl)phenyl)-1H-indole-4- carboxamide 0.94 (m, 3 H), 1.44 (d, J = 6.57 Hz, 6 H),1.54-1.63 (m, 2 H), 2.12 (s, 3 H), 2.18 (s, 3 H), 3.04 (t, J = 5.31 Hz,2 H), 3.41 (s, 2 H), 3.64 (t, J = 5.31 Hz, 2 H), 4.37 (d, J = 5.05 Hz, 2H), 4.87 (quin, J = 6.63 Hz, 1 H), 5.90 (s, 1 H), 7.25 (d, J = 1.26 Hz,1 H), 7.34 (s, 1 H), 7.40 (d, J = 8.59 Hz, 2 H), 7.70-7.83 (m, 3 H),8.18 (t, J = 5.05 Hz, 1 H) 554.4 278

N-[(4,6-dimethyl-2- oxo-1,2-dihydro-3- pyridinyl)methyl]-3- methyl-1-(1-methylethyl)-6-[6-(3- methyl-1- piperazinyl)-3- pyridinyl]-1H-indole-4-carboxamide 11.47 (s, 1 H) 8.50 (d, J = 2.53 Hz, 1 H) 8.16 (t, J =5.05 Hz, 1 H) 7.92 (dd, J = 8.84, 2.53 Hz, 1 H) 7.73 (d, J = 1.26 Hz, 1H) 7.26 (s, 1 H) 7.17 (d, J = 1.52 Hz, 1 H) 6.92 (d, J = 9.09 Hz, 1 H)5.87 (s, 1 H) 4.56-4.65 (m, 1 H) 4.36 (s, 1 H) 4.34 (s, 1 H) 3.49-3.55(m, 4 H) 2.40-2.44 (m, 4 H) 2.24 (s, 3 H) 2.23 (s, 3 H) 2.16 (s, 3 H)2.11 (s, 3 H) 1.76-1.87 (m, 2 H) 1.41 (d, J = 6.57 Hz, 3 H) 0.73 (t, J =7.33 Hz, 3 H) 527.3 279

N-((4,6-dimethyl-2- oxo-1,2- dihydropyridin-3- yl)methyl)-1-isopropyl-3-methyl- 6-(1-(piperidin-4-yl)- 1H-pyrazol-4-yl)-1H-indole-4- carboxamide 1.42 (m, 6 H), 1.81 (qd, J = 11.96, 4.04 Hz, 2 H),1.98 (m, 2 H), 2.12 (d, J = 6.57 Hz, 6 H), 2.24 (s, 3 H), 2.55-2.66 (m,2 H), 3.05 (d, J = 12.63 Hz, 2 H), 4.18 (tt, J = 11.49, 4.04 Hz, 1 H),4.34 (d, J = 5.05 Hz, 2 H), 4.78 (quin, J = 6.69 Hz, 1 H), 5.87 (s, 1H), 7.18 (d, J = 1.26 Hz, 1 H), 7.22 (d, J = 1.01 Hz, 1 H), 7.71 (d, J =1.01 Hz, 1 H), 7.89 (s, 1 H), 8.03 (t, J = 5.18 Hz, 1 H), 8.24 (s, 1 H)501.1 280

6-methyl-3-[(2-{3- methyl-1-(1- methylethyl)-6-[6-(1- piperazinyl)-3-pyridinyl]-1H-indol-4- yl}-2- oxoethyl)amino]-4- propyl-2(1H)-pyridinone 0.93 (t, J = 7.33 Hz, 3 H), 1.42 (d, J = 6.57 Hz, 6 H), 1.56(qt, J = 7.56, 7.36 Hz, 2 H), 2.12 (s, 3 H), 2.16 (s, 3 H), 2.52-2.58(m, 2 H), 2.77-2.90 (m, 4 H), 3.42-3.51 (m, 4 H), 4.36 (d, J = 5.05 Hz,2 H), 4.84 (dt, J = 13.20, 6.66 Hz, 1 H), 5.90 (s, 1 H), 6.89 (d, J =8.84 Hz, 1 H), 7.17 (d, J = 1.26 Hz, 1 H), 7.29 (s, 1 H), 7.72 (s, 1 H),7.91 (dd, J = 8.84, 2.53 Hz, 1 H), 8.12 (t, J = 4.93 Hz, 1 H), 8.49 (d,J = 2.27 Hz, 1 H), 11.49 (br.s., 1 H) 541.5 281

N-((4,6-dimethyl-2- oxo-1,2- dihydropyridin-3- yl)methyl)-1-isopropyl-3-methyl- 6-(2-(piperazin-1- yl)pyrimidin-5-yl)- 1H-indole-4-carboxamide 11.47 (br.s., 1 H), 8.75 (s, 2 H), 8.13 (t, J = 5.1 Hz, 1H), 7.76 (d, J = 1.5 Hz, 1 H), 7.30 (s, 1 H), 7.19 (d, J = 1.3 Hz, 1 H),5.87 (s, 1 H), 4.83 (m, 1 H), 4.34 (d, J = 5.1 Hz, 2 H), 3.71 (m, 4 H),2.77 (m, 4 H), 2.24 (s, 3 H), 2.15 (s, 3 H), 2.11 (s, 3 H), 1.42 (d, J =6.6 Hz, 6 H) 514.2 282

3-methyl-1-(1- methylethyl)-N-[(6- methyl-2-oxo-4- propyl-1,2-dihydro-3-pyridinyl)methyl]- 6-(1H-pyrazol-4-yl)- 1H-indole-4- carboxamide 12.85(br.s., 1 H), 11.49 (br.s., 1 H), 8.01 (t, J = 5.2 Hz, 3 H), 7.72 (d, J= 1.3 Hz, 1 H), 7.20 (m, 2 H), 5.90 (s, 1 H), 4.78 (quin, J = 6.6 Hz, 1H), 4.35 (d, J = 5.1 Hz, 2 H), 2.55 (m, 2 H), 2.11 (m, 6 H), 1.57 (sxt,J = 7.5 Hz, 2 H), 1.42 (d, J = 6.6 Hz, 6 H), 0.94 (m, 3 H) 446.0 283

N-((4,6-dimethyl-2- oxo-1,2- dihydropyridin-3- yl)methyl)-1-isopropyl-3-methyl- 6-(5-(piperazin-1- yl)pyridin-3-yl)-1H- indole-4-carboxamide 11.48 (br.s., 1 H), 8.36 (d, J = 1.8 Hz, 1 H), 8.20 (m, 2H), 7.84 (d, J = 1.3 Hz, 1 H), 7.55 (t, J = 2.3 Hz, 1 H), 7.35 (d, J =1.0 Hz, 1 H), 7.26 (d, J = 1.5 Hz, 1 H), 5.87 (s, 1 H), 4.91 (quin, J =6.6 Hz, 1 H), 4.35 (d, J = 5.1 Hz, 2 H), 3.19 (m, 4 H), 2.88 (m, 4 H),2.24 (s, 3 H), 2.16 (s, 3 H), 2.11 (s, 3 H), 1.43 (d, J = 6.6 Hz, 6 H)513.3 284

4-[4-({[(4,6-dimethyl- 2-oxo-1,2-dihydro-3- pyridinyl)methyl]amino}carbonyl)-3- methyl-1-(1- methylethyl)-1H- indol-6-yl]-L-phenylalanine 11.48 (br.s., 1 H) 8.18 (t, J = 4.93 Hz, 1 H) 7.75 (s, 1H) 7.70 (d, J = 8.08 Hz, 2 H) 7.31- 7.37 (m, 3 H) 7.24 (s, 1 H) 5.87 (s,1 H) 4.89-4.82 (m, 1 H) 4.35 (d, J = 4.80 Hz, 2 H) 3.85 (br.s., 1 H)2.97-3.22 (m, 2 H) 2.24 (s, 3 H) 2.17 (s, 3 H) 2.11 (s, 3 H) 1.43 (d, J= 6.57 Hz, 6 H) 515.3 285

6-[6-(aminomethyl)- 3-pyridinyl]-N-[(4,6- dimethyl-2-oxo-1,2- dihydro-3-pyridinyl)methyl]-3- methyl-1-(1- methylethyl)-1H- indole-4- carboxamide11.47 (br.s., 1 H) 8.37 ( s, 1 H) 8.13 (br.s., 1 H) 7.79-7.76 (m, 1 H)7.66 (s, 1 H) 7.26 (s, 1 H) 7.14 (s, 1 H) 6.53 (d, J = 8.34 Hz, 2 H)5.87 (br.s., 1 H) 4.88- 4.75 (m, 1 H) 4.35 (d, J = 4.04 Hz, 2 H) 2.81(d, J = 4.29 Hz, 3 H) 2.24 (s, 3 H) 2.16 (s, 3 H) 2.11 (s, 3 H) 1.43 (d,J = 6.32 Hz, 6 H) 458.3

Some examples were prepared as above from a boronic acid (or boronate)containing an alkyl ester. These examples required saponification of theester to provide the corresponding carboxylic acids.

Example 2864-[4-({[(4,6-Dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]amino}carbonyl)-3-methyl-1-(1-methylethyl)-1H-indol-6-yl]benzoicacid

To a solution of methyl4-[4-({[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]amino}carbonyl)-3-methyl-1-(1-methylethyl)-1H-indol-6-yl]benzoate(30 mg, 0.062 mmol) in MeOH (2 mL) and THF (1 mL) was 3 N NaOH (0.031mL, 0.185 mmol). The reaction was heated at 50° C. for 12 h, at whichtime it was allowed to cool to ambient temperature and treated withacidic ice water to bring pH to 6. The solid was filtered and washedseveral times with water and an 8:2 mixture of acidic (pH2) ice water:MeOH. Purification by reverse phase Gilson HPLC (10-80%,acetonitrile/water+0.1% TFA, YMC ODS-A C18 Column 75×30 mm ID S-5 um, 12nM Column 7 minutes) provided the title compound (12 mg, 0.024 mmol,39.5% yield) as an off-white solid. ¹H NMR (400 MHz, DMSO-d₆) δ ppm12.91 (br. s., 1H) 11.48 (br. s., 1H) 8.23 (t, J=5.05 Hz, 1H) 8.02 (d,J=8.34 Hz, 3H) 7.87-7.94 (m, 4H) 7.38 (s, 1H) 7.32 (d, J=1.52 Hz, 1H)5.87 (s, 1H) 4.91 (quin, J=6.63 Hz, 1H) 4.36 (d, J=4.80 Hz, 2H) 2.24 (s,3H) 2.18 (s, 3H) 2.11 (s, 3H) 1.44 (d, J=6.57 Hz, 6H). MS(ES) [M+H]⁺486.1.

Examples 287-288 were prepared by the methods described above forExample 286, or routine variations thereof, starting from the requisitealkylester:

¹H NMR MS(ES) Ex Structure Name (400 MHz, DMSO-d₆) δ ppm [M + H]⁺ 287

3-[3-methyl-1-(1- methylethyl)-4-({[(6- methyl-2-oxo-4-propyl-1,2-dihydro-3- pyridinyl)methyl]amino} carbonyl)-1H-indol-6-yl]benzoic acid 13.07 (br.s., 1 H) 11.49 (br. s., 1 H) 8.27 (s, 1 H)8.23 (t, J = 4.67 Hz, 1 H) 8.00 (d, J = 8.08 Hz, 1 H) 7.90 (d, J = 7.58Hz, 1 H) 7.84 (s, 1 H) 7.59 (t, J = 7.71 Hz, 1 H) 7.36 (s, 1 H) 7.26 (s,1 H) 5.90 (s, 1 H) 4.98-4.95 (m, 1 H) 4.38 (d, J = 5.05 Hz, 2 H) 2.56(d, J = 7.58 Hz, 2 H) 2.19 (s, 3 H) 2.12 (s, 3H) 1.54-1.62 (m, 2 H) 1.44(d, J = 6.57 Hz, 6 H) 0.94 (t, J = 7.33 Hz, 3 H) 500.1 288

5-[3-methyl-1-(1- methylethyl)-4-({[(6- methyl-2-oxo-4-propyl-1,2-dihydro-3- pyridinyl)methyl]amino} carbonyl)-1H-indol-6-yl]-2- pyridinecarboxylic acid 13.22 (br.s., 1 H) 11.51 (br. s., 1 H)9.11 (br.s., 1 H) 8.31-8.38 (m, 1 H) 8.23 (br. s., 1 H) 8.12 (br.s., 1H) 8.02 (br.s., 1 H) 7.42 (br.s., 1 H) 7.37 (br.s., 1 H) 5.91 (br.s., 1H) 4.88-4.98 (m, 1 H) 4.38 (br.s., 2 H) 2.55- 2.61 (m, 2 H) 2.19 (br.s.,3 H) 2.12 (br.s., 3 H) 1.54- 1.62 (m, 2 H) 1.46 (br.s., 6 H) 0.90-0.99(m, 3 H) 501.1

Example 289N-[(4,6-Dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-1-(1-methylethyl)-1H-indole-4-carboxamide

To a flask under N₂ atmosphere was added 10% palladium on carbon (0.028g, 0.026 mmol) and ethanol (1 mL) (to wet catalyst). The flask was thencharged with6-bromo-N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-1-(1-methylethyl)-1H-indole-4-carboxamide(0.11 g, 0.264 mmol), ethanol (4 mL) and tetrahydrofuran (1 mL). Thesuspension was stirred under N₂, then evacuated and refilled with H₂(balloon) and stirred overnight. The reaction was then placed back underN₂ and diluted with 10% methanol/dichloromethane. Celite was added andthe mixture was stirred for 15 min, filtered through a pad of Celite,washed with 10% methanol/dichloromethane, and concentrated. The residuewas dissolved in dimethylsulfoxide and acetonitrile (with 0.1%trifluoroacetic acid and purified by Gilson prep HPLC (Sunfire 30×75 mm;Gradient B: 15-75%; A: water+0.1% TFA; B: acetonitrile+0.1% TFA). Theresulting residue was dissolved in 10% methanol/dichloromethane andtreated with Silicycle carbonate resin (1.5 g). The mixture was stirredfor 30 min, filtered through Celite, washed with 10%methanol/dichloromethane, and concentrated. The residue was dissolved indichloromethane and treated with methyl-t-butylether. The solvents wereremoved by via N₂ stream and the solids dried in a vacuum oven at 45° C.for 18 h to giveN-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-1-(1-methylethyl)-1H-indole-4-carboxamide(56 mg, 0.159 mmol, 60% yield). ¹H NMR (400 MHz, DMSO-d₆) δ ppm1.41-1.48 (m, 6H) 2.09-2.15 (m, 3H) 2.24 (s, 3H) 4.35 (d, J=5.31 Hz, 2H)4.79 (quin, J=6.63 Hz, 1H) 5.88 (s, 1H) 6.84 (d, J=3.03 Hz, 1H)7.11-7.18 (m, 1H) 7.39 (d, J=6.57 Hz, 1H) 7.58 (d, J=3.28 Hz, 1H) 7.65(d, J=8.34 Hz, 1H) 8.08 (t, J=5.31 Hz, 1H) 11.54 (br. s., 1H). MS(ES)[M+H]⁺ 338.6.

Examples 290-295 were prepared by the methods described above forExample 289, or routine variations thereof, starting from the requisite6-haloindole, alkene, or CBz-protected amine:

¹H NMR MS(ES) Ex Structure Name (400 MHz, DMSO-d₆) δ ppm [M + H]⁺ 290

N-((4-benzyl-6- methyl-2-oxo-1,2- dihydropyridin-3- yl)methyl)-1-isopropyl-1H-indole- 4-carboxamide 11.60 (br.s., 1 H) 8.10-8.20 (m, 1 H)7.66 (d, J = 8.34 Hz, 1 H) 7.59 (d, J = 3.28 Hz, 1 H) 7.40 (d, J = 7.07Hz, 1 H) 7.14- 7.31 (m, 6 H) 6.85 (d, J = 3.03 Hz, 1 H) 5.82 (s, 1 H)4.80 (quin, J = 6.69 Hz, 1 H) 4.44 (s, 1 H) 4.42 (s, 1 H) 4.01 (s, 2 H)2.10 (s, 3 H) 1.47 (s, 3 H) 1.45 (s, 3 H) 413.9 291

N-((4-benzyl-6- methyl-2-oxo-1,2- dihydropyridin-3- yl)methyl)-1-isopropyl-3-methyl- 1H-indole-4- carboxamide 11.55 (s, 1 H) 8.08 (t, J =5.18 Hz, 1 H) 7.50 (d, J = 7.83 Hz, 1 H) 7.20-7.33 (m, 6 H) 7.04- 7.08(m, 1 H) 6.90 (d, J = 7.07 Hz, 1 H) 5.79 (s, 1 H) 4.72 (quin, J = 6.63Hz, 1 H) 4.41 (d, J = 5.31 Hz, 2 H) 3.99 (s, 2 H) 2.15 (s, 3 H) 2.09 (s,3 H) 1.42 (s, 3 H) 1.40 (s, 3 H) 427.8 292

1-cyclopentyl-N- ((4,6-dimethyl-2- oxo-1,2- dihydropyridin-3-yl)methyl)-3-methyl- 1H-indole-4- carboxamide 11.47 (br.s., 1 H) 7.99(t, J = 4.93 Hz, 1 H) 7.51 (d, J = 7.83 Hz, 1 H) 7.24 (s, 1 H) 7.06 (t,J = 7.71 Hz, 1 H) 6.93 (d, J = 6.82 Hz, 1 H) 5.87 (s, 1 H) 4.86 (d, J =7.33 Hz, 1 H) 4.33 (s, 1 H) 4.32 (s, 1 H) 2.23 (s, 3 H) 2.07-2.16 (m, 8H) 1.76-1.86 (m, 4 H) 1.69 (d, J = 3.54 Hz, 2 H) 378.3 293

6-methyl-3-({2-[3- methyl-1-(1- methylethyl)-6-(4-piperidinyl)-1H-indol- 4-yl]-2- oxoethyl}amino)-4- propyl-2(1H)-pyridinone 0.93 (t, J = 7.33 Hz, 3 H), 1.39 (d, J = 6.57 Hz, 6 H), 1.48-1.64 (m, 4 H), 1.68 (br.s., 2 H), 2.12 (s, 6 H), 2.54 (m, 4 H), 3.01 (d,J = 11.87 Hz, 2 H), 3.16 (d, J = 4.55 Hz, 1 H), 4.33 (d, J = 5.05 Hz, 2H), 4.70 (dt, J = 13.20, 6.66 Hz, 1 H), 5.89 (s, 1 H), 6.82 (s, 1 H),7.19 (s, 1 H), 7.30 (s, 1 H), 7.93 (t, J = 4.80 Hz, 1 H), 8.55 (s, 1 H)463.1 294

N-[(4,6-dimethyl-2- oxo-1,2-dihydro-3- pyridinyl)methyl]-3- methyl-1-(1-methylethyl)-6-[6-(2- piperidinyl)-3- pyridinyl]-1H-indole-4-carboxamide 1H NMR (400 MHz, METHANOL-d4) δ ppm 1.51-1.53 (d, 6 H)1.82- 1.84 (m, 3 H) 1.99-2.05 (m, 2 H) 2.24-2.26 (d, J = 7.83 Hz, 6 H)2.26-2.31 (m, 1 H) 2.46 (s, 3 H) 3.13-3.25 (m, 1 H) 3.52-3.55 (m, 1 H)4.36- 4.49 (m, 1 H) 4.58 (s, 2 H) 4.83-4.89 (m, 1 H) 6.15 (s, 1 H) 7.30(s, 1 H) 7.39 (s, 1 H) 7.52-7.54 (d, J = 8.08 Hz, 1 H) 7.80 (s, 1 H)8.19-8.22 (dd, J = 8.08, 2.02 Hz, 1 H) 8.99-9.00 (d, J = 1.77 Hz, 1 H)512.3 295

N-[(4,6-dimethyl-2- oxo-1,2-dihydro-3- pyridinyl)methyl]-3- methyl-1-(1-methylethyl)-1H- indole-4- carboxamide 11.47 (s, 1 H) 7.99 (t, J = 5.05Hz, 1 H) 7.49 (d, J = 8.08 Hz, 1 H) 7.28 (s, 1 H) 7.04-7.09 (m, 1 H)6.92 (d, J = 6.32 Hz, 1 H) 5.87 (s, 1 H) 4.71 (quin, J = 6.63 Hz, 1 H)4.33 (s, 1 H) 4.32 (s, 1 H) 2.23 (s, 3 H) 2.14 (s, 3 H) 2.11 (s, 3 H)1.42 (s, 3 H) 1.40 (s, 3 H) 352.2

Example 2961-Cyclopropyl-N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-3-methyl-6-(methylsulfonyl)-1H-indole-4-carboxamide

To a vial under a stream of N2 was added copper(II)trifluoromethanesulfonate (0.084 g, 0.233 mmol), sodium methanesulfinate(0.056 g, 0.467 mmol), DMSO (1.3 mL), and N,N-dimethylethylene diamine(0.053 mL, 0.490 mmol). The deep blue reaction was stirred for 5 min,then was added6-bromo-1-cyclopropyl-N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-3-methyl-1H-indole-4-carboxamide(0.10 g, 0.233 mmol). The vial was sealed and heated at 120° C. for 3 h,at which time it was diluted with water (50 ml). The mixture wasextracted with 30% THF/EtOAc (2×) (needed to warm to break up emulsion).Combined organics, dried over magnesium sulfate, filtered throughCelite, and concentrated. Purification of the residue by columnchromatography (12 gram Isco GOLD silica column; gradient B: 5-85%; A:dichloromethane, B: 10% (2 M ammonia in MeOH) in chloroform) provided1-cyclopropyl-N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-3-methyl-6-(methylsulfonyl)-1H-indole-4-carboxamide(83 mg, 0.184 mmol, 79% yield) as a white solid. ¹H NMR (400 MHz,DMSO-d₆) δ ppm 11.50 (s, 1H), 8.38 (t, J=5.1 Hz, 1H), 8.06 (d, J=1.8 Hz,1H), 7.46 (dd, J=7.8, 1.3 Hz, 2H), 5.87 (s, 1H), 4.34 (d, J=5.1 Hz, 2H),3.52 (tt, J=7.0, 3.6 Hz, 1H), 3.20 (s, 3H), 2.23 (s, 3H), 2.11 (s, 3H),2.14 (s, 3H), 1.09 (m, 2H), 0.96 (m, 2H). MS(ES) [M+H]⁺ 427.8.

Examples 297-302 were prepared by the methods described above forExample 296, or routine variations thereof, starting from the requisite6-bromoindole:

¹H NMR MS(ES) Ex Structure Name (400 MHz, DMSO-d₆) δ ppm [M + H]⁺ 297

1-cyclopentyl-6- (cyclopropylsulfonyl)- N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3- pyridinyl)methyl]-3- methyl-1H-indole-4- carboxamide11.49 (s, 1 H), 8.39 (t, J = 4.9 Hz, 1 H), 8.04 (d, J = 1.5 Hz, 1 H),7.61 (s, 1 H), 7.35 (d, J = 1.5 Hz, 1 H), 5.87 (s, 1 H), 5.03 (t, J =6.9 Hz, 1 H), 4.34 (d, J = 4.8 Hz, 2 H), 2.85 (m, 1 H), 2.23 (s, 3 H),2.14 (m, 8 H), 1.81 (m, 4 H), 1.74 (m, 2 H), 1.13 (m, 2 H), 1.00 (m, 2H) 481.9 298

1-cyclopentyl-N- [(4,6-dimethyl-2-oxo- 1,2-dihydro-3-pyridinyl)methyl]-3- methyl-6- (methylsulfonyl)-1H- indole-4-carboxamide 11.50 (s, 1 H), 8.36 (t, J = 4.9 Hz, 1 H), 8.09 (d, J = 1.5Hz, 1 H), 7.61 (s, 1 H), 7.40 (d, J = 1.5 Hz, 1 H), 5.87 (s, 1 H), 5.01(t, J = 7.1 Hz, 1 H), 4.35 (d, J = 5.1 Hz, 2 H), 3.19 (s, 3 H), 2.23 (s,3 H), 2.15 (m, 8 H), 1.78 (m, 6 H) 455.9 299

3-({2-[6- (cyclopropylsulfonyl)- 3-methyl-1-(1- methylethyl)-1H-indol-4-yl]-2- oxoethyl}amino)-4,6- dimethyl-2(1H)- pyridinone 0.93-1.06(m, 2 H), 1.11- 1.25 (m, 2 H), 1.49 (d, J = 6.57 Hz, 6 H), 2.13 (s, 3H), 2.24 (s, 3 H), 2.81-2.98 (m, 1 H), 4.37 (d, J = 5.05 Hz, 2 H), 4.99(dt, J = 13.33, 6.60 Hz, 1 H), 5.90 (s, 1 H), 6.99 (d, J = 3.28 Hz, 1H), 7.85 (d, J = 1.52 Hz, 1 H), 7.93 (d, J = 3.28 Hz, 1 H), 8.16 (s, 1H), 8.49 (t, J = 4.93 Hz, 1 H), 11.57 (br.s., 1 H) 442.0 300

3-({2-[6- (cyclopropylsulfonyl)- 3-methyl-1-(1- methylethyl)-1H-indol-4-yl]-2- oxoethyl}amino)-4,6- dimethyl-2(1H)- pyridinone 1.00 (dd,J = 7.71, 2.65 Hz, 2 H), 1.13 (dd, J = 4.67, 2.40 Hz, 2 H), 1.45 (d, J =6.57 Hz, 6 H), 2.12 (s, 3 H), 2.19 (s, 3 H), 2.23 (s, 3 H), 2.76-2.95(m, 1 H), 4.35 (d, J = 5.05 Hz, 2 H), 4.91 (quin, J = 6.63 Hz, 1 H),5.88 (s, 1 H), 7.36 (d, J = 1.52 Hz, 1 H), 7.66 (s, 1 H), 8.03 (d, J =1.52 Hz, 1 H), 8.40 (t, J = 4.93 Hz, 1 H), 11.51 (s, 1 H) 455.9 301

1-cyclopentyl-6- (cyclopropylsulfonyl)- N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3- pyridinyl)methyl]-3- methyl-1H-indole-4- carboxamide11.49 (s, 1 H), 8.39 (t, J = 4.9 Hz, 1 H), 8.04 (d, J = 1.5 Hz, 1 H),7.61 (s, 1 H), 7.35 (d, J = 1.5 Hz, 1 H), 5.87 (s, 1 H), 5.03 (t, J =6.9 Hz, 1 H), 4.34 (d, J = 4.8 Hz, 2 H), 2.85 (m, 1 H), 2.23 (s, 3 H),2.14 (m, 8 H), 1.81 (m, 4 H), 1.74 (m, 2 H), 1.13 (m, 2 H), 1.00 (m, 2H) 481.9 302

1-cyclopentyl-N- [(4,6-dimethyl-2-oxo- 1,2-dihydro-3-pyridinyl)methyl]-3- methyl-6- (methylsulfonyl)-1H- indole-4-carboxamide 11.50 (s, 1 H), 8.36 (t, J = 4.9 Hz, 1 H), 8.09 (d, J = 1.5Hz, 1 H), 7.61 (s, 1 H), 7.40 (d, J = 1.5 Hz, 1 H), 5.87 (s, 1 H), 5.01(t, J = 7.1 Hz, 1 H), 4.35 (d, J = 5.1 Hz, 2 H), 3.19 (s, 3 H), 2.23 (s,3 H), 2.15 (m, 8 H), 1.78 (m, 6 H) 455.9

Example 303N-[(4,6-Dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-1-(1-methylethyl)-6-(trifluoromethyl)-1H-indole-4-carboxamide

a) 4-Bromo-1-(1-methylethyl)-6-(trifluoromethyl)-1H-indole

To a solution of 4-bromo-6-(trifluoromethyl)-1H-indole (1 g, 3.79 mmol)in DMF (6 mL) was added 60% sodium hydride (0.182 g, 4.54 mmol), and themixture was stirred for 30 min. 2-bromopropane (0.533 mL, 5.68 mmol) wasadded and the mixture was stirred overnight. The reaction was thenquenched with 10% NaHCO3 and extracted with EtOAc (3×). The extract wasdried over Na2SO4 and concentrated. The residue was purified usingcolumn chromatography (Silica gel, 0 to 100% EtOAc/hexanes) to give thetitle compound (460 mg, 40%) as white solid. ¹H NMR (400 MHz,CHLOROFORM-d) δ ppm 1.56-1.61 (m, 6H), 4.66-4.79 (m, 1H), 6.65 (d,J=3.03 Hz, 1H), 7.27-7.31 (m, 1H), 7.45 (d, J=3.03 Hz, 1H), 7.54 (s,1H), 7.63 (s, 1H). MS: (M+H)⁺=306.2.

b) 1-Isopropyl-6-(trifluoromethyl)-1H-indole-4-carbonitrile

To a 10-mL microwave tube were added4-bromo-1-(1-methylethyl)-6-(trifluoromethyl)-1H-indole (330 mg, 1.078mmol), dicyanozinc (146 mg, 1.240 mmol), DMF (4 mL) and water (0.040mL), and the mixture was degassed for 5 min by bubbling N₂. s-Phos (48.7mg, 0.119 mmol) and tris(dibenzylideneacetone)dipalladium(0) (49.4 mg,0.054 mmol) were added. The tube was sealed and the mixture was heatedat 120° C. for 2.5 h. 1 N NaOH (3 mL) was added and the mixture wasextracted with EtOAc (3×). The extract was dried over Na₂SO₄ andconcentrated. The residue was purified using column chromatography(Silica gel, 0 to 70% EtOAc/hexanes) to give the title compound (210 mg,77%) as white solid. ¹H NMR (400 MHz, CHLOROFORM-d) δ ppm 1.61 (m, 6H),4.79 (spt, J=6.69 Hz, 1H), 6.84 (d, J=3.28 Hz, 1H), 7.59 (d, J=3.28 Hz,1H), 7.73 (s, 1H), 7.88 (s, 1H). MS: (M+H)⁺=253.2.

c) 1-Isopropyl-6-(trifluoromethyl)-1H-indole-4-carboxylic acid

To a solution of1-(1-methylethyl)-6-(trifluoromethyl)-1H-indole-4-carbonitrile (180 mg,0.714 mmol) in ethanol (5 mL) was added 10% sodium hydroxide (5 mL,0.714 mmol), and the mixture was heated at reflux overnight. The mixturewas concentrated to remove EtOH and the aqueous phase was acidifiedusing 1N HCl to ˜pH 4. The precipitate was collected by filtration anddried under high vacuum to give the title compound (167 mg, 86%) asbrown solid. ¹H NMR (400 MHz, DMSO-d₆) δ ppm 1.43-1.60 (m, 6H),4.96-5.13 (m, 1H), 7.11 (d, J=3.28 Hz, 1H), 7.89-8.05 (m, 2H), 8.25 (s,1H), 13.15 (br. s., 1H). MS: (M+H)⁺=272.0.

d)N-((4,6-Dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-6-(trifluoromethyl)-1H-indole-4-carboxamide

To a solution of1-(1-methylethyl)-6-(trifluoromethyl)-1H-indole-4-carboxylic acid (40mg, 0.147 mmol) in dimethyl sulfoxide (1 mL) were added3-(aminomethyl)-4,6-dimethyl-2(1H)-pyridinone (41.7 mg, 0.221 mmol),N-methylmorpholine (0.065 mL, 0.590 mmol), 1-hydroxy-7-azabenzotriazole(40.1 mg, 0.295 mmol) and EDC (56.5 mg, 0.295 mmol), and the mixture wasstirred overnight. The mixture was quenched with water (5 mL) andstirred for 10 min. The precipitate was collected by filtration anddried under high vacuum to give the title compound (39 mg, 63%) as anoff-white solid. ¹H NMR (400 MHz, DMSO-d₆) δ ppm 1.47 (m, 6H), 2.13 (s,3H), 2.23 (s, 3H), 4.36 (d, J=5.05 Hz, 2H), 4.99 (dt, J=13.20, 6.66 Hz,1H), 5.89 (s, 1H), 6.98 (d, J=3.03 Hz, 1H), 7.68 (s, 1H), 7.86 (d,J=3.28 Hz, 1H), 8.08 (s, 1H), 8.45 (t, J=4.93 Hz, 1H), 11.56 (s, 1H).MS: (M+H)⁺=406.1.

Example 3041-Isopropyl-N-((6-methyl-2-oxo-4-propyl-1,2-dihydropyridin-3-yl)methyl)-6-(trifluoromethyl)-1H-indole-4-carboxamide

The title compound was prepared using procedures as described forN-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-6-(trifluoromethyl)-1H-indole-4-carboxamide.¹H NMR (400 MHz, DMSO-d₆) δ ppm 0.91 (t, J=8.00 Hz 3H), 1.39-1.63 (m,8H), 2.14 (s, 3H), 4.39 (d, J=5.05 Hz, 2H), 4.99 (dt, J=13.26, 6.76 Hz,1H), 5.92 (s, 1H), 6.98 (d, J=3.28 Hz, 1H), 7.68 (s, 1H), 7.87 (d,J=3.03 Hz, 1H), 8.08 (s, 1H), 8.44 (t, J=5.05 Hz, 1H), 11.57 (s, 1H).MS: (M+H)⁺=434.1.

Example 305N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-6-(4-((dimethylamino)methyl)piperidin-1-yl)-1-isopropyl-3-methyl-1H-indole-4-carboxamide

a)6-(4-((Dimethylamino)methyl)piperidin-1-yl)-1-isopropyl-3-methyl-1H-indole-4-carboxylicacid

To a 10-mL microwave tube were added6-bromo-3-methyl-1-(1-methylethyl)-1H-indole-4-carboxylic acid (100 mg,0.338 mmol), 1,4-dioxane (2 mL),N,N-dimethyl-1-(4-piperidinyl)methanamine (52.8 mg, 0.371 mmol) andsodium tert-butoxide (71.4 mg, 0.743 mmol), and the mixture was degassedfor 5 min.Choro(2-dicyclohexylphosphino-2′,4′,6′-tri-i-propyl-1,1′-biphenyl)[2-(2-aminoethyl)phenyl]Pd(11)Me-t-butyletheradduct (13.96 mg, 0.017 mmol) was added and the tube was sealed. Themixture was stirred at 98° C. with stirring for 20 h. The mixture wasthen concentrated and the residue was purified using reverse-phase HPLC(Gemini 5u C18(2) 100A, AXIA; 30×100 mm 5 micron; (30 mL/min, 7%ACN/H2O, 0.1% formic acid to 37% ACN/H2O, 0.1% formic acid) to give thetitle compound (65 mg, 54%) as pale yellow solid. ¹H NMR (400 MHz,DMSO-d₆) δ ppm 1.19-1.34 (m, 2H), 1.39 (d, J=6.57 Hz, 6H), 1.58-1.71 (m,1H), 1.82 (d, J=11.87 Hz, 2H), 2.23-2.31 (m, 10H), 2.66 (td, J=11.94,1.89 Hz, 2H), 3.57-3.71 (m, 2H), 4.70 (quin, J=6.63 Hz, 1H), 7.09 (d,J=2.02 Hz, 1H), 7.15 (dd, J=9.60, 1.52 Hz, 2H). MS: (M+H)⁺=358.2.

b)N-((4,6-Dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-6-(4-((dimethylamino)methyl)piperidin-1-yl)-1-isopropyl-3-methyl-1H-indole-4-carboxamide

To a solution of6-{4-[(dimethylamino)methyl]-1-piperidinyl}-3-methyl-1-(1-methylethyl)-1H-indole-4-carboxylicacid (62 mg, 0.173 mmol) in dimethyl sulfoxide (1 mL) were added3-(aminomethyl)-4,6-dimethyl-2(1H)-pyridinone (42.5 mg, 0.225 mmol),N-methylmorpholine (0.095 mL, 0.867 mmol), 1-hydroxy-7-azabenzotriazole(47.2 mg, 0.347 mmol) and EDC (66.5 mg, 0.347 mmol), and the mixture wasstirred overnight. The mixture was purified using reverse-phase HPLC(Gemini 5u C18(2) 100A, AXIA; 30×100 mm 5 micron; 30 mL/min, 8% ACN/H2O,0.1% formic acid to 38% ACN/H2O, 0.1% formic acid) to give the titlecompound (52 mg, 55%) as an off-white solid. ¹H NMR (400 MHz, DMSO-d₆)ppm 1.26 (m, 2H), 1.35-1.41 (m, 6H), 1.57-1.71 (m, 1H), 1.80 (d, J=11.12Hz, 2H), 2.10 (d, J=10.36 Hz, 6H), 2.22 (s, 3H), 2.26-2.33 (m, 8H),2.57-2.72 (m, 2H), 3.61 (d, J=12.13 Hz, 2H), 4.31 (d, J=5.05 Hz, 2H),4.58-4.72 (m, 1H), 5.86 (s, 1H), 6.69 (d, J=2.02 Hz, 1H), 6.92 (d,J=1.77 Hz, 1H), 7.05 (d, J=1.01 Hz, 1H), 7.92-7.99 (m, 1H). MS:(M+H)⁺=492.1.

Examples 306-317 were prepared by the methods described above forExample 305, or routine variations thereof, using the requisite amine:

¹H NMR MS(ES) Ex Structure Name (400 MHz, DMSO-d₆) δ ppm [M + H]⁺ 306

N-((4,6-dimethyl-2- oxo-1,2- dihydropyridin-3- yl)methyl)-6-(3-((dimethylamino)meth- yl)pyrrolidin-1-yl)-1- isopropyl-3-methyl-1H-indole-4- carboxamide 1.36 (m, 6 H), 1.68 (dd, J = 12.13, 7.58 Hz, 1H), 2.01- 2.38 (m, 20 H), 2.99 (dd, J = 9.09, 6.57 Hz, 1 H), 3.20- 3.30(m, 1 H), 3.35-3.44 (m, 1 H), 4.31 (d, J = 5.05 Hz, 2 H), 4.53-4.67 (m,1 H), 5.87 (s, 1 H), 6.35 (d, J = 2.02 Hz, 1 H), 6.45 (d, J = 1.77 Hz, 1H), 6.93 (d, J = 1.01 Hz, 1 H), 7.88 (t, J = 5.18 Hz, 1 H), 11.47 (s, 1H) 478.0 307

1-cyclopentyl-N- ((4,6-dimethyl-2- oxo-1,2- dihydropyridin-3-yl)methyl)-6- (pyrrolidin-1-yl)-1H- indole-4- carboxamide 1.65-1.88 (m,7 H), 1.95- 2.02 (m, 5 H), 2.08-2.18 (m, 6 H), 2.24 (s, 3 H), 3.29 (t, J= 6.32 Hz, 4 H), 4.34 (d, J = 5.31 Hz, 2 H), 4.74-4.90 (m, 1 H), 5.89(s, 1 H), 6.59- 6.70 (m, 2 H), 6.83 (d, J = 1.77 Hz, 1 H), 7.22 (d, J =3.28 Hz, 1 H), 8.03 (t, J = 5.31 Hz, 1 H) 433.2 308

6-(1,1- dioxidothiomorpholino)- 1-isopropyl-3- methyl-N-((6-methyl-2-oxo-4-propyl-1,2- dihydropyridin-3- yl)methyl)-1H- indole-4-carboxamide 1.06 (m, 3 H), 1.43-1.54 (m, 6 H), 1.68 (sxt, J = 7.58 Hz, 2H), 2.19 (s, 3 H), 2.27 (s, 3 H), 2.69-2.82 (m, 2 H), 3.17- 3.26 (m, 4H), 3.76-3.86 (m, 4 H), 4.52-4.58 (m, 2 H), 4.69 (dt, J = 13.39, 6.69Hz, 1 H), 6.11-6.21 (m, 1 H), 6.88 (d, J = 2.02 Hz, 1 H), 7.09 (dd, J =11.75, 1.64 Hz, 2H) 513.2 309

N-((4,6-dimethyl-2- oxo-1,2- dihydropyridin-3- yl)methyl)-1-isopropyl-3-methyl- 6-(pyridin-3- ylamino)-1H-indole- 4-carboxamide 1.39(m, 6 H), 2.11 (d, J = 3.28 Hz, 6 H), 2.22 (s, 3 H), 4.32 (d, J = 4.80Hz, 2 H), 4.59 (dt, J = 13.14, 6.57 Hz, 1 H), 5.86 (s, 1 H), 6.76 (d, J= 1.26 Hz, 1 H), 7.12-7.25 (m, 3 H), 7.41 (d, J = 8.34 Hz, 1 H), 7.95(d, J = 3.54 Hz, 1 H), 8.10 (t, J = 4.80 Hz, 1 H), 8.25 (s, 1 H),8.30-8.39 (m, 1 H), 11.47 (br. s., 1 H) 444.1 310

N-((4,6-dimethyl-2- oxo-1,2- dihydropyridin-3- yl)methyl)-6-(4-(4-fluorophenyl)piperidin- 1-yl)-1-isopropyl- 3-methyl-1H-indole-4-carboxamide 11.48 (s, 1 H), 8.01 (br.s., 1 H), 6.48-7.39 (m, 6H), 5.87(s, 1H), 4.68 (dt, J = 6.09, 12.32 Hz, 1H), 4.33 (d, J = 5.05 Hz, 2H),3.74 (d, J = 12.13 Hz, 2H), 2.23 (s, 3H), 2.11 (s, 6H), 1.89 (br.s.,3H), 1.39 (d, J = 6.32 Hz, 6H) 528.9 311

N-((4,6-dimethyl-2- oxo-1,2- dihydropyridin-3- yl)methyl)-1-isopropyl-3-methyl- 6-(4-(4- methylpiperazin-1- yl)piperidin-1-yl)-1H-indole-4- carboxamide 7.97 (br.s., 1H), 7.05 (s, 1H), 6.92 (d, J = 1.77Hz, 1H), 6.68 (d, J = 2.02 Hz, 1H), 5.86 (s, 1H), 4.60-4.69 (m, J =6.44, 6.44 Hz, 1H), 4.31 (d, J = 4.80 Hz, 2H), 3.65 (d, J = 11.37 Hz,2H), 3.25-3.32 (m, 4H), 2.68 (ddd, J = 1.89, 2.02, 3.66 Hz, 2H), 2.62(dd, J = 1.14, 11.24 Hz, 2H), 2.33 (dt, J = 1.77, 3.54 Hz, 1H), 2.22 (s,3H), 2.14 (s, 3H), 2.11 (s, 5H), 2.08 (s, 4H), 1.80-1.91 (m, J = 10.36Hz, 2H), 1.55 (br.s., 1H), 1.37 (d, J = 6.57 Hz, 6H) 533.0 312

N-((4,6-dimethyl-2- oxo-1,2- dihydropyridin-3- yl)methyl)-1-isopropyl-3-methyl- 6-(4-(1- methylpiperidin-4- yl)piperazin-1-yl)-1H-indole-4- carboxamide 7.04 (s, 1H), 7.00 (d, J = 1.77 Hz, 1H), 6.87(d, J = 2.02 Hz, 1H), 6.13 (s, 1H), 4.66 (quin, J = 6.69 Hz, 1H), 4.54(s, 2H), 3.18-3.29 (m, 4H), 3.11- 3.18 (m, 1H), 2.98 (d, J = 11.87 Hz,2H), 2.76-2.85 (m, 4H), 2.43 (s, 3H), 2.27-2.35 (m, 5H), 2.26 (s, 3H),2.17 (s, 3H), 2.04-2.14 (m, 2H), 1.93- 2.02 (m, 2H), 1.54-1.72 (m, 2H),1.45 (d, J = 6.57 Hz, 6H) 533.0 313

N-((4,6-dimethyl-2- oxo-1,2- dihydropyridin-3- yl)methyl)-6-(4-fluoropiperidin-1-yl)- 1-isopropyl-3- methyl-1H-indole-4- carboxamide7.01-7.06 (m, 2H), 6.88 (d, J = 2.02 Hz, 1H), 6.14 (s, 1H), 4.81-4.88(m, 1H), 4.59- 4.71 (m, 1H), 4.54 (s, 2H), 3.09-3.19 (m, 2H), 2.44 (s,3H), 2.26 (s, 3H), 2.17 (s, 3H), 1.88-2.15 (m, 4H), 1.46 (d, J = 6.82Hz, 6H) 452.8 314

N-((4,6-dimethyl-2- oxo-1,2- dihydropyridin-3- yl)methyl)-6-(4-(3-fluorophenyl)piperidin- 1-yl)-1-isopropyl- 3-methyl-1H-indole-4-carboxamide 8.01 (t, 1H), 7.36 (td, J = 6.32, 7.96 Hz, 1H), 7.12-7.19(m, 2H), 7.07 (d, J = 1.01 Hz, 1H), 7.00-7.06 (m, 1H), 6.98 (d, J = 1.77Hz, 1H), 6.74 (d, J = 2.02 Hz, 1H), 5.87 (s, 1H), 4.68 (quin, J = 6.57Hz, 1H), 4.32 (d, J = 5.05 Hz, 2H), 3.75 (d, J = 11.87 Hz, 2H), 2.65-2.82 (m, 3H), 2.23 (s, 3H), 2.10 (d, J = 4.04 Hz, 6H), 1.75- 1.96 (m,4H), 1.38 (d, J = 6.57 Hz, 6H) 529.0 315

N-[(4-ethyl-6-methyl- 2-oxo-1,2-dihydro-3- pyridinyl)methyl]-3-methyl-1-(1- methylethyl)-6-(4- morpholinyl)-1H- indole-4- carboxamide11.43 (br.s., 1 H) 7.96 (t, J = 5.05 Hz, 1 H) 7.08 (d, J = 1.01 Hz, 1 H)6.95 (d, J = 2.02 Hz, 1 H) 6.70 (d, J = 2.02 Hz, 1 H) 5.91 (s, 1 H) 4.67(quin, J = 6.63 Hz, 1 H) 4.34 (s, 1 H) 4.32 (s, 1 H) 3.74- 3.77 (m, 4 H)3.07-3.11 (m, 4 H) 2.54-2.60 (m, 2 H) 2.13 (s, 3 H) 2.09 (s, 3 H) 1.38(s, 3 H) 1.37 (s, 3 H) 1.13 (t, J = 7.58 Hz, 3 H) 451.0 316

N-[(4,6-dimethyl-2- oxo-1,2-dihydro-3- pyridinyl)methyl]-3- methyl-1-(1-methylethyl)-6-(4- morpholinyl)-1H- indole-4- carboxamide 11.34 (br.s.,1 H) 7.99 (t, J = 4.93 Hz, 1 H) 7.08 (s, 1 H) 6.94 (d, J = 2.02 Hz, 1 H)6.70 (d, J = 1.77 Hz, 1 H) 5.86 (s, 1 H) 4.67 (quin, J = 6.57 Hz, 1 H)4.32 (s, 1 H) 4.30 (s, 1 H) 3.72- 3.80 (m, 4 H) 3.06-3.13 (m, 4 H) 2.22(s, 3 H) 2.11 (s, 3 H) 2.09 (s, 3 H) 1.38 (s, 3 H) 1.37 (s, 3 H) 437.1317

N-[(4,6-dimethyl-2- oxo-1,2-dihydro-3- pyridinyl)methyl]-3- methyl-1-(1-methylethyl)-6-{[3- methyl-1-(1- methylethyl)-1H- pyrazol-5-yl]amino}-1H-indole-4- carboxamide 1.30 (m, 6 H), 1.35 (d, J = 6.82 Hz, 6 H), 2.08(s, 3 H), 2.11 (s, 3 H), 2.13 (s, 3 H), 2.21 (s, 3 H), 4.31 (d, J = 5.05Hz, 2 H), 4.37-4.49 (m, 2 H), 5.70- 5.77 (m, 1 H), 5.86 (s, 1 H), 6.60(d, J = 1.77 Hz, 1 H), 6.71 (d, J = 1.77 Hz, 1 H), 6.99- 7.07 (m, 1 H),7.67 (s, 1 H), 7.93-8.03 (m, 1 H), 11.46 (br. s., 1 H) 489.0

Example 3186-(2-Dimethylamino-ethoxy)-1-isopropyl-1H-indole-4-carboxylic acid(6-methyl-2-oxo-4-propyl-1,2-dihydro-pyridin-3-ylmethyl)-amide

a) 6-(2-Dimethylamino-ethoxy)-1-isopropyl-1H-indole-4-carboxylic acidmethyl ester

To a cooled (0° C.) mixture of6-hydroxy-1-isopropyl-1H-indole-4-carboxylic acid methyl ester (700 mg,3 mmol), 2-dimethylamino-ethanol (320 mg, 3.60 mmol) and PPh₃ (948 mg,3.60 mmol) in THF (10 mL) was added DEAD (620 mg, 3.60 mmol) and stirredfor 16 h at RT. Reaction mixture was concentrated under reduced pressureand the residue was purified by column chromatography by eluting with 2%MeOH in chloroform to afford the title compound (550 mg, 60%) ascolorless gum. LCMS (ES+): m/z=305.36[M+H].

b) 6-(2-Dimethylamino-ethoxy)-1-isopropyl-1H-indole-4-carboxylic acid

To a solution of6-(2-dimethylamino-ethoxy)-1-isopropyl-1H-indole-4-carboxylic acidmethyl ester (500 mg, 1.64 mmol) in THF (5 mL) was added LiOH.H₂O (200mg, 4.93 mmol) in water (5 mL). the reaction was heated at reflux for 5h, at which time the THF was removed under reduced pressure. Theremaining mixture was acidified with 1 N HCl (pH˜6) and extracted with10% MeOH in chloroform (4×30 mL). The combined organic layer was driedover anhydrous Na₂SO₄ and concentrated to yield6-(2-dimethylamino-ethoxy)-1-isopropyl-1H-indole-4-carboxylic acid (400mg), which was used in the next stage without further purification. LCMS(ES+): m/z=291.30 [M+H].

c) 6-(2-Dimethylamino-ethoxy)-1-isopropyl-1H-indole-4-carboxylic acid(6-methyl-2-oxo-4-propyl-1,2-dihydro-pyridin-3-ylmethyl)-amide

To a cooled (0° C.) mixture of6-(2-dimethylamino-ethoxy)-1-isopropyl-1H-indole-4-carboxylic acid (400mg, 1.37 mmol) in DMF (10 mL) was added EDC.HCl (310 mg, 1.65 mmol) andHOBt.H₂O (250 mg, 1.65 mmol). The reaction was stirred for 15 min, thenDIPEA (1.2 mL, 6.89 mmol) and3-aminomethyl-6-methyl-4-propyl-1H-pyridin-2-one (240 mg, 1.37 mmol)were added. The reaction was allowed to warm to RT and stirred for 16 h,at which time it was diluted with water (20 mL) and extracted with DCM(2×15 mL). The combined DCM layer was dried over Na₂SO₄ andconcentrated. The residue was purified by flash column chromatographyeluting with 3% MeOH in chloroform and then further purified bypreparative HPLC to furnish6-(2-dimethylamino-ethoxy)-1-isopropyl-1H-indole-4-carboxylic acid(6-methyl-2-oxo-4-propyl-1,2-dihydro-pyridin-3-ylmethyl)-amide (120 mg,19%) as an off white solid. ¹H NMR (400 MHz, DMSO-d₆): δ 0.92-0.88 (t,3H), 1.43-1.41 (d, J=6.8 Hz, 6H), 1.56 (m, 2H), 2.12 (s, 3H), 2.22 (s,6H), 2.55-2.53 (m, 2H), 2.06 (m, 2H), 4.11-4.09 (t, 2H), 4.36-4.34 (d,J=4.8 Hz, 2H), 4.76-4.73 (m, 1H), 5.90 (s, 1H), 6.74-6.73 (d, J=2.8 Hz,1H), 7.04 (s, 1H), 7.20 (s, 1H), 7.43-7.42 (d, J=3.2 Hz, 1H), 8.10-8.07(bs, 1H), 11.55 (bs, 1H). LCMS (ES+): m/z=453.23[M+H].

Examples 319-320 were prepared by the methods described above forExample 318, or routine variations thereof, using the requisite alcohol(Mitsunobu reaction) and aminomethylpyridone:

¹H NMR MS(ES) Ex Structure Name (400 MHz, DMSO-d₆) δ ppm [M + H]⁺ 319

1-isopropyl-6-[2-(4- methyl-piperazin-1- yl)-ethoxy]-1H-indole-4-carboxylic acid (6-methyl-2- oxo-4-propyl-1,2-dihydro-pyridin-3- ylmethyl)-amide 0.92 (t, 3H), 1.42 (d, J = 6.8 Hz,6H), 1.57 (m, 2H), 2.14 (d, 6H), 2.32 (m, 8H), 2.54 (m, 2H), 2.71 (t,2H), 4.13-4.11 (m, 2H), 4.35 (d, J = 5.2 Hz, 2H), 4.78-4.72 (m, 1H),5.90 (s, 1H), 6.74 (d, J = 3.2 Hz, 1H), 7.05 (s, 1H), 7.22 (s, 1H), 7.42(d, J = 3.2 Hz, 1H), 8.12 (t, 1H), 11.55 (bs, 1H) 506.26 320

1-isopropyl-6-(2- morpholin-4-yl- ethoxy)-1H-indole-4- carboxylic acid(6- methyl-2-oxo-4- propyl-1,2-dihydro- pyridin-3-ylmethyl)- amide 0.94(t, 3H), 1.42 (d, J = 6.8 Hz, 6H), 1.57 (m, 2H), 2.14 (s, 3H), 2.46-2.50(m, 4H), 2.75 (t, 2H), 2.68-2.75 (t, 4H), 4.15- 4.19 (m, 2H), 4.35 (d,2H), 4.78-4.72 (m, 1 H), 5.91 (s, 1H), 6.73 (d, 1H), 7.10 (s, 1H), 7.25(s, 1H), 7.62 (d, 1H), 8.12 (t, 1H), 11.55 (bs, 1H) 495.22

Example 3211-Isopropyl-6-(2-piperazin-1-yl-ethoxy)-1H-indole-4-carboxylic acid(6-methyl-2-oxo-4-propyl-1,2-dihydro-pyridin-3-ylmethyl)-amide

To a stirred solution of4-(2-{1-isopropyl-4-[(6-methyl-2-oxo-4-propyl-1,2-dihydro-pyridin-3-ylmethyl)-carbamoyl]-1H-indol-6-yloxy}-ethyl)-piperazine-1-carboxylicacid tert-butyl ester (280 mg, 0.472 mmol; prepared following theprocedure of Example xx) in dichloromethane (15 mL) was added TFA (1.5mL) at room temperature and then stirred for 3 h at room temperature.Reaction mixture was concentrated under reduced pressure, diluted withwater (20 mL) and washed the resulting aqueous layer with diethyl ether(2×15 mL). The aqueous layer was basified with (pH˜8) with saturatedaqueous NaHCO₃ solution and extracted with dichloromethane (3×20 mL).The combined organic layer was washed with brine solution (2×25 mL) andconcentrated. Purification by preparative HPLC afforded1-isopropyl-6-(2-piperazin-1-yl-ethoxy)-1H-indole-4-carboxylic acid(6-methyl-2-oxo-4-propyl-1,2-dihydro-pyridin-3-ylmethyl)-amide (48 mg,20%) as an off white solid. ¹H NMR (400 MHz, DMSO-d₆): δ 0.93 (t, 3H),1.42 (d, 6H, J=6.8 Hz), 1.57 (m, 2H), 2.14 (s, 3H), 2.45-2.2 (m, 4H),2.68 (t, 2H), 2.75 (t, 4H), 4.15-4.19 (m, 2H), 4.35 (d, 2H), 4.78-4.72(m, 1H), 5.91 (s, 1H), 6.73 (d, 1H), 7.03 (s, 1H), 7.24 (s, 1H), 7.42(d, 1H), 8.12 (t, 1H), 11.58 (bs, 1H). LCMS (ES+): m/z=494.57[M+H].

Example 322N-{[4-(ethylamino)-6-methyl-2-oxo-1,2-dihydro-3-pyridinyl]methyl}-1-(1-methylethyl)-6-[6-(4-methyl-1-piperazinyl)-3-pyridinyl]-1H-indole-4-carboxamide

a) 4-Chloro-6-methyl-2-oxo-1,2-dihydro-3-pyridinecarbonitrile

Using a 100 ml round bottom with reflux condenser, PCI₅ (6.7 g, 32mmol), POCl₃ (3.0 mL, 32 mmol) and 30 ml CHCl₃ (dry) were stirred for 5min (see: Heterocycles, vol. 60, No. 6, 2003, 1461-1468). Added4-hydroxy-6-methyl-2-oxo-1,2-dihydro-3-pyridinecarbonitrile (4 g, 26.6mmol) and stirred for 2 h at 80° C. Quenched reaction while hot andpoured into 1 L beaker with 100 “g” ice, 24 mL NH₄OH, pH by paper was8-9. Stirred 5 min and filtered. Washed solid with water. Suspendedsolid in ethanol and filtered and washed with ethanol. Gave:4-chloro-6-methyl-2-oxo-1,2-dihydro-3-pyridinecarbonitrile (1.7 g, 9.58mmol, 40% yield)¹H NMR (400 MHz, DMSO-d₆) δ ppm 12.85 (br. s., 1H) 6.53(s, 1H) 2.28 (s, 3H) MS(ES) [M+H]⁺ 168.9.

b) 4-(Ethylamino)-6-methyl-2-oxo-1,2-dihydro-3-pyridinecarbonitrile

To a 10 ml microwave vial added4-chloro-6-methyl-2-oxo-1,2-dihydro-3-pyridinecarbonitrile (750 mg, 4.45mmol) and methanol (1 mL) then added ethylamine (5.56 mL, 11.12 mmol).One drop on conc. HCl was added and the vial was capped and the reactionwas microwaved to 120° C. for 1 hr. The reaction was cooled and thesolid was filtered and washed with cold MeOH. Gave4-(ethylamino)-6-methyl-2-oxo-1,2-dihydro-3-pyridinecarbonitrile (500mg, 2.77 mmol, 62.2% yield)¹H NMR (400 MHz, DMSO-d₆) δ ppm 11.05 (br.s., 1H) 7.11 (br. s., 1H) 5.78 (br. s., 1H) 3.22-3.32 (m, 2H) 2.11 (s,3H) 1.10 (t, J=7.07 Hz, 3H) MS(ES) [M+H]⁺ 177.8.

c) 1,1-Dimethylethyl{[4-(ethylamino)-6-methyl-2-oxo-1,2-dihydro-3-pyridinyl]methyl}carbamate

In a 250 ml, round bottom flask under N₂ added4-(ethylamino)-6-methyl-2-oxo-1,2-dihydro-3-pyridinecarbonitrile (500mg, 2.82 mmol) as a solid then added Methanol (50 mL) and cooled to 0°C. in an ice bath. Next di-tert-butyl dicarbonate (1.310 mL, 5.64 mmol)was added and the suspension stirred for 5 min. NickelChloride-hexahydrate (335 mg, 1.411 mmol) solid was added followed byNaBH₄ (747 mg, 19.75 mmol) as a solid (in 3 portions—allowed 1 min inbetween portions b/c it turns black and there is gas evolution). Afteraddition and stirring at 0° C. for ˜10 min the ice bath was removed andthe mix stirred at rt ON. The next morning the reaction was quenchedwith—Diethylene triamine (0.613 mL, 5.64 mmol) via syringe and the mixcontinued to stir 20 min. The reaction was diluted with EtOAc and wastreated with sat NaHCO₃ and stirred 10 min. The mixture was transferredto a sep. funnel and the organic layer was separated out and washed(2×s) with sat NaHCO₃. The organic layer was concentrated in vacuo to asolid. The solid was stirred with 5% MeOH/Water (50 mL) then filtered.The solid was washed with 5% MeOH/Water and water (2×s) and dried togive 1,1-dimethylethyl{[4-(ethylamino)-6-methyl-2-oxo-1,2-dihydro-3-pyridinyl]methyl}carbamate(500 mg, 1.599 mmol, 56.7% yield). ¹H NMR (400 MHz, DMSO-d₆) δ ppm 10.64(br. s., 1H) 7.08 (br. s., 1H) 6.25 (br. s., 1H) 5.64 (s, 1H) 3.96 (d,J=6.06 Hz, 2H) 3.09-3.18 (m, 2H) 2.06 (s, 3H) 1.38 (s, 9H) 1.14 (t, 3H)[M+H]⁺ 282.5.

d)6-Bromo-N-{[4-(ethylamino)-6-methyl-2-oxo-1,2-dihydro-3-pyridinyl]methyl}-1-(1-methylethyl)-1H-indole-4-carboxamide

In a 50 mL round bottom was added 1,1-dimethylethyl{[4-(ethylamino)-6-methyl-2-oxo-1,2-dihydro-3-pyridinyl]methyl}carbamate(500 mg, 1.777 mmol) and Dichloromethane (DCM) (20.00 mL). TFA (1.095mL, 14.22 mmol) was added and the reaction stirred at rt for 3.5 h. TheLCMS indicated deprotection. The reaction was evaporated and evaporatedfrom DCM. Dimethyl Sulfoxide (DMSO) (20 mL) was added to the roundbottom followed by 6-bromo-1-(1-methylethyl)-1H-indole-4-carboxylic acid(501 mg, 1.777 mmol), to the solution was added N-methylmorpholine(1.172 mL, 10.66 mmol) 1-hydroxy-7-azabenzotriazole (363 mg, 2.67 mmol)and EDC (511 mg, 2.67 mmol). The reaction stirred at rt for 12 hr. Thereaction was poured onto Ice water (10 mL) and was stirred for 20 minlet it rest for 10 min and filter. Rinse solid with water (10 mL).Purification of solid by reverse phase Gilson HPLC (10-90%acetonitrile/water+0.1% TFA, YMC ODS-A C18 Column 75×30 mm ID S-5 um, 12nM Column 7 minutes) provided the desired product as a white solid afterneutralization with 0.1N NaOH and evaporation and precipitation fromwater.6-bromo-N-{[4-(ethylamino)-6-methyl-2-oxo-1,2-dihydro-3-pyridinyl]methyl}-1-(1-methylethyl)-1H-indole-4-carboxamide(240 mg, 0.523 mmol, 29.4% yield). ¹H NMR (400 MHz, DMSO-d₆) δ ppm 10.70(s, 1H) 8.87 (m, 1H) 7.93 (s, 1H) 7.57-7.71 (m, 2H) 6.89 (d, J=3.28 Hz,1H) 6.71 (m, 1H) 5.66 (s, 1H) 4.82 (m, 1H) 4.34 (d, J=5.81 Hz, 2H)3.12-3.23 (m, 2H) 2.08 (s, 3H) 1.43 (d, J=6.57 Hz, 6H) 1.18 (t, 3H)MS(ES) [M+H]⁺ 445.1.

e)N-{[4-(ethylamino)-6-methyl-2-oxo-1,2-dihydro-3-pyridinyl]methyl}-1-(1-methylethyl)-6-[6-(4-methyl-1-piperazinyl)-3-pyridinyl]-1H-indole-4-carboxamide

To a 20 mL microwave vial was added6-bromo-N-{[4-(ethylamino)-6-methyl-2-oxo-1,2-dihydro-3-pyridinyl]methyl}-1-(1-methylethyl)-1H-indole-4-carboxamide(70 mg, 0.170 mmol), and1-methyl-4-[5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2-pyridinyl]piperazine(59.9 mg, 0.198 mmol). PdCl2(dppf)-CH2Cl2 adduct (14.67 mg, 0.018 mmol)and sodium bicarbonate (45.3 mg, 0.539 mmol) were added followed by1,2-Dimethoxyethane (DME) (5 mL) and Water (2 mL). The vial was sealedand the reaction was heated to 85° C. for 1 hr. The reaction was cooledand evaporated. The material was taken into Methanol/DMSO and wasfiltered through an acrodisk and purified by reverse phase Gilson HPLC(5-80% acetonitrile/water+0.1% TFA, YMC ODS-A C18 Column 75×30 mm ID S-5um, 12 nM Column, 6 minutes) the desired fractions were collected andevaporated from 0.1N NaOH which provided the desired productN-{[4-(ethylamino)-6-methyl-2-oxo-1,2-dihydro-3-pyridinyl]methyl}-1-(1-methylethyl)-6-[6-(4-methyl-1-piperazinyl)-3-pyridinyl]-1H-indole-4-carboxamide(57 mg, 0.101 mmol, 56.2% yield). ¹H NMR (400 MHz, DMSO-d₆) δ ppm 10.68(s, 1H) 8.89 (t, J=5.94 Hz, 1H) 8.66 (d, J=2.02 Hz, 1H) 8.09 (dd,J=8.59, 2.02 Hz, 1H) 7.91 (s, 1H) 7.80 (s, 1H) 7.60 (d, J=3.03 Hz, 1H)6.99 (d, J=8.84 Hz, 1H) 6.89-6.96 (m, 2H) 5.66 (s, 1H) 4.85-4.98 (m, 1H)4.39 (d, J=5.81 Hz, 2H) 3.63 (br. s., 4H) 3.11-3.24 (m, 2H) 2.7 (bs, 4H)2.08 (s, 3H) 1.47 (d, J=6.57 Hz, 6H) 1.20 (t, 3H). MS(ES) [M+H]⁺ 542.4.

Examples 323-324 were prepared by the methods described above forExample 322, or routine variations thereof, using the requisite amine:

¹H NMR MS(ES) Ex Structure Name (400 MHz, DMSO-d₆) δ ppm [M + H]⁺ 323

6-bromo-1-(1- methylethyl)-N-{[6- methyl-2-oxo-4-(1- pyrrolidinyl)-1,2-dihydro-3- pyridinyl]methyl}-1H- indole-4- carboxamide 10.86 (s, 1 H)8.22 (t, J = 4.29 Hz, 1 H) 7.93 (s, 1 H) 7.64 (d, J = 3.28 Hz, 1 H) 7.53(d, J = 1.77 Hz, 1 H) 6.85 (d, J = 3.28 Hz, 1 H) 5.74 (s, 1 H) 4.78-4.89(m, 1 H) 4.42 (d, J = 4.29 Hz, 2 H) 3.43-3.54 (m, 4 H) 2.09 (s, 3 H)1.80- 1.89 (m, 4 H) 1.44 (d, J = 6.57 Hz, 6 H) 473.0 324

6-bromo-1-(1- methylethyl)-N-{[6- methyl-2-oxo-4- (phenylamino)-1,2-dihydro-3- pyridinyl]methyl}-1H- indole-4- carboxamide 11.02 (s, 1 H)9.45 (s, 1 H) 9.15-9.21 (m, 1 H) 7.96 (s, 1 H) 7.67 (dd, J = 10.11, 2.53Hz, 2 H) 7.34-7.40 (m, 2 H) 7.15 (d, J = 7.33 Hz, 2 H) 7.04- 7.09 (m, 1H) 6.91 (d, J = 3.03 Hz, 1 H) 5.91 (s, 1 H) 4.80-4.87 (m, 1 H) 4.39 (d,J = 5.81 Hz, 2 H) 2.06 (s, 3 H) 1.44 (d, J = 6.57 Hz, 6 H) 493.0

Example 325N-((6-Amino-4-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-6-bromo-1-isopropyl-3-methyl-1H-indole-4-carboxamide

a) tert-Butyl(5-((6-bromo-1-isopropyl-3-methyl-1H-indole-4-carboxamido)methyl)-6-methoxy-4-methylpyridin-2-yl)carbamate

To a stirred solution of tert-butyl(5-(aminomethyl)-6-methoxy-4-methylpyridin-2-yl)carbamate (0.40 g, 1.496mmol), 6-bromo-1-isopropyl-3-methyl-1H-indole-4-carboxylic acid (0.44 g,1.486 mmol), and HOAt (0.21 g, 1.543 mmol) in DMF (25 mL) was added EDCfree base (0.25 g, 1.610 mmol). The reaction was stirred at RT overnightthen evaporated to dryness under vacuum. The remaining was purified bysilica gel chromatography (Analogix, SF25-60 g, 0 to 30% EtOAc inhexanes) to give the product tert-butyl(5-((6-bromo-1-isopropyl-3-methyl-1H-indole-4-carboxamido)methyl)-6-methoxy-4-methylpyridin-2-yl)carbamate(0.81 g, 1.485 mmol, 99% yield) as a white solid. ¹H NMR (400 MHz,DMSO-d₆) δ=9.42 (s, 1H), 8.41 (t, J=4.8 Hz, 1H), 7.77 (d, J=1.5 Hz, 1H),7.33 (s, 1H), 7.21 (s, 1H), 6.99 (d, J=1.8 Hz, 1H), 4.40 (d, J=5.1 Hz,2H), 3.81 (s, 3H), 2.35 (s, 3H), 2.10 (d, J=1.0 Hz, 3H), 1.47 (s, 9H),1.38 (d, J=6.6 Hz, 6H). MS(ES)+ m/e 545.2 [M+H]⁺.

b)N-((6-Amino-4-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-6-bromo-1-isopropyl-3-methyl-1H-indole-4-carboxamide

To a stirred solution of tert-butyl(5-((6-bromo-1-isopropyl-3-methyl-1H-indole-4-carboxamido)methyl)-6-methoxy-4-methylpyridin-2-yl)carbamate(0.80 g, 1.467 mmol) in acetonitrile (20 mL) was added dropwise at RTTMSI (0.50 ml, 3.67 mmol). A reflux condenser was attached and thereaction was purged with N₂ and heated to 70° C. After stirring for 30minutes LCMS indicated that the reaction was complete (89% pure with 11%possible iodinated side product as the only other impurity). After 1 hrthe reaction was quenched with MeOH (5 mL) and stirred for 30 minutes.The clear brown solution was evaporated to dryness under vacuum, takenup in CH₂Cl₂, washed with aq. Na₂S₂O₃, (a ppt. formed that was filteredoff), dried (Na₂SO₄), filtered, and concentrated under vacuum.Purification by silica gel chromatography (Analogix, SF25-10 g, 0 to 7%(5% NH₄OH/MeOH) in CH₂Cl₂) gave the productN-((6-amino-4-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-6-bromo-1-isopropyl-3-methyl-1H-indole-4-carboxamide(59.6 mg, 0.138 mmol, 9.4% yield) as a white solid. Note: The ppt. thatwas filtered off during the aq. Na₂S₂O₃ wash was later shown to containproduct. This solid was washed with water and dried under vacuum to giveadditional product as an off-white solid (602 mg, 1.4 mmol, 95%, 100%pure by LCMS). ¹H NMR (400 MHz, DMSO-d₆) δ=10.59 (br. s., 1H), 8.13 (t,J=4.4 Hz, 1H), 7.76 (d, J=1.5 Hz, 1H), 7.33 (s, 1H), 6.99 (d, J=1.5 Hz,1H), 5.83 (br. s., 2H), 5.19 (s, 1H), 4.74 (dt, J=6.6, 13.3 Hz, 1H),4.22 (d, J=4.8 Hz, 2H), 2.14 (s, 3H), 2.11 (s, 3H), 1.39 (d, J=6.6 Hz,6H). MS(ES)+ m/e 431.1 [M+H]⁺.

Examples 326-334 were prepared by the methods described above forExample 325, or routine variations thereof, using the requisite amine:

¹H NMR MS(ES) Ex Structure Name (400 MHz, DMSO-d₆) δ ppm [M + H]⁺ 326

N-((6-amino-4- methyl-2-oxo-1,2- dihydropyridin-3- yl)methyl)-6-chloro-1-isopropyl-3- methyl-1H-indole-4- carboxamide 10.62 (br.s., 1 H), 8.14(t, J = 4.4 Hz, 1 H), 7.63 (d, J = 1.8 Hz, 1 H), 7.34 (s, 1 H), 6.89 (d,J = 1.8 Hz, 1 H), 5.85 (br. s., 2 H), 5.20 (s, 1 H), 4.73 (dt, J = 6.7,13.2 Hz, 1 H), 4.22 (d, J = 4.8 Hz, 2 H), 2.14 (s, 3 H), 2.12 (s, 3 H),1.39 (d, J = 6.6 Hz, 6 H) 387.2 327

N-[(6-amino-4- methyl-2-oxo-1,2- dihydro-3- pyridinyl)methyl]-3-methyl-1-(1- methylethyl)-6-[6-(4- methyl-1- piperazinyl)-3-pyridinyl]-1H-indole- 4-carboxamide 10.49 (br.s., 1 H), 8.51 (d, J = 2.5Hz, 1 H), 7.98 (t, J = 4.8 Hz, 1 H), 7.93 (dd, J = 2.5, 8.8 Hz, 1 H),7.71 (d, J = 1.3 Hz, 1 H), 7.29 (s, 1 H), 7.17 (d, J = 1.5 Hz, 1 H),6.92 (d, J = 8.8 Hz, 1 H), 5.77 (s, 2 H), 5.16 (s, 1 H), 4.84 (quin, J =6.6 Hz, 1 H), 4.26 (d, J = 5.1 Hz, 2 H), 3.61-3.46 (m, 4 H), 2.43 (t, J= 4.7 Hz, 4 H), 2.24 (s, 3 H), 2.18 (s, 3 H), 2.13 (s, 3 H), 1.43 (d, J= 6.6 Hz, 6 H) 528.6 328

N-[(6-amino-4- methyl-2-oxo-1,2- dihydro-3- pyridinyl)methyl]-6- {3-[(dimethylamino)meth- yl]phenyl}-3- methyl-1-(1- methylethyl)-1H-indole-4- carboxamide 10.48 (br.s., 1 H), 8.03 (t, J = 4.9 Hz, 1 H),7.75 (d, J = 1.3 Hz, 1 H), 7.64 (s, 1 H), 7.63 (d, 1 H), 7.40 (t, J =7.6 Hz, 1 H), 7.33 (s, 1 H), 7.24 (d, J = 7.6 Hz, 1 H), 7.22 (d, J = 1.5Hz, 1 H), 5.77 (s, 2 H), 5.16 (s, 1 H), 4.88 (quin, J = 6.6 Hz, 1 H),4.26 (d, J = 5.1 Hz, 2 H), 3.48 (s, 2 H), 2.19 (s, 9 H), 2.13 (s, 3 H),1.44 (d, J = 6.6 Hz, 6 H) 486.3 329

N-[(6-amino-4- methyl-2-oxo-1,2- dihydro-3- pyridinyl)methyl]-6-bromo-3-methyl-1- (1-methylpropyl)-1H- indole-4- carboxamide 0.70 (t, J= 7.33 Hz, 3 H) 1.36 (d, J = 6.82 Hz, 3 H) 1.69-1.84 (m, 2 H) 2.15 (s, 2H) 2.10 (s, 4 H) 4.21 (d, J = 4.80 Hz, 2 H) 4.41-4.58 (m, 1 H) 5.15 (s,1 H) 5.77 (s, 2 H) 6.97 (d, J = 1.52 Hz, 1 H) 7.29 (s, 1 H) 7.76 (d, J =1.77 Hz, 1 H) 8.06 (t, J = 4.80 Hz, 1 H) 10.47 (br. s., 1 H) 447.2 330

N-[(6-amino-4- methyl-2-oxo-1,2- dihydro-3- pyridinyl)methyl]-6-bromo-3-methyl-1- (1-methylpropyl)-1H- indole-4- carboxamide 0.668 (t, J= 7.4 Hz, 3H), 1.36 (d, J = 6.8 Hz, 3H), 1.76-1.78 (m, 2H), 2.11 (s,3H), 2.15 (s, 3H), 4.21 (d, J = 4.8 Hz, 2H), 4.35-4.38 (m, 1H), 5.15 (s,1H), 5.78 (s, 2H), 6.97 (s, 1H), 7.30 (s, 1H), 7.76 (s, 1H), 8.07- 8,.09(m, 1H), 10.4-10.5 (br s, 1H) 445.2 331

N-[(6-amino-4- methyl-2-oxo-1,2- dihydro-3- pyridinyl)methyl]-6-bromo-3-methyl-1- (1-methylpropyl)-1H- indole-4- carboxamide 0.668 (t, J= 7.4 Hz, 3H), 1.36 (d, J = 6.8 Hz, 3H), 1.76-1.78 (m, 2H), 2.11 (s,3H), 2.15 (s, 3H), 4.21 (d, J = 4.8 Hz, 2H), 4.35-4.38 (m, 1H), 5.15 (s,1H), 5.78 (s, 2H), 6.97 (s, 1H), 7.30 (s, 1H), 7.76 (s, 1H), 8.07- 8,.09(m, 1H), 10.4-10.5 (br s, 1H) 445.2 332

N-[(6-amino-4- methyl-2-oxo-1,2- dihydro-3- pyridinyl)methyl]-3-methyl-6-[6-(4- methyl-1- piperazinyl)-3- pyridinyl]-1-(1-methylpropyl)-1H- indole-4- carboxamide 10.47 (br.s., 1 H) 8.50 (d, J =2.53 Hz, 1 H) 7.98 (br.s., 1 H) 7.92 (dd, J = 8.84, 2.53 Hz, 1 H)7.71-7.74 (m, 1 H) 7.26 (s, 1 H) 7.16 (d, J = 1.26 Hz, 1 H) 6.92 (d, J =9.09 Hz, 1 H) 5.76 (s, 2 H) 5.16 (br.s., 1 H) 4.57-4.65 (m, 1 H) 4.26(br. s., 1 H) 4.25 (br.s., 1 H) 3.52 (br.s., 4 H) 2.42 (br.s., 4 H) 2.23(s, 3 H) 2.18 (s, 3 H) 2.13 (s, 3 H) 1.81 (td, J = 7.20, 3.03 Hz, 2 H)1.41 (d, J = 6.82 Hz, 3 H) 0.73 (t, J = 7.20 Hz, 3 H) 542.6 333

N-((6-amino-2-oxo- 4-propyl-1,2- dihydropyridin-3- yl)methyl)-6-bromo-1-isopropyl-3- methyl-1H-indole-4- carboxamide 10.52 (br.s., 1 H), 8.04(t, J = 4.7 Hz, 1 H), 7.76 (d, J = 1.8 Hz, 1 H), 7.33 (s, 1 H), 6.98 (d,J = 1.8 Hz, 1 H), 5.77 (s, 2 H), 5.17 (s, 1 H), 4.74 (quin, J = 6.6 Hz,1 H), 4.23 (d, J = 4.8 Hz, 2 H), 2.45-2.34 (m, 2 H), 2.15 (s, 3 H), 1.52(dq, J = 7.4, 15.1 Hz, 2 H), 1.39 (d, J = 6.6 Hz, 6 H), 0.93 (t, J = 7.3Hz, 3 H) 459.2 334

6-bromo-1- isopropyl-3-methyl- N-((4-methyl-6- (methylamino)-2- oxo-1,2-dihydropyridin-3- yl)methyl)-1H- indole-4- carboxamide 10.48 (br.s., 1H), 8.11 (t, J = 4.5 Hz, 1 H), 7.75 (d, J = 1.5 Hz, 1 H), 7.33 (s, 1 H),6.99 (d, J = 1.5 Hz, 1 H), 5.76 (q, J = 4.4 Hz, 1 H), 5.13 (br.s., 1 H),4.74 (quin, J = 6.6 Hz, 1 H), 4.24 (d, J = 4.8 Hz, 2 H), 2.67 (d, J =5.1 Hz, 3 H), 2.17 (s, 3 H), 2.15 (s, 3 H), 1.39 (d, J = 6.6 Hz, 6 H)445.2

Example 335N-[(4,6-Dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-3-methyl-1-(1-methylethyl)-6-{6-[(2R)-2-methyl-1-piperazinyl]-3-pyridinyl}-1H-indole-4-carboxamide

a) (R)-tert-Butyl4-(5-(4-(((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)carbamoyl)-1-isopropyl-3-methyl-1H-indol-6-yl)pyridin-2-yl)-3-methylpiperazine-1-carboxylate

Added6-(6-chloropyridin-3-yl)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-3-methyl-1H-indole-4-carboxamide(131 mg, 0.283 mmol), (R)-tert-butyl 3-methylpiperazine-1-carboxylate(70.8 mg, 0.354 mmol), sodium tert-butoxide (59.8 mg, 0.623 mmol) and1,4-Dioxane (2 mL) to a microwave vial and degassed for 10 minutes.Added Pd XPhos (10.45 mg, 0.014 mmol) and heated to 100° C. for 16hours. Concentrated, added DCM and water. Filtered, separated phases.Extracted aqueous phase twice more with DCM. Combined DCM extracts andwashed with water, brine, dried (MgSO4), filtered and rotovapped offDCM. The residue was purified via Biotage (0% to 5% MeOH:DCM; 10g-HP-silica gel column). Obtained 28 mg of the title compound. ¹H NMR(400 MHz, CHLOROFORM-d) δ ppm 1.16 (d, J=6.32 Hz, 3H), 1.44-1.57 (m,15H), 2.06 (s, 3H), 2.28 (s, 3H), 2.39 (s, 3H), 2.87-3.36 (m, 3H), 3.57(s, 1H), 3.86-4.30 (m, 3H), 4.50 (d, J=9.35 Hz, 1H), 4.58-4.79 (m, 3H),5.87 (s, 1H), 6.64 (d, J=8.59 Hz, 1H), 7.01 (s, 1H), 7.45 (s, 1H), 7.76(d, J=8.08 Hz, 1H), 8.46 (d, J=2.27 Hz, 1H), 12.42 (br. s., 1H). LCMS:[M+H]⁺ 627.5.

b)N-[(4,6-Dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-3-methyl-1-(1-methylethyl)-6-{6-[(2R)-2-methyl-1-piperazinyl]-3-pyridinyl}-1H-indole-4-carboxamide

Added trifluoroacetic acid (1 ml, 12.98 mmol) to a solution of(R)-tert-butyl4-(5-(4-(((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)carbamoyl)-1-isopropyl-3-methyl-1H-indol-6-yl)pyridin-2-yl)-3-methylpiperazine-1-carboxylate(57 mg, 0.091 mmol) in DCM (3 mL) and let stir at RT for 1 hour.Concentrated on rotovap. Partitioned between DCM and sat'd Na2CO3,separated and washed DCM phase with water, brine, dried (MgSO4),filtered and rotovapped off DCM. Obtained 25 mg of the title compound asa tan solid. ¹H NMR (400 MHz, CHLOROFORM-d) δ ppm 1.19 (d, 2H),1.46-1.59 (m, 6H), 2.21 (s, 3H), 2.27 (s, 3H), 2.44 (s, 3H), 2.83 (dd,J=12.13, 3.54 Hz, 1H), 2.96-3.29 (m, 4H), 3.90 (br. s., 1H), 4.47-4.76(m, 5H), 6.00 (s, 1H), 6.51 (d, J=8.59 Hz, 1H), 7.05 (s, 1H), 7.45 (s,1H), 7.68 (dd, J=8.72, 2.40 Hz, 1H), 8.43 (d, J=2.27 Hz, 1H),10.11-12.70 (m, 1H). LCMS: [M+H]⁺ 527.5.

Examples 336-346 were prepared by the methods described above forExample 335, or routine variations thereof, using the requisite amine:

¹H NMR MS(ES) Ex Structure Name (400 MHz, DMSO-d₆) δ ppm [M + H]⁺ 336

N-[(4,6-dimethyl-2- oxo-1,2-dihydro-3- pyridinyl)methyl]-6-[6-(3,4-dimethyl-1- piperazinyl)-3- pyridinyl]-3-methyl-1-(1-methylethyl)- 1H-indole-4- carboxamide (CHLOROFORM-d) 1.16 (d, J =6.06 Hz, 3 H), 1.47 (d, J = 6.57 Hz, 6 H), 2.03 (s, 3 H), 2.14-2.29 (m,4 H), 2.30- 2.42 (m, 7 H), 2.69 (dd, J = 12.25, 10.74 Hz, 1 H), 2.91 (d,J = 11.62 Hz, 1 H), 3.00- 3.13 (m, 1 H), 4.06 (d, J = 12.63 Hz, 2 H),4.38-4.75 (m, 3 H), 5.85 (s, 1 H), 6.64 (d, J = 8.59 Hz, 1 H), 6.99 (s,1 H), 7.42 (d, J = 1.52 Hz, 1 H), 7.70 (dd, J = 8.84, 2.53 Hz, 1 H),8.43 (d, J = 2.27 Hz, 1 H), 12.55 (br.s., 1 H) 541.3 337

N-[(4,6-dimethyl-2- oxo-1,2-dihydro-3- pyridinyl)methyl]-6- [6-(hexahydropyrrolo[3,4- b]pyrrol-5(1H)-yl)- 3-pyridinyl]-3- methyl-1-(1-methylethyl)-1H- indole-4- carboxamide (CHLOROFORM-d) 1.24 (s, 3 H),1.49 (d, J = 6.57 Hz, 6 H), 1.60-1.73 (m, 4 H), 2.10 (s, 3 H), 2.28 (s,3 H), 2.38 (s, 2 H), 3.39-3.53 (m, 2 H), 3.57- 3.70 (m, 2 H), 4.54-4.75(m, 3 H), 5.88 (s, 1 H), 6.61 (d, J = 8.84 Hz, 1 H), 7.01 (s, 1 H), 7.26(br.s., 1 H), 7.29 (d, J = 5.81 Hz, 1 H), 7.44 (s, 1 H), 7.66 (dd, J =8.84, 2.27 Hz, 2 H), 8.41 (d, J = 2.02 Hz, 2 H), 10.07-13.76 (m, 1 H)541.5 338

N-[(4,6-dimethyl-2- oxo-1,2-dihydro-3- pyridinyl)methyl]-6- [6-(hexahydropyrrolo[3,4- b]pyrrol-5(1H)-yl)- 3-pyridinyl]-3- methyl-1-(1-methylethyl)-1H- indole-4- carboxamide (CHLOROFORM-d) 1.48 (t, J = 6.57Hz, 6 H), 1.54-1.69 (m, 1 H), 2.10 (s, 3 H), 2.31 (s, 3 H), 2.42 (s, 3H), 2.77-3.05 (m, 3 H), 3.22 (dd, J = 10.86, 4.55 Hz, 1 H), 3.31-3.46(m, 2 H), 3.46-3.58 (m, 1 H), 4.03 (d, J = 5.56 Hz, 1 H), 4.39- 4.86 (m,3 H), 5.90 (s, 1 H), 6.16 (d, J = 8.59 Hz, 1 H), 7.03 (s, 1 H), 7.21 (s,1 H), 7.41 (s, 1 H), 7.53 (d, J = 6.32 Hz, 2 H), 8.32 (d, J = 2.02 Hz, 1H) 539.5 339

N-[(4,6-dimethyl-2- oxo-1,2-dihydro-3- pyridinyl)methyl]-6-[6-(3,3-dimethyl-1- piperazinyl)-3- pyridinyl]-3-methyl-1-(1-methylethyl)- 1H-indole-4- carboxamide (CHLOROFORM-d) 1.21 (s, 6H), 1.49 (d, J = 6.82 Hz, 6 H), 2.09 (s, 3 H), 2.28 (s, 3 H), 2.40 (s, 3H), 2.99-3.12 (m, 2 H), 3.33 (s, 2 H), 3.45-3.60 (m, 2 H), 4.55-4.77 (m,3 H), 5.89 (s, 1 H), 6.63 (d, J = 8.84 Hz, 1 H), 7.01 (s, 1 H), 7.22-7.26 (m, 1 H), 7.28 (d, J = 1.26 Hz, 1 H), 7.44 (d, J = 1.01 Hz, 1 H),7.70 (dd, J = 8.84, 2.53 Hz, 1 H), 8.42 (d, J = 2.27 Hz, 1 H) 541.6 340

N-[(4,6-dimethyl-2- oxo-1,2-dihydro-3- pyridinyl)methyl]-3- methyl-1-(1-methylethyl)-6-{6- [(2S)-2-methyl-1- piperazinyl]-3-pyridinyl}-1H-indole- 4-carboxamide (CHLOROFORM-d) 1.21 (d, J = 6.57 Hz,3 H), 1.49 (d, J = 6.82 Hz, 6 H), 2.07 (s, 3 H), 2.28 (s, 3 H), 2.39 (s,3 H), 2.76-2.99 (m, 2 H), 3.02- 3.21 (m, 3 H), 3.94 (d, J = 12.63 Hz, 1H), 4.38-4.48 (m, 1 H), 4.56-4.77 (m, 3 H), 5.88 (s, 1 H), 6.59 (d, J =9.09 Hz, 1 H), 7.01 (s, 1 H), 7.30 (d, 1 H), 7.45 (d, J = 1.01 Hz, 1 H),7.71 (dd, J = 8.84, 2.53 Hz, 1 H), 8.45 (d, J = 2.27 Hz, 1 H) 527.5 341

N-[(4,6-dimethyl-2- oxo-1,2-dihydro-3- pyridinyl)methyl]-6- [6-(hexahydropyrrolo[3,4- c]pyrrol-2(1H)-yl)- 3-pyridinyl]-3- methyl-1-(1-methylethyl)-1H- indole-4- carboxamide (CHLOROFORM-d) 1.49 (d, 6 H),2.18 (s, 3 H), 2.33 (s, 3 H), 2.44 (s, 3 H), 2.63 (d, J = 6.32 Hz, 2 H),2.89 (br.s., 2 H), 3.02 (d, J = 9.60 Hz, 2 H), 3.24 (dd, J = 10.99, 6.19Hz, 2 H), 3.35 (dd, J = 9.85, 7.07 Hz, 2 H), 4.55-4.72 (m, 3 H), 5.91-6.01 (m, 2 H), 7.09 (s, 1 H), 7.13 (s, 1 H), 7.35-7.49 (m, 2 H),7.60-7.81 (m, 1 H), 8.26 (d, J = 2.02 Hz, 1 H) 539.5 342

6-{6-[(1S,4S)-2,5- diazabicyclo[2.2.1] hept-2-yl]-3-pyridinyl}-N-[(4,6-dimethyl-2- oxo-1,2-dihydro-3- pyridinyl)methyl]-3- methyl-1-(1-methylethyl)-1H- indole-4- carboxamide 1.43 (d, J = 6.57 Hz, 6 H), 1.68(d, J = 9.35 Hz, 1 H), 1.80 (d, J = 8.84 Hz, 1 H), 2.11 (s, 3 H), 2.16(s, 3 H), 2.24 (s, 3 H), 2.82 (d, J = 9.35 Hz, 1 H), 2.89- 2.97 (m, 1H), 3.16-3.25 (m, 2 H), 3.49 (d, J = 8.34 Hz, 1 H), 3.69 (br.s., 1 H),4.35 (d, J = 4.80 Hz, 2 H), 4.69 (s, 1 H), 4.83 (quin, J = 6.63 Hz, 1H), 5.87 (s, 1 H), 6.56 (d, J = 8.84 Hz, 1 H), 7.16 (d, J = 1.26 Hz, 1H), 7.27 (s, 1 H), 7.68 (d, J = 1.26 Hz, 1 H), 7.86 (dd, J = 8.72, 2.40Hz, 1 H), 8.14 (t, J = 5.05 Hz, 1 H), 8.44 (d, J = 2.27 Hz, 1 H) 525.3343

6-{6-[(1R,4R)-2,5- diazabicyclo[2.2.1] hept-2-yl]-3-pyridinyl}-N-[(4,6-dimethyl-2- oxo-1,2-dihydro-3- pyridinyl)methyl]-3- methyl-1-(1-methylethyl)-1H- indole-4- carboxamide 1.43 (d, 6 H), 1.70 (m, 1 H),1.80 (m, 1 H), 2.11 (s, 3 H), 2.16 (s, 3 H), 2.24 (s, 3 H), 2.80-2.87(m, 1 H), 2.91- 2.98 (m, 1 H,) 3.23 (d, J = 9.35 Hz, 1 H), 3.49 (dd, J =9.35, 2.02 Hz, 1 H), 3.72 (s, 1 H), 4.35 (d, J = 5.05 Hz, 2 H), 4.70 (s,1 H), 4.83 (quin, J = 6.63 Hz, 1 H), 5.87 (s, 1 H), 6.56 (d, J = 8.84Hz, 1 H), 7.16 (d, J = 1.52 Hz, 1 H), 7.27 (s, 1 H), 7.68 (d, J = 1.26Hz, 1 H), 7.87 (dd, J = 8.84, 2.53 Hz, 1 H), 8.14 (t, J = 4.93 Hz, 1 H),8.44 (d, J = 2.27 Hz, 1H) 525.7 344

N-[(4,6-dimethyl-2- oxo-1,2-dihydro-3- pyridinyl)methyl]-6-{6-[(2S,5S)-2,5- dimethyl-1- piperazinyl]-3- pyridinyl}-3-methyl-1-(1-methylethyl)- 1H-indole-4- carboxamide 1.10 (m, 6 H), 1.43 (d, J =6.82 Hz, 6 H), 2.11 (s, 3 H), 2.14- 2.19 (m, 3 H), 2.24 (s, 3 H),2.61-2.74 (m, 1 H), 2.79- 2.96 (m, 2 H), 3.93-4.04 (m, 1 H), 4.35 (d, J= 5.05 Hz, 3 H), 4.76-4.90 (m, 1 H), 5.87 (s, 1 H), 6.82 (d, J = 8.84Hz, 1 H), 7.17 (d, J = 1.52 Hz, 1 H), 7.28 (s, 1 H), 7.70 (d, J = 1.26Hz, 1 H), 7.89 (dd, J = 8.84, 2.53 Hz, 1 H), 8.14 (t, J = 5.05 Hz, 1 H),8.49 (d, J = 2.53 Hz, 1 H) 541.6 345

6-[6-(3,8- diazabicyclo[3.2.1] oct-3-yl)-3-pyridinyl]-N-[(4,6-dimethyl-2- oxo-1,2-dihydro-3- pyridinyl)methyl]-3- methyl-1-(1-methylethyl)-1H- indole-4- carboxamide 1.38-1.48 (m, 6 H), 1.60- 1.74(m, 4 H), 2.11 (s, 3 H), 2.16 (s, 3 H), 2.24 (s, 3 H), 2.79-2.95 (m, 2H), 3.35 (d, J = 1.26 Hz, 5 H), 3.54 (br.s., 2 H), 3.83-3.91 (m, 2 H),4.35 (d, J = 5.05 Hz, 2 H), 4.83 (quin, J = 6.57 Hz, 1 H), 5.87 (s, 1H), 6.75 (d, J = 8.84 Hz, 1 H), 7.17 (d, J = 1.52 Hz, 1 H), 7.28 (s, 1H), 7.70 (d, J = 1.26 Hz, 1 H), 7.89 (dd, J = 8.84, 2.53 Hz, 1 H), 8.15(t, J = 5.05 Hz, 1 H), 8.45-8.51 (m, 1 H) 539.6 346

N-((4,6-dimethyl-2- oxo-1,2- dihydropyridin-3- yl)methyl)-6-(6-((2R,5R)-2,5- dimethylpiperazin-1- yl)pyridin-3-yl)-1-isopropyl-3-methyl- 1H-indole-4- carboxamide (METHANOL-d4)1.25 (d, 3 H),1.31 (d, J = 6.32 Hz, 3 H), 1.49 (d, J = 6.57 Hz, 6 H), 2.23 (d, J =10.11 Hz, 6 H), 2.43 (s, 3 H), 2.81 (dd, J = 13.39, 11.37 Hz, 1 H),2.92-3.28 (m, 3 H), 4.16 (dd, J = 13.52, 3.16 Hz, 1 H), 4.62 (br.s., 1H), 4.80 (quin, J = 6.69 Hz, 1 H), 6.12 (s, 1 H), 6.90 (d, J = 8.84 Hz,1 H), 7.20 (s, 1 H), 7.27 (d, J = 1.52 Hz, 1 H), 7.63 (d, J = 1.26 Hz, 1H), 7.92 (dd, J = 8.84, 2.53 Hz, 1 H), 8.44 (d, J = 2.27 Hz, 1 H) 541.3

Example 347N-((4,6-Dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-3-methyl-6-(6-(pyrrolidin-1-ylmethyl)pyridin-3-yl)-1H-indole-4-carboxamide

To a solution ofN-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-6-(6-formylpyridin-3-yl)-1-isopropyl-3-methyl-1H-indole-4-carboxamide(100 mg, 0.219 mmol), in DCM (10 mL) and methanol (2 mL) was addedpyrrolidine (0.035 mL, 0.438 mmol), followed by sodium sulfate (31.1 mg,0.219 mmol). The reaction stirred at rt for 12 h, at which time sodiumborohydride (16.57 mg, 0.438 mmol) was added and the reaction stirred rtfor 2 h and 45° C. for 2 h. The reaction was quenched with water andextracted with EtOAc. The organic layer was evaporated. Purification byreverse phase Gilson HPLC (10-60% acetonitrile/water+0.1% TFA, YMC ODS-AC18 Column 75×30 mm ID S-5 um, 12 nM Column 7 minutes), followed byisolation and extraction with EtOAc/0.1 N NaOH providedN-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-3-methyl-6-(6-(pyrrolidin-1-ylmethyl)pyridin-3-yl)-1H-indole-4-carboxamide,which was evaporated from the organic layer as a yellow foam solid (68mg, 0.125 mmol, 57.0% yield). ¹H NMR (400 MHz, DMSO-d₆) δ ppm 11.48 (br.s., 1H) 9.06 (d, J=2.02 Hz, 1H) 8.30 (dd, J=8.08, 2.27 Hz, 1H) 8.20 (t,J=5.18 Hz, 1H) 7.94 (d, J=1.26 Hz, 1H) 7.60 (d, J=8.08 Hz, 1H) 7.40 (s,1H) 7.32 (s, 1H) 5.88 (s, 1H) 4.92-4.89 (m, 1H) 4.59 (d, J=5.56 Hz, 2H)4.36 (d, J=5.05 Hz, 2H) 3.34 (br. s., 4H) 2.25 (s, 3H) 2.17 (d, J=1.01Hz, 3H) 2.11 (s, 3H) 1.99 (br. s., 4H) 1.45 (d, J=6.57 Hz, 6H). LCMS:[M+H]⁺=512.3.

Examples 348-350 were prepared by the methods described above forExample 347, or routine variations thereof, using the requisite amine:

¹H NMR (400 MHz, DMSO-d₆) δ MS(ES) EZH2 Ex Structure Name ppm [M + H]⁺pIC50 348

6-(6-{[(2R,6S)-2,6- dimethyl-4- morpholinyl]methyl}-3-pyridinyl)-N-[(4,6- dimethyl-2-oxo-1,2- dihydro-3-pyridinyl)methyl]-3- methyl-1-(1- methylethyl)-1H- indole-4- carboxamide11.48 (br.s., 1 H) 9.09 (d, J = 2.02 Hz, 1 H) 8.32 (dd, J = 8.08, 2.27Hz, 1 H) 8.19 (t, J = 5.05 Hz, 1 H) 7.94 (d, J = 1.26 Hz, 1 H) 7.62 (d,J = 8.08 Hz, 1 H) 7.41 (s, 1 H) 7.33 (d, J = 1.52 Hz, 1 H) 5.88 (s, 1 H)4.87-4.94 (m, 1 H) 4.52 (br.s., 2 H) 4.36 (d, J = 4.80 Hz, 2 H) 3.87-3.96 (m, 2 H) 3.35-3.45 (m, 2 H) 2.75-2.85 (m, 2 H) 2.25 (s, 3 H) 2.17(s, 3 H) 2.11 (s, 3 H) 1.45 (d, J = 6.57 Hz, 6 H) 1.14 (d, J = 6.06 Hz,6 H) 556.4 7.44 349

N-[(4,6-dimethyl-2- oxo-1,2-dihydro-3- pyridinyl)methyl]-3- methyl-1-(1-methylethyl)-6-{6- [(4-methyl-1- piperazinyl)methyl]- 3-pyridinyl}-1H-indole-4- carboxamide 11.50 (br.s., 1 H) 9.03 (d, J = 2.02 Hz, 1 H) 8.37(dd, J = 8.08, 2.02 Hz, 1 H) 8.21 (t, J = 5.05 Hz, 1 H) 7.93 (d, J =1.26 Hz, 1 H) 7.65 (d, J = 8.08 Hz, 1 H) 7.41 (s, 1 H) 7.32 (d, J = 1.52Hz, 1 H) 5.88 (s, 1 H) 4.90 (quin, J = 6.63 Hz, 1 H) 4.36 (d, J = 5.05Hz, 2 H) 4.08 (br.s., 2 H) 3.07-3.56 (m, 8 H) 2.83 (s, 3 H) 2.24-2.28(m, 3 H) 2.17 (s, 3 H) 2.12 (s, 3 H) 1.45 (d, J = 6.57 Hz, 6 H) 541.37.6 350

N-[(4,6-dimethyl-2- oxo-1,2-dihydro-3- pyridinyl)methyl]-3- methyl-1-(1-methylethyl)-6-[6-(4- morpholinylmethyl)- 3-pyridinyl]-1H- indole-4-carboxamide 11.49 (br.s., 1 H) 8.88 (d, J = 2.02 Hz, 1 H) 8.21 (t, J =4.93 Hz, 1 H) 8.12 (dd, J = 8.08, 2.27 Hz, 1 H) 7.86 (d, J = 1.26 Hz, 1H) 7.51 (d, J = 8.08 Hz, 1 H) 7.36 (s, 1 H) 7.27 (d, J = 1.52 Hz, 1 H)5.87 (s, 1 H) 4.85-4.93 (m, 1 H) 4.36 (d, J = 4.80 Hz, 2 H) 3.62 (dd, J= 9.47, 4.93 Hz, 6 H) 2.45 (br.s., 4 H) 2.24 (s, 3 H) 2.18 (s, 3 H) 2.11(s, 3 H) 1.44 (d, J = 6.57 Hz, 6 H) 528.3 7.64

Example 3516-Bromo-N-((6-(hydroxymethyl)-4-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-3-methyl-1H-indole-4-carboxamide

a)6-Bromo-N-((6-(hydroxymethyl)-2-methoxy-4-methylpyridin-3-yl)methyl)-1-isopropyl-3-methyl-1H-indole-4-carboxamide

To a stirred solution of(5-(aminomethyl)-6-methoxy-4-methylpyridin-2-yl)methanol (0.29 g, 1.591mmol), 6-bromo-1-isopropyl-3-methyl-1H-indole-4-carboxylic acid (0.48 g,1.621 mmol), and HOAt (0.22 g, 1.616 mmol) in Dichloromethane (15 mL)and DMF (5 mL) was added EDC free base (0.30 g, 1.932 mmol). Thereaction was stirred at RT for 3 h then evaporated to dryness undervacuum. The remaining was purified by silica gel chromatography(Analogix, SF25-60 g, 0 to 20% EtOAc in CH₂Cl₂) to give the product6-bromo-N-((6-(hydroxymethyl)-2-methoxy-4-methylpyridin-3-yl)methyl)-1-isopropyl-3-methyl-1H-indole-4-carboxamide(0.73 g, 1.586 mmol, 100% yield) as a white solid. ¹H NMR (400 MHz,DMSO-d₆) δ=8.46 (t, J=4.9 Hz, 1H), 7.77 (d, J=1.8 Hz, 1H), 7.33 (d,J=1.0 Hz, 1H), 6.99 (d, J=1.5 Hz, 1H), 6.90 (s, 1H), 5.31 (t, J=5.9 Hz,1H), 4.74 (quin, J=6.6 Hz, 1H), 4.45 (d, J=5.1 Hz, 1H), 4.43 (d, J=5.8Hz, 2H), 3.83 (s, 3H), 2.40 (s, 3H), 2.10 (s, 3H), 1.38 (d, J=6.8 Hz,6H). MS(ES)+ m/e 460.2 [M+H]⁺.

b)6-Bromo-N-((6-(hydroxymethyl)-4-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-3-methyl-1H-indole-4-carboxamide

To a stirred solution of6-bromo-N-((6-(hydroxymethyl)-2-methoxy-4-methylpyridin-3-yl)methyl)-1-isopropyl-3-methyl-1H-indole-4-carboxamide(500 mg, 1.086 mmol) in tetrahydrofuran (5 mL) was added 6 N HCl (15 mL,15.00 mmol). The reaction was stirred under N₂ with heating at 80° C.for 18 hr. The reaction was cooled to RT and evaporated to dryness undervacuum. The remaining was purified by silica gel chromatography(Analogix, SF25-60 g, 4% MeOH in CH₂Cl₂). The pure fractions werecombined and evaporated to dryness under vacuum. Triturated with a smallvolume of water, filtered, washed with water and dried under vacuum togive the product6-bromo-N-((6-(hydroxymethyl)-4-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-3-methyl-1H-indole-4-carboxamide(189 mg, 0.423 mmol, 39.0% yield) as a white solid. ¹H NMR (400 MHz,DMSO-d₆) δ=11.30 (s, 1H), 8.27 (t, J=4.9 Hz, 1H), 7.76 (d, J=1.8 Hz,1H), 7.33 (s, 1H), 7.01 (d, J=1.8 Hz, 1H), 6.05 (s, 1H), 5.38 (t, J=5.9Hz, 1H), 4.74 (dt, J=6.7, 13.2 Hz, 1H), 4.32 (d, J=5.1 Hz, 2H), 4.25 (d,J=5.8 Hz, 2H), 2.26 (s, 3H), 2.13 (s, 3H), 1.39 (d, J=6.6 Hz, 6H).MS(ES)+ m/e 446.1 [M+H]⁺.

Example 352N-((6-(aminomethyl)-4-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-6-bromo-1-isopropyl-3-methyl-1H-indole-4-carboxamidE

a) tert-Butyl((5-((6-bromo-1-isopropyl-3-methyl-1H-indole-4-carboxamido)methyl)-6-methoxy-4-methylpyridin-2-yl)methyl)carbamate

To a stirred solution of tert-butyl((5-(aminomethyl)-6-methoxy-4-methylpyridin-2-yl)methyl)carbamate (0.55g, 1.955 mmol), 6-bromo-1-isopropyl-3-methyl-1H-indole-4-carboxylic acid(0.63 g, 2.127 mmol), and HOAt (0.27 g, 1.984 mmol) in Dichloromethane(20 mL) and DMF (5 mL) was added EDC free base (0.34 g, 2.190 mmol). Thereaction was stirred at RT for 2 hr then evaporated to dryness undervacuum. The remaining was purified by silica gel chromatography(Analogix, SF25-60 g, 0 to 40% EtOAc in hexanes) to give the producttert-butyl((5-((6-bromo-1-isopropyl-3-methyl-1H-indole-4-carboxamido)methyl)-6-methoxy-4-methylpyridin-2-yl)methyl)carbamate(1.07 g, 1.912 mmol, 98% yield) as a white solid. ¹H NMR (400 MHz,DMSO-d₆) δ=8.47 (t, J=4.8 Hz, 1H), 7.76 (d, J=1.8 Hz, 1H), 7.35 (t, 1H),7.33 (d, J=1.0 Hz, 1H), 6.99 (d, J=1.5 Hz, 1H), 6.67 (s, 1H), 4.74(quin, J=6.6 Hz, 1H), 4.44 (d, J=4.8 Hz, 2H), 4.08 (d, J=6.3 Hz, 2H),3.85 (s, 3H), 2.37 (s, 3H), 2.10 (s, 3H), 1.41 (s, 9H), 1.38 (d, J=6.6Hz, 6H). MS(ES)+ m/e 559.3 [M+H]⁺.

b)N-((6-(Aminomethyl)-4-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-6-bromo-1-isopropyl-3-methyl-1H-indole-4-carboxamide

To a stirred solution of tert-butyl((5-((6-bromo-1-isopropyl-3-methyl-1H-indole-4-carboxamido)methyl)-6-methoxy-4-methylpyridin-2-yl)methyl)carbamate(500 mg, 0.894 mmol) in Tetrahydrofuran (THF) (5 mL) was added 6N HCl(15 mL, 15.00 mmol). The reaction was stirred under N2 with heating at80° C. for 18 hr. The reaction was cooled to RT and evaporated todryness under vacuum. The remaining was purified by silica gelchromatography (Analogix, SF25-40 g, 0 to 10% (5% NH4OH in MeOH) inCH2Cl2). The pure fractions were combined and evaporated to drynessunder vacuum. Dissolved with a small volume of CH2Cl2, scratched out byslowly adding hexanes, filtered, washed with hexanes and dried undervacuum to give the productN-((6-(aminomethyl)-4-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-6-bromo-1-isopropyl-3-methyl-1H-indole-4-carboxamide(328 mg, 0.736 mmol, 82% yield) as an off-white solid. ¹H NMR (400 MHz,DMSO-d₆) δ=8.26 (t, J=5.1 Hz, 1H), 7.76 (d, J=1.8 Hz, 1H), 7.33 (d,J=1.0 Hz, 1H), 7.01 (d, J=1.5 Hz, 1H), 6.01 (s, 1H), 5.77 (s, 0H), 4.74(quin, J=6.6 Hz, 1H), 4.32 (d, J=5.1 Hz, 2H), 3.46 (s, 2H), 2.25 (s,3H), 2.14 (s, 3H), 1.39 (d, J=6.8 Hz, 6H). MS(ES)+ m/e 445.2 [M+H]⁺.

Example 3533-Methyl-1-(1-methylethyl)-4-({[(6-methyl-2-oxo-4-propyl-1,2-dihydro-3-pyridinyl)methyl]amino}carbonyl)-1H-indole-6-carboxylicacid

To a 5 ml microwave vial was added,6-cyano-3-methyl-1-(1-methylethyl)-N-[(6-methyl-2-oxo-4-propyl-1,2-dihydro-3-pyridinyl)methyl]-1H-indole-4-carboxamide(100 mg, 0.247 mmol), KOH (41.6 mg, 0.742 mmol) was ground and addedfollowed by Ethanol (8 mL) the reaction was microwaved at 145° C. for 22hr. The reaction was poured onto acidic Ice water (20 mL) and wasstirred for 20 min. EtOAc was added and the mix was stirred anadditional 10 min. The layers were separated and the majority of theproduct was in the EtOAc which was evaporated. The residue was dissolvedin MeOH (1 mL) and material was crashed out with ice and was filtered togive product3-methyl-1-(1-methylethyl)-4-({[(6-methyl-2-oxo-4-propyl-1,2-dihydro-3-pyridinyl)methyl]amino}carbonyl)-1H-indole-6-carboxylicacid (70 mg, 0.160 mmol, 64.9% yield)¹H NMR (400 MHz, DMSO-d₆) δ ppm11.49 (br. s., 1H) 8.18 (s, 1H) 8.10 (s, 1H) 7.53 (d, J=7.58 Hz, 2H)5.90 (s, 1H) 4.76-4.90 (m, 1H) 4.36 (d, J=4.80 Hz, 2H) 2.55 (br. s., 1H)2.18 (s, 3H) 2.13 (s, 3H) 1.52-1.61 (m, 2H) 1.44 (d, J=6.57 Hz, 6H) 0.94(t, J=7.33 Hz, 3H) MS(ES) [M+H]⁺ 423.8

Example 3543-[3-Methyl-1-(1-methylethyl)-4-({[(6-methyl-2-oxo-4-propyl-1,2-dihydro-3-pyridinyl)methyl]amino}carbonyl)-1H-indol-6-yl]propanoicacid

a) Ethyl(2E)-3-[3-methyl-1-(1-methylethyl)-4-({[(6-methyl-2-oxo-4-propyl-1,2-dihydro-3-pyridinyl)methyl]amino}carbonyl)-1H-indol-6-yl]-2-propenoate

Following the general procedure detailed above for Suzukicross-couplings (see Example 2), ethyl(2E)-3-[3-methyl-1-(1-methylethyl)-4-({[(6-methyl-2-oxo-4-propyl-1,2-dihydro-3-pyridinyl)methyl]amino}carbonyl)-1H-indol-6-yl]-2-propenoate(120 mg, 0.234 mmol, 53.6% yield) was prepared. ¹H NMR (400 MHz,DMSO-d₆) δ ppm 11.49 (s, 1H) 8.12 (t, J=4.93 Hz, 1H) 7.97 (d, J=1.01 Hz,1H) 7.74 (d, J=15.92 Hz, 1H) 7.43 (s, 1H) 7.27 (d, J=1.26 Hz, 1H) 6.61(d, J=15.92 Hz, 1H) 5.90 (s, 1H) 4.78-4.86 (m, 1H) 4.35 (d, J=5.05 Hz,2H) 4.19 (q, J=7.07 Hz, 2H) 2.53-2.58 (m, 2H) 2.14 (d, J=11.12 Hz, 6H)1.53-1.62 (m, 2H) 1.43 (d, J=6.82 Hz, 6H) 1.27 (t, J=7.07 Hz, 3H)0.93-0.97 (m, 3H). MS(ES) [M+H]⁺ 477.9

b) Ethyl3-[3-methyl-1-(1-methylethyl)-4-({[(6-methyl-2-oxo-4-propyl-1,2-dihydro-3-pyridinyl)methyl]amino}carbonyl)-1H-indol-6-yl]propanoate

In a 50 ml flask was added ethyl(2E)-3-[3-methyl-1-(1-methylethyl)-4-({[(6-methyl-2-oxo-4-propyl-1,2-dihydro-3-pyridinyl)methyl]amino}carbonyl)-1H-indol-6-yl]-2-propenoate(120 mg, 0.251 mmol), and Ethanol (10 mL). PdOH2 (70.6 mg, 0.503 mmol)was added and the reaction was degassed with N2 for 15 min then H2 wasbubbled in (via balloon) and the reaction stirred for 12 hr. Thereaction was purged with N2 for 30 min and then filtered through an acrodisc and evaporated. The residue was suspended in MeOH/Water (2 mL/4 mL)and filtered and washed with water to give a white solid. ethyl3-[3-methyl-1-(1-methylethyl)-4-({[(6-methyl-2-oxo-4-propyl-1,2-dihydro-3-pyridinyl)methyl]amino}carbonyl)-1H-indol-6-yl]propanoate(70 mg, 0.146 mmol, 58.1% yield). ¹H NMR (400 MHz, DMSO-d₆) δ ppm 11.49(br. s., 1H) 7.90 (br. s., 1H) 7.34 (s, 1H) 7.21 (s, 1H) 6.82 (s, 1H)5.90 (s, 1H) 4.63-4.73 (m, 1H) 4.34 (d, J=4.55 Hz, 2H) 4.04 (q, J=7.07Hz, 2H) 2.92 (t, J=7.33 Hz, 2H) 2.64 (t, J=7.45 Hz, 2H) 2.55-2.62 (m,2H) 2.12 (s, 6H) 1.52-1.62 (m, 2H) 1.40 (d, J=6.32 Hz, 6H) 1.16 (t,J=7.07 Hz, 3H) 0.94 (t, J=7.20 Hz, 3H). MS(ES) [M+H]⁺ 479.8.

c)3-[3-Methyl-1-(1-methylethyl)-4-({[(6-methyl-2-oxo-4-propyl-1,2-dihydro-3-pyridinyl)methyl]amino}carbonyl)-1H-indol-6-yl]propanoicacid

Following the general procedure detailed above for Suzukicross-couplings (see Example 2),3-[3-methyl-1-(1-methylethyl)-4-({[(6-methyl-2-oxo-4-propyl-1,2-dihydro-3-pyridinyl)methyl]amino}carbonyl)-1H-indol-6-yl]propanoicacid (45 mg, 0.095 mmol, 64.9% yield) was prepared. ¹H NMR (400 MHz,DMSO-d₆) δ ppm 12.05 (br. s, 1H) 11.49 (br. s., 1H) 7.88-7.95 (m, 1H)7.34 (s, 1H) 7.20 (s, 1H) 6.82 (s, 1H) 5.90 (s, 1H) 4.64-4.73 (m, 1H)4.34 (d, J=4.80 Hz, 2H) 2.89 (t, J=7.71 Hz, 2H) 2.55-2.60 (m, 4H) 2.12(s, 6H) 1.53-1.61 (m, 2H) 1.40 (d, J=6.57 Hz, 6H) 0.92-0.96 (m, 3H).MS(ES) [M+H]⁺ 451.9.

Example 3556-(2-Aminoethyl)-N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-3-methyl-1-(1-methylethyl)-1H-indole-4-carboxamide

a)6-[2-({[(1,1-Dimethylethyl)oxy]carbonyl}amino)ethyl]-3-methyl-1-(1-methylethyl)-1H-indole-4-carboxylicacid

In a glass pressure bottle was added methyl6-bromo-3-methyl-1-(1-methylethyl)-1H-indole-4-carboxylate (1.00 g, 2.77mmol), potassium t-butyl-N-[2-(trifluoroboranuidyl)ethyl]carbamate (900mg, 3.58 mmol), cesium carbonate (3.2 g, 9.82 mmol), toluene (24 mL) andwater (8 mL). The mixture was stirred and purged with N2. To thereaction was added palladium(II) acetate (40 mg, 0.178 mmol) and RuPhos(160 mg, 0.342 mmol), the reaction capped and stirred at 95° C. for 18hr. LCMS showed that the reaction was complete. The reaction was takenup in EtOAc, diluted with water, and filtered to remove insolubles. Theorganic phase was removed, dried (MgSO4), filtered and concentratedunder vacuum. Purification by silica gel chromatography (Analogix,SF25-60 g, 0 to 20% EtOAc in hexanes gave the methyl ester.

To the ester in THF (10 mL) and MeOH (30 mL) was added 1 N NaOH (10 mL,10 mmol). The solution was stirred at reflux 80° C. for 24 hr (slowsaponification). After cooling to RT the reaction was concentrated undervacuum, neutralized with 1 N HCl (10 mL), triturated with water,filtered and dried under vacuum to give the product6-[2-({[(1,1-dimethylethyl)oxy]carbonyl}amino)ethyl]-3-methyl-1-(1-methylethyl)-1H-indole-4-carboxylicacid (865 mg, 2.31 mmol, 83.0% yield) as a white solid. ¹H NMR (400 MHz,DMSO-d₆) δ 12.69 (br. s., 1H), 7.43 (s, 1H), 7.31 (s, 1H), 7.25 (s, 1H),6.89 (t, J=5.6 Hz, 1H), 4.71 (dt, J=6.6, 13.3 Hz, 1H), 3.23-3.10 (m,2H), 2.80 (t, J=7.3 Hz, 2H), 2.30 (s, 3H), 1.42 (d, J=6.6 Hz, 6H), 1.37(s, 9H). MS(ES)+ m/e 361.2 [M+H]⁺.

b)6-(2-Aminoethyl)-N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-3-methyl-1-(1-methylethyl)-1H-indole-4-carboxamidehydrochloride salt

To a stirred suspension of6-[2-({[(1,1-dimethylethyl)oxy]carbonyl}amino)ethyl]-3-methyl-1-(1-methylethyl)-1H-indole-4-carboxylicacid (500 mg, 1.387 mmol), 3-(aminomethyl)-4,6-dimethyl-2(1H)-pyridinoneHCl salt (340 mg, 1.802 mmol), HOAt (245 mg, 1.800 mmol) in DMF (20 mL)was added N-methylmorpholine (200 μL, 1.819 mmol) and EDC free base (280mg, 1.804 mmol). The reaction was stirred overnight at RT. LCMS showedthat the reaction was complete. The reaction was evaporated to drynessand purified by silica gel chromatography (Analogix, SF25-40 g, 0 to 10%CH₂Cl₂/20%(5% NH₄OH in MeOH) in CH₂Cl₂). The pure fractions werecombined and evaporated to dryness. Triturated with 50% MeOH in water,filtered and dried under vacuum to give the Boc protected product as anoff-white solid. The Boc protected product was suspended in a smallvolume of MeOH (2 mL) and treated with 4 N HCl in dioxane (25 mL) andstirred at RT for 1 hr. LCMS showed that the reaction was complete. Thereaction was evaporated to dryness, triturated with Et₂O, filtered anddried under vacuum to give the product6-(2-aminoethyl)-N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-3-methyl-1-(1-methylethyl)-1H-indole-4-carboxamide(460 mg, 1.067 mmol, 77% yield) as an off-white solid. ¹H NMR (400 MHz,DMSO-d₆+D₂O) δ 8.05 (t, J=5.2 Hz, 1H), 8.00 (br. s., 2H), 7.39 (d, J=1.0Hz, 1H), 7.25 (s, 1H), 6.86 (d, J=1.3 Hz, 1H), 5.93 (s, 1H), 4.69 (dt,J=6.6, 13.3 Hz, 1H), 4.34 (d, J=5.1 Hz, 2H), 3.06 (dd, J=5.8, 7.6 Hz,2H), 3.01-2.91 (m, 2H), 2.25 (s, 3H), 2.13 (s, 3H), 2.12 (s, 3H), 1.41(d, J=6.8 Hz, 6H). MS(ES)+ m/e 394.9 [M+H]⁺.

Example 3566-{3-[(Dimethylamino)methyl]-4-fluorophenyl}-N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-3-methyl-1-(1-methylethyl)-1H-indole-4-carboxamide

a) Methyl6-(4-fluoro-3-formylphenyl)-3-methyl-1-(1-methylethyl)-1H-indole-4-carboxylate

To a glass pressure vessel was added methyl6-bromo-3-methyl-1-(1-methylethyl)-1H-indole-4-carboxylate (500 mg,1.612 mmol), 4-fluoro-3-formylbenzeneboronic acid (375 mg, 2.233 mmol),Potassium phosphate (1.1 g, 5.18 mmol), dioxane (12 mL) and water (3mL). The reaction was purged with N₂ and charged with PdCl₂(dppf)-CH₂Cl₂adduct (120 mg, 0.147 mmol). The reaction was capped and stirred at 110°C. for 4 hr. LCMS showed that the reaction was complete. The reactionwas diluted with water, extracted with EtOAc, washed with brine, dried(MgSO₄), filtered, and concentrated under vacuum. Purification by silicagel chromatography (Analogix, SF25-60 g, 0 to 50% EtOAc in hexanes) gavethe product methyl6-(4-fluoro-3-formylphenyl)-3-methyl-1-(1-methylethyl)-1H-indole-4-carboxylate(560 mg, 1.585 mmol, 98% yield) as an off-white solid. ¹H NMR (400 MHz,DMSO-d₆) δ=10.30 (s, 1H), 8.24-8.13 (m, 2H), 8.10 (d, J=1.5 Hz, 1H),7.75 (d, J=1.8 Hz, 1H), 7.57-7.46 (m, 2H), 4.98 (quin, J=6.6 Hz, 1H),3.91 (s, 3H), 2.31 (s, 3H), 1.46 (d, J=6.6 Hz, 6H). MS(ES)+ m/e 354.2[M+H]⁺.

b)6-{3-[(Dimethylamino)methyl]-4-fluorophenyl}-3-methyl-1-(1-methylethyl)-1H-indole-4-carboxylicacid

To a stirred solution of methyl6-(4-fluoro-3-formylphenyl)-3-methyl-1-(1-methylethyl)-1H-indole-4-carboxylate(550 mg, 1.556 mmol) in CH₂Cl₂ (25 mL) was added 2N dimethylamine in THF(3.0 mL, 6.00 mmol) and acetic acid (170 μL, 2.97 mmol). After stirringat RT for 1 hr sodium triacetoxyborohydride (1.0 g, 4.72 mmol) was addedportionwise over 10 minutes. The reaction was stirred at RT overnight.LCMS showed the product as well as a substantial amount of the alcoholand one unidentifiable side product. The reaction was purified by silicagel chromatography (Analogix, SF25-60 g, 0 to 50% CH₂Cl₂/20%(5% NH₄OH inMeOH) in CH₂Cl₂). The last fraction contained the desired product andwas combined and evaporated to dryness. Trituration with hexanes,filtration and drying under vacuum gave the methyl ester product (0.25g, 0.65 mMol, 41%) as an off-white solid.

The ester was taken up in THF (15 mL) and MeOH (5 mL) and treated with 1N NaOH (4 mL). The reaction was refluxed (80° C. oil bath) overnight.LCMS showed that the reaction was complete. The reaction was cooled toRT and concentrated under vacuum. Neutralization with 1 N HCl (4 mL)ppt. out the product, which was triturated with a small amount of coldwater, filtered, and dried under vacuum to give the product6-{3-[(dimethylamino)methyl]-4-fluorophenyl}-3-methyl-1-(1-methylethyl)-1H-indole-4-carboxylicacid (210 mg, 0.570 mmol, 36.6% yield) as a white solid. ¹H NMR (400MHz, DMSO-d₆) δ=12.84 (br. s., 1H), 10.80 (br. s., 1H), 8.18 (dd, J=2.0,7.1 Hz, 1H), 8.12 (s, 1H), 8.01-7.85 (m, 1H), 7.76 (d, J=1.3 Hz, 1H),7.49 (s, 1H), 7.43 (t, J=9.1 Hz, 1H), 4.95 (dt, J=6.6, 13.1 Hz, 1H),4.43 (br. s., 2H), 2.80 (s, 6H), 2.34 (s, 3H), 1.46 (d, J=6.6 Hz, 6H).MS(ES)+ m/e 369.0 [M+H]⁺.

c)6-{3-[(Dimethylamino)methyl]-4-fluorophenyl}-N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-3-methyl-1-(1-methylethyl)-1H-indole-4-carboxamide

To a stirred suspension of6-{3-[(dimethylamino)methyl]-4-fluorophenyl}-3-methyl-1-(1-methylethyl)-1H-indole-4-carboxylicacid (210 mg, 0.570 mmol), 3-(aminomethyl)-4,6-dimethyl-2(1H)-pyridinoneHCl salt (140 mg, 0.742 mmol) and HOAt (100 mg, 0.735 mmol) in DMF (15mL) was added N-methylmorpholine (82 μl, 0.746 mmol) and EDC free base(110 mg, 0.709 mmol). The reaction was stirred for 4 h at RT andconcentrated to near dryness under vacuum. Water was added till theproduct ppt. out. The suspension was triturated, filtered, rinsed withcold water then dried under vacuum to give the product6-{3-[(dimethylamino)methyl]-4-fluorophenyl}-N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-3-methyl-1-(1-methylethyl)-1H-indole-4-carboxamide(186 mg, 0.370 mmol, 64.9% yield) as a light tan solid. ¹H NMR (400 MHz,DMSO-d₆) δ=11.47 (br. s., 1H), 8.15 (t, J=4.9 Hz, 1H), 8.04 (d, J=5.3Hz, 1H), 7.90-7.86 (m, 1H), 7.39 (t, J=9.2 Hz, 1H), 7.35 (s, 1H), 7.27(d, J=1.3 Hz, 1H), 5.87 (s, 1H), 4.88 (dt, J=6.6, 13.3 Hz, 1H), 4.36 (d,J=5.1 Hz, 2H), 4.26 (br. s., 2H), 2.69 (s, 6H), 2.24 (s, 3H), 2.17 (s,3H), 2.11 (s, 3H), 1.44 (d, J=6.6 Hz, 6H). MS(ES)+ m/e 503.0 [M+H]⁺.

Example 3576-(4,5-Dihydro-1H-imidazol-2-yl)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-3-methyl-1H-indole-4-carboxamide

To a 10-mL microwave tube were added6-cyano-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-3-methyl-1H-indole-4-carboxamide(33 mg, 0.088 mmol), ethylenediamine (1 mL, 14.81 mmol), and phosphoruspentasulfide (0.585 mg, 2.63 μmol), and the mixture was degassed for 5min. The tube was sealed and the mixture was heated at 120° C. in amicrowave. The mixture was concentrated and the residue was purifiedusing reverse-phase HPLC under acidic conditions to give 32 mg ofproduct as off-white solid. ¹H NMR (400 MHz, DMSO-d₆) ppm 1.46 (m, 6H),2.11 (s, 3H), 2.17 (s, 3H), 2.24 (s, 3H), 4.35 (d, J=5.05 Hz, 2H), 4.75(quin, J=6.69 Hz, 1H), 5.87 (s, 1H), 7.49-7.60 (m, 2H), 8.16-8.26 (m,2H), 8.39 (s, 1H). MS: (M+H)⁺=419.9.

Examples 358-366 were prepared following the general methods describedabove and/or well established synthetic procedures:

¹H NMR (400 MHz, DMSO-d₆) δ MS(ES) EZH2 Ex Structure Name ppm [M + H]⁺pIC50 358

[4-({[(4,6-dimethyl-2- oxo-1,2-dihydro-3- pyridinyl)methyl]amino}carbonyl)-3- methyl-1-(1- methylethyl)-1H- indol-6-yl]boronic acid11.48 (br.s., 1H), 8.04 (s, 2H), 7.95 (s, 1 H), 7.88 (t, J = 5.05 Hz,1H), 7.40 (s, 1H), 7.31 (s, 1H), 5.87 (s, 1H), 4.64-4.76 (m, 1H), 4.34(d, J = 5.05 Hz, 2H), 2.23 (s, 3H), 2.15 (s, 3H), 2.11 (s, 3H), 1.44 (d,J = 6.57 Hz, 6H) 396.3 6.33 359

N-[(4,6-dimethyl-2- oxo-1,2-dihydro-3- pyridinyl)methyl]-6-[6-(hydroxymethyl)- 3-pyridinyl]-3- methyl-1-(1- methylethyl)-1H-indole-4- carboxamide 11.51 (br.s., 1 H) 9.01 (br.s., 1 H) 8.55 (br.s.,1 H) 8.23 (t, J = 5.18 Hz, 1 H) 7.99 (s, 1 H) 7.79 (d, J = 8.08 Hz, 1 H)7.41 (s, 1 H) 7.35 (d, J = 1.26 Hz, 1 H) 5.88 (s, 1 H) 4.86- 4.98 (m, 1H) 4.76 (s, 2 H) 4.36 (d, J = 5.05 Hz, 2 H) 2.25 (s, 3 H) 2.17 (s, 3 H)2.11 (s, 3 H) 1.45 (d, J = 6.57 Hz, 6 H) 459.1 7.23 360

N-[(4,6-dimethyl-2- oxo-1,2-dihydro-3- pyridinyl)methyl]-3- methyl-1-(1-methylethyl)-6-(3- oxetanyl)-1H-indole- 4-carboxamide 1.41 (d, J = 6.57Hz, 6 H), 2.11 (s, 3 H), 2.14 (s, 3 H), 2.23 (s, 3 H), 4.30- 4.39 (m, 3H), 4.67-4.81 (m, 3 H), 4.96 (dd, J = 8.46, 5.68 Hz, 2 H), 5.87 (s, 1H), 7.03 (d, J = 1.26 Hz, 1 H), 7.25 (d, J = 1.01 Hz, 1 H), 7.48 (d, J =1.26 Hz, 1 H), 8.05 (t, J = 5.05 Hz, 1 H), 11.47 (br.s., 1 H). 408 6.54361

N-[(4,6-dimethyl-2- oxo-1,2-dihydro-3- pyridinyl)methyl]-3- methyl-1-(1-methylethyl)-6-{[6- (4-methyl-1- piperazinyl)-3- pyridinyl]amino}-1H-indole-4- carboxamide 1.36 (m, 6 H), 2.08 (s, 3 H), 2.11 (s, 3 H), 2.21(s, 3 H), 2.24 (s, 3 H), 2.40- 2.47 (m, 4 H), 3.33-3.42 (m, 4 H), 4.30(d, J = 5.05 Hz, 2 H), 4.47 (quin, J = 6.63 Hz, 1 H), 5.86 (s, 1 H),6.60 (d, J = 2.02 Hz, 1 H), 6.81 (d, J = 8.84 Hz, 1 H), 6.88 (d, J =1.77 Hz, 1 H), 7.02 (d, J = 1.01 Hz, 1 H), 7.39 (dd, J = 8.84, 2.78 Hz,1 H), 7.66 (s, 1 H), 7.95-8.04 (m, 2 H) 542.1 7.26 362

N-[(4,6-dimethyl-2- oxo-1,2-dihydro-3- pyridinyl)methyl]-3- methyl-1-(1-methylethyl)-6-{[(4- methyl-1- piperazinyl)carbonyl] amino}-1H-indole-4-carboxamide 1.40 (m, 6 H), 2.11 (s, 6 H), 2.21 (d, J = 9.09 Hz, 6 H),2.28-2.35 (m, 4 H), 3.40-3.47 (m, 4 H), 4.32 (d, J = 5.31 Hz, 2 H), 4.51(quin, J = 6.63 Hz, 1 H), 5.87 (s, 1 H), 7.03 (d, J = 1.77 Hz, 1 H),7.12 (d, J = 1.01 Hz, 1 H), 7.73 (d, J = 1.77 Hz, 1 H), 7.90 (t, J =5.05 Hz, 1 H), 8.47 (s, 3 H) 11.47 (br.s., 2 H) 493.3 6.89 363

6-{[3- (dimethylamino)prop- yl]thio}-N-[(4,6- dimethyl-2-oxo-1,2-dihydro-3- pyridinyl)methyl]-3- methyl-1-(1- methylethyl)-1H- indole-4-carboxamide 11.47 (s, 1 H), 8.12 (t, J = 5.1 Hz, 1 H), 7.51 (d, J = 1.5Hz, 1 H), 7.27 (s, 1 H), 6.91 (d, J = 1.3 Hz, 1 H), 5.86 (s, 1 H), 4.74(m, 1 H), 4.31 (d, J = 5.1 Hz, 2 H), 2.95 (t, J = 7.2 Hz, 2 H), 2.29 (t,J = 7.1 Hz, 2 H), 2.22 (s, 3 H), 2.10 (m, 12 H), 1.65 (quin, J = 7.1 Hz,2 H), 1.39 (d, J = 6.6 Hz, 6 H) 469.1 364

N-[(4,6-dimethyl-2- oxo-1,2-dihydro-3- pyridinyl)methyl]-6-(3-hydroxy-3-methyl- 1-butyn-1-yl)-3- methyl-1-(1- methylethyl)-1H-indole-4- carboxamide 11.46 (s, 1 H), 8.16 (t, J = 5.1 Hz, 1 H), 7.54(d, J = 1.3 Hz, 1 H), 7.37 (s, 1 H), 6.90 (d, J = 1.3 Hz, 1 H), 5.86 (s,1 H), 5.41 (s, 1 H), 4.75 (m, 1 H), 4.31 (d, J = 5.1 Hz, 2 H), 2.21 (s,3 H), 2.11 (s, 3 H), 2.14 (s, 3 H), 1.47 (s, 6 H), 1.39 (d, J = 6.6 Hz,6 H) 434.0 365

6-(3-hydroxy-3- methyl-1-butyn-1-yl)- 3-methyl-1-(1- methylethyl)-N-[(6-methyl-2-oxo-4- propyl-1,2-dihydro- 3-pyridinyl)methyl]- 1H-indole-4-carboxamide 11.48 (s, 1 H), 8.12 (t, J = 5.1 Hz, 1 H), 7.55 (d, J = 1.3Hz, 1 H), 7.38 (s, 1 H), 6.90 (d, J = 1.3 Hz, 1 H), 5.89 (s, 1 H), 5.41(s, 1 H), 4.76 (m, 1 H), 4.32 (d, J = 4.8 Hz, 2 H), 2.54 (s, 1 H), 2.13(d, J = 9.3 Hz, 6 H), 1.55 (m, 2 H), 1.47 (s, 6 H), 1.40 (m, 6 H), 0.93(t, J = 7.3 Hz, 3 H) 462.1 366

6- (cyclopropylethynyl)- 3-methyl-1-(1- methylethyl)-N-[(6-methyl-2-oxo-4- propyl-1,2-dihydro- 3-pyridinyl)methyl]- 1H-indole-4-carboxamide 11.48 (s, 1 H), 8.09 (t, J = 4.9 Hz, 1 H), 7.54 (d, J = 1.3Hz, 1 H), 7.35 (s, 1 H), 6.87 (d, J = 1.3 Hz, 1 H), 5.89 (s, 1 H), 4.72(quin, J = 6.6 Hz, 1 H), 4.31 (d, J = 5.1 Hz, 2 H), 2.13 (d, J = 4.0 Hz,6 H), 1.54 (m, 3 H), 1.38 (d, J = 6.6 Hz, 6H), 0.93 (t, J = 7.3 Hz, 3H), 0.87 (m, 2 H), 0.71 (m, 2 H) 444.1

Example 367N-[(4,6-Dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-7-methyl-1-(1-methylethyl)-1H-indole-4-carboxamidea) Methyl 7-methyl-1H-indole-4-carboxylate

Under N2 atmosphere, 7-methyl-1H-indole-4-carboxylic acid (1 g, 5.71mmol), sulfuric acid (300 μL, 5.63 mmol) and methanol (50 mL) wereheated at reflux for 10 h. The MeOH was removed in vacuo and the residuedissolved in 30 mL DCM. The solution was washed with water and saturatedNaHCO₃, dried over MgSO₄, filtered and concentrated. The residue waspurified by column chromatography (Biotage; 0% to 100% EtOAc:Hex; 25g-HP-silica gel column) to give the title compound. ¹H NMR (400 MHz,CHLOROFORM-d) δ ppm 2.59 (s, 3H), 4.00 (s, 3H), 7.08 (d, J=7.58 Hz, 1H),7.20-7.26 (m, 1H), 7.38 (t, J=2.78 Hz, 1H), 7.88 (d, J=7.58 Hz, 1H),8.32 (br. s., 1H).

b) Methyl 7-methyl-1-(1-methylethyl)-1H-indole-4-carboxylate

A cooled (ice/water bath) solution of methyl methyl7-methyl-1H-indole-4-carboxylate (260 mg, 1.374 mmol) in DMF (20 mL) wasadded sodium hydride (43.4 mg, 1.718 mmol). After 10 minutes2-iodopropane (0.151 mL, 1.512 mmol) was added and the reaction wasstirred for 16 h. LCMS showed reaction only 10% complete. Added sodiumhydride (43.4 mg, 1.718 mmol) followed by 2-iodopropane (0.151 mL, 1.512mmol). After 2 hours LCMS showed reaction was 15% compete. Added moresodium hydride (43.4 mg, 1.718 mmol) and let stir for 5 minutes, thenadded more 2-bromopropane (0.142 mL, 1.512 mmol). Heated to 70° C. for16 h. LCMS showed reaction 50% complete. Concentrated reaction mixture.Added DCM and washed with water and brine, dried over MgSO₄, filteredand concentrated. The residue was purified by column chromatography(Biotage; 0% to 100% DCM:Hex; 25 g-HP-silica gel column) to give 137 mgof the title compound. ¹H NMR (400 MHz, CHLOROFORM-d) δ ppm 1.48-1.60(m, 6H), 2.78 (s, 3H), 3.94-4.02 (m, 3H), 5.17 (dt, J=13.20, 6.66 Hz,1H), 6.96 (d, J=7.83 Hz, 1H), 7.28 1H, 7.40 (d, J=3.28 Hz, 1H), 7.81 (d,J=7.58 Hz, 1H). MS(ES) [M+H]⁺232.1

c) 7-Methyl-1-(1-methylethyl)-1H-indole-4-carboxylic acid

To a solution of methyl7-methyl-1-(1-methylethyl)-1H-indole-4-carboxylate (137 mg, 0.592 mmol)in ethanol (30 mL) was added 1 N sodium hydroxide (2.369 mL, 2.369mmol). The mixture was heated at reflux for 2 h, at which time it wasconcentrated. The residue was dissolved in water (20 mL) and acidifiedby addition of 1 N HCl. The mixture was extracted with DCM (4×30 mL) andthe combined extracts and washed with water and brine, dried over MgSO₄,filtered and concentrated to give 104 mg of the title compound. ¹H NMR(400 MHz, CHLOROFORM-d) δ ppm 1.55 (d, 6H), 2.82 (s, 3H), 5.11-5.28 (m,1H), 7.00 (d, J=7.83 Hz, 1H), 7.31 (d, J=3.54 Hz, 1H), 7.44 (d, J=3.28Hz, 1H), 7.89 (d, J=7.58 Hz, 1H). MS(ES) [M+H]⁺218.3.

d)N-[(4,6-Dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-7-methyl-1-(1-methylethyl)-1H-indole-4-carboxamide

Added 7-methyl-1-(1-methylethyl)-1H-indole-4-carboxylic acid (52 mg,0.239 mmol), 3-(aminomethyl)-4,6-dimethyl-2(1H)-pyridinone (56.4 mg,0.299 mmol), 1-hydroxy-7-azabenzotriazole (65.2 mg, 0.479 mmol), EDC (92mg, 0.479 mmol) and N-methylmorpholine (0.105 mL, 0.957 mmol) toDimethyl Sulfoxide (DMSO) (10 mL) and stirred at RT for 16 h. Added 25ml of water and let stir for 10 minutes. Filtered off solids. Dissolvedsolids in DCM, washed with water, dried over MgSO₄, filtered andconcentrated. The residue was purified by column chromatography(Biotage; 0% to 20% gradient MeOH:DCM; 10 g-HP-silica gel column) togive 55 mg ofN-[(4,6-Dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-7-methyl-1-(1-methylethyl)-1H-indole-4-carboxamide.¹H NMR (400 MHz, CHLOROFORM-d) δ ppm 1.49 (d, 6H), 2.24 (s, 3H), 2.44(s, 3H), 2.75 (s, 3H), 4.63 (d, J=4.55 Hz, 2H), 5.17 (dt, J=13.20, 6.66Hz, 1H), 5.97 (s, 1H), 6.91 (d, J=7.58 Hz, 1H), 7.01 (d, J=3.54 Hz, 1H),7.29 (d, J=3.28 Hz, 1H), 7.39 (d, J=7.33 Hz, 1H), 7.69 (br. s., 1H),12.59 (br. s., 1H). MS(ES) [M+H]⁺352.4.

Example 3687-Methyl-1-(1-methylethyl)-N-[(6-methyl-2-oxo-4-propyl-1,2-dihydro-3-pyridinyl)methyl]-1H-indole-4-carboxamide

7-Methyl-1-(1-methylethyl)-N-[(6-methyl-2-oxo-4-propyl-1,2-dihydro-3-pyridinyl)methyl]-1H-indole-4-carboxamidewas prepared following the procedure of Example 367. ¹H NMR (400 MHz,CHLOROFORM-d) δ ppm 0.95-1.07 (m, 3H), 1.50 (d, J=6.57 Hz, 6H), 1.63(qt, J=7.56, 7.36 Hz, 2H), 2.27 (s, 3H), 2.68-2.82 (m, 5H), 4.64 (d,J=2.53 Hz, 2H), 5.17 (dq, J=6.82, 6.65 Hz, 1H), 6.04 (s, 1H), 6.91 (d,J=7.58 Hz, 1H), 7.00 (d, J=3.54 Hz, 1H), 7.31 (d, J=3.54 Hz, 1H), 7.39(d, J=7.33 Hz, 1H), 7.64 (br. s., 1H), 12.13 (br. s., 1H). MS(ES)[M+H]⁺380.2.

Example 3691-(1-Methylethyl)-N-[(6-methyl-2-oxo-4-propyl-1,2-dihydro-3-pyridinyl)methyl]-7-(methyloxy)-1H-indole-4-carboxamide

a) 7-(Methyloxy)-1-(phenylsulfonyl)-1H-indole

To a cooled (ice water bath) solution of 7-(methyloxy)-1H-indole (3 g,20.38 mmol) in DMF (100 mL) was added sodium hydride (0.618 g, 24.46mmol) portionwise. After 15 minutes a solution of benzenesulfonylchloride (3.94 mL, 30.6 mmol) in 20 ml of DMF was added dropwise. Thereaction mixture was stirred at RT for 24 h, at which time it wasconcentrated. The residue was dissolved in DCM (100 ml) and washed withwater and brine, dried over MgSO₄, filtered and concentrated. Theresidue was purified by column chromatography (Biotage; 0% to 100%DCM:Hex; 50 g-HP-silica gel column) to give 3.65 g of the titlecompound. ¹H NMR (400 MHz, CHLOROFORM-d) δ ppm 3.65 (s, 3H), 6.60-6.75(m, 2H), 7.08-7.22 (m, 2H), 7.40-7.62 (m, 3H), 7.77-7.92 (m, 3H). MS(ES)[M+H]⁺ 288.0.

b) Methyl 7-(methyloxy)-1-(phenylsulfonyl)-1H-indole-4-carboxylate

To a cooled (0° C.) suspension of aluminium chloride (8.47 g, 63.5 mmol)in DCM (100 mL) was added oxalyl chloride (5.56 mL, 63.5 mmol) dropwise.After stirring for 30 minutes a solution of7-(methyloxy)-1-(phenylsulfonyl)-1H-indole (3.65 g, 12.70 mmol) in DCM(15 ml) was added dropwise. The reaction was stirred at RT for 1 h, atwhich time it was poured into brine and extracted with DCM. The DCMextracts were dried over MgSO₄, filtered, and evaporated to dryness.Added 100 ml of MeOH to the residue and heated at reflux for 3 h. Themixture was concentrated and the residue purified by columnchromatography (Biotage; 0% to 100% DCM:Hex; 50 g-HP-silica gel column)to give 2.3 g of the title compound. ¹H NMR (400 MHz, CHLOROFORM-d) δppm 3.70 (s, 3H), 3.95 (s, 3H), 6.67 (d, J=8.59 Hz, 1H), 7.41 (d, J=3.79Hz, 1H), 7.46-7.53 (m, 2H), 7.54-7.62 (m, 1H), 7.79-7.86 (m, 2H), 7.94(d, J=8.59 Hz, 1H), 7.98 (d, J=3.54 Hz, 1H). MS(ES) [M+H]⁺ 346.0.

c) Methyl 1-(1-methylethyl)-7-(methyloxy)-1H-indole-4-carboxylate

To a cooled (ice/water bath) solution of methyl7-(methyloxy)-1H-indole-4-carboxylate (350 mg, 1.706 mmol) in DMF (20mL) was added sodium hydride (56.0 mg, 2.217 mmol). After 10 minutesadded 2-iodopropane (0.188 mL, 1.876 mmol). The reaction was stirred atRT for 1 h, followed by heating at 50° C. for 2 h. The reaction was thencooled in an ice water bath and more sodium hydride (56.0 mg, 2.217mmol) and 2-iodopropane (0.188 mL, 1.876 mmol) were added. The reactionwas heated at 50° C. for 3 h, at which time it was concentrated. Theresidue was dissolved in DCM and washed with water and brine, dried overMgSO₄, filtered and concentrated to give 400 mg of the title compound.¹H NMR (400 MHz, CHLOROFORM-d) δ ppm 1.49 (d, 6H), 3.95 (s, 3H), 4.01(s, 3H), 5.46 (dt, J=13.39, 6.69 Hz, 1H), 6.66 (d, J=8.34 Hz, 1H), 7.15(d, J=3.03 Hz, 1H), 7.34 (d, J=3.28 Hz, 1H), 7.87 (d, J=8.34 Hz, 1H).MS(ES) [M+H]⁺ 248.2.

d) 1-(1-Methylethyl)-7-(methyloxy)-1H-indole-4-carboxylic acid

Added 1 N sodium hydroxide (6.47 mL, 6.47 mmol) to a solution of methyl1-(1-methylethyl)-7-(methyloxy)-1H-indole-4-carboxylate (400 mg, 1.618mmol) in ethanol (30 mL) and heated at reflux for 3 h. The EtOH wasremoved in vacuo and the residue dissolved in 20 ml of water. Acidifiedsolution by addition of 1 N HCl and extracted with DCM. the combined DCMextracts were washed with water and brine, dried over MgSO₄, filteredand concentrated to give 350 mg of the title compound. ¹H NMR (400 MHz,CHLOROFORM-d) δ ppm 1.51 (d, 6H), 4.03 (s, 3H), 5.47 (dt, J=13.39, 6.69Hz, 2H), 6.70 (d, J=8.34 Hz, 2H), 7.23 (d, J=3.28 Hz, 2H), 7.37 (d,J=3.03 Hz, 2H), 7.99 (d, J=8.34 Hz, 2H). MS(ES) [M+H]⁺ 234.0.

e)1-(1-Methylethyl)-N-[(6-methyl-2-oxo-4-propyl-1,2-dihydro-3-pyridinyl)methyl]-7-(methyloxy)-1H-indole-4-carboxamide

Added 1-(1-methylethyl)-7-(methyloxy)-1H-indole-4-carboxylic acid (160mg, 0.686 mmol), 3-(aminomethyl)-6-methyl-4-propyl-2(1H)-pyridinone (186mg, 0.857 mmol), 1-hydroxy-7-azabenzotriazole (187 mg, 1.372 mmol), EDC(263 mg, 1.372 mmol) and N-methylmorpholine (0.302 mL, 2.74 mmol) toDMSO (10 mL) and stirred mixture at RT for 16 h. Added 25 ml of waterand stirred for 10 minutes. Filtered off solids and dried in vacuo. Thesolids were purified by column chromatography (Biotage; 0% to 15%gradient MeOH:DCM; 10 g-HP-silica gel column) to give 165 mg of1-(1-methylethyl)-N-[(6-methyl-2-oxo-4-propyl-1,2-dihydro-3-pyridinyl)methyl]-7-(methyloxy)-1H-indole-4-carboxamide.¹H NMR (400 MHz, CHLOROFORM-d) δ ppm 1.01 (t, 3H), 1.45 (d, J=6.57 Hz,6H), 1.63 (m, J=7.45, 7.45, 7.45, 7.45, 7.33 Hz, 2H), 2.24 (s, 3H), 2.74(t, J=7.58 Hz, 2H), 3.96 (s, 3H), 4.64 (br. s., 2H), 5.45 (quin, J=6.63Hz, 1H), 5.97 (s, 1H), 6.62 (d, J=8.08 Hz, 1H), 6.94 (d, J=3.28 Hz, 1H),7.24 (d, J=3.28 Hz, 1H), 7.53 (d, J=8.08 Hz, 1H), 7.74 (br. s., 1H),12.46 (br. s., 1H). MS(ES) [M+H]⁺ 395.7.

Example 370N-[(4,6-Dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-1-(1-methylethyl)-7-(methyloxy)-1H-indole-4-carboxamide

N-[(4,6-Dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-1-(1-methylethyl)-7-(methyloxy)-1H-indole-4-carboxamidewas prepared following the procedure of Example 369. ¹H NMR (400 MHz,CHLOROFORM-d) δ ppm 1.45 (d, 6H), 2.21 (s, 3H), 2.43 (s, 3H), 3.96 (s,3H), 4.63 (d, J=5.56 Hz, 2H), 5.35-5.57 (m, 1H), 5.94 (s, 1H), 6.61 (d,J=8.34 Hz, 1H), 6.94 (d, J=3.28 Hz, 1H), 7.23 (d, J=3.03 Hz, 1H), 7.52(d, J=8.08 Hz, 1H), 7.66 (br. s., 1H), 12.73 (br. s., 1H). MS(ES) [M+H]⁺368.1.

Example 3716-chloro-1-isopropyl-2,3-dimethyl-N-((6-methyl-2-oxo-4-propyl-1,2-dihydropyridin-3-yl)methyl)-1H-indole-4-carboxamide

a) Methyl 6-chloro-1-isopropyl-2,3-dimethyl-1H-indole-4-carboxylate

To a stirred solution of methyl2-bromo-6-chloro-1-isopropyl-3-methyl-1H-indole-4-carboxylate (0.50 g,1.451 mmol), Trimethylboroxine (0.30 mL, 2.146 mmol) and potassiumcarbonate (0.31 g, 2.243 mmol) in 1,4-Dioxane (20 mL) under N₂ was addedpalladium tetrakis (0.18 g, 0.156 mmol). The reaction was heated to 110°C. and stirred for 18 hr. After 3 hr an additional 100 uLTrimethylboroxine was added. The reaction was concentrated under vacuum,taken up in EtOAc, washed with water, dried (MgSO₄), filtered andconcentrated under vacuum. Purification by silica gel chromatography(Analogix, SF25-60 g, 0 to 10% EtOAc in hexanes) gave the product methyl6-chloro-1-isopropyl-2,3-dimethyl-1H-indole-4-carboxylate (0.33 g, 1.180mmol, 81% yield) as a clear thick oil. ¹H NMR (400 MHz, DMSO-d₆) δ=7.80(d, J=2.0 Hz, 1H), 7.28 (d, J=1.8 Hz, 1H), 4.81 (dt, J=6.9, 13.9 Hz,1H), 3.87 (s, 3H), 2.39 (s, 3H), 2.13 (s, 3H), 1.51 (d, J=7.1 Hz, 6H)

MS(ES)+ m/e 280.1 [M+H]⁺.

b)6-Chloro-1-isopropyl-2,3-dimethyl-N-((6-methyl-2-oxo-4-propyl-1,2-dihydropyridin-3-yl)methyl)-1H-indole-4-carboxamide

To a stirred solution of methyl6-chloro-1-isopropyl-2,3-dimethyl-1H-indole-4-carboxylate (320 mg, 1.144mmol) in Methanol (12 mL) and Tetrahydrofuran (THF) (4 mL) was added 1 NNaOH (4 mL, 4.00 mmol). The reaction was refluxed (70° C. oil bath) for18 h. The reaction was concentrated under vacuum, diluted with water,acidified with 1 N HCl (4 mL), filtered, washed with water and driedunder vacuum to give the carboxylic acid (0.30 g, 1.14 mmol, 100%) as alight yellow solid. MS(ES)+ m/e 266.1 [M+H]⁺.

To the carboxylic acid above was added3-(aminomethyl)-6-methyl-4-propylpyridin-2(1H)-one (230 mg, 1.276 mmol),HOAt (160 mg, 1.176 mmol), Dichloromethane (12 mL) andN,N-Dimethylformamide (4.00 mL) to dissolve. With stirring was added EDCfree base (210 mg, 1.353 mmol) and the reaction stirred at RT for 3 hr.LCMS showed that the reaction was complete. The reaction was evaporatedto dryness under vacuum then purified by silica gel chromatography(SF25-40 g, 50 to 100% EtOAc in CH₂Cl₂) (streaked off). The purefractions were combined and evaporated under vacuum. The remaining solidwas triturated with 25% CH₂Cl₂ in hexanes, filtered, washed with hexanesand dried under vacuum to give the product6-chloro-1-isopropyl-2,3-dimethyl-N-((6-methyl-2-oxo-4-propyl-1,2-dihydropyridin-3-yl)methyl)-1H-indole-4-carboxamide(431 mg, 1.007 mmol, 88% yield) as an off-white solid. ¹H NMR (400 MHz,DMSO-d₆) δ=11.49 (s, 1H), 8.16 (t, J=5.1 Hz, 1H), 7.58 (d, J=1.8 Hz,1H), 6.82 (d, J=1.8 Hz, 1H), 5.89 (s, 1H), 4.75 (dt, J=6.9, 13.9 Hz,1H), 4.31 (d, J=5.1 Hz, 2H), 2.52 (2H under DMSO), 2.33 (s, 3H), 2.12(s, 3H), 2.04 (s, 3H), 1.61-1.51 (m, 2H), 1.49 (d, J=6.8 Hz, 6H), 0.94(t, J=7.3 Hz, 3H). MS(ES)+ m/e 428.3 [M+H]⁺.

Example 3726-Chloro-2-((dimethylamino)methyl)-1-isopropyl-3-methyl-N-((6-methyl-2-oxo-4-propyl-1,2-dihydropyridin-3-yl)methyl)-1H-indole-4-carboxamide

a) Methyl6-chloro-2-((dimethylamino)methyl)-1-isopropyl-3-methyl-1H-indole-4-carboxylate

To a stirred mixture of methyl2-bromo-6-chloro-1-isopropyl-3-methyl-1H-indole-4-carboxylate (1.0 g,2.90 mmol), potassium ((dimethylamino)methyl)trifluoroborate (0.5 g,3.03 mmol) and Potassium phosphate (1.9 g, 8.95 mmol) (purged with N₂))in dioxane (3 mL) and water (3 mL) was added palladium(II) acetate (25mg, 0.111 mmol) and sPhos (90 mg, 0.219 mmol). The reaction was heatedto 100° C. and stirred for 18 hr under N₂. LCMS showed that the reactionwas complete. The reaction was diluted with EtOAc and water, andfiltered to remove insolubles. The EtOAc phase was removed, dried(Na₂SO₄), filtered, and concentrated under vacuum. The crude waspurified by silica gel chromatography (Analogix, SF25-40 g, 0 to 2% (5%NH₄OH/MeOH) in CH₂Cl₂). The product fractions were combined, evaporatedto dryness under vacuum to give the product methyl6-chloro-2-((dimethylamino)methyl)-1-isopropyl-3-methyl-1H-indole-4-carboxylate(0.45 g, 1.394 mmol, 48.0% yield) as a light yellow oil (Only 84% pureby LCMS). This was used as is in the next reaction. ¹H NMR (400 MHz,DMSO-d₆) δ=7.82 (d, J=1.8 Hz, 1H), 7.28 (d, J=1.8 Hz, 1H), 4.96 (dt,J=7.1, 14.1 Hz, 1H), 3.88 (s, 3H), 3.52 (s, 2H), 2.17 (s, 3H), 2.16 (s,6H), 1.53 (d, J=7.1 Hz, 6H). MS(ES)+ m/e 323.2 [M+H]⁺, 278.1 [M+H]⁺ −45(HNMe₂).

b)6-Chloro-2-((dimethylamino)methyl)-1-isopropyl-3-methyl-1H-indole-4-carboxylicacid hydrochloride salt

To methyl6-chloro-2-((dimethylamino)methyl)-1-isopropyl-3-methyl-1H-indole-4-carboxylate(0.44 g, 1.363 mmol) was added 6 N HCl (20 ml, 120 mmol). The reactionwas purged with N₂, attached a reflux condenser, heated to 80° C., andstirred for 18 hr. LCMS showed that the reaction was complete. Thereaction was cooled to RT, diluted with an equal volume of water, washedwith EtOAc, and evaporated to dryness under vacuum to give the product6-chloro-2-((dimethylamino)methyl)-1-isopropyl-3-methyl-1H-indole-4-carboxylicacid hydrochloride salt (0.42 g, 1.216 mmol, 89% yield) as a beigesolid. (86% pure by LCMS, contains ˜10% of the des-chloro side productfrom the previous reaction.) Used as is in the next step. ¹H NMR (400MHz, DMSO-d₆) δ=13.19 (br. s., 1H), 10.45 (br. s., 1H), 7.90 (d, J=1.8Hz, 1H), 7.33 (d, J=1.8 Hz, 1H), 4.91 (quin, J=6.9 Hz, 1H), 4.58 (d,J=5.6 Hz, 2H), 2.79 (d, J=4.8 Hz, 6H), 2.34 (s, 3H), 1.58 (d, J=6.8 Hz,6H). MS(ES)+ m/e 309.2 [M+H]⁺, 264.1 [M+H]⁺ −45 (HNMe₂).

c)6-Chloro-2-((dimethylamino)methyl)-1-isopropyl-3-methyl-N-((6-methyl-2-oxo-4-propyl-1,2-dihydropyridin-3-yl)methyl)-1H-indole-4-carboxamide

To6-chloro-2-((dimethylamino)methyl)-1-isopropyl-3-methyl-1H-indole-4-carboxylicacid hydrochloride salt (0.42 g, 1.216 mmol),3-(aminomethyl)-6-methyl-4-propylpyridin-2(1H)-one (0.22 g, 1.221 mmol),HOAt (0.17 g, 1.249 mmol) was added Dichloromethane (16 mL),N,N-Dimethylformamide (4 mL) and N-methylmorpholine (135 μL, 1.228mmol). The mixture was stirred and EDC free base (0.20 g, 1.288 mmol)was added. After stirring for 2 hr LCMS showed that the reaction wascomplete. The reaction was evaporated to dryness under vacuum andpurified by silica gel chromatography (Analogix, SF25-60 g, 0 to 8% (5%NH₄OH in MeOH) in CH₂Cl₂). The pure fractions were combined, evaporatedto dryness then taken up in 20% EtOAc in hexanes. Scratchingcrystallized out the product which was filtered and washed with hexanesto give the product6-chloro-2-((dimethylamino)methyl)-1-isopropyl-3-methyl-N-((6-methyl-2-oxo-4-propyl-1,2-dihydropyridin-3-yl)methyl)-1H-indole-4-carboxamide(362 mg, 0.769 mmol, 63.2% yield) as an off-white solid. ¹H NMR (400MHz, DMSO-d₆) δ=11.49 (s, 1H), 8.24 (t, J=4.9 Hz, 1H), 7.61 (d, J=1.8Hz, 1H), 6.83 (d, J=1.8 Hz, 1H), 5.89 (s, 1H), 4.91 (quin, J=7.0 Hz,1H), 4.31 (d, J=5.1 Hz, 2H), 3.47 (s, 2H), 2.52 (2H under DMSO), 2.14(s, 6H), 2.12 (s, 3H), 2.10 (s, 3H), 1.62-1.53 (m, 2H), 1.51 (d, J=7.1Hz, 6H), 0.94 (t, J=7.3 Hz, 3H). MS(ES)+ m/e 471.3 [M+H]⁺.

Example 3732-(2-Aminoethyl)-6-chloro-1-isopropyl-3-methyl-N-((6-methyl-2-oxo-4-propyl-1,2-dihydropyridin-3-yl)methyl)-1H-indole-4-carboxamide

a) Methyl2-(2-((tert-butoxycarbonyl)amino)ethyl)-6-chloro-1-isopropyl-3-methyl-1H-indole-4-carboxylate

To a stirred mixture of methyl2-bromo-6-chloro-1-isopropyl-3-methyl-1H-indole-4-carboxylate (0.37 g,1.074 mmol), potassium(2-((tert-butoxycarbonyl)amino)ethyl)trifluoroborate (0.30 g, 1.195mmol) and Cs₂CO₃ (1.0 g, 3.07 mmol) (purged with N₂) in toluene (12 mL)and water (4 mL) was added palladium(II) acetate (20 mg, 0.089 mmol) andRuPhos (80 mg, 0.171 mmol). The reaction was heated to 95° C. andstirred for 18 hr under N₂. LCMS still showed SM. Another portion ofpalladium(II) acetate (20 mg, 0.089 mmol) and RuPhos (80 mg, 0.171 mmol)was added and the reaction stirred at 95° C. for another 18 hr. LCMSshowed that the reaction was now mostly done. The reaction was dilutedwith EtOAc and water, and filtered to remove insolubles. The EtOAc phasewas removed, dried (MgSO₄), filtered, and concentrated under vacuum. Thecrude was purified by silica gel chromatography (Analogix, SF25-60 g, 0to 25% EtOAc in hexanes). Three fractions were collected. The firstfraction contained a significant amount of the desbromo product, thesecond fraction was a mixture of unknowns, and the last fractioncontained product (Note; opposite order from the TLC). The productfractions were combined, evaporated to dryness under vacuum, trituratedwith hexanes, filtered and dried under vacuum to give the product methyl2-(2-((tert-butoxycarbonyl)amino)ethyl)-6-chloro-1-isopropyl-3-methyl-1H-indole-4-carboxylate(148 mg, 0.362 mmol, 33.7% yield) as a white solid. ¹H NMR (400 MHz,DMSO-d₆) δ=7.81 (d, J=1.5 Hz, 1H), 7.28 (d, J=1.8 Hz, 1H), 7.00 (t,J=5.6 Hz, 1H), 3.87 (s, 3H), 3.07 (q, J=6.7 Hz, 2H), 2.97-2.85 (m, 2H),2.13 (s, 3H), 1.56 (d, J=7.1 Hz, 6H), 1.36 (s, 9H). MS(ES)+ m/e 409.2[M+H]⁺.

b)2-(2-Aminoethyl)-6-chloro-1-isopropyl-3-methyl-N-((6-methyl-2-oxo-4-propyl-1,2-dihydropyridin-3-yl)methyl)-1H-indole-4-carboxamide

3-Methyl-1H-indole-4-carboxylate (140 mg, 0.342 mmol) in Methanol (9 mL)and Tetrahydrofuran (3 mL) was added 1 N NaOH (2 mL, 2.000 mmol). Thereaction was refluxed (70° C. oil bath) for 18 h (reaction proceededvery slowly at 60° C. with only 1 mL 1 N NaOH). The reaction wasconcentrated under vacuum, diluted with water, acidified with 1 N HCl (2mL), filtered, washed with water and dried under vacuum to give thecarboxylic acid (0.14 g, 0.354 mmol, 100%) as a white solid. MS(ES)+ m/e395.0 [M+H]⁺.

To the carboxylic acid above was added3-(aminomethyl)-6-methyl-4-propylpyridin-2(1H)-one (80 mg, 0.444 mmol),HOAt (60 mg, 0.441 mmol), Dichloromethane (12 mL) andN,N-Dimethylformamide (3.00 mL) to dissolve. With stirring was added EDCfree base (70 mg, 0.451 mmol) and the reaction stirred at RT overnight.LCMS showed that the reaction was complete. The reaction was evaporatedto dryness under vacuum then purified by silica gel chromatography(SF25-40 g, 50 to 100% EtOAc in CH₂Cl₂) to give the Boc protected finalproduct (0.20 g, 3.59 mmol, 100%) as a white solid. MS(ES)+ m/e 557.3[M+H]⁺.

The above was dissolved with MeOH (5 mL) then treated, while stirring,with a solution of 4 N HCl in dioxane (10 mL, 40.0 mmol). The reactionwas stirred for 30 minutes then evaporated to dryness under vacuum. Thesolid was triturated with Et₂O, filtered, washed with hexanes and driedunder vacuum to give the product2-(2-aminoethyl)-6-chloro-1-isopropyl-3-methyl-N-((6-methyl-2-oxo-4-propyl-1,2-dihydropyridin-3-yl)methyl)-1H-indole-4-carboxamidehydrochloride salt (161 mg, 0.326 mmol, 95% yield) as a light yellowsolid. MS(ES)+ m/e 457.2 [M+H]⁺.

Intermediates Intermediate 13-(Aminomethyl)-4,6-dimethyl-2(1H)-pyridinone hydrochloride

Palladium on carbon (10%) (3.24 g) was charged into a 2 L dry Parrbottle and a small amount of acetic acid was added. Next added4,6-dimethyl-2-oxo-1,2-dihydro-pyridine-3-carbonitrile (30 g, 202.7mmol), sodium acetate (30.75 g, 375.0 mmol), platinum oxide (0.218 g),and acetic acid (1 L). The bottle was capped, placed on Parr apparatus,and shaken under an atmosphere of H₂ (100 psi) for 2 days. The reactionmixture was filtered. The solvent was removed to give a residue, whichwas treated with 150 mL of conc. HCl, and the formed solids werefiltered. The yellow filtrate was concentrated. To the crude compoundwas added 30 mL of conc. HCl and 150 mL EtOH, the contents cooled to 0°C., and stirred at 0° C. for 2 h. The formed solids were filtered,washed with cold EtOH, ether, and dried. The product was collected as 36g. This batch was combined with other batches prepared on smaller scalesand triturated with ether to give 51 g of pure compound. ¹H NMR (400MHz, DMSO-d₆) δ ppm 11.85 (br s, 1H) 8.13 (br s, 3H) 5.93-6.01 (m, 1H)3.72-3.80 (m, 2H) 2.22 (s, 3H) 2.16 (s, 3H).

Intermediate 23-(Aminomethyl)-6-methyl-4-(trifluoromethyl)-2(1H)-pyridinone

To a dried 500 mL Parr bottle equipped with nitrogen inlet were addedsodium acetate (1.502 g, 18.30 mmol), 10% palladium on carbon (1.579 g,0.742 mmol), platinum(IV) oxide (0.011 g, 0.049 mmol) and a small amountof acetic acid to wet the catalysts, under nitrogen stream. Next wasadded 2-hydroxy-6-methyl-4-(trifluoromethyl)-3-pyridinecarbonitrile (2.0g, 9.89 mmol) followed by acetic acid (175 mL) while under nitrogenatmosphere. The contents were sealed, placed on a Parr shaker, andreacted at 40 psi of H₂ for ca. 6 hr, keeping the H₂ psi between 20 and40 psi (vessel was refilled twice). The vessel was purged with nitrogenand the reaction mixture filtered through Celite, and the filter pad wasfurther washed with a small amount of acetic acid. The volatiles wereremoved in vacuo to afford a residue, which was dried under high vacuumfor 45 min. The solid was suspended in conc. HCl (12 mL), stirred, andfiltered. The clear filtrate was concentrated in vacuo and the residuedried under high vacuum. The collected solid was suspended in conc. HCl(2 mL) and diluted with EtOH (13 mL). The contents were agitated andstored at ca. 0° C. (freezer) for 30 min to give a white solid. Thesolid was filtered and washed with cold ethanol (5 mL). The solid wasfiltered and dried in vacuum oven for 1 h to give3-(aminomethyl)-6-methyl-4-(trifluoromethyl)-2(1H)-pyridinone (0.95 g,40%). LCMS E-S (M+H)=206.9. ¹H NMR (400 MHz, DMSO-d₆) δ ppm 2.31 (s,3H), 3.40-3.62 (m, 2H), 3.87 (d, J=5.05 Hz, 2H), 8.12-8.37 (m, 3H).

Intermediate 3 3-(Aminomethyl)-4-cyclohexyl-6-methyl-2(1H)-pyridinone

3a) 4-Cyclohexyl-6-methyl-2-oxo-1,2-dihydro-3-pyridinecarbonitrile

To a stirred suspension of CrCl₂ (58 g, 472.8 mmol) in THF (1500 mL) wasadded a THF solution (500 mL) of 1,1-dichloro-2-propanone (10 g, 78.8mmol) and cyclohexanecarbaldehyde (8.84 g, 78.8 mmol). The reactionmixture was heated at reflux for 2 h, and then quenched by the additionof 1.0 M HCl. The reaction mixture was filtered through a pad of Celiteand concentrated in vacuo. The crude residue (10 g) was added to asolution of DMSO (150 mL) containing t-BuOK (7.5 g, 65.7 mmol) andcyanoacetamide (6.1 g, 72.3 mmol) and stirred at room temperature for 30min. Additional t-BuOK (22.5 g, 197.1 mmol) was added and the reactionmixture was stirred under an atmosphere of oxygen for an additional 1 h.The contents were purged with argon, diluted with 4 volumes of H₂O, andthen 5 volumes of 4 N HCl, which were added slowly. The reaction mixturewas filtered, washed with water and dried to give4-cyclohexyl-6-methyl-2-oxo-1,2-dihydro-3-pyridinecarbonitrile (4.5 g,32%). ¹H NMR (400 MHz, DMSO-d₆) δ ppm 6.25 (s, 1H), 2.61-2.65 (m, 1H),2.22 (s, 3H), 1.66-1.79 (m, 4H), 1.24-1.46 (m, 6H).

3b) 3-(Aminomethyl)-4-cyclohexyl-6-methyl-2(1H)-pyridinone

To an ice-bath cooled THF (100 mL) solution of the product from step 1(2 g, 9.26 mmol) was added NaBH₄ (0.81 g, 21.3 mmol) and I₂ (2.3 g, 9.26mmol), and the mixture stirred for 30 min. The reaction mixture was thenheated at reflux for 3 h, and then allowed to cool to room temperature.After cooling to 0° C., the reaction mixture was acidified by slowaddition of 3 N HCl (1 mL). The reaction mixture was concentrated invacuo and the crude product purified by reverse phase HPLC to give3-(aminomethyl)-4-cyclohexyl-6-methyl-2(1H)-pyridinone as a solid (0.5g, 25%). LCMS E-S (M+H)=221.1. ¹H NMR (400 MHz, DMSO-d₆) δ ppm 11.8-11.9(br s, 1H), 7.80-7.93 (br s, 3H), 6.07 (s, 1H), 3.69 (s, 2H), 2.67-2.75(m, 1H), 2.17 (s, 3H), 1.58-1.72 (m, 5H), 1.19-1.41 (m, 5H).

Intermediate 4 3-(Aminomethyl)-4-cyclopropyl-6-methyl-2(1H)-pyridinone

The title compound was prepared in the same manner as described for3-(aminomethyl)-4-cyclohexyl-6-methyl-2(1H)-pyridinone (Intermediate 3)using 4-cyclopropyl-6-methyl-2-oxo-1,2-dihydro-3-pyridinecarbonitrile (5g, 28.7 mmol). Obtained: 0.50 g (10%). LCMS E-S (M+H)=179.1. ¹H NMR (400MHz, DMSO-d₆) δ ppm 11.76-11.78 (br s, 1H), 7.82-7.92 (br s, 3H), 5.61(s, 1H), 3.94-3.99 (m, 2H), 2.11 (s, 3H), 1.98-2.05 (m, 1H), 0.95-1.01(m, 2H), 0.74-0.79 (m, 2H).

Intermediate 5 3-(Aminomethyl)-6-methyl-4-propyl-2(1H)-pyridinone

5a) 6-Methyl-2-oxo-4-propyl-1,2-dihydro-3-pyridinecarbonitrile

To a solution of DMSO (300 mL) containing t-BuOK (20 g, 178 mmol) andcyanoacetamide (16.5 g, 196 mmol) was added (3E)-3-hepten-2-one (20 g,178 mmol), and the contents were stirred at room temperature for 30 min.Additional t-BuOK (60 g, 534 mmol) was added and the reaction mixturewas placed under an atmosphere of oxygen for an additional 1 h. Thereaction mixture was purged with argon, diluted with 4 volumes of H₂O,and then 5 volumes of 4 N HCl, which were added slowly. The reactionmixture was filtered, washed with water, and dried to give6-methyl-2-oxo-4-propyl-1,2-dihydro-3-pyridinecarbonitrile (10 g, 32%).¹H NMR (400 MHz, DMSO-d₆) δ ppm 12.25-12.40 (br s, 1H), 6.18 (s, 1H),2.53 (t, 2H), 2.22 (s, 3H), 1.57-1.64 (m, 2H), 0.84 (t, 3H).

5b) 3-(Aminomethyl)-6-methyl-4-propyl-2(1H)-pyridinone

The title compound was prepared in the same manner as described for3-(aminomethyl)-4-cyclohexyl-6-methyl-2(1H)-pyridinone (Intermediate 3)using 6-methyl-2-oxo-4-propyl-1,2-dihydro-3-pyridinecarbonitrile (2 g,11.2 mmol). Obtained: 1.2 g (60%). LCMS E-S (M+H)=181.1. ¹H NMR (400MHz, DMSO-d₆) δ ppm 7.85-7.95 (br s, 3H), 5.99 (s, 1H), 3.80-3.85 (m,2H), 2.42 (t, 2H), 2.14 (s, 3H), 1.43-1.49 (m, 2H), 0.86 (t, 3H).

Intermediate 6 3-(Aminomethyl)-6-methyl-4-phenyl-2(1H)-pyridinone

The title compound was prepared in the same manner as described for3-(aminomethyl)-6-methyl-4-propyl-2(1H)-pyridinone (Intermediate 5)using (3E)-4-phenyl-3-buten-2-one (20 g, 137 mmol). LCMS E-S(M+H)=215.0. ¹H NMR (400 MHz, DMSO-d₆) δ ppm 12.2-12.3 (br s, 1H),7.88-8.00 (br s, 3H), 7.43-7.51 (m, 3H), 7.29-7.38 (m, 2H), 6.08 (s,1H), 3.67-3.70 (m, 2H), 2.23 (s, 3H).

Intermediate 73-(Aminomethyl)-6-methyl-4-(1-methylethyl)-2(1H)-pyridinone

The title compound was prepared in the same manner as described for3-(aminomethyl)-6-methyl-4-propyl-2(1H)-pyridinone (Intermediate 5)using (3E)-5-methyl-3-hexen-2-one (20 g, 137 mmol). LCMS E-S(M+H)=181.1. ¹H NMR (400 MHz, DMSO-d₆) δ ppm 11.8-11.9 (br s, 1H),7.86-7.96 (br s, 3H), 6.10 (s, 1H), 3.82-3.86 (m, 2H), 3.02-3.09 (m,1H), 2.17 (s, 3H), 1.08 (d, 6H).

Intermediate 8 3-(Aminomethyl)-4-methyl-6-propyl-2(1H)-pyridinone

8a) 4-Methyl-2-oxo-6-propyl-1,2-dihydro-3-pyridinecarbonitrile

To a solution of NaNH₂ (32.5 g, 862 mmol) in anhydrous ether (500 mL) at30° C. was added dropwise a mixture of butyric acid ethyl ester (50 g,431 mmol) and acetone (37.5 g, 646.5 mol). After addition, the reactionmixture was stirred for 4 h. The reaction mixture was poured onto icewater with stirring. Additional ether was added, and the layers wereseparated. The aqueous layer was acidified to pH 5.0 with 2 N HCl andthen to pH 7.5 with Na₂CO₃. The aqueous layer was then extracted withether. The combined organic layers were dried over Na₂SO₄, filtered, andconcentrated in vacuo. The crude product, 2,4-heptanedione (20 g, 156mmol), and 2-cyanoacetamide (13.12 g, 156 mmol) were suspended in EtOH(160 mL) at 75° C., followed by addition of piperidine (13.2 g, 156mmol). The contents were stirred and heated at reflux for 1 h. Themixture was cooled to room temperature and filtered. The collected solidwas suspended in water and stirred for 1 h. The mixture was filtered anddried to give 4-methyl-2-oxo-6-propyl-1,2-dihydro-3-pyridinecarbonitrile(11 g, 40%). LCMS E-S (M+H)=181.1. ¹H NMR (400 MHz, DMSO-d₆) δ ppm12.3-12.4 (br s, 1H), 6.25 (s, 1H), 3.64 (s, 3H), 2.50 (t, 2H), 1.63 (m,2H), 0.94 (t, 3H).

8b) 3-(Aminomethyl)-4-methyl-6-propyl-2(1H)-pyridinone

Sodium acetate (3.5 g, 42.6 mmol), palladium on carbon (0.81 g) andplatinum oxide (0.1 g) were placed in a dried Parr bottle flushed withnitrogen, followed by addition of a small amount of acetic acid (to wetthe catalysts). A solution of4-methyl-2-oxo-6-propyl-1,2-dihydro-pyridine-3-carbonitrile (5 g, 28mmol) in acetic acid was added to the Parr bottle followed by additionalacetic acid (200 mL). The vessel was capped, placed on Parr apparatusand hydrogenated at 45 psi for 12 h. The reaction mixture was filteredand the filtrate concentrated in vacuo. The crude product was purifiedby preparative HPLC to afford the title compound (TFA salt) as 4.1 g(87%). LCMS E-S (M+H))=181.1. ¹H NMR (400 MHz, DMSO-d₆) δ ppm 11.8-11.9(br s, 1H), 7.83-7.88 (br s, 3H), 5.99 (s, 1H), 3.77-3.81 (m, 2H), 2.37(t, 2H), 1.53 (m, 2H), 0.83 (t, 3H).

Intermediate 9 3-(Aminomethyl)-6-cyclopropyl-4-methyl-2(1H)-pyridinonehydrochloride

9a) 1-Cyclopropyl-1,3-butanedione

To a stirring solution of THF (100 mL) was added potassium tert-butoxide(5.60 g, 49.5 mmol), followed by a mixture of cyclopropyl methyl ketone(3.27 mL, 33 mmol) and ethyl acetate (9.69 mL, 99 mmol) in 30 mL THF at35° C., via addition funnel over a 25 min period. The contents wereheated and stirred at 60° C. After 3 h, the contents were removed fromheating, and allowed to cool to room temperature. The reaction mixturewas carefully diluted with 30 mL 2 N HCl and stirred for 10 min. Themixture was extracted with diethyl ether (3×50 mL), and the combinedorganic layers washed with brine (1×50 mL). The organic layer was driedover MgSO₄, filtered, and concentrated in vacuo. Purification bychromatography on silica gel (eluent: 0 to 15% EtOAc in hexanes) withgood separation afforded 1-cyclopropyl-1,3-butanedione as a light yellowcolored oil, 3.9 g in ˜75% purity (residual solvent), for an overallyield of 70%. ¹H NMR (400 MHz, CDCl₃) δ ppm 0.89-0.96 (m, 2H), 1.09-1.15(m, 2H), 1.59-1.69 (m, 1H), 2.04 (s, 3H), 5.63 (s, 1H), 15.5-16.0 (br s,1H).

9b) 6-Cyclopropyl-4-methyl-2-oxo-1,2-dihydro-3-pyridinecarbonitrile

To a stirred solution of ethanol (5 mL) were added1-cyclopropyl-1,3-butanedione (505 mg, 3.00 mmol) and cyanoacetamide(252 mg, 3.00 mmol), and the heterogenous contents heated untilhomogenous (ca. 75° C.). Piperidine was added (0.395 mL, 4.00 mmol) andthe mixture was heated at reflux for 30 min. The reaction mixture wasallowed to cool to room temperature, wherein precipitation ensued. Thesolid precipitate was filtered and set aside. The filtrate wasconcentrated in vacuo and the oily residue treated with minimal EtOAcand then 10 mL hexanes to afford a second crop of solid. The solidproduct crops were combined, suspended in water (7 mL), vigorouslystirred, and vacuum filtered to afford6-cyclopropyl-4-methyl-2-oxo-1,2-dihydro-3-pyridinecarbonitrile as anearly white solid (380 mg, 73%). LCMS E-S (M+H)=175.1. ¹H NMR (400 MHz,CDCl₃) δ ppm 1.01-1.09 (m, 2H), 1.28 (dd, J=8.59, 2.27 Hz, 2H),1.95-2.01 (m, 1H), 2.43 (s, 3H), 5.82 (s, 1H).

9c) 1,1-Dimethylethyl[(6-cyclopropyl-4-methyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]carbamate

6-Cyclopropyl-4-methyl-2-oxo-1,2-dihydro-3-pyridinecarbonitrile (0.35 g,2.01 mmol) was added to methanol (20 mL) and the stirred contents cooledto −10° C. Next was added di-tert-butyloxycarbonyl (0.933 mL, 4.02 mmol)and the suspension stirred for 15 min. Next was added in NiCl₂-6H₂O(0.055 g, 0.201 mmol) as a solid and stirred for 5 min. Then NaBH₄(0.532 g, 14.06 mmol) was added in 6 portions with 5 min. incrementsbetween each portion. Then the ice bath was removed and the contentswere stirred with warming to room temperature overnight. The reactionmixture was returned to −10° C., followed by addition of 3 more portionsof NaBH₄ (0.532 g, 14.06 mmol). The ice bath was removed and the mixturestirred at room temperature for 1 h. The contents were quenched byaddition of diethylethylene amine (0.218 mL, 2.01 mmol) and stirred for45 min at room temperature. The volatiles were removed in vacuo and theresidue suspended in EtOAc and saturated NaHCO₃. The organic layer waswashed with additional NaHCO₃. The layers were separated, and theorganic layer dried over MgSO₄, filtered, and concentrated in vacuo. Thecrude product was purified by silica gel chromatography (eluent: 10%methanol in dichloromethane). The collected product was dried underhi-vacuum for 1 h, and then treated with ether and filtered. Afterdrying in vacuum oven at 45° C. for 2 h,1,1-dimethylethyl[(6-cyclopropyl-4-methyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]carbamatewas collected (0.28 g, 50%). ¹H NMR (400 MHz, DMSO-d₆) δ ppm 0.73-0.80(m, 2H), 0.88-0.96 (m, 2H), 1.36 (s, 9H), 1.70-1.82 (m, 1H), 2.11 (s,3H), 3.95 (d, J=5.31 Hz, 2H), 5.66 (s, 1H), 6.51 (t, J=4.80 Hz, 1H),11.50 (br. s., 1H).

9d) 3-(Aminomethyl)-6-cyclopropyl-4-methyl-2(1H)-pyridinonehydrochloride

1,1-Dimethylethyl[(6-cyclopropyl-4-methyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]carbamate(0.28 g, 1.006 mmol) was added to EtOAc (9 mL) and methanol (1.0 mL).The suspension was stirred at room temperature for 5 min, followed byaddition of 4 M HCl in dioxane (5.03 mL, 20.12 mmol), and the contentswere stirred at room temperature overnight. The volatiles were thenremoved in vacuo to afford a solid. The solid was triturated with ether,filtered, and dried in a vacuum oven at 45° C. for 4 h. The titlecompound was collected (0.22 g, 100% yield). ¹H NMR (400 MHz, DMSO-d₆) δppm 0.78-0.86 (m, 2H), 0.95-1.03 (m, 2H), 1.83 (tt, J=8.46, 5.05 Hz,1H), 2.16-2.22 (m, 3H), 3.75 (q, J=5.47 Hz, 2H), 5.79 (s, 1H), 8.02 (br.s., 3H), 11.92 (br. s., 1H).

Intermediate 10 3-(Aminomethyl)-4-ethyl-6-methyl-2(1H)-pyridinonehydrochloride

10a) Hex-3-en-2-one

To a stirred solution of 1-(triphenylphosphoranylidene)-2-propanone (100g, 307 mmol) in DCM (500 mL) was added propionaldehyde (140 mL, 1929mmol) at room temperature. The reaction mixture was then stirred at roomtemperature for 18 hours. The reaction was monitored by TLC. The solvent(DCM) was distilled off using ordinary distillation. The residue wasthen distilled using fractional distillation under vacuum (˜450 mbar)and the desired product was isolated. The title compound, hex-3-en-2-one(20 g, 66%), was collected at 110° C. ¹H NMR (CDCl₃, 400 MHz) δ ppm1.071-1.121 (t, 3H, J=7.4 Hz), 2.250-2.299 (m, 5H), 6.054-6.094 (d, 1H,J=16 Hz), 6.823-6.895 (m, 1H).

10b) 4-Ethyl-1,2-dihydro-6-methyl-2-oxopyridine-3-carbonitrile

To a stirred solution of t-BuOK (22.85 g, 204.08 mmol) andcyanoacetamide (18.8 g, 224.1 mmol) in DMSO (300 mL) was addedhex-3-en-2-one (20 g, 204.08 mmol) under argon atmosphere at roomtemperature. The reaction mixture was then stirred at room temperaturefor 30 min and then added additional t-BuOK (68.5 g, 612.05 mmol) wasadded. Argon gas was displaced by oxygen gas and the mixture stirred for48 hrs at room temperature in presence of oxygen. Reaction was monitoredby TLC. The reaction mixture was cooled to 0° C. and diluted with water(100 mL) followed by 4 N HCl (120 mL). The mixture was stirred for 15min and the resulting solid was filtered. The solid was washed withwater (1 L) and dried to afford the title compound,4-ethyl-1,2-dihydro-6-methyl-2-oxopyridine-3-carbonitrile (10.5 g, 31%),as an off white solid. ¹H NMR (CDCl₃ 400 MHz): δ ppm 1.148-1.185 (t, 3H,J=7.4 Hz), 2.237 (s, 3H), 2.557-2.614 (m, 2H), 6.211 (s, 1H), 12.330(broad s, 1H). MS(ES) [M+H]⁺ 161.06.

10c) 3-(Amino methyl)-4-ethyl-6-methylpyridin-2(1H)-one

To a suspension of Raney Nickel (6 g) in methanol (200 mL) was added4-ethyl-1,2-dihydro-6-methyl-2-oxopyridine-3-carbonitrile (10 g, 61.7mmol) and methanolic ammonia (750 mL). The reaction mixture was stirredat room temperature under hydrogen pressure (80 psi) for 48 hrs. Thereaction mixture was filtered through Celite and washed with methanol(250 mL). The filtrate was concentrated under reduced pressure and theresidue purified by filter column using silica gel (60-120 mesh), elutedwith 10% MeOH in CHCl₃, to afford 3-(aminomethyl)-4-ethyl-6-methylpyridin-2(1H)-one (5.6 g, 54%) as an off whitesolid. ¹H NMR (DMSO-D₆, 400 MHz) (free amine): δ ppm 1.063-1.101 (t, 3H,J=7.6 Hz), 2.101 (s, 3H), 2.412-2.449 (m, 2H), 3.448 (s, 2H), 5.835 (s,1H). MS(ES) [M+H]⁺ 167.06.

10d) 3-(Aminomethyl)-4-ethyl-6-methylpyridin-2(1H)-one hydrochloride

3-(Amino methyl)-4-ethyl-6-methylpyridin-2(1H)-one, (5.6 g, 33 mmol) wassuspended in DCM (560 mL) and the insoluble contents/particles werefiltered. The filtrate was concentrated and dried. The residue wasdissolved in DCM (10 mL) and 4 M HCl in 1,4-dioxane (16 mL, 66 mmol) wasadded at 0° C. and stirred for 10 min, at which time the reactionmixture was concentrated under high-vacuum and dried. The resultingcrude solid was triturated with hexane (150 mL) and filtered. The solidwas dried under vacuum. Collected 3-(aminomethyl)-4-ethyl-6-methylpyridin-2(1H)-one hydrochloride (5.9 g, 86%). ¹HNMR (400 MHz, DMSO-d₆) δ ppm 1.082-1.120 (t, 3H, J=7.6 Hz), 2.179 (s,3H), 2.503-2.544 (m, 2H), 3.785-3.798 (d, 2H, J=5.2 Hz), 6.024 (s, 1H),7.985 (broad s, 2H), 11.858 (broad s, 1H). MS(ES) [M+H]⁺ 167.2.

Intermediate 11 3-(aminomethyl)-6-ethyl-4-methyl-2(1H)-pyridinone

11a) 4-ethyl-6-methyl-2-oxo-1,2-dihydro-3-pyridinecarbonitrile

To a solution of t-BuOK (17.2 g, 153 mmol) and cyanoacetamide (13 g, 153mmol) in CH₃CN (225 mL) was added (3E)-3-hexen-2-one (15 g, 153 mmol) atroom temperature under N₂ atmosphere. The reaction mixture was stirredfor 30 min. To the reaction mixture was added additional t-BuOK (51.4g), and the N₂ was displaced by oxygen. After stirring for 1 h withoutexternal cooling, the mixture was diluted with 4 N HCl, which was addedslowly and with good stirring. The mixture was filtered, washed withEtOH, dried to give6-ethyl-4-methyl-2-oxo-1,2-dihydro-3-pyridinecarbonitrile (5 g, 21%). ¹HNMR (400 MHz, DMSO-d₆) δ 12.33 (br. s., 1H), 6.18 (s, 1H), 2.45 (q, 2H),2.30 (s, 3H), 1.11 (t, 3H).

11b) 3-(aminomethyl)-6-ethyl-4-methyl-2(1H)-pyridinone

To an ice bath cooled THF solution (200 mL) of6-ethyl-4-methyl-2-oxo-1,2-dihydro-3-pyridinecarbonitrile (7 g, 43.2mmol) was added NaBH₄ (4.2 g, 108 mmol), and I₂ (11.2 g, 43.2 mmol), andthe contents were stirred for 30 min. The reaction mixture was thenheated at reflux overnight. The reaction mixture was cooled, andcarefully neutralized by slow addition of 4 N HCl at 0° C. The mixturewas dried over MgSO₄, filtered, and concentrated in vacuo. The productwas purified by HPLC to give3-(aminomethyl)-6-ethyl-4-methyl-2(1H)-pyridinone as a TFA salt (1.9 g,26.4%). LCMS MH+=167.1 ¹H NMR (400 MHz, DMSO-d₆) δ 11.82 (br. s., 1H),7.82 (br s, 3H), 5.97 (s, 1H), 3.75-3.77 (m, 2H), 2.39 (q, 2H), 2.17 (s,3H), 1.09 (t, 3H).

Intermediate 12 3-(aminomethyl)-6-methyl-4,4′-bipyridin-2(1H)-one

12a) (2Z)-3-Hydroxy-1-(4-pyridinyl)-2-buten-1-one

To a solution of ethyl 4-pyridinecarboxylate (30 g, 198 mmol) andacetone (34.58 g, 595 mmol) in THF (150 mL) was slowly added NaOMe(12.87 g, 238 mmol) at 35-40° C. The mixture was stirred at roomtemperature for 0.5 h, and then heated at reflux for 3 h. The mixturewas cooled to room temperature and filtered to give a solid, which waswashed with t-BuOMe, and dissolved in H₂O. The solution was acidifiedwith acetic acid and the resulting oily product was extracted withCHCl₃. The solvent was removed in vacuo, and the crude product wasobtained (12 g, 37%) and used without further purification. ¹H NMR (400MHz, DMSO-d₆) δ 8.73 (d, 2H), 7.76 (d, 2H), 6.63 (s, 1H), 2.21 (s, 3H);note: enolic OH does not appear.

12b) 6-Methyl-2-oxo-1,2-dihydro-4,4′-bipyridine-3-carbonitrile and4-methyl-6-oxo-1,6-dihydro-2,4′-bipyridine-5-carbonitrile

To a solution of (2Z)-3-hydroxy-1-(4-pyridinyl)-2-buten-1-one (8 g,crude, 49 mmol) and cyanoacetamide (4.12 g, 49 mmol) in anhydrous EtOH(100 mL) was added piperidine (4.17 g, 49 mmol) under N₂ at 75° C. Themixture was heated at reflux for 1 h, and then cooled to roomtemperature. After filtration, the solid was collected and washed withH₂O to give the crude product (4 g) as two isomers. After separation byHPLC, 1.8 g of 6-methyl-2-oxo-1,2-dihydro-4,4′-bipyridine-3-carbonitrileand 1.2 g of 4-methyl-6-oxo-1,6-dihydro-2,4′-bipyridine-5-carbonitrilewere obtained. The identity of6-methyl-2-oxo-1,2-dihydro-4,4′-bipyridine-3-carbonitrile wasestablished by nOE analysis. ¹H NMR (400 MHz, DMSO-d₆) δ 12.79 (br. s.,1H), 8.75 (d, 2H), 7.58 (d, 2H), 6.37 (s, 1H), 2.31 (s, 3H).

12c) 3-(Aminomethyl)-6-methyl-4,4′-bipyridin-2(1H)-one

To an ice bath cooled THF (100 mL) solution of6-methyl-2-oxo-1,2-dihydro-4,4′-bipyridine-3-carbonitrile (4 g, 18.9mmol) was added NaBH₄ (1.43 g, 37.9 mmol), and I₂ (4.81 g, 18.9 mmol),and the mixture was stirred for 0.5 h. The reaction mixture was thenheated at reflux for 4 h. After cooling to 0° C., the reaction mixturewas adjusted to pH 5 with 4 N HCl. The mixture was concentrated in vacuoto give the crude compound, which was purified by HPLC to give3-(aminomethyl)-6-methyl-4,4′-bipyridin-2(1H)-one (1.9 g, 31%) as a TFAsalt. LCMS MH+=216.0 ¹H NMR (400 MHz, DMSO-d6 in D₂O) δ 8.87 (d, 2H),7.87 (d, 2H), 6.13 (s, 1H), 3.65 (br s, 2H), 2.17 (s, 3H).

Intermediate 13 3-(Aminomethyl)-6-cyclobutyl-4-methyl-2(1H)-pyridinone

13a) Ethyl cyclobutanecarboxylate

To a solution of cyclobutanecarboxylic acid (50 g, 500 mmol) in EtOH(1.2 L) was slowly added H₂SO₄ (20 mL) at room temperature. The solutionwas stirred at reflux overnight, and then cooled and poured into H₂O.The aqueous layer was extracted with ether. The combined organic layerswere washed with brine, dried over Na₂SO₄, and concentrated in vacuo togive ethyl cyclobutanecarboxylate as a colorless oil (44 g, 69%). ¹H NMR(400 MHz, CDCl3-d₃) δ 4.04 (q, 2H), 3.04 (m, 1H), 2.12 (m, 4H), 1.88 (m,2H), 1.18 (t, 3H).

13b) 1-Cyclobutyl-1,3-butanedione

To a solution of NaNH₂ (11.7 g, 91 mmol) in anhydrous ether (150 mL)under N₂ at 30° C. was added dropwise a mixture of ethylcyclobutanecarboxylate (19.2 g, 150 mmol) and acetone (21.75 g, 375mmol). After addition, the reaction mixture was stirred for 4 h, thenpoured onto ice water with stirring. Ether was added and the unreactedcomponents were extracted into the organic phase. The clear aqueousextract was acidified to pH 5.0 with 2 N HCl, and then to pH 7.5 withNa₂CO₃. The solution was extracted with ether. The combined organiclayers were dried (Na₂SO₄), filtered, and concentrated to give the crudeproduct of 1-cyclobutyl-1,3-butanedione (9.7 g, 76%), which was used inthe next step without further purification. ¹H NMR (400 MHz, CDCl3-d₃) δ5.42 (s, 1H), 3.66 (s, 1H), 2.11-2.23 (m, 4H), 2.02 (s, 3H), 1.93-1.99(m, 2H).

13c) 6-Cyclobutyl-4-methyl-2-oxo-1,2-dihydro-3-pyridinecarbonitrile and4-cyclobutyl-6-methyl-2-oxo-1,2-dihydro-3-pyridinecarbonitrile

To a solution of 1-cyclobutyl-1,3-butanedione (1.5 g, 10.7 mmol) andcyanoacetamide (1.07 g, 12.8 mmol) in EtOH (25 mL) was added piperidine(1.08 g, 12.8 mmol) at 75° C. After addition, the mixture was stirredwith warming to reflux. After 1 h, the mixture was cooled to roomtemperature during which time precipitation occurred. The contents werefiltered, and the filtered solid suspended in water and stirred for 1 h.The heterogenous mixture was filtered and dried to give a mixture of6-cyclobutyl-4-methyl-2-oxo-1,2-dihydro-3-pyridinecarbonitrile and4-cyclobutyl-6-methyl-2-oxo-1,2-dihydro-3-pyridinecarbonitrile (1.14 g,57%). ¹H NMR (400 MHz, DMSO-d₆ in D₂O) δ 12.15-12.30 (br s, 2H), 6.39(s, 1H), 6.34 (s, 1H), 2.40-2.28 (m, 7H), 2.23-2.25 (m, 3H), 2.18-2.21(m, 4H), 1.99-2.11 (m, 2H), 1.84-1.90 (m, 2H).

13d) 3-(Aminomethyl)-6-cyclobutyl-4-methyl-2(1H)-pyridinone and3-(aminomethyl)-4-cyclobutyl-6-methyl-2(1H)-pyridinone

To an ice bath cooled THF (100 mL) solution of6-cyclobutyl-4-methyl-2-oxo-1,2-dihydro-3-pyridinecarbonitrile and4-cyclobutyl-6-methyl-2-oxo-1,2-dihydro-3-pyridinecarbonitrile (6 g, 32mmol) was added NaBH₄ (2.73 g, 71.8 mmol), and I₂ (8.3 g, 32 mmol), andthe mixture was stirred for 30 min. The reaction mixture was then heatedat reflux for 3 h. After cooling to 0° C., the reaction mixture wasadjusted to pH 5 with 6N HCl. The contents were dried, filtered, andconcentrated in vacuo. The crude product was purified by HPLC to give amixture of 3-(aminomethyl)-6-cyclobutyl-4-methyl-2(1H)-pyridinone and3-(aminomethyl)-4-cyclobutyl-6-methyl-2(1H)-pyridinone (5.6 g, 91%). ¹HNMR (400 MHz, DMSO-d₆) δ 11.60-11.70 (br s, 2H), 7.85 (br s, 4H), 6.15(s, 1H), 6.03 (s, 1H), 3.72-3.79 (m, 2H), 3.29-3.33 (m, 2H), 2.16 (s,6H), 2.05-2.10 (m, 6H), 1.88-1.93 (m, 4H), 1.69-1.79 (m, 4H).

13e) 1,1-Dimethylethyl[(6-cyclobutyl-4-methyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]carbamateand 1,1-dimethylethyl[(4-cyclobutyl-6-methyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]carbamate

To an ice bath cooled solution of3-(aminomethyl)-6-cyclobutyl-4-methyl-2(1H)-pyridinone and3-(aminomethyl)-4-cyclobutyl-6-methyl-2(1H)-pyridinone (3.5 g, 18 mmol)in THF (10 mL) and DMF (10 mL) were added Boc₂O (4.68 g, 21.8 mmol) andtriethylamine (5.4 g, 54 mmol). The contents were then stirred for 30min. at 30° C. The reaction was quenched by addition of ice water,during which time precipitation occurred. The reaction mixture wasfiltered and dried to give a mixture of the crude products. The crudeproducts were separated by HPLC to give 1,1-dimethylethyl[(6-cyclobutyl-4-methyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]carbamate(2.1 g, 20%) and 1,1-dimethylethyl[(4-cyclobutyl-6-methyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]carbamate(1 g, 9.5%). Data for 1,1-dimethylethyl[(6-cyclobutyl-4-methyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]carbamate:¹H NMR (400 MHz, DMSO-d₆) δ 11.28 (br s, 1H), 6.49 (br s, 1H), 5.86 (brs, 1H), 3.85 (br s, 2H), 1.97-2.14 (m, 7H), 1.87-1.94 (m, 1H), 1.72-1.77(m, 1H), 1.28 (s, 9H).

13f) 3-(Aminomethyl)-6-cyclobutyl-4-methyl-2(1H)-pyridinonehydrochloride

A solution of 1,1-dimethylethyl[(6-cyclobutyl-4-methyl-2-oxo-1,2-dihydro-3pyridinyl)methyl]carbamate(2.1 g, 7.2 mmol) in 4 N HCl (in 15 mL 1,4 dioxane) was heated to 60° C.for 1 h. The mixture was cooled to room temperature. The mixture wasfiltered and dried to give3-(aminomethyl)-6-cyclobutyl-4-methyl-2(1H)-pyridinone as an HCl salt(1.95 g, 90%). LCMS MH+=193.1 ¹H NMR (400 MHz, DMSO-d₆) δ 11.70 (br s,1H), 8.01 (s, 3H), 6.04 (s, 1H), 3.74 (d, 2H), 3.32-3.39 (m, 1H), 2.22(s, 3H), 2.17-2.20 (m, 2H), 2.06-2.11 (m, 2H), 1.85-1.95 (m, 1H),1.71-1.79 (m, 1H).

Intermediate 143-(Aminomethyl)-6-methyl-4-[(methyloxy)methyl]-2(1H)-pyridinone

14a) 1-(Methyloxy)-2,4-pentanedione

To a solution of sodium (5.83 g, 243.3 mmol) in dry toluene (62.5 mL)was added ethyl (methyloxy)acetate (24 g, 203.4 mmol) at −5° C. Afterstirring for 3 h, acetone (14 g, 231.4 mmol) was slowly added, uponwhich the mixture became brown and viscous. Next added 72 mL oftert-butyl methyl ether, and the reaction mixture was stirred at roomtemperature for 12 h, after which time the sodium salt precipitated.After collection and washing with additional tert-butyl methyl ether,the sodium salt was dissolved in 46 mL of 20% H₂SO₄. The contents wereextracted with tert-butyl methyl ether and the organic layersconcentrated to afford 1-(methyloxy)-2,4-pentanedione (9.76 g, 36.9%).¹H NMR (400 MHz, CDCl3-d₃) δ 5.76 (s, 1H), 3.96 (s, 2H), 3.38 (s, 3H),2.07 (s, 3H).

14b)6-Methyl-4-[(methyloxy)methyl]-2-oxo-1,2-dihydro-3-pyridinecarbonitrile

1-(Methyloxy)-2,4-pentanedione (9.51 g, 73.12 mmol) and cyanoacetamide(6.17 g, 73.12 mmol) were dissolved in EtOH (76 mL) and heated untilhomogenous (ca. 75° C.). Piperidine (6.25 g, 73.12 mmol) was added andthe reaction mixture heated at reflux for 20 mins, followed by coolingto room temperature. The contents were filtered to give a solid whichwas suspended in 140 mL water and stirred vigorously for 20 min. Theheterogenous mixture was filtered to afford6-methyl-4-[(methyloxy)methyl]-2-oxo-1,2-dihydro-3-pyridinecarbonitrile(7.8 g, 65.6%). LCMS MH+=179.0 ¹H NMR (400 MHz, DMSO-d₆) δ 12.47 (br s,1H), 6.26 (s, 1H), 4.40 (s, 2H), 3.29 (s, 3H), 2.25 (s, 3H).

14c) 3-(Aminomethyl)-6-methyl-4-[(methyloxy)methyl]-2(1H)-pyridinone

6-Methyl-4-[(methyloxy)methyl]-2-oxo-1,2-dihydro-3-pyridinecarbonitrile(1.000 g, 5.61 mmol) was suspended in acetic acid (150 ml) and thesolution passed through an H-cube instrument equipped with Raney-Nicartridge at a rate of 1 mL/min at 50 psi and 60° C. After 18 h. theacetic acid was removed under reduced pressure and the remaining residuewas dissolved in MeOH. The methanolic solution was passed through a 0.2μm teflon syringe filter. The methanolic filtrate was purified byreverse phase HPLC (Gemini 50×100 5 μm column. Run 1: 3 min, 90-10%. Run2, 5 min 0-10%. Run 3, 10 min, 0-20%. The product fractions wereconcentrated to dryness on a Genevac HT-4 instrument to afford3-(aminomethyl)-6-methyl-4-[(methyloxy)methyl]-2(1H)-pyridinone as apale grey waxy solid (900 mg, 70.2% yield) LCMS MH+=183.0 ¹H NMR (400MHz, DMSO-d₆) δ 8.40 (br. s., 1H), 6.10 (s, 1H), 4.39 (s, 2H), 3.66 (br.s., 2H), 3.32 (s, 3H), 2.19 (s, 3H).

Intermediate 153-(Aminomethyl)-6-methyl-4-(phenylmethyl)-2(1H)-pyridinone and3-(aminomethyl)-4-methyl-6-(phenylmethyl)-2(1H)-pyridinone

15a) 1-Phenyl-2,4-pentanedione

To a solution of NaNH₂ (19.02 g, 480 mmol) in anhydrous ether (400 mL)under N₂ at −5° C. was added dropwise ethyl phenylacetate (19.2 g, 150mmol) and then acetone (21.23 g, 370 mmol) with vigorous stirring. Afteraddition, the reaction mixture was stirred at room temperatureovernight. The mixture was then acidified to pH 4.0-5.0 with 1N HCl. Theorganic layer was separated and concentrated in vacuo. The crude productwas purified by silica gel chromatography to give1-phenyl-2,4-pentanedione (18.32 g, 44%). ¹H NMR (400 MHz, CDCl3-d₃) δ15.49 (br s, 1H), 7.33-7.45 (m, 5H), 5.53 (s, 1H), 3.66 (s, 2H), 2.10(s, 3H).

15b) 6-Methyl-2-oxo-4-(phenylmethyl)-1,2-dihydro-3-pyridinecarbonitrileand 4-methyl-2-oxo-6-(phenylmethyl)-1,2-dihydro-3-pyridinecarbonitrile

1-Phenyl-2,4-pentanedione (18.32 g, 104 mmol) and cyanoacetamide (8.74g, 104 mmol) were dissolved in EtOH (104 mL) and heated until homogenous(ca. 75° C.). Piperidine (8.86 g, 104 mmol) was added and the reactionmixture heated at reflux for 15-30 min. followed by cooling to roomtemperature, during which time precipitation occurred. The heterogenouscontents were filtered to give a solid which was suspended in 200 mLwater and stirred vigorously for 20 min. The heterogenous mixture wasfiltered to afford6-methyl-2-oxo-4-(phenylmethyl)-1,2-dihydro-3-pyridinecarbonitrile and4-methyl-2-oxo-6-(phenylmethyl)-1,2-dihydro-3-pyridinecarbonitrile(12.06 g, 52%). LCMS MH+=225.1 ¹H NMR (400 MHz, DMSO-d₆) (mixture ofcompounds) δ 7.21-7.31 (m, 10H), 6.06 (s, 2H), 3.89 (s, 2H), 3.79 (s,2H), 2.24 (s, 3H), 2.15 (s, 3H).

15c) 3-(Aminomethyl)-6-methyl-4-(phenylmethyl)-2(1H)-pyridinone and3-(aminomethyl)-4-methyl-6-(phenylmethyl)-2(1H)-pyridinone

Sodium acetate (6.14 g, 74.8 mmol), Pd/C (0.65 g, 1 mmol), and platinum(II) oxide (45 mg, 1 mmol) were placed in a dried Parr bottle equippedwith nitrogen inlet. A small amount of acetic acid was added to wet thecatalysts. A solution of6-methyl-2-oxo-4-(phenylmethyl)-1,2-dihydro-3-pyridinecarbonitrile and4-methyl-2-oxo-6-(phenylmethyl)-1,2-dihydro-3-pyridinecarbonitrile (6 g,26.7 mmol) in acetic acid (300 mL) was added to the vessel. The contentswere sealed and hydrogenated on Parr shaker at 45 psi for 12 h. Thereaction mixture was filtered and washed with acetic acid. The filtratewas removed under reduced pressure. The residue was washed with methanoland filtered to afford a crude mixture of3-(aminomethyl)-6-methyl-4-(phenylmethyl)-2(1H)-pyridinone and3-(aminomethyl)-4-methyl-6-(phenylmethyl)-2(1H)-pyridinone. The reactionwas run in duplicate to afford a total crude recovery of 14.5 g. To asolution of the above crude product mixture (4.0 g, 17.5 mmol) in THF(10 mL) and DMF (10 mL) was added di-tert-butoxycarbonyl anhydride (5.0g, 23.4 mmoL) and triethylamine (5.2 g, 52.5 mmol) at 0° C. The reactionmixture was stirred with warming to room temperature and then stirredfor an additional 4 h. The contents were diluted with ice water and thenfiltered. The collected solid was dried and the products separated byHPLC to furnish 1.2 g of 1,1-dimethylethyl{[4-methyl-2-oxo-6-(phenylmethyl)-1,2-dihydro-3-pyridinyl]methyl}carbamate(¹H NMR (400 MHz, DMSO-d₆) δ 11.55-1.60 (br s, 1H), 7.20-7.29 (m, 5H),5.85 (s, 1H), 3.92 (s, 2H), 3.90 (s, 2H), 2.10 (s, 3H), 1.32 (s, 9H) and1.0 g of 1,1-dimethylethyl{[6-methyl-2-oxo-4-(phenylmethyl)-1,2-dihydro-3-pyridinyl]methyl}carbamate(¹H NMR (400 MHz, DMSO-d₆) δ 11.50-11.55 (br s, 1H), 7.18-7.25 (m, 5H),5.75 (s, 1H), 4.02 (s, 2H), 3.85 (s, 2H), 2.05 (s, 3H), 1.32 (s, 9H).

15d) 3-(Aminomethyl)-4-methyl-6-(phenylmethyl)-2(1H)-pyridinonehydrochloride

A solution of 1,1-dimethylethyl{[4-methyl-2-oxo-6-(phenylmethyl)-1,2-dihydro-3-pyridinyl]methyl}carbamate(1.2 g, 3.66 mmol) in 4N HCl (in 15 mL 1,4 dioxane) was heated to 60° C.for 1 h. The mixture was cooled to room temperature. The mixture wasfiltered and dried to give3-(aminomethyl)-4-methyl-6-(phenylmethyl)-2(1H)-pyridinone as an HClsalt (0.725 g, 87%). LCMS MH+=229.1 ¹H NMR (400 MHz, DMSO-d₆) δ11.9-12.0 (br s, 1H), 7.99 (br s, 3H), 7.20 (s, 5H), 5.97 (s, 1H),3.72-3.75 (m, 4H), 2.17 (s, 3H).

15e) 3-(Aminomethyl)-6-methyl-4-(phenylmethyl)-2(1H)-pyridinonehydrochloride

A solution of 1,1-dimethylethyl{[6-methyl-2-oxo-4-(phenylmethyl)-1,2-dihydro-3-pyridinyl]methyl}carbamate(1.0 g, 3.0 mmol) in 4N HCl (in 15 mL 1,4 dioxane) was heated to 60° C.for 1 h. The mixture was cooled to room temperature. The mixture wasfiltered and dried to give3-(aminomethyl)-6-methyl-4-(phenylmethyl)-2(1H)-pyridinone as an HClsalt (0.600 g, 86%). LCMS MH+=229.1 ¹H NMR (400 MHz, DMSO-d₆) δ11.9-12.0 (br s, 1H), 8.03 (br s, 3H), 7.16-7.30 (m, 5H), 5.84 (s, 1H),3.91 (s, 2H), 3.81 (s, 2H), 2.10 (s, 3H).

Intermediate 163-(Aminomethyl)-6-methyl-4-(4-morpholinylmethyl)-2(1H)-pyridinone

a) 5-(4-Morpholinyl)-3-pentyn-2-one

To a cooled (−40° C., CH₃CN/CO₂) solution of 4-(2-propyn-1-yl)morpholine(2.2 g, 17.58 mmol) in THF (5 mL) was added dropwise via. syringe underN₂ a solution of 2 M isopropylmagnesium chloride in THF (10 mL, 20.00mmol). The reaction was stirred for 1 hr then a solution ofN-methoxy-N-methylacetamide (2.2 mL, 20.69 mmol) in THF (5 mL) was addedin one portion. The reaction was stirred for 2 hr (allowed to slowlywarm to RT), quenched with aq. NH₄Cl, extracted with EtOAc, washed withbrine, dried (Na₂SO₄), filtered and evaporated to dryness under vacuum.The remaining was purified by silica gel chromatography (Analogix,SF25-60 g, 0 to 80% EtOAc in hexanes). The pure fractions were combinedand evaporated to dryness to give the product5-(4-morpholinyl)-3-pentyn-2-one (2.09 g, 12.50 mmol, 71.1% yield) as ayellow oil. ¹H NMR (400 MHz, DMSO-d₆) δ 3.62-3.57 (m, 4H), 3.56 (s, 2H),2.49-2.43 (m, 4H), 2.34 (s, 3H). MS(ES)+ m/e 168.0 [M+H]⁺.

b)6-Methyl-4-(4-morpholinylmethyl)-2-oxo-1,2-dihydro-3-pyridinecarbonitrile

To a stirred solution of 21 wt % sodium ethoxide in EtOH (4.2 g, 12.96mmol) in EtOH (30 mL) was added 2-cyanoacetamide (1.1 g, 13.08 mmol).The reaction was stirred for 15 min. then a solution of5-(4-morpholinyl)-3-pentyn-2-one (2.0 g, 11.96 mmol) in EtOH was addedto the reaction in one portion. (The reaction quickly turned dark red.)The reaction was stirred overnight at RT, neutralized with 6 N HCl (2.17mL, 13.02 mmol) and evaporated to dryness under vacuum. Dried undervacuum overnight. The remaining dark solid was triturated with asolution of (9:1) CH₂Cl₂, MeOH (50 mL), filtered from insolublematerial, washed with (9:1) CH₂Cl₂, MeOH, and the filtrate evaporated todryness under vacuum. The dark solid was triturated with a solution of(1:1) EtOAc in hexanes, filtered, washed with (1:1) EtOAc in hexanes,and dried under vacuum to give a brown solid (removed a lot of fastrunning non-polar impurities). The crude product was purified by silicagel chromatography (Analogix, SF25-60 g, 0 to 15% CH₂Cl₂/20%(5% NH₄OH inMeOH) in CH₂Cl₂). The pure fractions were combined, evaporated todryness, triturated with hexanes and dried under vacuum to give theproduct6-methyl-4-(4-morpholinylmethyl)-2-oxo-1,2-dihydro-3-pyridinecarbonitrile(0.90 g, 3.86 mmol, 32.3% yield) as a light tan solid.

¹H NMR (400 MHz, DMSO-d₆) δ 12.44 (br. s., 1H), 6.34 (s, 1H), 3.63-3.56(m, 4H), 3.48 (s, 2H), 2.45-2.36 (m, 4H), 2.27 (s, 3H) MS(ES)+ m/e 234.1[M+H]⁺.

c) 3-(Aminomethyl)-6-methyl-4-(4-morpholinylmethyl)-2(1H)-pyridinone

A clear solution of6-methyl-4-(4-morpholinylmethyl)-2-oxo-1,2-dihydro-3-pyridinecarbonitrile(0.60 g, 2.57 mmol) in HOAc (20 mL) was treated on an H-Cube apparatus(50 psi, 60° C., 1 mL/min., Raney Nickel cartridge) for 18 hr overnight.LCMS showed that the reaction was complete. The reaction was evaporatedto dryness, taken up in a small volume of MeOH and treated with 4 N HClin dioxane (5 mL, 20.00 mmol). The mixture was evaporated to drynessunder vacuum (began to ppt. out during evaporation), triturated withEt2O, filtered and dried under vacuum to give the product3-(aminomethyl)-6-methyl-4-(4-morpholinylmethyl)-2(1H)-pyridinone (0.76g, 2.450 mmol, 95% yield) as a light grey solid. ¹H NMR (400 MHz,DMSO-d₆) δ 6.39 (s, 1H), 4.28 (s, 2H), 3.99 (s, 2H), 3.87 (br. s., 4H),3.27 (br. s., 4H), 2.22 (s, 3H). MS(ES)+ m/e 238.0 [M+H]⁺ (weak), 221.3[M+H]⁺-NH₃ (strong).

Intermediate 17 tert-Butyl(5-(aminomethyl)-6-methoxy-4-methylpyridin-2-yl)carbamate

a) Ethyl 4-ethoxy-2-oxopent-3-enoate

To a stirred solution of ethyl 2,4-dioxopentanoate (36.5 g, 231 mmol)and triethyl orthoformate (41 mL, 246 mmol) in ethanol (60 mL) was addedammonium chloride (3.7 g, 69 mmol). The suspension was stirred at RTovernight. LCMS showed that the reaction was mostly complete.(Hydrolyzes on LCMS to some degree?) The reaction was concentrated undervacuum. The remaining oil was taken up in Et₂O (300 mL), filtered toremove insolubles, rinsed with Et₂O, and concentrated under vacuum. Theproduct was obtained by short path distillation under vacuum (bp 70 to77° C. at 0.09 mmHg) to give the product ethyl4-ethoxy-2-oxopent-3-enoate (36.5 g, 47.3 mmol, 79% yield) as a lightyellow oil.

¹H NMR (400 MHz, CHLOROFORM-d) δ 6.24 (s, 1H), 4.32 (q, J=7.2 Hz, 2H),4.02 (q, J=6.9 Hz, 2H), 2.41 (s, 3H), 1.41 (t, J=7.1 Hz, 3H), 1.39 (t,J=7.2 Hz, 3H). MS(ES)+ m/e 186.8 [M+H]⁺, 208.8 M+Na⁺.

b) Ethyl 5-cyano-4-methyl-6-oxo-1,6-dihydropyridine-2-carboxylate

To a stirred solution of ethyl 4-ethoxy-2-oxopent-3-enoate (22.5 g, 121mmol) and 2-cyanoacetamide (9.0 g, 107 mmol) in acetone (250 mL) wasadded potassium carbonate (15.8 g, 114 mmol). The reaction was refluxed(85° C. oil bath) for 10 hr (the reaction formed a thick ppt. in a deepred solution). The slurry was added to cold 1 N HCl (230 mL) in ice.After stirring for 30 min. the suspension was filtered, washed withwater and dried under vacuum to give the product ethyl5-cyano-4-methyl-6-oxo-1,6-dihydropyridine-2-carboxylate (14.51 g, 70.4mmol, 65.7% yield) as a light pink solid. ¹H NMR (400 MHz, DMSO-d₆)δ12.60 (br. s., 1H), 7.05 (br. s., 1H), 4.34 (q, J=7.1 Hz, 2H), 2.45 (s,3H), 1.32 (t, J=7.1 Hz, 3H). MS(ES)+ m/e 206.8 [M+H]⁺.

c) Ethyl 5-cyano-6-methoxy-4-methylpicolinate

To a stirred suspension of ethyl5-cyano-4-methyl-6-oxo-1,6-dihydropyridine-2-carboxylate (2.0 g, 9.70mmol) in CH₂Cl₂ (25 mL) was added trimethyloxonium tetrafluoroborate(2.0 g, 13.52 mmol). The reaction was rinsed down with CH₂Cl₂ andstirred at RT for 24 hr. (The reaction eventually cleared up.) To thereaction was added 1N NaOH (75 mL). After stirring for 10 minutes themixture was poured into a separatory funnel. The CH₂Cl₂ phase wasremoved, dried (Na2SO₄), filtered and concentrated under vacuum.Purification by silica gel chromatography (Analogix SF25-40 g, 50 to100% CH₂Cl₂ in hexanes) gave the product ethyl5-cyano-6-methoxy-4-methylpicolinate (1.13 g, 5.13 mmol, 52.9% yield) asa white solid. ¹H NMR (400 MHz, DMSO-d₆) δ 7.75 (s, 1H), 4.37 (q, J=7.1Hz, 2H), 4.03 (s, 3H), 2.55 (s, 3H), 1.33 (t, J=7.2 Hz, 3H). MS(ES)+m/e221.2 [M+H]⁺.

d) 5-Cyano-6-methoxy-4-methylpicolinic acid

To a stirred solution of ethyl 5-cyano-6-methoxy-4-methylpicolinate (1.0g, 4.54 mmol) in MeOH (30 mL) and THF (10 mL) was added 6N NaOH (2 mL,12.00 mmol). The suspension was heated to 60° C. and stirred for 2 hr.(The reaction cleared up right away.) LCMS indicated that the reactionwas complete. The reaction was cooled to RT and concentrated to neardryness. The slurry was neutralized with 6N HCl (2 mL) diluted withwater, filtered, washed with water and dried under vacuum to give theproduct 5-cyano-6-methoxy-4-methylpicolinic acid (0.76 g, 3.95 mmol, 87%yield) as a white solid. ¹H NMR (400 MHz, DMSO-d₆) δ 13.65 (br. s., 1H),7.73 (s, 1H), 4.03 (s, 3H), 2.54 (s, 3H). MS(ES)+ m/e 192.9 [M+H]⁺.

e) tert-Butyl (5-cyano-6-methoxy-4-methylpyridin-2-yl)carbamate

To a stirred solution of 5-cyano-6-methoxy-4-methylpicolinic acid (0.75g, 3.90 mmol) in tert-butanol (25 mL) was added triethylamine (0.7 mL,5.02 mmol). After the reaction became clear DPPA (1 mL, 4.64 mmol) wasadded dropwise over 5 minutes. The reaction was slowly heated to 100° C.and stirred for 4 hr. The reaction was cooled to RT and evaporated todryness under vacuum. Purified by silica gel chromatography (Analogix,SF25-60 g, 0 to 20% EtOAc in hexanes) to give, after trituration andfiltration from hexanes, the product tert-butyl(5-cyano-6-methoxy-4-methylpyridin-2-yl)carbamate (0.61 g, 2.317 mmol,59.4% yield) as a white solid. ¹H NMR (400 MHz, DMSO-d₆) δ 10.20 (s,1H), 7.44 (s, 1H), 3.91 (s, 3H), 2.40 (s, 3H), 1.48 (s, 9H). MS(ES)+ m/e264.0 [M+H]⁺.

f) tert-Butyl (5-(aminomethyl)-6-methoxy-4-methylpyridin-2-yl)carbamate

A clear solution of tert-butyl(5-cyano-6-methoxy-4-methylpyridin-2-yl)carbamate (0.60 g, 2.279 mmol)in HOAc (5 mL) and ethanol (20 mL) was treated on an H-Cube apparatus(50 psi, 40° C., 1 mL/min., Raney Nickel cartridge) for 18 hr. LCMSshowed that the reaction was complete (86% pure). The reaction wasevaporated to dryness under vacuum. Purified by silica gelchromatography (Analogix, SF25-60 g, 0 to 12% (5% NH₄OH/MeOH) inCH₂Cl₂). The pure fractions were combined and evaporated to drynessunder vacuum to give the product tert-butyl(5-(aminomethyl)-6-methoxy-4-methylpyridin-2-yl)carbamate (0.42 g, 1.571mmol, 68.9% yield) as a white solid. ¹H NMR (400 MHz, DMSO-d₆) δ 9.33(s, 1H), 7.16 (s, 1H), 3.80 (s, 3H), 3.57 (s, 2H), 2.28 (s, 3H), 1.46(s, 9H). MS(ES)+ m/e 268.1 [M+H]⁺.

Intermediate 18[5-(Aminomethyl)-4-methyl-6-(methyloxy)-2-pyridinyl]methanol

a) 6-(Hydroxymethyl)-2-methoxy-4-methylnicotinonitrile

To a stirred suspension of ethyl 5-cyano-6-methoxy-4-methylpicolinate(5.0 g, 22.70 mmol) and calcium chloride (10 g, 90 mmol) intetrahydrofuran (50 mL) and ethanol (50.0 mL) at 0° C. in an ice bathwas added sodium borohydride (2.5 g, 66.1 mmol). The reaction was slowlyallowed to warm to RT and stirred for 18 hr. A large amount of ppt.formed and LCMS showed that the reaction was complete. An equal volumeof EtOAc was added and the reaction stirred for 1 hr. The suspension wasfiltered through a pad of Celite and washed with EtOAc. The filtrate wastransferred to a separatory funnel, washed with aq. NH₄Cl, brine, dried(Na₂SO₄), filtered and concentrated under vacuum. Purification by silicagel chromatography (Analogix, SF40-120 g, 0 to 30% EtOAc in CH₂Cl₂) gavethe product 6-(hydroxymethyl)-2-methoxy-4-methylnicotinonitrile (3.75 g,21.05 mmol, 93% yield) as a white solid. ¹H NMR (400 MHz, DMSO-d₆) δ7.16 (s, 1H), 5.61 (t, J=5.8 Hz, 1H), 4.51 (d, J=5.8 Hz, 2H), 3.94 (s,3H), 2.47 (s, 3H). MS(ES)+ m/e 179.1 [M+H]⁺.

b) (5-(Aminomethyl)-6-methoxy-4-methylpyridin-2-yl)methanol

A clear solution of 6-(hydroxymethyl)-2-methoxy-4-methylnicotinonitrile(0.50 g, 2.81 mmol) in HOAc (5 mL) and Ethanol (20 mL) was treated on anH-Cube apparatus (50 psi, 40° C., 1 mL/min., Raney Nickel cartridge) for18 hr overnight. LCMS showed that the reaction was complete (crudecontained 57% product and 43% dimeric side product). The reaction wasevaporated to dryness under vacuum. Purified by silica gelchromatography (Analogix, SF25-40 g, 0 to 12% (5% NH₄OH in MeOH) inCH₂Cl₂) (step gradient to 8% to elute off the dimeric side product thento 12% to elute off the product). The pure fractions were combined andevaporated to dryness under vacuum to give the product(5-(aminomethyl)-6-methoxy-4-methylpyridin-2-yl)methanol (0.30 g, 1.646mmol, 58.7% yield) as a white solid. MS(ES)+ m/e 183.1 [M+H]⁺, 166.1[M+H]⁺-NH₃.

Intermediate 19 tert-Butyl((5-(aminomethyl)-6-methoxy-4-methylpyridin-2-yl)methyl)carbamate

a)6-((1,3-Dioxoisoindolin-2-yl)methyl)-2-methoxy-4-methylnicotinonitrile

To a stirred solution of6-(hydroxymethyl)-2-methoxy-4-methylnicotinonitrile (1.50 g, 8.42 mmol),phthalimide (1.3 g, 8.84 mmol) and triphenylphosphine (2.3 g, 8.77 mmol)in Tetrahydrofuran (THF) (50 mL) at 0° C. in an ice bath was addeddropwise DIAD (1.8 mL, 9.26 mmol). Within minutes a white suspensionformed. Additional THF (˜50 mL) was added to allow stirring. Thereaction was allowed to warm to RT and stirred for 3 h. LCMS showed thatthe reaction was complete. The reaction was evaporated to dryness undervacuum. The remaining solid was triturated with a small volume of EtOAc,filtered, washed with a small volume of EtOAc, then dried under vacuumto give the product6-((1,3-dioxoisoindolin-2-yl)methyl)-2-methoxy-4-methylnicotinonitrile(2.12 g, 6.90 mmol, 82% yield) as a white solid. ¹H NMR (400 MHz,DMSO-d₆) δ 8.00-7.92 (m, 2H), 7.92-7.87 (m, 2H), 7.15 (s, 1H), 4.86 (s,2H), 3.74 (s, 3H), 2.43 (s, 3H). MS(ES)+ m/e 308.2 [M+H]⁺.

b) tert-Butyl ((5-cyano-6-methoxy-4-methylpyridin-2-yl)methyl)carbamate

To a stirred fine suspension of6-((1,3-dioxoisoindolin-2-yl)methyl)-2-methoxy-4-methylnicotinonitrile(2.1 g, 6.83 mmol) in Ethanol (100 mL) was added hydrazine monohydrate(1.4 ml, 28.9 mmol). The reaction was stirred at RT for 18 hr. LCMSshowed that the reaction was done. The thick white suspension wasfiltered, pressed dry, washed with EtOH, and the filtrate evaporated todryness under vacuum. The remaining solid was taken up inDichloromethane (50 ml), filtered to remove additional insolublematerial, and washed with CH₂Cl₂. To the clear filtrate with stirringwas added Boc₂O (1.809 ml, 7.79 mmol). After stirring at RT for 1 hrLCMS showed that the reaction was complete. The reaction wasconcentrated under vacuum and purified by silica gel chromatography(Analogix, SF25-60, 0 to 10% EtOAc in hexanes). The pure fractions werecombined and evaporated to dryness to give the product tert-butyl((5-cyano-6-methoxy-4-methylpyridin-2-yl)methyl)carbamate (1.42 g, 5.12mmol, 74.9% yield) as a white solid. ¹H NMR (400 MHz, DMSO-d₆) δ 7.48(t, J=6.1 Hz, 1H), 6.91 (s, 1H), 4.16 (d, J=6.1 Hz, 2H), 3.96 (s, 3H),2.45 (s, 3H), 1.41 (s, 9H). MS(ES)+ m/e 278.2 [M+H]⁺.

c) tert-Butyl((5-(aminomethyl)-6-methoxy-4-methylpyridin-2-yl)methyl)carbamate

A clear solution of tert-butyl((5-cyano-6-methoxy-4-methylpyridin-2-yl)methyl)carbamate (0.65 g, 2.344mmol) in HOAc (5 mL) and Ethanol (20 mL) was treated on an H-Cubeapparatus (50 psi, 40° C., 1 mL/min., Raney Nickel cartridge) for 18 hrovernight. LCMS showed that the reaction was complete. The reaction wasevaporated to dryness under vacuum. Purified by silica gelchromatography (Analogix, SF25-60 g, 0 to 10% (5% NH₄OH/MeOH) inCH₂Cl₂). The pure fractions were combined and evaporated to drynessunder vacuum to give the product tert-butyl((5-(aminomethyl)-6-methoxy-4-methylpyridin-2-yl)methyl)carbamate (0.58g, 2.061 mmol, 88% yield) as a clear thick oil. ¹H NMR (400 MHz,DMSO-d₆) δ 7.31 (t, J=6.1 Hz, 1H), 6.63 (s, 1H), 4.06 (d, J=6.3 Hz, 2H),3.84 (s, 3H), 3.61 (s, 2H), 2.29 (s, 3H), 1.53 (br. s., 2H), 1.41 (s,9H). MS(ES)+ m/e 282.2 [M+H]⁺.

Intermediate 20

The title compound was prepared in the same manner as described for3-(aminomethyl)-4-ethyl-6-methyl-2(1H)-pyridinone (Intermediate 10c).LCMS (ES+) m/z=195.22 (M+H). ¹H NMR (DMSO-d₆, 400 MHz): δ 0.809-0.774(t, 3H, J=6.8 Hz), 1.113-1.097 (d, 3H, J=6.4 Hz), 1.504-1.468 (t, 2H,J=7.2 Hz), 2.184 (s, 3H), 2.839-2.822 (d, 1H, J=6.8 Hz), 3.822 (s, 2H),6.059 (s, 1H), 8.315 (bs, 2H).

Intermediate 21 Methyl 6-bromo-1-isopropyl-1H-indole-4-carboxylate a)5-Bromo-2-methyl-3-nitro-benzoic acid

To a stirred solution of 2-methyl-3-nitro benzoic acid (300 g, 1647mmol) in conc. H₂SO₄ (1.5 L) was added 1,3-dibromo-5,5dimethyl-2,4-imadazolidinedione (258 g, 906 mmol) and the mixture wasstirred at room temperature for 5 h. The reaction mixture was slowlyadded to ice water (4 L), and solid was precipitated out. The solid wasfiltered off and washed with water (1.2 L), pet ether (1 l) and dried toafford the title compound as a white solid (411 g, 96%), which was usedwithout further purification. ¹H NMR (DMSO, 400 MHz): δ 2.446 (s, 3H),8.136 (s, 1H), 8.294 (s, 1H). LCMS (ES−) m/z=257.93 (M−H)⁻

b) Methyl 6-bromo-1H-indole-4-carboxylate

To a stirred solution of 5-bromo-2-methyl-3-nitro-benzoic acid (140 g,538.4 mmol) in DMF (550 ml) was added DMF-DMA (599 mL, 4846 mmol) atroom temperature. The reaction mixture was stirred at 115° C. for 18 h.The reaction mixture was then concentrated in vacuo. The residualcontents (176 g, 536.5 mmol) were dissolved in acetic acid (696 mL) andadded to a suspension of iron (329.2 g, 5902 mmol) in acetic acid (1.4L) at 50° C. After completion of addition, the reaction mixture wasstirred at 80-90° C. for 4 h. The reaction mixture was then filteredthrough a Celite pad. The filtrate was poured onto ice water (1 L) andextracted with diethyl ether (3×700 ml). The combined organic layerswere washed with sat NaHCO₃, brine, and dried over anhydrous Na₂SO₄,filtered, and evaporated under vacuum. The crude product was purified bysilica gel chromatography (eluent: 10% ethyl acetate in pet ether) andafforded the title compound as a solid (80 g, 59%). ¹H NMR (DMSO-d₆, 400MHz) δ: 3.980 (s, 3H), 7.168 (d, J=3.2 Hz, 1H), 7.334 (d, J=3.2 Hz, 1H),7.734 (s, 1H), 8.017 (s, 1H), 8.384 (brs, 1H); LCMS (ES−) m/z=251.9(M−H).

c) Methyl 6-bromo-1-isopropyl-1H-indole-4-carboxylate

To a stirred solution of methyl 6-bromo-1H-indole-4-carboxylate (100 g,393.7 mmol) in DMF (800 mL) was added 2-iodopropane (160 g, 944.8 mmol)followed by portionwise addition of sodium hydride (20.4 g, 511.8 mmol)at 0° C. The reaction mixture was stirred at room temperature for 18 h.Diluted the reaction mixture with cold water and extracted withethylacetate (200 mL×4), finally organic layer was washed with coldwater, brine solution dried over anhydrous Na₂SO₄ and concentrated underreduced pressure to afford crude, which was purified by columnchromatography using silica gel (60-120 mesh) with 5% EtOAC: pet etheras an eluent to afford methyl6-bromo-1-isopropyl-1H-indole-4-carboxylate (65 g, 55.7%) as a solid. ¹HNMR (CDCl₃, 400 MHz) δ 1.53 (d, 6H, J=6.4 Hz), 3.973 (s, 3H),4.598-4.664 (m, 1H), 7.111 (d, 1H, J=2.4 Hz), 7.338 (d, 1H, J=2.8 Hz),7.711 (s, 1H), 7.987 (s, 1H).

d) 6-Bromo-1-(1-methylethyl)-1H-indole-4-carboxylic acid

To a solution of methyl6-bromo-1-(1-methylethyl)-1H-indole-4-carboxylate (0.52 g, 1.756 mmol)in methanol (15 mL) and tetrahydrofuran (3 mL) was added 3 M NaOH (1.756mL, 5.27 mmol) via syringe drop wise (over 2 min). The solution wasmaintained at RT for 2 h, at which time LCMS showed only 12% conversionto product. Then 1.5 mL 3 M NaOH was added and the solution wasmaintained at RT overnight. LCMS showed complete conversion to product.Removed volatiles in vacuo and dissolved the residue in water and slowlyacidified with 1 M HCl (solids precipitated). Extracted with EtOAc (2×),combined organics and dried over MgSO₄. Filtered and concentrated invacuo to give 6-bromo-1-(1-methylethyl)-1H-indole-4-carboxylic acid(0.50 g, 1.737 mmol, 99% yield) as a white solid.

Alternatively, the alkylation of the indole nitrogen could be performedas follows: To a cooled (0° C.) suspension of methyl6-bromo-1H-indole-4-carboxylate (10 g, 39.4 mmol) and(cyanomethyl)(trimethyl)phosphonium chloride (14.91 g, 98 mmol) in THF(400 mL) was added 2-propanol (6.06 mL, 79 mmol), followed by sodiumhydride (3.46 g, 87 mmol). The mixture was stirred at ambienttemperature for 2 h, at which time LCMS showed no product formation.Heated at 50° C. for 18 h. LC/MS showed reaction complete. Filteredreaction mixture and concentrated in vacuo. The residue was diluted withmethylene chloride and passed through a pad of silica (washed withmethylene chloride). Purification by flash chromatography (AnalogixSF65-200 g; 5-10% EtOAc/hexanes) gave methyl6-bromo-1-(1-methylethyl)-1H-indole-4-carboxylate (9.7 g, 31.4 mmol, 80%yield). MS(ES) [M+H]⁺ 296.2, 298.4.

Examples 22-23 were prepared by the methods described above forIntermediate 16 or routine variations thereof, starting from therequisite 2-methyl-3-nitrobenzoic acid:

MS(ES) Ex Structure Name 1H NMR [M + H]⁺ 22

6-fluoro-1-(1- methylethyl)-1H-indole- 4-carboxylic acid 1.44 (d, 6 H),4.63-4.96 (m, 1 H), 6.97 (d, J = 3.03 Hz, 1 H), 7.46 (dd, J = 10.36,2.27 Hz, 1 H), 7.67 (d, J = 3.28 Hz, 1 H), 7.75 (dd, J = 10.11, 2.02 Hz,1 H), 12.97 (s, 1 H) 222.1 23

6-chloro-1-(1- methylethyl)-1H-indole- 4-carboxylic acid (CHLOROFORM-d)1.57 (d, 6 H), 4.67 (spt, J = 6.69 Hz, 1 H), 7.19 (d, J = 3.03 Hz, 1 H),7.41 (d, J = 3.28 Hz, 1 H), 7.63 (d, J = 1.01 Hz, 1 H), 7.97 (d, J =1.77 Hz, 1 H) 237.9

Intermediate 24 Methyl 6-bromo-1-isopropyl-1H-indole-4-carboxylate

24a) Methyl 6-bromo-3-formyl-1-isopropyl-1H-indole-4-carboxylate

To a stirred solution of DMF (1.04 lit) POCl₃ (40.3 g, 263 mmol) wasadded at 0° C. and stirred for 20 min. Then methyl6-bromo-1-isopropyl-1H-indole-4-carboxylate (65 g, 219.5 mmol) in DMF(260 mL) was added to the reaction mixture at 0° C. The reaction mixturewas stirred at room temperature for 3 h. Diluted the reaction mixturewith cold water and adjusted PH˜8 using with 2N NaOH solution, extractedwith ethylacetate (4×1 lit). The organic layer washed with cold water,brine solution, dried over anhydrous Na₂SO₄ and concentrated underreduced pressure to afford desired product methyl6-bromo-3-formyl-1-isopropyl-1H-indole-4-carboxylate (65 g, 91.3%). ¹HNMR (CDCl₃, 400 MHz): δ 1.588 (d, 6H, J=6.8 Hz), 3.994 (s, 3H),4.634-4.701 (m, 1H), 7.760 (d, 1H, J=1.6 Hz), 7.958 (d, 1H, J=1.6 Hz),8.122 (s, 1H), 10.446 (s, 1H). LC-MS (ES+) m/z=324.02 (M+H)

24b) Methyl 6-bromo-1-isopropyl-3-methyl-1H-indole-4-carboxylate

To a stirred solution of methyl6-bromo-3-formyl-1-isopropyl-1H-indole-4-carboxylate (60 g, 185 mmol) inDMF (220 mL) was added p-toluenesulfonic acid mono hydride (4.57 g, 24mmol), p-toluenesulfonyl hydrazide (44.8 g, 240 mmol) followed bysulfolane (220 mL). The mixture was stirred at 100° C. for 1 h. Thecontents were cooled to room temperature and then sodiumcyanoborohydride (46.5 g, 740 mmol) was added portion wise over a periodof 25 min. Then the mixture was stirred at 100° C. for 2 h. Then thereaction mixture was stirred for 16 h at room temperature. The reactionmixture was diluted with water and extracted with 20% EtOAc: Pet ether,finally organic layer was washed with cold water, brine solution driedover anhydrous Na₂SO₄ and concentrated. Crude compound was purified bycolumn chromatography using silica gel (100-200 mesh) and 20% DCM: Petether as an eluent to afford desired product methyl6-bromo-1-isopropyl-3-methyl-1H-indole-4-carboxylate (24 g, 89.2%purity), (16 g, and 62.2% purity). ¹H NMR (CDCl₃, 400 MHz) δ 1.486 (d,J=6.4 Hz, 6H), 2.361 (s, 3H), 3.947 (s, 3H), 4.535-4.602 (m, 1H), 7.080(s, 1H), 7.619 (s, 1H), 7.684 (s, 1H). LCMS (ES+) m/z=310.07 (M+H)

24c) 6-Bromo-1-isopropyl-3-methyl-1H-indole-4-carboxylic acid

To a stirred solution of methyl6-bromo-1-isopropyl-3-methyl-1H-indole-4-carboxylate (24 g, 77.4 mmol)in ethanol (400 mL) was added sodium hydroxide (4.02 g, 100.6 mmol),water (11 mL) and the mixture was stirred at reflux condition for 6 h.Ethanol was distilled off and residue was diluted with water, extractedwith ethylacetate (40 mL) adjusted aqueous layer to PH˜3 with 1N HCl andextracted with ethyl acetate (3×250 mL), finally organic layer waswashed with brine solution, dried over anhydrous Na₂SO₄ andconcentrated. The crude was washed with pet ether, filtered the solidand dried to afford desired product6-bromo-1-isopropyl-3-methyl-1H-indole-4-carboxylic acid (20.6 g,89.8%). ¹H NMR (DMSO-d₆, 400 MHz): δ 1.407 (d, J=6.4 Hz, 6H), 2.296 (s,3H), 4.754-4.819 (m, 1H), 7.455 (s, 1H), 7.472 (s, 1H), 7.938 (s, 1H),12.950 (brs, 1H). LCMS (ES+) m/z=296.15 (M+H).

Intermediate 25 6-Bromo-1-(sec-butyl)-3-methyl-1H-indole-4-carboxylicacid

a) Methyl 6-bromo-1-sec-butyl-1H-indole-4-carboxylate

To a stirred suspension of sodium hydride (5.66 g, 141.7 mmol) in DMF(100 mL) was added a solution of methyl 6-bromo-1H-indole-4-carboxylate(4) (30 g, 118.1 mmol) in DMF (50 mL) at 0° C. and stirred for 20 min.Then 2-Bromo butane (29.1 g, 212.5 mmol) was added at 0° C. and thereaction mixture was stirred at room temperature for 16 h. The reactionmixture was diluted with cold water and extracted with ethyl acetate(4×150 mL). The combined organic layer was washed with cold water (150mL), brine (100 mL) and dried over anhydrous Na₂SO₄ and concentratedunder reduced pressure to afford crude, which was purified by columnchromatography over silica gel (60-120 mesh) using 5% EtOAc: Pet etheras eluent to afford the title compound methyl6-bromo-1-sec-butyl-1H-indole-4-carboxylate, 5 (14 g, 40.1%) as paleyellow solid. ¹H NMR (CDCl₃, 400 MHz) δ 0.843-0.870 (m, 3H), 1.512 (d,J=6.4 Hz, 3H), 1.844-1.926 (m, 2H), 3.976 (s, 3H), 4.333-4.385 (m, 1H),7.132 (d, J=3.2 Hz, 1H), 7.302 (d, J=3.6 Hz, 1H), 7.707 (s, 1H), 7.984(d, J=1.6 Hz, 1H).

b) Methyl 6-bromo-1-sec-butyl-3-formyl-1H-indole-4-carboxylate

POCl₃ (8.3 g, 54.3 mmol) was added at 0° C. to anhydrous DMF (230 mL) ina round bottom flask and stirred for 30 min. Then a solution of methyl6-bromo-1-sec-butyl-1H-indole-4-carboxylate, 5 (14 g, 45.3 mmol) in DMF(60 mL) was added to the reaction mixture at 0° C. and stirred at roomtemperature for 2.5 h. The reaction mixture was diluted with cold water,adjusted pH˜8 using with 2N NaOH solution and extracted with ethylacetate (4×200 mL). The combined organic layer was washed with coldwater (2×100 mL), brine (100 mL), dried over anhydrous Na₂SO₄ andconcentrated under reduced pressure to afford desired product methyl6-bromo-1-sec-butyl-3-formyl-1H-indole-4-carboxylate, 6 (15.2 g, 99%) aspale yellow solid. This was used as such in the next step withoutpurification. ¹H NMR (CDCl₃, 400 MHz) δ (0.831-0.859 (m, 3H),1.515-1.574 (d, J=6.8 Hz, 3H), 1.729-1.972 (m, 2H) 3.997 (s, 3H),4.394-4.445 (m, 1H), 7.756 (d, J=1.2 Hz, 1H), 7.958 (d, J=2 Hz, 1H),8.079 (s, 1H), 10.452 (s, 1H).

c) Methyl 6-bromo-1-sec-butyl-3-methyl-1H-indole-4-carboxylate

To a stirred solution of methyl6-bromo-1-sec-butyl-3-formyl-1H-indole-4-carboxylate (15 g, 44.6 mmol)in DMF (115 mL) was added p-toluenesulfonic acid mono hydrate (1.1 g,5.8 mmol), p-toluenesulfonyl hydrazide (10.8 g, 58 mmol) followed bysulfolane (115 mL) at RT and the reaction mixture was stirred at 100° C.for 1 h. The reaction mixture was cooled to room temperature, treatedwith sodium cyanoborohydride (11.9 g, 178.5 mmol) portion wise over aperiod of 5 min and stirred at 100° C. for 2 h. The reaction mixture wascooled to room temperature and stirred at the same temperature for 16 h.The reaction mixture was diluted with water and extracted with 30%EtOAc: Pet ether. The organic layer was washed with cold water (100 mL),brine (100 mL) and dried over anhydrous Na₂SO₄ and concentrated underreduced pressure to afford crude, which was purified by columnchromatography over silica gel (100-200 mesh) using 5% EtOAc: Pet etheras eluent to afford title compound methyl6-bromo-1-sec-butyl-3-methyl-1H-indole-4-carboxylate (7.88 g, 54.6%) aspale yellow gum. ¹H NMR (CDCl₃, 400 MHz): δ 0.804-0.841 (t, J=7.4 Hz,3H), 1.454-1.470 (d, J=6.4 Hz, 3H), 1.865-1.884 (m, 2H), 2.363 (s, 3H),3.950 (s, 3H), 4.265-4.316 (m, 1H), 7.038 (s, 1H), 7.609 (d, J=1.2 Hz,1H), 7.671 (d, J=2 Hz, 1H). MS (ES+): 324.19 [M+H] ion present.

d) 6-Bromo-1-(sec-butyl)-3-methyl-1H-indole-4-carboxylic acid

Methyl 6-bromo-1-(sec-butyl)-3-methyl-1H-indole-4-carboxylate (3.24 g,9.99 mmol) was dissolved in methanol (30 mL) and tetrahydrofuran (THF)(7 mL). The contents were stirred for 5 min., and then aq. 3N NaOH(19.99 mL, 60.0 mmol) was added via addition funnel over 3 min. Thecontents rapidly became a yellow suspension and were stirred at roomtemperature for 65 h. The volatiles were removed in vacuo and theresidue dissolved in water (60 mL). The contents were washed with ether(1×50 mL). The aq layer was cooled in an ice bath and adjusted to pH 3-4with 1M HCl, from which an oily residue precipitated. The contents wereextracted with EtOAc (2×60 mL). The combined organic layers were driedover magnesium sulfate, filtered through celite, and concentrated invacuo. The residue obtained was treated with TBME, concentrated invacuo, and then dried under hi vacuum to afford a yellow foam as 3.08 g(93%). ¹H NMR (400 MHz, DMSO-d6) δ ppm 0.70 (t, J=7.33 Hz, 3H), 1.39 (d,J=6.82 Hz, 3H), 1.71-1.86 (m, 2H), 2.30 (s, 3H), 4.48-4.62 (m, 1H),7.40-7.49 (m, 2H), 7.96 (d, J=1.77 Hz, 1H), 12.99 (s, 1H);LCMS=310.0/312.0 (MH+).

Examples 26-27 were prepared by the methods described above forIntermediate 16 or routine variations thereof, starting from therequisite 6-substituted indole:

MS(ES) Ex Structure Name 1H NMR [M + H]⁺ 26

6-chloro-3-methyl-1-(1- methylethyl)-1H-indole-4- carboxylic acid 12.99(br.s., 1 H), 7.82 (d, J = 2.0 Hz, 1 H), 7.47 (d, J = 1.0 Hz, 1 H), 7.36(d, J = 2.0 Hz, 1 H), 4.78 (quin, J = 6.6 Hz, 1 H), 2.30 (d, J = 1.0 Hz,3 H), 1.41 (d, J = 6.6 Hz, 6 H) 252.4 27

6-bromo-1-(sec-butyl)-3- methyl-1H-indole-4- carboxylic acid 0.70 (t, J= 7.33 Hz, 3 H) 1.39 (d, J = 6.82 Hz, 3 H) 1.71-1.86 (m, 2 H) 2.30 (s, 3H) 4.48-4.62 (m, 1 H) 7.40-7.49 (m, 2 H) 7.96 (d, J = 1.77 Hz, 1 H)12.99 (s, 1 H) 310.0

Intermediate 28 6-Bromo-1-cyclopropyl-1H-indole-4-carboxylic acid

a) Methyl 6-bromo-1-cyclopropyl-1H-indole-4-carboxylate

In a oven dried 100 ml RBF equipped, stir bar, septum and Nitrogen inletwas added methyl 6-bromo-1H-indole-4-carboxylate (0.508 g, 2.0 mmol) and1,2-dichloroethane (7 mL). The solution was stirred for 15 min, thencyclopropylboronic acid (0.344 g, 4.00 mmol) and sodium carbonate (0.424g, 4.00 mmol) were added. Diluted copper(II) acetate (0.363 g, 2.000mmol) and 2,2′-bipyridine (0.312 g, 2.000 mmol) in 1,2-dichloroethane(12 mL), heated the mixture, and added the hot suspension to thereaction. The reaction was heated at 70° C. and monitored by LCMS.Stopped heating after 6 h and allowed to sit for 3 days at RT. Added toreaction saturated NH4Cl and water. Extracted with DCM (2×). Thecombined organics were washed with brine, dried over magnesium sulfate,filtered and concentrated in vacuo. Purification of the residue bycolumn chromatography (24 g Isco silica column; gradient B: 3-25%. A:hexane. B: ethyl acetate) to give methyl6-bromo-1-cyclopropyl-1H-indole-4-carboxylate (0.43 g, 1.433 mmol, 71.6%yield) as a yellow residue. 1H NMR (400 MHz, DMSO-d6) δ ppm 0.96-1.01(m, 2H) 1.06-1.12 (m, 2H) 3.52 (dt, J=7.20, 3.47 Hz, 1H) 3.90 (s, 3H)6.85-6.91 (m, 1H) 7.57 (d, J=3.03 Hz, 1H) 7.82 (d, J=1.77 Hz, 1H) 8.04(d, J=1.01 Hz, 1H). MS(ES) [M+H]⁺ 294.1.

b) 6-Bromo-1-cyclopropyl-1H-indole-4-carboxylic acid

To a solution of methyl 6-bromo-1-cyclopropyl-1H-indole-4-carboxylate(0.43 g, 1.462 mmol) in MeOH (12 mL) and THF (3 mL) was added 3 M NaOH(1.949 mL, 5.85 mmol). The reaction was stirred for 18 h at RT, at whichtime the volatiles were removed in vacuo. The residue was diluted withwater and slowly acidified with 1 N HCl to pH 4-5, then extracted withEtOAc (2×). The combine organics were wash with brine, dried overmagnesium sulfate, filtered, and concentrated to give6-bromo-1-cyclopropyl-1H-indole-4-carboxylic acid (0.376 g, 1.315 mmol,90% yield) as a pale yellow solid. 1H NMR (400 MHz, DMSO-d6) δ ppm0.92-1.01 (m, 2H) 1.05-1.12 (m, 2H) 3.51 (tt, J=7.07, 3.66 Hz, 1H) 6.89(d, J=2.53 Hz, 1H) 7.52 (d, J=3.03 Hz, 1H) 7.80 (d, J=1.77 Hz, 1H) 7.99(d, J=1.01 Hz, 1H) 13.05 (br. s., 1H). MS(ES) [M+H]⁺ 280.1.

Intermediate 29 6-Bromo-1-cyclobutyl-1H-indole-4-carboxylic acid

a) Methyl 6-bromo-1-cyclobutyl-1H-indole-4-carboxylate

In an oven dried 100 ml RBF, equipped with a stir bar, septum, nitrogeninlet was added methyl 6-bromo-1H-indole-4-carboxylate (1.0 g, 3.94mmol) and (cyanomethyl)(trimethyl)phosphonium chloride (1.491 g, 9.84mmol). Added in THF (40 mL) and stirred suspension for 5 min. Thereaction was cooled with an ice bath for 10 min, then was addedcyclobutanol (0.616 mL, 7.87 mmol), followed by sodium hydride (0.346 g,8.66 mmol) portionwise. The ice bath was removed and the reactionstirred at ambient temperature for 45 min, then heated at 50° C. for 18h. LCMS showed mostly SM. Heated at 75° C. for 24 h. The reaction wasallowed to cool to RT, then poured into water (200 ml) and extractedwith EtOAc (2×). The combined organics were dried over magnesiumsulfate, filtered, and concentrated. Purification of the residue bycolumn chromatography (40 g Isco silica column; gradient B: 2-25%; A:hexane, B: EtOAc) gave methyl6-bromo-1-cyclobutyl-1H-indole-4-carboxylate (0.3 g, 25% yield, ˜45%pure by HPLC). MS(ES) [M+H]⁺ 308.2.

b) 6-Bromo-1-cyclobutyl-1H-indole-4-carboxylic acid

To a solution of ethyl 6-bromo-1-cyclobutyl-1H-indole-4-carboxylate (0.3g, 0.973 mmol) (crude residue from above) in MeOH (8 mL) and THF (2 mL)was added 3 M NaOH (1.298 mL, 3.89 mmol). The reaction was stirred at RTfor 16 h, at which time the volatiles were removed in vacuo. The residuewas diluted with water and slowly acidified with 1 N HCl to pH 3-4. Thesolids were filtered and dried on hivac for 16 h to give6-bromo-1-cyclobutyl-1H-indole-4-carboxylic acid (0.21 g, 0.535 mmol,55.0% yield). 1H NMR (400 MHz, DMSO-d6) δ ppm 1.79-1.89 (m, 2H)2.34-2.46 (m, 2H) 3.84 (s, 1H) 5.08 (t, J=8.21 Hz, 1H) 6.99 (d, J=3.03Hz, 1H) 7.75-7.79 (m, 1H) 7.81 (d, J=3.03 Hz, 1H) 8.01-8.05 (m, 1H)13.03 (br. s., 1H). MS(ES) [M+H]⁺ 294.1.

Intermediate 301-Isopropyl-3-methyl-6-(methylsulfonyl)-1H-indole-4-carboxylic acid

To a 30-mL microwave tube were added methyl6-bromo-3-methyl-1-(1-methylethyl)-1H-indole-4-carboxylate (490 mg,1.580 mmol), methanesulfinic acid (212 mg, 2.054 mmol), DMSO (7 mL),N,N′-dimethyl-1,2-ethanediamine (18.10 mg, 0.205 mmol), and the mixturewas degassed for 5 min by bubbling N2. Copper(I)trifluoromethanesulfonate benzene complex (63.6 mg, 0.126 mmol) wasadded and the tube was sealed. The mixture was heated at 165° C.overnight with stirring. The mixture was allowed to cool, filtered andpurified using reverse-phase HPLC (Gemini 5u C18(2) 100A, AXIA; 30×100mm 5 micron; 30 mL/min, 30% ACN/H2O, 0.1% formic acid to 60% ACN/H2O,0.1% formic acid) to give the title compound (118 mg, 25%) as a whitesolid. ¹H NMR (400 MHz, DMSO-d₆) ppm 1.47 (d, J=8.00 Hz, 6H), 2.30-2.41(m, 3H), 4.94 (quin, J=6.63 Hz, 1H), 7.80 (s, 1H), 7.88 (d, J=1.77 Hz,1H), 8.24 (d, J=1.52 Hz, 1H), 13.17 (br. s., 1H). MS: (M+H)⁺=296.3.

Intermediate 31 1-Isopropyl-6-(methylsulfonyl)-1H-indole-4-carboxylicacid

To a 10-mL microwave tube were added methyl6-bromo-1-(1-methylethyl)-1H-indole-4-carboxylate (160 mg, 0.540 mmol),sodium methanesulfinate (80 mg, 0.702 mmol), DMSO (2 mL), andN,N′-dimethyl-1,2-ethanediamine (6.19 mg, 0.070 mmol), and the mixturewas degassed for 5 min by bubbling N₂. Copper(I)trifluoromethanesulfonate benzene complex (25.6 mg, 0.043 mmol) wasadded and the mixture was heated to 165° C. for 2 h with stirring. Themixture was filtered and the DMSO solution was purified usingreverse-phase HPLC to give 14 mg of product as white solid. ¹H NMR (400MHz, DMSO-d₆) ppm 1.51 (d, J=4.00 Hz, 6H), 4.90-5.11 (m, 1H), 7.13 (d,J=3.03 Hz, 1H), 7.98-8.08 (m, 1H), 8.15-8.23 (m, 1H), 8.32-8.46 (m, 1H),13.19 (br. s., 1H). MS: (M+H)⁺=281.9.

Intermediate 326-(Cyclopropylsulfonyl)-1-(1-methylethyl)-1H-indole-4-carboxylic acid

¹H NMR (400 MHz, DMSO-d₆) δ ppm 1.03 (dd, J=7.71, 2.40 Hz, 2H), 1.17(dd, J=7.20, 3.41 Hz, 2H), 1.50 (d, 6H), 2.83-2.97 (m, 1H), 5.02 (dt,J=13.14, 6.57 Hz, 1H), 7.17 (d, J=2.27 Hz, 1H), 7.99 (d, J=3.03 Hz, 1H),8.13 (s, 1H), 8.28 (s, 1H). MS: (M+H)⁺=308.3.

Intermediate 33 6-Hydroxy-1-isopropyl-1H-indole-4-carboxylic acid methylester

Freshly prepared sodium methoxide (500 mg in 5 mL methanol) was added toa stirred suspension of 6-bromo-1-isopropyl-1H-indole-4-carboxylic acidmethyl ester (500 mg, 1.68 mmol) and Cul (480 mg, 2.53 mmol) in NMP (8mL) and then heated at 120° C. for 2 h. The reaction mixture was cooledto room temperature, diluted with water (5 mL) and acidified with 1NHCl. The reaction mixture was filtered through Celite and washed withEtOAc (5 mL). Separated the EtOAc layer from filtrate, dried overanhydrous Na₂SO₄ and concentrated under reduced pressure to furnish thecrude 1-isopropyl-6-methoxy-1H-indole-4-carboxylic acid (700 mg), whichwas used in the next stage without further purification. ¹H NMR (400MHz, DMSO-d₆): δ 1.44 (d, J=6.4 Hz, 6H), 3.84 (s, 3H), 4.80-4.76 (m,1H), 6.87 (d, 1H), 7.33 (t, J=3.2 Hz, 2H), 7.49 (d, J=3.2 Hz, 1H), 12.65(bs, 1H). LCMS (ES+): m/z=234.11 [M+H].

To a stirred suspension of 1-isopropyl-6-methoxy-1H-indole-4-carboxylicacid (700 mg, 3.00 mmol) in MeOH was added H₂SO₄ (440 mg, 4.50 mmol) andthen heated at reflux for 3 h. Methanol was distilled off completelyunder reduced pressure and the residue basified with saturated aqueousNaHCO₃ solution and extracted with ethyl acetate (2×5 mL). The combinedorganic layers were dried over anhydrous Na₂SO₄, filtered andconcentrated. The residue was purified by column chromatography (SiO₂,100-200) by eluting 5% ethyl acetate in petroleum ether to afford1-isopropyl-6-methoxy-1H-indole-4-carboxylic acid methyl ester (240 mg,32.4%) as white solid. ¹H NMR (400 MHz, DMSO-d₆): δ 1.45 (d, J=6.8 Hz,6H), 3.84 (s, 3H), 3.88 (s, 3H), 4.81-4.78 (m, 1H), 6.86 (d, J=3.2 Hz,1H), 7.34 (d, J=2.4 Hz, 1H), 7.39 (d, J=2 Hz, 1H), 7.54 (d, J=3.6 Hz,1H). LCMS (ES+): m/z=248.16[M+H].

Intermediate 34 1-Isopropyl-6-methoxy-1H-indole-4-carboxylic acid

To a stirred solution of 1-isopropyl-6-methoxy-1H-indole-4-carboxylicacid methyl ester (320 mg, 1.29 mmol) in THF (2 mL) was added LiOH.H₂O(160 mg, 3.88 mmol) in water (2 mL) at room temperature and heated atreflux for 2 h. The THF was removed under reduced pressure and theresulting aqueous layer was acidified with 1 N HCl (pH ˜6) and extractedwith ethyl acetate (2×5 mL). The combined organic layer was dried overanhydrous Na₂SO₄ and concentrated to afford1-isopropyl-6-methoxy-1H-indole-4-carboxylic acid (210 mg). ¹H NMR (400MHz, DMSO-d₆): δ 1.42 (d, 6H), 3.88 (s, 3H), 4.85 (m, 1H), 6.81 (d,J=2.8 Hz, 1H), 7.26 (s, 2H), 7.45 (s, 1H), 12.68 (s, 1H).

Intermediate 35 6-Hydroxy-1-isopropyl-1H-indole-4-carboxylic acid methylester

To a stirred solution of 1-isopropyl-6-methoxy-1H-indole-4-carboxylicacid methyl ester (1.9 g, 7.69 mmol) in toluene (20 mL) was addedanhydrous aluminum chloride (5.11 g, 38.4 mmol) at room temperature andthen heated to reflux for 2 h. The reaction mixture was diluted withwater and extracted with ethyl acetate (2×20 mL). The combined organiclayer was dried over Na₂SO₄ and concentrated under reduced pressure. Theresidue was purified by column chromatography by eluting 3-15% Ethylacetate in petroleum ether to afford the title compound6-hydroxy-1-isopropyl-1H-indole-4-carboxylic acid methyl ester (1.5 g,83%) as yellow colored gum. ¹H NMR (400 MHz, DMSO-d₆): δ 1.43 (d, J=6.8Hz, 6H), 3.86 (s, 3H), 4.65-4.61 (m, 1H), 6.81 (d, J=2.8 Hz, 1H), 7.11(s, 1H), 7.29 (s, 1H), 7.44 (d, J=2.8 Hz, 1H), 9.32 (bs, 1H). LCMS(ES+): m/z=234.09 [M+H]

Intermediate 363-Methyl-1-(1-methylethyl)-6-(methyloxy)-1H-indole-4-carboxylic acid

To methyl 6-bromo-3-methyl-1-(1-methylethyl)-1H-indole-4-carboxylate(1.3 g, 4.19 mmol) and copper(I) iodide (1.0 g, 5.25 mmol) was added NMP(8 mL). To the mixture was added dropwise a solution of sodium methoxide25 wt % in methanol (4.0 mL, 17.49 mmol) with stirring. The reaction washeated to 120° C. and stirred for 1.5 hr. The reaction was allowed tocool and when the temperature reached 80° C., water (200 uL) was added.The reaction was allowed to continue to cool to RT and stirredovernight. The reaction was acidified with 1 N HCl (17 mL) and dilutedwith water and EtOAc. The mixture was filtered through Celite and washedwith EtOAc. The filtrate was poured into a separatory funnel and theorganic phase was separated, washed with brine, dried (MgSO4), filtered,and concentrated under vacuum. Purification by silica gel chromatography(Analogix, SF25-60 g, 20 to 50% EtOAc in hexanes) gave afterconcentration, trituration with hexanes, filtration and drying undervacuum 3-methyl-1-(1-methylethyl)-6-(methyloxy)-1H-indole-4-carboxylicacid (825 mg, 3.34 mmol, 80% yield) as an light yellow solid. MS(ES)+m/e 248.3 [M+H]⁺.

Intermediate 37 6-Iodo-1-(1-methylethyl)-1H-indole-4-carboxylic acid

To a stirred solution of methyl6-bromo-1-(1-methylethyl)-1H-indole-4-carboxylate (1.1 g, 3.71 mmol) indioxane (50 mL) was added sodium iodide (1.2 g, 8.01 mmol),N,N′-dimethylethylenediamine (200 μL, 1.858 mmol) and copper(I) iodide(150 mg, 0.788 mmol). The reaction was purged with N₂ then refluxed(110° C. oil bath) overnight. LCMS indicated that the reaction was 90%complete with 6% remaining SM. Another 0.75 g sodium iodide and 75 mgcopper(I) iodide was added and the reaction refluxed for another 24 hr.(LCMS showed less than 4% bromide SM.) The reaction was concentratedunder vacuum, taken up in EtOAc, washed with water, brine, dried(MgSO4), filtered and concentrated under vacuum. Purification by silicagel chromatography (Analogix, SF25-60 g, 0 to 10% EtOAc in hexanes) gavethe ester product as a light yellow oil. (1.27 g, 100%). MS(ES)+ m/e344.0 [M+H]⁺.

The above ester was taken up in 40 mL (3:1) MeOH, THF and treated with 1N NaOH (15 mL). The reaction was refluxed overnight, cooled to RT andconcentrated under vacuum. Neutralization with 1 N HCl (15 mL) gave awhite suspension that was filtered, washed with cold water and driedunder vacuum to give the product6-iodo-1-(1-methylethyl)-1H-indole-4-carboxylic acid (1.12 g, 3.40 mmol,92% yield) as a light yellow solid. ¹H NMR (400 MHz, DMSO-d₆) δ=12.94(br. s., 1H), 8.20 (s, 1H), 7.94 (d, J=1.5 Hz, 1H), 7.66 (d, J=3.3 Hz,1H), 6.97 (d, 1H), 4.86 (quin, J=6.6 Hz, 1H), 1.44 (d, J=6.6 Hz, 6H).MS(ES)+ m/e 330.0 [M+H]⁺.

Intermediate 38 6-Cyano-1-isopropyl-3-methyl-1H-indole-4-carboxylic acid

a) Methyl 6-cyano-3-methyl-1-(1-methylethyl)-1H-indole-4-carboxylate

To a 10 ml microwave vial was added methyl6-bromo-3-methyl-1-(1-methylethyl)-1H-indole-4-carboxylate (500 mg,1.612 mmol), dicyanozinc (150 mg, 1.277 mmol) and DMF (5 mL). Themixture was degassed and stirred at rt under N2 for 15 min. To themixture was added palladium tetrakis (118 mg, 0.102 mmol) and thereaction was stirred at 95° C. for 1 h. The reaction was allowed to cooland poured into saturated aqueous Na₂CO₃ (50 mL) and EtOAc (50 mL) andstirred for 20 min. The mixture was extracted with ether (100 ml) andEtOAc (100 ml) (1:1), followed by filtration and evaporation to yield aresidue. The residue was purified by silica gel chromatography (AnalogixIF280, 0-8% EtOAc/hexanes, SF25-40 g, 30 minutes) to give methyl6-cyano-3-methyl-1-(1-methylethyl)-1H-indole-4-carboxylate (130 mg,0.497 mmol, 38.9% yield) as a white solid. ¹H NMR (400 MHz, DMSO-d₆) δppm 8.38 (d, J=1.52 Hz, 1H) 7.82 (s, 1H) 7.71 (d, J=1.52 Hz, 1H)4.85-4.97 (m, 1H) 3.90 (s, 3H) 2.29 (s, 3H) 1.45 (d, J=6.57 Hz, 6H).MS(ES) [M+H]⁺ 257.4.

b) 6-Cyano-1-isopropyl-3-methyl-1H-indole-4-carboxylic acid

To a 50 ml round bottom was added methyl6-cyano-3-methyl-1-(1-methylethyl)-1H-indole-4-carboxylate (230 mg,0.897 mmol), followed by methanol (1 mL) and THF (1 mL). To the solutionwas added 3 M NaOH (0.449 mL, 2.69 mmol). The reaction stirred at rt for20 h. The reaction was evaporated and treated with acidic water to pH 5.A brown solid crashed out and was collected by filtration. The solid wasan impurity. The pH of the liquid was adjusted to 3 and the liquid wasevaporated leaving a residue. Trituration of the residue with water,followed by filtration yielded6-cyano-3-methyl-1-(1-methylethyl)-1H-indole-4-carboxylic acid (155 mg,0.576 mmol, 64.2% yield) as a yellow solid. ¹H NMR (400 MHz, DMSO-δ₆) δppm 13.16 (br. s., 1H) 8.33 (s, 1H) 7.78 (s, 1H) 7.66 (s, 1H) 4.81-4.98(m, 1H) 2.33 (s, 4H) 1.45 (d, J=6.57 Hz, 6H). MS(ES) [M+H]⁺ 243.3.

Intermediate 391-Isopropyl-3-methyl-6-(1H-tetrazol-5-yl)-1H-indole-4-carboxylic acid

a) Methyl1-isopropyl-3-methyl-6-(1H-tetrazol-5-yl)-1H-indole-4-carboxylate

To a stirred suspension of methyl6-cyano-1-isopropyl-3-methyl-1H-indole-4-carboxylate (0.50 g, 1.951mmol) in azidotrimethylsilane (1.0 mL, 7.53 mmol) in a small vial wasadded tetrabutylammonium fluoride trihydrate (300 mg, 0.951 mmol). Thereaction was heated to 85° C. and stirred for 18 hr (attached a smallreflux condenser). (The reaction became a semi-solid mass.) The reactionwas taken up in EtOAc (75 mL), washed with 1 N HCl (75 mL) (stirred tilldissolved). The organic phase was removed, dried (Na2SO4), filtered andconcentrated under vacuum. Purification by silica gel chromatography(Analogix, SF40-80 g, 0 to 3% MeOH/CH2Cl2 with 0.1% HOAc) gave theproduct methyl1-isopropyl-3-methyl-6-(1H-tetrazol-5-yl)-1H-indole-4-carboxylate (0.28g, 0.935 mmol, 48.0% yield) as a white solid. ¹H NMR (400 MHz, DMSO-d₆)δ 8.40 (d, J=1.3 Hz, 1H), 8.15 (d, J=1.5 Hz, 1H), 7.69 (s, 1H), 4.86(quin, J=6.6 Hz, 1H), 3.94 (s, 3H), 2.33 (s, 3H), 1.50 (d, J=6.6 Hz,6H). MS(ES)+ m/e 300.3 [M+H]⁺.

b) 1-isopropyl-3-methyl-6-(1H-tetrazol-5-yl)-1H-indole-4-carboxylic acid

To a stirred solution of methyl1-isopropyl-3-methyl-6-(1H-tetrazol-5-yl)-1H-indole-4-carboxylate (0.27g, 0.902 mmol) in MeOH (15 mL) and tetrahydrofuran (5 mL) was added 1NNaOH (5 mL, 5.00 mmol). The reaction was heated to 60° C. and stirredfor 48 hr. LCMS showed that the reaction was complete. The reaction wasconcentrated to near dryness under vacuum, acidified with 1 N HCl (5mL), triturated, filtered and washed with a small volume of water, anddried under vacuum to give the product1-isopropyl-3-methyl-6-(1H-tetrazol-5-yl)-1H-indole-4-carboxylic acid(0.26 g, 0.911 mmol, 101% yield) as a light yellow solid. ¹H NMR (400MHz, DMSO-d₆) δ 13.04 (br. s., 1H), 8.36 (d, J=1.5 Hz, 1H), 8.13 (d,J=1.3 Hz, 1H), 7.65 (s, 1H), 4.85 (quin, J=6.6 Hz, 1H), 2.36 (s, 3H),1.50 (d, J=6.6 Hz, 6H). MS(ES)+ m/e 286.1 [M+H]⁺.

Intermediate 40 6-Bromo-3-chloro-1-isopropyl-1H-indole-4-carboxylic acid

To a 100 ml round bottom flask was added methyl6-bromo-1-(1-methylethyl)-1H-indole-4-carboxylate (1.100 g, 3.71 mmol)as a solution in THF and a magnetic stir bar. To the same was added1-chloro-2,5-pyrrolidinedione (0.546 g, 4.09 mmol) and the systemstirred at room temperature overnight. The solvent was removed underreduced pressure and the residue dissolved in EtOAc (60 ml) and washedwith saturated NaHCO3 (20 ml) and brine (8 ml). The organic layer wasdried over Na2SO4, filtered and concentrated. Purification of theresidue by column chromatography provided methyl6-bromo-3-chloro-1-isopropyl-1H-indole-4-carboxylate (as a thick goldoil), which was used in the next step. ¹H NMR (400 MHz, DMSO-d₆) δ 8.15(d, J=1.52 Hz, 1H), 7.93 (s, 1H), 7.50 (d, J=1.77 Hz, 1H), 4.90 (quin,J=6.63 Hz, 1H), 3.89 (s, 3H), 1.43 (d, J=6.57 Hz, 6H). MS(ES) [M+H]⁺332.2.

To a solution of methyl6-bromo-3-chloro-1-(1-methylethyl)-1H-indole-4-carboxylate (1.2 g, 3.63mmol) in THF (2.368 ml) and MeOH (14.21 ml) was added 3 N NaOH (1.573ml, 4.72 mmol). The resulting mixture was heated at 55° C. for 4 h. Thereaction was removed from the heat and the solvent removed in-vacuo. Theremaining residue was dissolved with water (12 ml) and made acidicdropwise with 1 N HCl. The product precipitated and the slurry becametoo thick to stir and was diluted with water (10 ml). After theprecipitation haulted no more acid was added. The solid was collected byvacuum filtration, washed with water, and air dried under vacuumovernight to give6-bromo-3-chloro-1-(1-methylethyl)-1H-indole-4-carboxylic acid (650 mg,2.033 mmol, 56.0% yield over 2 steps) as a white solid. ¹H NMR (400 MHz,DMSO-d₆) δ 13.22 (s, 1H), 8.09 (d, J=1.77 Hz, 1H), 7.89 (s, 1H), 7.45(d, J=1.77 Hz, 1H), 4.88 (quin, J=6.63 Hz, 1H), 1.43 (d, J=6.57 Hz, 6H).MS(ES) [M+H]⁺ 316.0.

Intermediate 41 Methyl2-bromo-6-chloro-1-isopropyl-3-methyl-1H-indole-4-carboxylate

To a stirred solution of methyl6-chloro-1-isopropyl-3-methyl-1H-indole-4-carboxylate (2.5 g, 9.41 mmol)in DMF (25 mL) was added NBS (1.7 g, 9.55 mmol). The reaction wasstirred for 18 h then evaporated to dryness under vacuum. The reactionwas purified by silica gel chromatography (Analogix, SF40-80 g, 0 to 5%EtOAc in hexanes) then (Analogix, SF25-60 g, 25% CH₂Cl₂ in hexanes) togive the product methyl2-bromo-6-chloro-1-isopropyl-3-methyl-1H-indole-4-carboxylate (1.79 g,5.19 mmol, 55.2% yield) as a clear oil. ¹H NMR (400 MHz, DMSO-d₆) δ=7.98(d, J=1.8 Hz, 1H), 7.41 (d, J=1.8 Hz, 1H), 5.05 (dt, J=6.7, 13.4 Hz,1H), 3.89 (s, 3H), 2.22 (s, 3H), 1.57 (d, J=7.1 Hz, 6H). MS(ES)+ m/e344.0 [M+H]⁺.

Intermediate 421-Isopropyl-3-methyl-6-(pyridazin-4-yl)-1H-indole-4-carboxylic acid

a) Methyl1-isopropyl-3-methyl-6-(pyridazin-4-yl)-1H-indole-4-carboxylate

To a 50 ml round bottom flask was added; methyl6-bromo-1-isopropyl-3-methyl-1H-indole-4-carboxylate (150 mg, 0.484mmol), PdCl2(dppf)-CH2Cl2 adduct (39.5 mg, 0.048 mmol) and 1,4-Dioxane(4836 μl) followed with 4-(tributylstannyl)pyridazine (179 mg, 0.484mmol) and a magnetic stir bar. The flask was equipped with a refluxcondenser and an exhaust bubbler and heated to 105° C. The reactionsolution changed to a dark brown at 30 minutes. LCMS (105 C-3 h) showedthe reaction to be complete. The reaction solvent was removed in-vacuoand the remaining residue taken up with DMSO. (1.5 ml). The DMSOsolution was purified by reverse phase HPLC using a Phenomenex Gemini100×30 mm column, neutral acetonitrile and 0.1% formic acid in water,40-70%, 10 min gradient. The desired fractions were dried in a GenovacEZ-2 evaporator and the solid residues combined. The product, methyl1-isopropyl-3-methyl-6-(pyridazin-4-yl)-1H-indole-4-carboxylate, wasobtained as a white solid. ¹H NMR (400 MHz, METHANOL-δ₄) δ 9.68 (δ,J=1.26 Hz, 1H), 9.19 (d, J=5.56 Hz, 1H), 8.20 (d, J=1.52 Hz, 1H), 8.13(dd, J=2.53, 5.56 Hz, 1H), 7.98 (d, J=1.52 Hz, 1H), 7.48 (s, 1H), 4.96(dt, J=6.60, 13.33 Hz, 1H), 4.00 (s, 3H), 2.39 (s, 3H), 1.56 (d, 6H).MS(ES) [M+H]⁺ 310.2.

b) 1-Isopropyl-3-methyl-6-(pyridazin-4-yl)-1H-indole-4-carboxylic acid

To a 100 ml round bottom flask was added methyl1-isopropyl-3-methyl-6-(pyridazin-4-yl)-1H-indole-4-carboxylate (74.0mg, 0.239 mmol), Methanol (1595 μl), Tetrahydrofuran (THF) (3189 μl) anda magnetic stir bar. To the same was added lithium hydroxide, H2O (30.1mg, 0.718 mmol) and the mixture was stirred at 55° C. Reaction progresswas monitored by LCMS. LCMS(weekend) showed 50% conversion. To thereaction mixture was added lithium hydroxide, H2O (20.08 mg, 0.478 mmol)The reaction was continued to stir and heated to 55° C. After completeconversion the reaction solvent was removed and the remaining residuedissolved with water (1.5 ml). The aqueous solution was made acidic dropwise with 1N HCl until precipitation was complete. The solid wascollected by vacuum filtration and washed with water (5 ml). The solidwas dried under vacuum open to the air overnight. The product,1-isopropyl-3-methyl-6-(pyridazin-4-yl)-1H-indole-4-carboxylic acid (68mg, 0.228 mmol, 95% yield), was obtained as a brown solid. ¹H NMR (400MHz, DMSO-δ₆) δ 9.71-9.83 (m, 1H), 9.23 (dd, J=1.26, 5.56 Hz, 1H), 8.32(s, 1H), 8.11 (dd, J=2.65, 5.43 Hz, 1H), 7.86 (s, 1H), 7.58 (s, 1H),4.90-5.09 (m, 1H), 2.34 (s, 3H), 1.47 (d, J=6.82 Hz, 6H). MS(ES)[M+H]⁺296.2.

Intermediate 43 6-Bromo-3-fluoro-1-isopropyl-1H-indole-4-carboxylic acid

a) Methyl 6-bromo-3-fluoro-1-isopropyl-1H-indole-4-carboxylate

To a 20 ml vial was added methyl6-bromo-1-isopropyl-1H-indole-4-carboxylate (50.0 mg, 0.169 mmol),(selectfluor) 1-(chloromethyl)-4-fluoro-1,4-diazoniabicyclo[2.2.2]octaneditetrafluoroborate (78 mg, 0.219 mmol) followed with a magnetic stirbar and nitroethane (2 ml). The vial was capped and the reaction stirredat room temperature. Reaction progress was monitored by LCMS. Afterreaction completion the reaction solvent was removed in-vacuo. Theresidue was dissolved with DCM (1.4 ml). The DCM solution was chargedonto an analogix Si35 SF10-8 gram column. The compound was eluted withEtOAc/Hexanes, 5-15%, 20 min. The desired product and side MW629co-eluted. The mixture was dissolved with DMSO (1 ml) and purified byreverse phase HPLC using a Gemini 5p 30×100 mm column, neutralacetonitrile/0.1% formic acid in water, 50-80%, 7 min gradient. Thedesired product eluted at 6.8 minutes and the side product MW 629 at 9.5minutes. The desired fractions were concentrated to a residue. LCMS andNMR support the desired structure and analytical HPLC showed 100%purity. The product, methyl6-bromo-3-fluoro-1-isopropyl-1H-indole-4-carboxylate (11 mg, 0.035 mmol,20.53% yield), was obtained as a white solid. ¹H NMR (400 MHz,METHANOL-d₄) δ 7.95 (t, J=1.77 Hz, 1H), 7.78 (d, J=1.77 Hz, 1H), 7.47(d, J=2.53 Hz, 1H), 4.76-4.84 (m, J=1.64, 6.65, 6.65, 13.36 Hz, 1H),3.96 (s, 3H), 1.50 (d, 6H). MS(ES)[M+H]⁺315.1.

b) 6-Bromo-3-fluoro-1-isopropyl-1H-indole-4-carboxylic acid

To a 100 ml round bottom flask was added methyl6-bromo-3-fluoro-1-isopropyl-1H-indole-4-carboxylate (33.0 mg, 0.105mmol), Methanol (700 μl), Tetrahydrofuran (THF) (1401 μl) and a magneticstir bar. To the same was added lithium hydroxide, H2O (13.22 mg, 0.315mmol) and the mixture was stirred at room temperature. Reaction progresswas monitored by LCMS. LCMS(18 h) showed 60% conversion. The reactionwas heated to 50° C. in an aluminum heating block with stirring. Aftercomplete conversion the solvent was removed in-vacuo and the remainingresidue was dissolved with water (1 ml) and 1N HCl was added dropwise (9drops) until precipitation stopped. The fine pale-yellow solid wascollected by vacuum filtration. LCMS and HPLC showed 100% purity and NMRsupports the desired structure. The product,6-bromo-3-fluoro-1-isopropyl-1H-indole-4-carboxylic acid (24 mg, 0.080mmol, 76% yield), was obtained as a yellow solid. ¹H NMR (400 MHz,DMSO-d₆) δ 13.07 (br. s., 1H), 8.12 (t, J=1.89 Hz, 1H), 7.77 (d, J=2.27Hz, 1H), 7.66 (d, J=1.77 Hz, 1H), 4.88 (qd, J=5.31, 6.65 Hz, 1H), 1.40(d, 6H). MS(ES) [M+H]⁺ 300.1.

Intermediate 44N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-3-methyl-1-(1-methylethyl)-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indole-4-carboxamide

Trial run: A mixture of6-bromo-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-3-methyl-1H-indole-4-carboxamide(1.0 g, 2.32 mmol, 1 equiv), bis(pinacolato)diboron (0.71 g, 2.79 mmol,1.2 equiv), KOAc (0.47 g, 4.76 mmol, 2 equiv) and PdCl₂(dppf)-CH₂Cl₂adduct (104 mg, 00.13 mmol, 0.1 equiv) in 10 mL of dioxane in a 20 mLmicrowave vial was bubbled with nitrogen for 10 min, followed by cappingand heating in an oil bath at 80° C. for 3 h. LCMS showed conversioncomplete. Only 4% debromo byproduct was detected.

Production run: A mixture of6-bromo-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-3-methyl-1H-indole-4-carboxamide(22.0 g, 51.1 mmol, 1 equiv), bis(pinacolato)diboron (15.58 g, 61.3mmol, 1.2 equiv), KOAc (10.29 g, 105 mmol, 2 equiv) and PdCl₂(dppf)-CH₂Cl₂ adduct (2.30 g, 2.81 mmol, 0.1 equiv) in 190 mL of dioxanewas degassed and backflushed with nitrogen (repeated 4×). The mixturewas heated in an oil bath at 90° C. for 2 h. The dark brownish mixturewas combined with the crude mixture from the trial run above, andfiltered through celite (rinsing with EtOAc). The filtrate was conc invacuo. The residue was taken up in CHCl₃ and split into 9 equalportions. One portion was absorbed onto a celite-packed dryloadcartridge. Purification was done on an SF40-80 g silica gel cartridgeusing gradient elution of 25% EtOAc in hexane to 100% EtOAc (gradient:0-5 min, 25% EtOAc, 5-20 min, linear gradient 25-100% EtOAc, 25-65 min,100% EtOAc). The desired product eluted at 100% EtOAc (with a longtail). The DASI portion was clogged during the process, and needed to beremoved to continue the chromatography, causing loss of material. Thusthe use of FCC was abandoned and switched to gravity column.

The remaining 8 portions were recombined and dissolved in CHCl₃,followed by adding to a silica gel column (500 g of coarse grade silicagel packed in 25% EtOAc in hexane), and then elution with 1 L of 25%EtOAc in hexane, 1 L of 50% EtOAc, 1 L of 75% EtOAc in hexane, 2 L of100% EtOAc, 1 L of EtOAc with 25 mL increments of MeOH. The desiredproduct eluted at 100% EtOAc, 25 mL-100 mL of MeOH in EtOAc fractions.

The EtOAc fractions were combined with the FCC purified material. Themixture was conc in vacuo. The residue was taken up in MTBE (5 mL) andhexane (100 mL) as a suspension, which was filtered. The cake was washedwith hexane (30 mL) and dried under vacuum at rt for 4 h to provideN-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-3-methyl-1-(1-methylethyl)-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indole-4-carboxamide(14.01 g) as light beige solid. ¹H NMR (400 MHz, DMSO-d₆) δ ppm 1.31 (s,12H), 1.41 (d, J=6.8 Hz, 6H), 2.11 (s, 3H), 2.16 (s, 3H), 2.22 (s, 3H),4.33 (d, J=8 Hz, 2H), 4.79 (quin, J=6.6 Hz, 1H), 5.87 (s, 1H), 7.23 (s,1H), 7.40 (d, J=1.0 Hz, 1H), 7.75 (s, 1H), 8.04 (t, J=5.1 Hz, 1H), 11.46(s, 1H).

Assay Protocol

Compounds contained herein were evaluated for their ability to inhibitthe methyltransferase activity of EZH2 within the PRC2 complex. HumanPRC2 complex was prepared by co-expressing each of the 5 member proteins(FLAG-EZH2, EED, SUZ12, RbAp48, AEBP2) in Sf9 cells followed byco-purification. Enzyme activity was measured in a scintillationproximity assay (SPA) where a tritiated methyl group is transferred from3H-SAM to a lysine residue on Histone H3 of a mononucleosome, purifiedfrom HeLa cells. Mononucleosomes were captured on SPA beads and theresulting signal is read on a ViewLux plate reader.

Part A. Compound Preparation

-   -   1. Prepare 10 mM stock of compounds from solid in 100% DMSO.    -   2. Set up an 11-point serial dilution (1:3 dilution, top        concentration 10 mM) in 100% DMSO for each test compound in a        384 well plate leaving columns 6 and 18 for DMSO controls.    -   3. Dispense 100 nL of compound from the dilution plate into        reaction plates (Grenier Bio-One, 384-well, Cat#784075).

Part B. Reagent Preparation

Prepare the following solutions:

-   -   1. 50 mM Tris-HCl, pH 8: Per 1 L of base buffer, combine 1 M        Tris-HCl, pH 8 (50 mL) and distilled water (950 mL).    -   2. 1× Assay Buffer: Per 10 mL of 1× Assay Buffer, combine 50 mM        Tris-HCl, pH 8 (9958 uL), 1 M MgCl₂ (20 uL), 2 M DTT (20 uL),        and 10% Tween-20 (2 uL) to provide a final concentration of 50        mM Tris-HCl, pH 8, 2 mM MgCl₂, 4 mM DTT, 0.002% Tween-20.    -   3. 2× Enzyme Solution: Per 10 mL of 2× Enzyme Solution, combine        1× Assay Buffer and PRC2 complex to provide a final enzyme        concentration of 10 nM. 4. SPA Bead Suspension: Per 1 mL of SPA        Bead Suspension, combine PS-PEI    -   coated LEADSeeker beads (40 mg) and ddH2O (1 mL) to provide a        final concentration of 40 mg/mL.    -   5. 2× Substrate Solution: Per 10 mL of 2× Substrate Solution,        combine 1× Assay Buffer (9728.55 uL), 800 ug/mL mononucleosomes        (125 uL), 1 mM cold SAM (4 uL), and 7.02 uM 3H-SAM (142.45 uL;        0.55 mCi/mL) to provide a final concentration of 5 ug/mL        nucleosomes, 0.2 uM cold SAM, and 0.05 uM 3H-SAM.    -   6. 2.67× Quench/Bead Mixture: Per 10 mL of 2.67× Quench/Bead        Mixture, combine ddH₂O (9358 uL), 10 mM cold SAM (267 uL), 40        mg/mL Bead Suspension (375 uL) to provide a final concentration        of 100 uM cold SAM and 0.5 mg/mL SPA beads.

Part C. Assay Reaction in 384-Well Grenier Bio-One Plates CompoundAddition

-   -   1. Dispense 100 nL/well of 100× Compound to test wells (as noted        above).    -   2. Dispense 100 nL/well of 100% DMSO to columns 6 & 18 for high        and low controls, respectively.

Assay

-   -   1. Dispense 5 uL/well of 1× Assay Buffer to column 18 (low        control reactions).    -   2. Dispense 5 uL/well of 2× Enzyme Solution to columns 1-17,        19-24.    -   3. Spin assay plates for ˜1 minute at 500 rpm.    -   4. Stack the assay plates, covering the top plate.    -   5. Incubate the compound/DMSO with the enzyme for 30 minutes at        room temperature.    -   6. Dispense 5 uL/well of 2× Substrate Solution to columns 1-24.    -   7. Spin assay plates for ˜1 minute at 500 rpm.    -   8. Stack the assay plates, covering the top plate.    -   9. Incubate the assay plates at room temperature for 1 hour.

Quench/Bead Addition

-   -   1. Dispense 5 uL/well of the 3× Quench/Bead Mixture to columns        1-24.    -   2. Seal the top of each assay plate with adhesive TopSeal.    -   3. Spin assay plates for ˜1 minute at 500 rpm.    -   4. Equilibrate the plates for >20 min.

Read Plates

-   -   1. Read the assay plates on the Viewlux Plate Reader utilizing        the 613 nm emission filter with a 300 s read time.        Reagent addition can be done manually or with automated liquid        handler.        The final DMSO concentration in this assay is 1%.        The positive control is in column 6; negative control is in        column 18.        Final starting concentration of compounds is 100 μM.

Part D. Data Analysis

Percent inhibition was calculated relative to the DMSO control for eachcompound concentration and the resulting values were fit using standardIC₅₀ fitting parameters within the ABASE data fitting software package.

Exemplified compounds of the present invention were generally testedaccording to the above or an analogous assay and were found to beinhibitors of EZH2. The IC₅₀ values ranged from about 1 nM to about 10μM; The IC₅₀ values of the more active compounds range from about 1 nMto about 500 nM; The most active compounds are under 50 nM. As tested inthe foregoing assay or an analogous assay, compounds of the variousExamples gave the pIC₅₀ data in the compound table above or the IC₅₀data in the paragraph below. Repeating the assay run(s) may result in asomewhat different.

Ex 78, 1800; Ex 174, 18; Ex 211, 14; Ex 212, 9; Ex 234, 1000; Ex 244,29; Ex 264, 13; Ex 265, 13; Ex 266, 25; Ex 267, 20; Ex 268, 40; Ex 269,4; Ex 270, 4; Ex 271, 8; Ex 272, 13; Ex 273, 10; Ex 274, 32; Ex 275, 3;Ex 339, 13.

Preparation of Specific Compounds (Compound a, B and C) that were Testedin the T Cell Proliferation and Cytokine Production StudiesN-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-6-(4-(2-(dimethylamino)ethoxy)phenyl)-1-isopropyl-1H-indazole-4-carboxamide

6-bromo-N-(4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-1H-indazole-4-carboxamide(80 mg, 0.19 mmol),N,N-dimethyl-2-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)ethanamine(84 mg, 0.29 mmol) and PdCl₂(dppf)-CH₂Cl₂ adduct (7.8 mg, 0.009 mmol) indioxane/water (3 ml:1 ml) were stirred for 10 min under nitrogen. Sodiumbicarbonate (48.3 mg, 0.58 mmol) was added and the insoluble mixture wasirradiated in a microwave at 100° C. for 20 min. The reaction mixturewas evaporated, dissolved in DCM/MeOH (1:1), and preabsorbed on silicagel and purified using silica gel chromatography (eluent:DCM/MeOH/NH₄OH; gradient 0 to 80:20:2 in DCM). The isolated product wasdissolved in hot DMSO/MeOH and purified using reversed-phase HPLC(25-80% gradient of MeCN in water with 0.1% TFA). Most of the solventfrom the combined product fractions were evaporated and sat. sol. NaHCO3was added, solids that crashed out were filtered, air-dried for 15 min,and dried in vacuum-oven overnight. The product was collected as a whitesolid (56 mg, 56%). ¹H NMR (400 MHz, DMSO-d₆)™ ppm 11.54 (br. s., 1H)8.64 (t, J=4.80 Hz, 1H) 8.35 (s, 1H) 8.05 (s, 1H) 7.81-7.84 (m, 2H).LC-MS (ES) m/z=528.1 [M+H]⁺

Compound A can be prepared according to a procedure analogous to theabove example:

Compound A1-(1-methylethyl)-N-[(6-methyl-2-oxo-4-propyl-1,2-dihydro-3-pyridinyl)methyl]-6-[6-(4-methyl-1-piperazinyl)-3-pyridinyl]-1H-indazole-4-carboxamide

The title compound was prepared in a similar manner as described for theabove example from6-bromo-1-(1-methylethyl)-N-[(6-methyl-2-oxo-4-propyl-1,2-dihydro-3-pyridinyl)methyl]-1H-indazole-4-carboxamide(90 mg, 0.202 mmol) and1-methyl[5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2-pyridinyl]piperazine(92 mg, 0.303 mmol). The final product was collected as a light brownsolid (54 mg, 49%). ¹H NMR (400 MHz, DMSO-d₆)™ ppm 1H NMR (400 MHz,DMSO-d6)™ ppm 11.54 (br. s., 1H) 8.65 (d, J=2.27 Hz, 1H) 8.61 (t, J=4.80Hz, 1H) 8.36 (s, 1H) 8.04-8.08 (m, 2H) 7.83 (s, 1H) 6.96 (d, J=9.09 Hz,1H) 5.92 (s, 1H) 5.14 (quin, J=6.57 Hz, 1H) 4.42 (d, J=4.80 Hz, 2H)3.53-3.59 (m, 4H) 2.53-2.61 (m, 2H) 2.40-2.45 (m, 4H) 2.23 (s, 3H) 2.14(s, 3H) 1.51-1.58 (m, 2H) 1.50 (s, 3H) 1.49 (s, 3H) 0.88 (t, J=7-7.33Hz, 3H). LC-MS (ES) m/z=542.2 [M+H]⁺

Compound BN-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-3-methyl-1-(1-methylethyl)-6-[6-(4-methyl-1-piperazinyl)-3-pyridinyl]-1H-indole-4-carboxamide

Compound B can be prepared according to the general procedure describedin the above experimental section.

6-Cyclopropyl-1-(1-methylethyl)-N-[(4-methyl-2-oxo-6-propyl-1,2-dihydro-3-pyridinyl)methyl]-1H-pyrazolo[3,4-b]pyridine-4-carboxamide

6-Cyclopropyl-1-(1-methylethyl)-1H-pyrazolo[3,4-b]pyridine-4-carboxylicacid (167 mg, 0.680 mmol),3-(aminomethyl)-4-methyl-6-propyl-2(1H)-pyridinone trifluoroacetate (200mg, 0.680 mmol), HOAT (139 mg, 1.019 mmol), EDC (195 mg, 1.019 mmol),and N-methylmorpholine (0.299 mL, 2.72 mmol) were dissolved in DMF (6mL) and stirred at 40° C. for 24 h. The reaction mixture was poured intowater (20 mL) and extracted with ethyl acetate (3×50 mL). The combinedorganic layers were dried over sodium sulfate and concentrated to anorange oil. The residue was dissolved in DMSO, and purified by reversephase HPLC (mobile phase: 40-60% ACN in H₂O, 0.1% TFA). The isolatedproduct was dried in a vacuum oven overnight and furnished the TFA saltof the title compound as a white solid, 0.113 g (32%). LCMS E-S(M+H)=408.1. ¹H NMR (400 MHz, DMSO-d₆) δ ppm 0.80-0.98 (m, 3H), 1.06 (d,J=7.07 Hz, 4H), 1.46 (d, J=6.82 Hz, 6H), 1.52-1.67 (m, 2H), 2.17-2.31(m, 4H), 2.37 (t, J=7.58 Hz, 2H), 4.36 (d, J=4.80 Hz, 2H), 5.02-5.27 (m,1H), 5.91 (s, 1H), 7.43 (s, 1H), 8.21 (s, 1H), 8.62-8.87 (m, 1H), 11.54(br. s., 1H).

Compound C can be prepared according to a procedure analogous to theabove example:

6-cyclopropyl-1-(1-methylethyl)-N-[(6-methyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-1H-pyrazolo[3,4-b]pyridine-4-carboxamide

EXAMPLES Proliferation Studies

The EZH1/EZH2 inhibitors, Compound A and Compound B,concentration-dependently impaired T cell receptor-induced proliferationof CD4+ T cells with a pIC50 of 5.30±0.06 and 4.93±0.05 respectively(n=4; FIG. 1). In contrast, Compound C had no effect on T cellreceptor-induced proliferation of CD4+ T cells (n=4).

Cytokine Production Studies:

The EZH1/EZH2 inhibitors, Compound A and Compound B,concentration-dependently impaired T cell receptor-induced production ofIL-10, IL-13, IL-17, IFN & TNF in CD4+ T cells with pIC50 values rangingbetween 5.65±0.06-5.23±0.03 and 5.21±0.09-4.94±0.03 respectively (n=4;FIG. 2 & FIG. 4. In contrast, Compound C had no effect on T cellreceptor-induced production of IL-17 or IFN in CD4+ T cells (n=4). Highconcentrations of Compound C (i.e. >15 μM) reduced IL-10, IL-13 & TNFproduction (n=4).

The EZH1/EZH2 inhibitors, Compound A and Compound B,concentration-dependently impaired T cell receptor-induced production ofIL-2 in CD4+ T cells with pIC50 values of 6.24±0.24 and 5.76±0.25respectively (n=4; FIG. 3). Compound C also impaired T cellreceptor-induced production of IL-2 in CD4+ T cells, although a pIC50could not be calculated (n=4; FIG. 3).

Methods:

CD4 T Cell Isolation from Human Blood:

15 mls ficoll was added to 8×50 mL accuspin tubes per donor andcentrifuged at 2000 RPM for 1 min. Whole blood samples (200 mL+1%heparin) were collected from human donors. Approximately 25 ml blood wasadded to each ficoll pre-filled 50 ml falcon tubes with filter andcentrifuged at 1500 RPM for 20 min with the brake off to avoiddisturbing cell separation. 45 ml with PBS was added to the PBMCfraction of each tube and centrifuged at 1500 RPM for 10 min with brake.Supernatant were discarded and cell pellets resuspended in 2 ml PBS.Cell suspensions for each donor were recombined into a single falcontube, made up to 45 ml with PBS and centrifuged at 1500 RPM for 10 min.CD4+ T cells were isolated by negative depletion using a CD4 T cellIsolation Kit from Miltenyi Biotech according to manufacturers protocol.

Proliferation Studies:

96-well flat-bottom plates were coated with 10 μg/mL anti-CD3+2 μg/mLanti-CD28 at 4′C overnight. The following day, plates were washed withPBS. For proliferation studies, cells were stained with CFSE(Invitrogen) according to manufacturer's protocol. Cells were then addedto anti-CD3+anti-CD28 pre-coated 96-well plates at 0.2×10⁶ cells/well inthe presence of EZH1/EZH2 inhibitors (Compound A & Compound B), aninactive control compound (Compound C) or vehicle (0.1% DMSO) andincubated for 6 days at 37′C/5% CO2. Cells were then transferred to96-well round-bottom plates, washed and then analysed by flow cytometry.

Cytokine Production Studies:

96-well flat-bottom plates were coated with 10 μg/mL anti-CD3+2 μg/mLanti-CD28 at 4′C overnight. The following day, plates were washed withPBS. For cytokine production studies, cells were added toanti-CD3+anti-CD28 pre-coated 96-well plates at 0.4×10⁶ cells/well inthe presence of EZH1/EZH2 inhibitors or vehicle and incubated at 37′C/5%CO2. Supernatants were taken 18 h (IL-2) or 72 h (IL-10, IL-13, IL-17,IFN, TNF) for determination of cytokine production by multiplex ELISAfrom Mesoscale discovery according to the manufacturers protocols.

Drugs and Materials

Anti-CD3 (HU CD3 NALE MAB UCHT1; Cat #555329) and anti-CD28 (HU CD28NALE MAB CD28.2; Cat #: 555725), were obtained from BD Pharmingen anddissolved in Dulbecco's Phosphate Buffered Saline (with Ca2+/Mg2+;Gibco). Ficoll-paque (Cat #17-1440-03) was obtained from GE Healthcare.The CD4+ T cell isolation kit (Cat #130-091-155) was obtained fromMiltenyi Biotec. Cells were cultured in RPMI 1640 containing 10% FCS+1%pen/strep+1% L-glutamine. The CellTrace CFSE cell proliferation kit (Cat#C34554) was obtained from Invitrogen.

Compound A, Compound B and Compound C were all synthesised in house anddissolved in 100% DMSO.

Data Analysis Proliferation Studies:

Flowjo Software was used to calculate a division index usingfluorescence intensity. Data are expressed as mean±standard error of themean; n values are the numbers of human donors used. pIC50 values weregenerated using GraphPad Prism software and non-linear sigmoid dosecurve-fit.

Cytokine Production Studies:

Data were analysed using Excel and are expressed as mean±standard errorof the mean; n values are the numbers of human donors used. pIC50 valueswere generated using GraphPad Prism software and non-linear sigmoid dosecurve-fit.

1. A method of treating a T cell mediated inflammatory immune disease,selected from a group consisting of solid organ transplant rejection andgraft versus host disease, comprising administering to a human in needthereof an effective amount of a compound which isN-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-3-methyl-1-[(1S)-1-methylpropyl]-6-[6-(1-piperazinyl)-3-pyridinyl]-1H-indole-4-carboxamide,or a pharmaceutically acceptable salt thereof.
 2. The method accordingto claim 1 wherein the T cell mediated inflammatory immune disease issolid organ transplant rejection.
 3. The method according to claim 1wherein the T cell mediated inflammatory immune disease is graft versushost disease.
 4. The method according to claim 1 wherein the compound isadministered as a free base.
 5. The method according to claim 2 whereinthe compound is administered as a free base.
 6. The method according toclaim 3 wherein the compound is administered as a free base.